

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 10, 2006, 18:01:46 ; Search time 40.1584 Seconds

Sequence: 1 MESPSPAPHRWCIPWQRLI.....LSAGATVGIMIGVILVGVALI 702

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Perfect score: 3721

Score: 1681.943 Million cell updates/sec

Title: US-10-734-564-72

Sequence: 1 MESPSPAPHRWCIPWQRLI.....LSAGATVGIMIGVILVGVALI 702

30	1080.5	29.0	395	2	D43354	pregnancy-specific
31	1078.5	29.0	397	2	C43354	pregnancy-specific
32	1070.5	28.8	521	2	S34338	biliary glycoprote
33	1069.5	28.7	458	2	JC1509	biliary glycoprote
34	1069	28.7	424	2	B36109	pregnancy-specific
35	1023.5	27.5	521	2	JC1508	biliary glycoprote
36	1018.5	27.4	458	1	WMM5R1	biliary glycoprote
37	988.5	26.6	519	2	A44783	ecto-ATPase precur
38	983	26.4	459	2	661177	C-CAM2a Protein is
39	965	25.9	458	2	S23969	cell-adhesion mole
40	919	24.7	402	2	A54312	pregnancy-specific
41	900.5	24.2	352	2	177374	pregnancy-specific
42	898	24.1	332	2	JN0067	pregnancy-specific
43	892	24.0	335	2	H43354	pregnancy-specific
44	890	23.9	335	2	A33514	pregnancy-specific
45	889	23.9	326	2	JC4124	pregnancy-specific

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR 80:*

- 1: pir1:*
- 2: pir2:*
- 3: pir3:*
- 4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	3721	100.0	702	A36319
2	1609	43.2	526	1 A32164
3	1600.5	43.0	464	2 C20127
4	1589.5	42.7	417	2 JH0394
5	1470	39.5	286	2 A28333
6	1443	38.8	344	2 A27681
7	1423	38.3	321	2 JH0396
8	1272	34.2	349	2 A24815
9	1157.5	31.1	428	2 A27658
10	1148.5	30.9	419	2 JG4123
11	1141.5	30.7	428	2 L57486
12	1133.5	30.5	428	2 A27658
13	1130	30.4	436	2 B55181
14	1127.5	30.3	426	2 A35964
15	1127.5	30.3	426	2 S09016
16	1127.5	30.3	426	2 A25341
17	1127.5	30.3	426	2 A55181
18	1127.5	30.3	495	2 A55181
19	1126.5	30.3	417	2 A28277
20	1126.5	30.3	419	2 A31135
21	1126.5	30.3	419	2 A35181
22	1126.5	30.3	426	2 B55334
23	1125.5	30.2	426	2 B33258
24	1124.5	30.2	419	2 A33258
25	1124.5	30.0	419	2 B54312
26	1107.5	29.8	435	2 D33258
27	1106.5	29.7	419	2 A36109
28	1089	29.5	424	2 A34595
29	1085.5	29.2	406	2 B43354

ALIGNMENTS

RESULT 1	A36319	carcinoembryonic antigen precursor - human	N	Alternate names: CEA; meconium antigen 100
	C;Species: Homo sapiens (man)		C;Date: 15-Sep-1992	#sequence_revision 15-Sep-1992 #text_change 09-Jul-2004
	C;Accession: A36319;		C;Accession: A27773;	A21037; A22845; S08106; S31737; A44476; I54224; I59098; -
	R;Schrewe, H.; Thompson, J.; Bona, M.; Refta, L.J.F.; Maruya, A.; Hasseauer, M.; Shive, M.; Cell, Biol, 10, 2748, 1990		R;Beauchemin, N.; Benchimol, S.; Cournoyer, D.; Fuk, A.; Stanners, C.P.	A;Title: Cloning of the complete gene for carcinoembryonic antigen: analysis of its p
	A;Reference number: A36319; MUID:9025861; PMID:2342461		A;Reference number: A31037; MUID:8912204; PMID:3220478	A;Title: Isolation and characterization of full-length functional cDNA clones for hum
	A;Molecule type: DNA		A;Accession: A27773; MUID:88038876; PMID:3670312	A;Cross-references: UNIPROT:UPI00003AB4C; GB:M17103; NID:g178676; PI
	A;Molecule type: mRNA		A;Residues: 1-702 <BAR>	A;Note: the authors show the codons TTA for residue 641-Phe and CAG for residue 64E-T
	A;Cross-references: UNIPARC:UPI00003AB4C; GB:M29540; NID:g180222; PIDN:AAA51967.1; E		R;Oikawa, S.; Nakazato, H.; Kosaki, G.; Biochem. Biophys. Res. Commun. 142, 511-518, 1987	A;Reference: Genomics 3, 59-66, 1988
	R;Barnett, T.; Goebel, S.J.; Notchardt, M.A.; Elting, J.J.		A;Title: Carcinoembryonic antigen family: characterization of cDNAs coding for NCA. ai	A;Accession: A31037; MUID:8912204; PMID:3220478
	Genomics 3, 59-66, 1988		A;Reference number: A31037; MUID:8912204; PMID:3220478	A;Cross-references: UNIPARC:UPI00003AB4C; GB:M29540; NID:g180222; PIDN:AAA51967.1;
	A;Title: Carcinoembryonic antigen family: characterization of cDNAs coding for NCA. ai		A;Residues: 1-702 <BAR>	A;Note: the authors translated the codon GTG for residue 130 as Leu
	A;Accession: A31037; MUID:8912204; PMID:3220478		A;Cross-references: UNIPARC:UPI00003AB4C; GB:M29540; NID:g180222; PIDN:AAA51967.1;	R;Oikawa, S.; Nakazato, H.; Kosaki, G.; Biochem. Biophys. Res. Commun. 142, 511-518, 1987
	A;Accession: A31037; MUID:8912204; PMID:3220478		A;Title: Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA	A;Title: Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA
	A;Reference number: A25845; MUID:87128144; PMID:3114146		A;Reference number: A25845; MUID:87128144; PMID:3114146	A;Reference number: A25845; MUID:87128144; PMID:3114146
	A;Accession: A25845; MUID:87128144; PMID:3114146		A;Molecule type: mRNA	A;Accession: A25845; MUID:87128144; PMID:3114146
	A;Residues: 5-702 <OJK>		A;Cross-references: UNIPARC:UPI000011D6BB; GB:M15042; NID:g180198; PIDN:AAA51963.1;	A;Cross-references: UNIPARC:UPI000011D6BB; GB:M15042; NID:g180198; PIDN:AAA51963.1;
	R;Oikawa, S.		R;Oikawa, S.	R;Oikawa, S.
	Submitted to the EMBL Data Library, September 1989		Submitted to the EMBL Data Library, September 1989	Submitted to the EMBL Data Library, September 1989
	A;Reference number: S08106		A;Reference number: S08106	A;Reference number: S08106
	A;Accession: S08106		A;Accession: S08106	A;Accession: S08106
	A;Molecule type: mRNA		A;Molecule type: mRNA	A;Molecule type: mRNA
	A;Cross-references: 5-319, 321-702 <O12>		A;Cross-references: 5-319, 321-702 <O12>	A;Cross-references: 5-319, 321-702 <O12>
	R;Barnett, T.		R;Barnett, T.	R;Barnett, T.
	Submitted to the EMBL Data Library, September 1991		Submitted to the EMBL Data Library, September 1991	Submitted to the EMBL Data Library, September 1991
	A;Reference number: S31737		A;Reference number: S31737	A;Reference number: S31737

EGRIT

b
661 ATGRNNNSIVKSIITVSAGTSPGLSAGATVGIMIGVILGVALLI 70

GUL FUSSLISGJAHNLDSCHASNSPFRKWSRKGJFOQHQUVLFARLIFNINGJIAFLVSNU GUL

601 PDSSVLGANLNLSCEASNSPQSKWRRINGIPQQHTQLVFKITPNNGTACFVSNL
666
601 POSSV-SGANTSPHSASNSPOYSPR TNGTPOOMTFAKTPNNNGTACFVSNL 666

b
541 LPVSPLQLSNGNRTLTLEVNTRNDARAVGCGIONWSANRSDPVTLDVLYGPDTPISP 600

b
481 NSASGHSSRTVVKITVASSALPKPSISSNSKVEDPAVAFCTCEPAAQNTLYWNGOS 546
541 LPVSIRLQLSNGNRNTTLENTNDRARAYVGIONSIANSNSDPVTLVYGDTPPISP 600

481 NSASCHSRRTVKTITVSAELDKPSLSSNNNSPVEDKDAVFTCEPEAQNTTYWAVANGOS 546

y
 421 SPSYYWYRPGVNLISCHAANSPPAQYSWILDGNITQQTQERFISNTTEKNSGUTCQAN 480
 b
 421 SPSYYWYRPGVNLISCHAANSPPAQYSWILDGNITQQTQERFISNTTEKNSGUYTCQAN 480

361 QSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIONELSVHDSPVILNVLYGPDDPRI 426

b
301 ÅHNSITGLNITIVTIVTIVYAEPPKPTITSNNSNPVEEDAVALTCEB1QNTTYLWWNN 360
361 QSLPVSPRLQSNDRRTLTLSVTRNDVGPGCIGIONEBSVHDSDP1LNLVYGPDDPTI 420

301 AHNSDTGLNRFTVPTITVVAEPPKPRITSNNNSNPVEDDAVALTCERBIONTYLWWTNN 366

Y
b
241 TISPNNTSRSGENINLSCSCHAASNPQSYFNGPQQSTOBFLINTVNSGTYCQ 300
241 TISPNNTSYSGENINLSCSCHAASNPQSYFNGTQOSTOBFLINTVNSGTYCQ 300

b 181 NNQSLPLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCTQNPPSARRSSVLNLVLYGPDAP 240

b
121 TLHVTKSDLVNEBEATGQFRVYPELPKESISSNNSPVEDKDAVFTCEPETODATLYMV
180
181 NNQSIPVSPIQLSNGNRTLTFLNVTRNDTASYCETQNQPVASRRSISVLNLVYGDPA 24

121 TLHVIKSILVNEATGQFRVYPELPKPSISSNNSPVEDKAVAFTCBEPETQDATLYMWV 186

61	HLRGFSWYKGERVUDGRNQIGVIGVQATGGPAXGREIYPNASLLIONTNDTSPY	120
61	HLFGFSWYKGERVUDGRNQIGVIGVQATGGPAXGREIYPNASLLIONTNDTSPY	120

1 MESFSAPPHRWCIPWQRLLTASLTLFWNPPTAKTITIESTPPFNVAGKEVLLVHNLPQ 60

A;Title: Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAe
A;Reference number: A92752; MUID:89139550; PMID:2537311
A;Molecule type: mRNA
A;Residues: I-526 <BAR1>
A;Cross-references: UNIPARC:UPI000127483; EMBL:X16354; NID:937197; PIDN:CAA34404.1; PID
A;Experimental source: splice form a
A;Accession: B30127
A;Molecule type: mRNA
A;Residues: I-319, 'D', 417-526 <BAR2>
A;Cross-references: UNIPARC:UPI0000373D2E; EMBL:X14831; NID:937199; PIDN:CAA32940.1; PID
A;Experimental source: splice form b
R;Barnett, T.R.; Drake, L.; Pickle II, W.
Mol. Cell. Biol. 13, 1273-1282, 1993
A;Title: Human biliary glycoprotein gene: characterization of a family of novel alternat
A;Reference number: A48078; MUID:93140765; PMID:8423792
A;Accession: A48078
A;Molecule type: mRNA
A;Residues: 124-141, 'H', 417-526 <BAR3>
A;Cross-references: UNIPARC:UPI000173868; GB:M76742; NID:9179480; PIDN:AAA57142.1; PID:
A;Experimental source: splice form x
A;Note: sequence extracted from NCBN backbone (NCBIN:123602, NCBIPI:123606)
A;Note: neither the complete nucleic acid sequence nor the complete translation are show
R;Hauck, 'W.'; Nadellec, 'P.'; Turpide, 'C.'; Stanners, 'C.'; Barnett, T.R.; Beauchemin, N.
Eur. J. Biochem. 223, 529-541, 1994
A;Title: Transcriptional control of the human biliary glycoprotein gene, a CEA gene fami
A;Reference number: S45664; MUID:94333343; PMID:8055923
A;Accession: S45664
A;Molecule type: DNA
A;Residues: 1-21 <HAU>
A;Cross-references: UNIPARC:UPI00006E9AC; EMBL:X67277; NID:929447; PIDN:CAA47694.1; PID
R;Nadellec, 'P.'; Turpide, 'C.'; Beauchemin, N.
Eur. J. Biochem. 231, 104-114, 1995
A;Title: Characterization and transcriptional activity of the mouse biliary glycoprotein
A;Reference number: S65939; MUID:95354678; PMID:768460
A;Accession: S65939
A;Status: preliminary; translation not shown
A;Molecule type: DNA
A;Residues: 1-21 <NEO>
A;Cross-references: UNIPARC:UPI00006E9AC; EMBL:X67277; NID:929447; PIDN:CAA47694.1; PID
A;Note: only a part of the coding sequence is given
R;Kraan, W.N.; Fraengsby, L.; Teglund, S.; Israelsson, A.; Bremer, K.; Hammarstrom, S.
Genomics 14, 384-390, 1992
A;Title: Identification of three new genes and estimation of the size of the carcinoembr
A;Reference number: A44476; MUID:93052339; PMID:1427854
A;Comments: annotation; alignment of related sequences
C;Genetics:
A;Gene: GDB:BGP
A;Cross-references: GDB:127992; OMIM:109770
A;Map position: 19q13.2-19q13.2
C;Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-terminal
C;Keywords: alternative splicing; glycoprotein; surface antigen; transmembrane protein
F;1-138/domain: carcinoembryonic antigen precursor amino-terminal homology <CEAN>
F;1-134/Domain: signal sequence #status predicted <SIG>
F;35-526/Product: biliary glycoprotein 1, splice form a #status predicted <NATA>
F;35-526/Domain: extracellular #status predicted <BXT>
F;35-319, 'D', 417-526/Product: biliary glycoprotein 1, splice form b #status predicted <M
F;35-319, 'H', 417-526/Product: biliary glycoprotein 1, splice form x #status predicted <M
F;150-217/Domain: immunoglobulin homology <IMM1>
F;222-301/Domain: immunoglobulin homology <IMM2>
F;31-349/Domain: immunoglobulin homology <IMM3>
F;45-526/Domain: transmembrane #status predicted <TMM>
F;453-526/Domain: intracellular #status predicted <INT>
F;104, 111, 115, 152, 182, 197, 208, 224, 232, 24, 274, 288, 292, 302, 309, 345, 351, 363, 378, 405, 475/Bi

Db 5 SAPLIRVVRPWQGLILITASLTFFWMNPPTAQTLTSEMPNVAEGKVLVLIHNLPOQLFG 64
Qy 65 YSWYKGERVTDGNRNLIGVIGTQQTGPGAVSGRHEIYPAULIQNIIQNDTGTYLHV 124
Db 65 YSWYKGERVTDGNRNLIGVIGTQQTGPGAVSGRHEIYPAULIQNIIQNDTGTYLHV 124
Db 125 IKSIVNEEBATGQFTRVLPKPSISSNNSKPVEDKDAVAFATCPEBTODAYLWVNNSQ 184
Db 185 LPVSPLQLSNGNRLITLUSVTRNDTGPANSRETTIVENASLJLQNTDGTQYTLQV 184
Qy 185 LPVSPLQLSNGNRLITLUSVTRNDTGPANSRETTIVENASLJLQNTDGTQYTLQV 184
Db 245 LNTSYRSGENLNSCHAASNPQAQSWMFNGTRQOSTQSLPILPITVNVNSGSYCAHNS 304
Db 245 SDTYVPGANTLSISCYAASNPPAQSYWSLINGTFOQSTQFLPITVNTNSGSYCAHNS 304
Qy 305 DTGLARTTVTTVYAEPP---KPFITSNNSNPVEDEADAVALTCEPEIQTYYWWVNNQ 361
Db 305 VTGCNRTWTKTIVTEBLSPWAKEQPKASKTIVGDKDSVNLTCSTNDGICSIWVPPKNO 364
Qy 362 SLPPSPRLQLSNDNRTTLLSVTRNDVGSYEGCIONELSVDHSDPPVILWLYG---PDDP 419
Db 365 SLPSSEBRMLKLSQSGNTLTSINPVREDAGIYWCVEVFNPKNSQSDPIMLVNNALPOENG 424
Qy 420 ISSYYTYRPGWLSLSCHAASNPQAQSWSLIDG---NIQOQHQLFISNITEK 470
Db 425 LSRCAI--AGIVIGVVALVALAWALCAFPLHFRGKTGRASDORDLITERHPS--VSNHQD 479
Qy 471 NSGLYTQANNSSASGHSRTVKITIVSABLPKPSISSNN 510
Db 480 HS-----NDPNPKMNSEVTYSTLNFEAQOPTSAPS 512

RESNUt 3

C30127 transmembrane carcinoembryonic antigen 3 precursor - human
N;Alternate names: CD66 splice form BGPC

C;Species: Homo sapiens (man)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004

C;Accession: C30127; 152597
R;Barnett, T.R.; Krebschmer, A.; Austen, D.A.; Goebel, S.J.; Hart, J.T.; Blting, J.J.
J. Cell. Biol. 108, 267-276, 1989

A;Title: Carcinoembryonic antigens: alternative splicing accounts for the multiple n
A;Reference number: A92752; MUID:89139550; PMID:2537311
A;Accession: C30127
A;Molecule type: mRNA
A;Residues: 1-464 <BAR>

A;Cross-references: UNIPROT:Q16170; UNIPARC:UPI000072309; EMBL:X16356; EMBL:X14784|
R;Watt, S.M.; Fawcett, J.; Murdoch, S.J.; Teixeira, A.M.; Schmeisser, S.E.; Hajib.
Blood 84, 200-210, 1994

A;Title: CD66 identifies the biliary glycoprotein (BGP) adhesion molecule: cloning,
A;Reference number: 152597; MUID:9489702; PMID:8018919
A;Accession: 152597
A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA
A;Cross-references: UNIPARC:UPI000072309; GB:S71326; NID:9550030; PIDN:AAB31183.1
A;Cross-references: UNIPARC:UPI000072309; GB:S71326; NID:9550030; PIDN:AAB31183.1
C;Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-terminal
C;Keywords: alternative splicing; glycoprotein; surface antigen; transmembrane protein
F;1-138/Domain: carcinoembryonic antigen precursor amino-terminal homology <CEAN>
F;1-34/Domain: signal sequence #status predicted <SIG>
F;35-464/Product: transmembrane carcinoembryonic antigen 3 #status predicted <MAT>
F;160-217/Domain: immunoglobulin homology <IMM1>
F;341-398/Domain: immunoglobulin homology <IMM3>
F;424-455/Domain: transmembrane #status predicted <TMM>
F;104, 111, 115, 152, 182, 197, 208, 224, 232, 254, 274, 288, 292, 302, 309, 345, 351, 363, 378, 405/1

Query Match Similarity 43.2%; Score 1609; DB 1; Length 526;
Best Local Similarity 62.7%; Pred. No. 3.7e-80;
Matches 325; Conservative 47; Mismatches 121; Indels 26; Gaps 6;

Query Match Similarity 43.0%; Score 1600.5; DB 2; Length 464;
Best Local Similarity 73.0%; Pred. No. 9.1e-80;
Matches 309; Conservative 30; Mismatches 79; Indels 5; Gaps 2;

QY	5 SAPPARWCTPWWRLTASLTFWNPPTAKTIESPPNPAEGKEVLLVHLNPLQLFG 64
Db	5 SAPLRRVRVPQMOGLITASLTFWNPPTAQTLITESMFPNVPAEGKEVLLVHLNPLQLFG 64
QY	65 YSWYKGGERVGNGRNQIGQYVQGPGAVPSGRERIYPNAILIONIQDGTGYLHV 124
Db	65 YSWYKGGERVGNGRNQIGQYVQGPGAVPSGRERIYPNAILIONIQDGTGYLHV 124
QY	125 IKSDJYNEATGQFRTYPELPKPSISSNNPSKVEDDAVATCEPETQDATYLWVWNQS 184
Db	125 IKSDJYNEATGQFRTYPELPKPSISSNNPSKVEDDAVATCEPETQDATYLWVWNQS 184
QY	125 LNTSYRSGENLNUUCHAASNPAQYSWVNGTQOSTQBLPIINTVNNSGSTCQAHNS 304
Db	125 LNTSYRSGENLNUUCHAASNPAQYSWVNGTQOSTQBLPIINTVNNSGSTCQAHNS 304
QY	185 LPVSPLQLSNGNRITLTSVTRNDGTYPELPKPSISSNNPSKVEDDAVATCEPETQDTYLWVWNQS 244
Db	185 LPVSPLQLSNGNRITLTSVTRNDGTYPELPKPSISSNNPSKVEDDAVATCEPETQDTYLWVWNQS 244
QY	245 LNTSRSGENLNUUCHAASNPAQYSWVNGTQOSTQBLPIINTVNNSGSTCQAHNS 304
Db	245 LNTSRSGENLNUUCHAASNPAQYSWVNGTQOSTQBLPIINTVNNSGSTCQAHNS 304
QY	305 DTGLNRTVTITIVAEPP--KPFITSNNSPNVEDDAVATCEPETQDATYLWVWNQS 361
Db	305 VTGCRRTTVKVLIVTELSPVAKPKASKTTGKDSVNLTCSTNDTGISIRWFHQ 364
QY	362 SLPVSPRQLQSNDRNRLTILSVTRNDGVPGYCGQNLBSVHSDPVLVLYG--DDPT 419
Db	362 SLPVSPRQLQSNDRNRLTILSVTRNDGVPGYCGQNLBSVHSDPVLVLYG--DDPT 419
QY	365 SLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFNPISKNSODPIMLNVNALPOENG 424
Db	365 SLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFNPISKNSODPIMLNVNALPOENG 424
QY	420 ISP 422
Db	420 ISP 422
QY	425 SDTYYRGPANLSCYAAASNPPAQYSWVNGTQOSTQBLPIINTVNNSGSTCQAHNS 304
Db	425 SDTYYRGPANLSCYAAASNPPAQYSWVNGTQOSTQBLPIINTVNNSGSTCQAHNS 304
RESULT 4	A28333
C:Species:	Homo sapiens (man)
C:Accession:	JH0394
R:Kuroki, M.; Arakawa, F.; Matsuo, Y.; Nakazato, H.; Matsuoka, Y.	
A:Title:	Three novel molecular forms of biliary glycoprotein deduced from cDNA clones for reference number: JH0394; MVID:9122218; PMID:2025273
A:Residues:	1-417 <RUR>
A:Cross-references:	UNIPROT:PI3688; UNIPARC:UPI00002A624; GB:MT2238; NID:9179436; PIDN: F:115-164/Domain: immunoglobulin homology <IMM2> F:2001-258/Domain: immunoglobulin homology <IMM3>
C:Comment:	Biliary glycoproteins belong to the carcinoembryonic antigen gene family.
C:Superfamily:	carcinoembryonic antigen; carcinoembryonic antigen precursor amino-terminal
C:Keywords:	Glycoprotein; transmembrane protein
F:1-138/Domain:	carcinoembryonic antigen precursor amino-terminal homology <CEAN>
F:1-34/Domain:	signal sequence #status predicted <SIG>
F:35-383/Domain:	biliary glycoprotein 9 #status predicted <MAT>
F:160-217/Domain:	immunoglobulin homology <IMM1>
F:252-317/Domain:	immunoglobulin homology <IMM2>
F:341-398/Domain:	immunoglobulin homology <IMM3>
Query Match	39.5%; Score 1470; DB 2; Length 286;
Best Local Similarity	98.6%; Pred. No. 5.8e-73;
Matches	276; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Db	322 PPKFITSNNSPNVEDDAVATCEPETQDATYLWVWNQS 381
QY	382 SVTRNDGVPGYEGCGQNLBSVHSDPVLVLYGDDPTIPSYYTYPGVNLSLCHAAS 441
Db	67 SVTRNDGVPGYEGCGQNLBSVHSDPVLVLYGDDPTIPSYYTYPGVNLSLCHAAS 126
QY	442 NPPAQYSWLDGNIQHQTQELFISNIKEGNGLYTQOANSASGRSRITWKTIVSAELP 501
Db	127 NPPAQYSWLDGNIQHQTQELFISNIKEGNGLYTQOANSASGRSRITWKTIVSAELP 186
QY	502 KPSISSNNPSKVEDDAVATCEPAQNTYLWVNGQSLPVSPRQLQSLNSGNRITLFWV 561
Db	187 KPSISSNNPSKVEDDAVATCEPAQNTYLWVNGQSLPVSPRQLQSLNSGNRITLFWV 246
QY	562 TRNDARAYGCGIONSVSANSRDPVTDLVYGPDPPISP 601
Db	247 TRNDARAYGCGIONSVSANSRDPVTDLVYGPDPPISP 286
Query Match	42.7%; Score 1589.5; DB 2; Length 417;
Best Local Similarity	74.4%; Pred. No. 3.1e-79;
Matches	305; Conservative 28; Mismatches 74; Indels 3; Gaps 1;
RESULT 6	A27681
nonspecific cross-reacting antigen precursor - human	
N:Alternative names:	NCA; TEX/NCA
C:Species:	Homo sapiens (man)
C:Accession:	J31-Mar-1989 #sequence_revision 16-Sep-1992 #text_change 09-Jul-2004
R:Oikawa, S.; Kosaki, G.; Nakazato, H.	
Biochem. Biophys. Res. Commun. 146, 464-469, 1987	
A:Title:	Molecular cloning of a gene for a member of carcinoembryonic antigen (CEA) gene

A;Reference number: A26902; MUID:87298464; PMID:3619891
A;Accession: A26902
A;Molecule type: DNA
A;Residues: 1-141 <OIK>
A;Cross-references: UNIPROT:Q13774; UNIPARC:UPI000072416; GB:M17082; NID:9180230; PIDN:
R;Thompson, J.A.; Pandé, H.; Paxton, R.J.; Shively, L.; Padma, A.; Simmer, R.L.; Todd, C.
Proc. Natl. Acad. Sci. U.S.A. 84, 2265-2269, 1987
A;Title: Molecular cloning of a gene belonging to the carcinoembryonic antigen gene family
A;Reference number: A29875; MUID:87204248; PMID:3033672
A;Accession: A29875
A;Molecule type: DNA
A;Residues: 23-141 <THO>
A;Cross-references: UNIPARC:UPI000177070; GB:M16337
A;Note: the authors translated the codon ACT for residue 64 as Tyr
R;Tawaragi, Y.; Oikawa, S.; Matsuo, Y.; Kosaki, G.; Nakazato, H.
Biophys. Res. Commun. 15, 89-96, 1988
A;Title: Primary structure of nonspecific cross-reacting antigen (NCA), a member of carcinoembryonic antigen family: characterization of cDNAs coding for NCA and C-glycoprotein
A;Reference number: A31037; MUID:89122014; PMID:3220478
A;Accession: A31037
A;Molecule type: mRNA
A;Residues: 1-137, 'L', 119-344 <BAR>
A;Cross-references: UNIPARC:UPI00016ADC6; GB:M29541; NID:9189103; PIDN:AA59915_1; PID:
R;Neumaier, M.; Zimmermann, W.; Shively, L.; Hinoda, Y.; Riggs, A.D.; Shively, J.E.
J. Biol. Chem. 263, 32203-32207, 1988
A;Title: Characterization of a cDNA clone for the nonspecific cross-reacting antigen (NCA)
A;Reference number: A29918; MUID:88139389; PMID:2830274
A;Accession: A29918
A;Molecule type: mRNA
A;Residues: 1-344 <NEU>
A;Cross-references: UNIPARC:UPI00006DF42; GB:M18216; GB:J03550; NID:9178690; PIDN:AA51
R;Gunerl, F.; Kolbinger, F.; Schwarz, K.; Schwaibold, H.; von Kleist, S.
Biochem. Biophys. Res. Commun. 153, 1105-1115, 1988
A;Title: Protein analysis of NCA 50 shows identity to NCA cDNA deduced sequences and indicates a reference number: A27709; MUID:88268882; PMID:3390172
A;Accession: A27709
A;Molecule type: protein
A;Residues: 35-95,99-120,123-138,149-151,'X',153-162,166,'X',168-172,'X',174-193,231-235
A;Cross-references: UNIPARC:UPI0000177071; UNIPARC:UPI0000177072; UNIPARC:UPI0000177073;
R;Hafsa, S.A.; Paxton, R.J.; Shively, J.B.
J. Biol. Chem. 265, 8618-8626, 1990
A;Title: Sequence and glycosylation site identity of two distinct glycoforms of non-specific reference number: A36271; MUID:9256782; PMID:2341397
A;Accession: A36271
A;Molecule type: protein
A;Residues: 35-42,44-53,55-80,83-134,139-160,166-172,174-180,191-194,204-224,233-308,310
A;Cross-references: UNIPARC:UPI000017707B; UNIPARC:UPI000017707C; UNIPARC:UPI000017707D;
082; UNIPARC:UPI00017703; UNIPARC:UPI0000177084
R;Paxton, R.J.; Mooser, G.; Pandé, H.; Lee, T.D.; Shively, J.B.
Proc. Natl. Acad. Sci. U.S.A. 84, 920-924, 1987
A;Title: Sequence analysis of carcinoembryonic antigen: identification of glycoylation
A;Reference number: A26414; MUID:87147209; PMID:3469650
A;Accession: C26414
A;Molecule type: protein
A;Residues: 35-69 <PAX>
A;Cross-references: UNIPARC:UPI0000177085
A;Accession: R;Khan, W.N.; Fraenzen, L.; Teglund, S.; Israelsson, A.; Bremer, K.; Hammarstrom, S.
Genomics 14, 384-390, 1992
A;Title: Identification of three new genes and estimation of the size of the carcinoembryonic antigen gene family
A;Reference number: A44476; MUID:93052319; PMID:1427854
A;Accession: Ba476
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 35-141 <KHA>

RESULT 7
JH0396
biliary glycoprotein i precursor - human
C;Species: Homo Sapiens (man)
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 09-Jul-2004
C;Accession: JH0396
R;Kuroki, M.; Arakawa, F.; Matsuo, Y.; Oikawa, S.; Nakazato, H.; Matsuo, Y.
Biophys. Res. Commun. 176, 578-585, 1991
A;Title: Three novel molecular forms of biliary glycoprotein deduced from cDNA clones
A;Reference number: JH0394; MUID:9122218; PMID:2025273
A;Accession: JH0396
A;Molecule type: mRNA
A;Residues: 1-351 <KUR>
A;Cross-references: UNIPROT:P13688; UNIPARC:UPI00002A626; GB:M72238; NID:9179436; 1
A;Experimental source: leukocyte
C;Comment: Biliary glycoproteins belong to the carcinoembryonic antigen gene family
C;Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-terminal homology <CEAN>
F;1-138/Domain: carcinoembryonic antigen precursor amino-terminal homology <CEAN>

RESULT 10

Db 125 IKUNLMSHETVGTGOPSVHFPKISSNNNSNPVEDKDAVAFTCPEPOTWVLLWWVNGQS 184
 Qy 185 LPVSPIRQLQSLNSNRNLTFLFNTVTRNDTASYCETONPYSARRSDSVILVLYGPDAPTSP 244
 Db 185 LFVSPRLQLQSLNSNRNLTFLFNTVTRNDVGPCECETONPASANFSDPVTWVLYGPDAPTSP 244
 Qy 245 LNTSYRSGENLNSCHASASNPPAQYSWVNGTFFQOSTQELFNPNTVNNSGTYTCQAHNS 304
 Db 245 SDTYYHAGVNLSCHASASNPPSQYSWVNGTFFQYQTLKFLPNITTONSGYACHTINS 304
 Qy 305 DTGLNRTVTTVTV 318
 Db 305 ATGRNRTTVRMIV 318

P;347-396-/Domain: immunoglobulin homology <IMM1>
 F;104,111,268,303/Binding site: carbohydrate (Asn) (covalent) #status predicted
 Query Match 31.1%; Score 1157.5; DB 2; Length 428;
 Best Local Similarity 47.8%; Pred. No. 8.7e-56; Pred. No. 8.7e-56;
 Matches 237; Conservative 51; Mismatches 121; Indels 87; Gaps 3;
 C;Species: Homo sapiens (man)
 C;Date: 31-Mar-1992 #sequence revision 31-Mar-1992 #text_change 09-Jul-2004
 C;Accession: J5032; PS0308; A22719; C35341; B34647; A35334
 R;Rooney, B.C.; Horne, C.H.W.; Hardman, N.
 Gene 71, 439-449, 1988
 A;Title: Molecular cloning of a cDNA for human pregnancy-specific beta 1-glycoprotein: Human
 A;Reference number: J5032; MUID:89138020; PMID:3265688
 A;Molecule type: mRNA
 A;Residues: 1-228 <R00>
 A;Accession: P50308
 A;Molecule type: protein
 A;Residues: 50-69;99-113;160-167;210-216;266-275;337-344 <R02>
 A;Cross-references: UNIPARC:UPI0001770A1; UNIPARC:UPI0001770A2; UNIPARC:UPI0001770A3;
 R;Streydio, C.; Swillens, S.; Georges, M.; Szpirer, C.; Vassart, G.
 A;Title: Structure, evolution and chromosomal localization of the human pregnancy-specific
 A;Reference number: A32719; MUID:90256167; PMID:2341148
 A;Accession: A32719
 A;Molecule type: mRNA
 A;Residues: 1-228 <STR>
 A;Cross-references: UNIPARC:UPI00002D1C2;
 R;Zoubir, F.; Khan, W.N.; Hammarstrom, S.
 Biochem. Biophys. Res. Commun. 169, 203-216, 1990
 A;Title: Carcinoembryonic antigen gene family members in submandibular salivary gland: differential
 A;Reference number: A35341; MUID:90274668; PMID:2350345
 A;Accession: C35341
 A;Molecule type: mRNA
 A;Residues: 1-428 <COU>
 A;Cross-references: UNIPARC:UPI00002D1C2; GB:M37399; NID:9180234; PID:AA160958; 1; PID:
 A;Note: the sequence shown differs from the translation of the nucleotide shown in the
 R;Borjigin, J.; Tease, L.A.; Barnes, W.; Chan, W.Y.
 Biochem. Biophys. Res. Commun. 166, 622-629, 1990
 A;Title: Expression of the pregnancy-specific beta 1-glycoprotein genes in human testis.
 A;Reference number: A34647; MUID:90147764; PMID:2302228
 A;Accession: B34647
 A;Molecule type: mRNA
 A;Residues: 23-329;384-428 <BOR>
 A;Cross-references: UNIPARC:UPI00001770A7; UNIPARC:UPI00001770A8
 C;Comment: This protein plays an essential role in normal pregnancy. It is a well-characterized protein.
 C;Genetics:
 A;Gene: GDB:PG33
 A;Cross-references: GDB:128239; OMIM:176392
 C;Superfamily: carcinoembryonic antigen precursor amino-terminal repeat
 C;Map Position: 19q13.2-19q13.2
 C;Keywords: glycoprotein
 F;1-138/Domain: carcinoembryonic antigen precursor amino-terminal homology <CEAN>
 F;1-34/Domain: signal sequence #status predicted <SIG>
 F;35-428/Product: pregnancy-specific glycoprotein 7a #status predicted <MAT>
 F;162-219/Region: cell attachment (R-G-D) motif
 F;255-312/Domain: immunoglobulin homology <IMM1>
 F;255-312/Domain: immunoglobulin homology <IMM2>

RESULT 11

JC4123
 P;347-396-/Domain: immunoglobulin homology <IMM1>
 F;104,111,268,303/Binding site: carbohydrate (Asn) (covalent) #status predicted
 Query Match 31.1%; Score 1157.5; DB 2; Length 428;
 Best Local Similarity 47.8%; Pred. No. 8.7e-56; Pred. No. 8.7e-56;
 Matches 237; Conservative 51; Mismatches 121; Indels 87; Gaps 3;
 C;Species: Homo sapiens (man)
 C;Date: 26-Jul-1995 #sequence_revision 19-Oct-1995 #text_change 09-Jul-2004
 C;Accession: JC4123
 R;Teglind, S.; Zhou, G.O.; Hammarstrom, S.
 Biochem. Biophys. Res. Commun. 211, 656-664, 1995
 A;Title: Characterization of cDNA encoding novel pregnancy-specific glycoprotein variants
 A;Reference number: JC4121; MUID:95314639; PMID:7794280
 A;Accession: JC4123
 A;Molecule type: mRNA
 A;Residues: 1-419 <TEG>
 A;Cross-references: UNIPROT:Q13046; UNIPARC:UPI0001327A2; GB:U18467; NID:9609313; PI: P13046
 A;Experimental source: fetal liver
 C;Comment: This protein belongs to the carcinoembryonic antigen family. This protein is a well-characterized protein.
 C;Genetics:
 A;Gene: GDB:PG37
 A;Cross-references: GDB:128241; OMIM:176396
 A;Map position: 19q13.2-19q13.2
 C;Superfamily: carcinoembryonic antigen precursor amino-terminal repeat
 C;Keywords: glycoprotein
 F;1-138/Domain: carcinoembryonic antigen precursor amino-terminal homology <CEAN>
 F;1-34/Domain: signal sequence #status predicted <SIG>
 F;35-428/Product: pregnancy-specific glycoprotein 7a #status predicted <MAT>
 F;127-129/Region: cell attachment (R-G-D) motif
 F;255-312/Domain: immunoglobulin homology <IMM1>
 F;255-312/Domain: immunoglobulin homology <IMM2>

F;347-396/Domain: immunoglobulin homology <IMM3>
F;61,104,111,199,209,268,303/Binding site: carbohydrate (Asn) (covalent) #status predict
Query Match 30.9%; Score 1148.5; DB 2; Length 419;
Best Local Similarity 48.1%; Pred. No. 2.6e-55; Mismatches 123; Indels 87; Gaps 3;
Matches 238; Conservative

QY 5 SAPPHRCIPWQOLLITASLITFNPPATAKLTTESTPFWVAEGKEVILLVHLNLPQHFG 64
Db 5 SAPPCQHTWKQMLLTASLNFPPTAQTIVTEAQPKVSQSGKDVLVHLNLPQHFG 64
QY 65 YSWYKGERUDGNRQIIGVIGTOQATPGPAYSREITYPNASLLIONTQNDGFTYHV 124
Db 65 YIWYKGQIRDLYHVTSVVDGQIKYGPAYSREITYPNASLLIONTQEDGSYTHI 124
QY 125 IKSDLVNEBATGQ--FRVYPELPKPSISSNNSPVEDKDAVFTCEBETQDAYLWNN 182
Db 125 IKRGDGDRGETSHTFTFLLETPKPSISSNNSPVEDKDAVFTCEBETQDAYLWNN 184
QY 183 QSLPVSPRLQLSGNRTTLFNTRNTDASYKCTQPVSAARRSDSVILNVLYGPDAPI 242
Db 185 QSLPMTHSLQLSQNKRAFLFLGTVKXAGPVCIEIRNPVSAASRSDPVTNLN---- 236
QY 243 SPLNTSYSGENLNLSCHAASNPQAQYSWFGNGTFOQSTOELFIPNITVNNSGYTCQAH 302
Db 243 SPLNTSYSGENLNLSCHAASNPQAQYSWFGNGTFOQSTOELFIPNITVNNSGYTCQAH 302
QY 237 -----PKL----- 237
Db 237 -----PKL----- 239
QY 303 NSDTGLNRITVTTIVVAEPPKPFITSNNSPVEDDAVLTCEPEQNTYLWNNQS 362
Db 303 NSDTGLNRITVTTIVVAEPPKPFITSNNSPVEDDAVLTCEPEQNTYLWNNQS 362
QY 363 LPSPRLQLSNDNRTTLISVTRNDQPYECGIONELSDVHDSPVILNLYGPDDPISP 422
Db 363 LPSPRLQLSNDNRTTLISVTRNDQPYECGIONELSDVHDSPVILNLYGPDDPISP 422
QY 280 LPVSPRVRKRIENRILPLPSVTRNETGPYCEBIRDYSGCRSPDVPLVNLGYDPLPRVY 339
Db 280 LPVSPRVRKRIENRILPLPSVTRNETGPYCEBIRDYSGCRSPDVPLVNLGYDPLPRVY 339
QY 423 SYTYRPGVNLISCHASNPQAQYSWFGNGTFOQSTOELFIPNITVNNSGYTCQANS 482
Db 423 SYTYRPGVNLISCHASNPQAQYSWFGNGTFOQSTOELFIPNITVNNSGYTCQANS 482
QY 340 SFTYHHSGENLYLSCFADSNNPAPAEYSTINGKQLSQKLFIPQITKHSGLYACSVRS 399
Db 340 SFTYHHSGENLYLSCFADSNNPAPAEYSTINGKQLSQKLFIPQITKHSGLYACSVRS 399
QY 483 ASHSRTRVKTIVS 497
Db 483 ASHSRTRVKTIVS 497
QY 400 ATGKESSKVTVRS 414
Db 400 ATGKESSKVTVRS 414

RESULT 12

157486 pregnancy-specific beta 1-glycoprotein - human
C;Species: Homo sapiens (man)
C;Accession: 157486
R;Shupert, W.L.; Chan, W.Y.
Mol. Cell. Biochem. 120, 159-170, 1993
A;Title: Pregnancy specific beta-1-glycoprotein in human intestine.
A;Reference number: 157486; MUID:93234418; PMID:8487756
A;Accession: 157486
A;Status: preliminary; translated from GB/EMBL/DDJB
A;Molecule type: mRNA
A;Residues: 1-428 <STR>
A;Cross-references: UNIPARC:UPI0000073DC1; GB:MI19662
C;Superfamily: carnoembryonic antigen; carnoembryonic antigen precursor amino-terminal homology <CEAN>
C;Keywords: glycoprotein
F;1-138/Domain: carnoembryonic antigen precursor amino-terminal homology <IMM1>
F;1-34/Domain: signal sequence #status predicted <SIG>
F;35-428/Product: pregnancy-specific beta-1 glycoprotein C #status predicted <MAT>
F;162-219/Domain: immunoglobulin homology <IMM2>
F;255-312/Domain: immunoglobulin homology <IMM2>
F;347-396/Domain: immunoglobulin homology <IMM3>
A;Reference number: A27658; MUID:8828076; PMID:3200773
A;Accession: A27658
A;Molecule type: mRNA
A;Residues: 1-428 <STR>
A;Cross-references: UNIPARC:UPI000006DBA43; GB:MI19662
C;Superfamily: carnoembryonic antigen; carnoembryonic antigen precursor amino-terminal homology <CEAN>
C;Keywords: glycoprotein
F;1-138/Domain: carnoembryonic antigen precursor amino-terminal homology <CEAN>
F;1-34/Domain: signal sequence #status predicted <SIG>
F;35-428/Product: pregnancy-specific beta-1 glycoprotein C #status predicted <MAT>
F;162-219/Domain: immunoglobulin homology <IMM2>
F;255-312/Domain: immunoglobulin homology <IMM2>
F;347-396/Domain: immunoglobulin homology <IMM3>
Query Match 30.5%; Score 1133.5; DB 2; Length 428;
Best Local Similarity 46.4%; Pred. No. 1.7e-54; Mismatches 131; Indels 87; Gaps 3;
Matches 237; Conservative

QY 1 MESPSAPPHRCIPWQOLLITASLITFNPPATAKLTTESTPFWVAEGKEVILLVHLNLPQ 60
Db 1 MESPSAPPHRCIPWQOLLITASLITFNPPATAKLTTESTPFWVAEGKEVILLVHLNLPQ 60
QY 61 HIFGYSWYKGERUDGNRQIIGVIGTOQATPGPAYSREITYPNASLLIONTQNDGFTY 120
Db 61 HIFGYSWYKGERUDGNRQIIGVIGTOQATPGPAYSREITYPNASLLIONTQNDGFTY 120
QY 179 WYNQSPVSPRLQLSGNRTTLFNTRNTDASYKCTQPVSAARRSDSVILNVLYGP 238
Db 179 WYNQSPVSPRLQLSGNRTTLFNTRNTDASYKCTQPVSAARRSDSVILNVLYGP 238

Db	181 WNGQSLPMTHSILKLSLTNRFLLGVTKYTAGPCBIRNPVSASRSDPVTNL---	Db	240 -----PIPYITNNLNPRENKDVLAFTCPEPKSENYYTWLNGSQL 280
Qy	239 APTISPLNTSYRSGENLNLSCHAASNPAPQISWFVNQTPQQSTQELFIPNITVNSGSY	Qy	364 PVSPLQLSNDRNTLILSVTRANDVGPYECGIONESVDHSDPVILNLVYGDPPSPS 423
Db	237 -----PKL-----	Db	281 PVSPGVPIERPIERILLPLSPVTRNETPQYCEFRDGGRLSPVILNLVYGDPLPRIPS 340
Qy	299 COAHNSDTGLNRTTVTIVYAEPPKPFITSNSNSNPVEDEDAVALTCPELEONTYLW 358	Qy	424 YTYVRPGVNLSSCHAASNPAPQYSWLDGNTQHOTELFSNITEKNGLYTCQANSA 483
Db	240 -----PKYITINLNPRENKDVLNFCTCPEPKSENYYTWL 275	Db	341 FTYRSSENLDISCFESNPAPAEYWFTWINGPQQSGOKLFIPQITRNHSGLYACSVHNSA 400
Qy	359 NNQSLPVSPRLQLSNDNRTLILSVTRENDVGPYEGCIONESEVDHSDPVILNLVYGDPP 418	Qy	484 SCHSRTRVKTIWSAELPKPSI 506
Db	276 NCQSLPVSPRVKPIERMLILSPVTRNETPQYCEFRDGGRLSPVILNLVYGDPL 335	Db	401 TCKEISKSMTVKVS-ETASPOVT 422
Qy	419 TISPSVYRPGVNLSSCHAASNPAPQYSWLDGNTQHOTELFSNITEKNGLYTCQ 478		
Db	336 RIYSPFVYRSGEVLYLSCADSNPAPQYSWLDGNTQHOTELFSNITEKNGLYTCQ 426		
RESULT 14			
B55181	pregnancy-specific beta-1-glycoprotein 11 form r precursor - human		
C;Species: Homo sapiens (man)			
C;Date: 23-Mar-1995 #sequence_revision 23-Mar-1995 #text_change 31-Oct-1997			
C;Accession: B55181			
R;McLeanachan, P.A.; Rutherford, K.J.; Bergs, K.T.; Sims, S.E.; Mansfield, B.C.			
Gemomics 22, 356-363, 1994			
A;Title: Characterization of the Psg11 gene.			
A;Reference number: A55181; MUID: 95104846; PMID: 7806221			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			
A;Geno: GDB: PSG1			
A;Cross-references: GDB:128242; OMIM:176398			
A;Accession: B55181			
A;Molecule type: DNA			
A;Residues: 1-436 <MCL>			
A;Cross-references: UNIPARC:UPI00001770AC; GB:U04324			

Db 181 WNGQSLRPMTHSLKLSERNTRFLIGTYKTAGPYECBIRNPVSAASRSDPVTNL--- 236
 Qy 239 APTISPLNTSYRSGENLNLSCHAASNPQAQYSWFNGFPOQSIQELFIPNITVNNSGSYT 298
 Db 237 ----- PKL----- 239
 Qy 299 CQAHNSDTGLNRRTVTTIVYAEPPKPEITSNNSNPVEDEAVALTCEPELONTYIWWV 358
 Db 240 ----- PKPYITINLNPRENKDVINFCTCBPKSENYTYIWVL 275
 Qy 359 NNOSLPSVPRLOISNDNRTLILSVTRNDVGPYECGIONELSVDHSUPVILNLYGRDDP 418
 Db 276 NGOSLPVSPRKPIENRILLPSVTRNTPYQCEFRDRYGGVRSPVTLVLYGDLP 335
 Qy 419 TISPSYYTYPGYNLISCHAAASNPPAQYSWLTDGNTQOHTBLFISNITEKNGLYTCQ 478
 Db 336 RIYPSFTYRSGEVLYLSCADSNNPPAQYSWINEKFOLPGQKLFIIRHITKGHSGLYVC 395
 Qy 479 ANNASHSRRTVKTTIVSAE 499
 Db 396 VRNSATGKESKSMTVEVSGK 416

Search completed: April 10, 2006, 18:07:34
 Job time : 42.1584 secs

GenCore version 5.1.7
 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 10, 2006, 17:55:34 ; Search time 237.861 Seconds
 (without alignments)

2082.225 Million cell updates/sec

Title: US-10-734-564-72
 Perfect score: 3721

Sequence: 1 MESPSPAPHRWCIPWORLIL.....LSAGATVGIMIGIVLVGVALL 702

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched:

2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt 05_80_*

1: uniprot_sprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	3721	100.0	702	1 CEAAMS_HUMAN
2	3717	99.9	702	2 QBN4D0_HUMAN
3	3713	99.8	702	2 Q53G30_HUMAN
4	2066	55.5	420	2 Q6BDM9_HUMAN
5	1609	43.3	526	1 CEAAMI_HUMAN
6	1600	43.0	464	2 Q16170_HUMAN
7	1600.5	43.0	468	2 Q86CA7_HUMAN
8	1526.5	41.0	525	2 Q8R9N6_PONY
9	1526.5	39.5	287	2 Q13984_HUMAN
10	1443	38.8	344	1 CEAAMG_HUMAN
11	1443	38.8	344	2 Q53XP7_HUMAN
12	1443	38.8	344	2 Q13774_HUMAN
13	1426.5	38.3	368	2 Q5UB49_HUMAN
14	1423	38.2	461	2 Q13854_HUMAN
15	1272	34.2	349	1 CRAMB_HUMAN
16	1194.5	32.1	373	2 Q7KPF5_HUMAN
17	1157.5	31.1	428	1 PSCS3_HUMAN
18	1148.5	30.9	419	1 PSGL1_HUMAN
19	1141.5	30.7	428	2 Q8BRW2_HUMAN
20	1140.5	30.7	426	1 PSCB_HUMAN
21	1134.5	30.5	419	2 Q8CR6_HUMAN
22	1127.5	30.3	426	2 Q5ICR4_HUMAN
23	1126.5	30.3	419	1 PSC1_HUMAN
24	1126.5	30.3	426	1 PSGL2_HUMAN
25	1125.5	30.2	426	2 Q8LEU7_HUMAN
26	1124.5	30.2	411	2 Q15228_HUMAN
27	1118.5	30.1	419	2 Q56QL5_HUMAN
28	1117.5	30.0	419	2 Q8FS20_HUMAN
29	1114.5	30.0	419	1 PSGL4_HUMAN
30	1107.5	29.8	435	1 PSGL6_HUMAN
31	1104	29.7	424	1 PSG10_HUMAN

ALIGNMENTS

32	1070.5	28.8	521	2 Q61352_MOUSE	Q61352 mus musculu
33	1065.5	28.6	458	2 Q61351_MOUSE	Q61351 mus musculu
34	1023.5	27.5	521	1 CEAAM1_MOUSE	P31809 mus musculu
35	1023.5	27.5	521	2 Q925P3_MOUSE	Q925P3 mus musculu
36	1018.5	27.4	454	2 Q91W54_MOUSE	Q91W54 mus musculu
37	998	26.8	520	2 Q925P2_MOUSE	Q925P2 mus musculu
38	992	26.7	459	2 Q9JFL6_RAT	Q9JFL6 rattus norv
39	983	26.4	458	2 Q63093_RAT	Q63093 rattus norv
40	980	26.3	448	2 Q9JHL7_RAT	Q9JHL7 rattus norv
41	970.5	26.1	519	1 CEAAM1_RAT	P16573 rattus norv
42	919	24.7	402	2 Q15227_HUMAN	Q15227 homo sapien
43	901.5	24.2	352	2 Q01266_HUMAN	Q01266 homo sapien
44	900.5	24.2	332	1 PSG11_HUMAN	Q8uq72 homo sapien
45	898	24.1			

OC OC
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
 OC OC
 Mammalia; Butheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 Homo
 NCBI_TaxID=9606;
 [1] RN
 NUCLEOTIDE SEQUENCE.
 RC
 TISSUE=Colon;
 RX
 MEDLINE2238557; PubMed1247932; DOI=10.1073/pnas.242603899;
 STRAUSBERG R. L., Feingold E.A., Grouse L.H., Derge J.G.,
 KLAUSER R.D., Collins F.S., Wagner L., Shemesh C.M., Schuler G.D.,
 ALTSCHEL S.F., Zeeberg B., Bustow K.H., Schaefer C.F., Bhat N.K.,
 HOPKINS R.F., Jordan H., Moore T., Max S.I., Wang J., Haile P.,
 DIATCENKO L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 STAPLETON M., Soares M.B., Bonaldo M.F., Cassavant T.L., Scheetz T.E.,
 BRONSTEIN M.J., Uedin T.B., Toshiriki S., Carninci P., Prange C.,
 RAHA S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulahy S.J.,
 BOEKER S.A., MCGRANAHAN P.J., McKERNAN K.J., Malek J.A., Guaratine P.H.,
 RICHARDS S., WORLEY K.C., HALE S., GARCIA E.J., GAY J.W., HULYK S.W.,
 VILLANO D.K., MUZNY D.M., SODERBERG E.J., LU X., GIBB R.A.,
 FAHEY J., HEITON E., KETTERMAN M., MADAN A., RODRIGUES S., SANCHEZ A.,
 WHITING M., MADAN A., YOUNG A.C., SHEVCHENKO Y., BOUFFARD G.G.,
 BLAKESLEY R.W., TOUCHMAN J.W., GREEN E.D., JACKSON M.C.,
 RODRIGUEZ A.C., GRIMWOOD J., SCHMIDT J., MYERS R.M.,
 BUTTERFIELD Y.S.N., KRZYZINSKI M.I., SKALSKA U., SMAILUS D.E.,
 SCHNEIDER A., SCHEIN J.B., JONES J.S.M., MARRA M.A.,
 "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
 [2] RN
 NUCLEOTIDE SEQUENCE.
 RP
 TISSUE=Colon;
 RA
 Serausberg R.;
 RL
 Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
 CC
 -1- SUBCELLULAR LOCATION TYPE I membrane protein (By similarity).
 EMBL: BC034671; AMH34671; 1; -, mRNA.
 HSSP: Q61355; 1_L6Z.
 ENSEMBL: ENSG00000105388; Homo sapiens.
 DR
 InterPro: IPR007110; Ig-like.
 DR
 InterPro: IPR003598; Ig_c2.
 DR
 Pfam: PF00047; ig; 6.
 DR
 SMART: SM00408; IgC2; 3.
 DR
 PROTEIN: PS50835; Ig_LIKE; 6.
 KW
 Immunoglobulin domain; Transmembrane.
 SEQUENCE 702 AA; 76782 MW; 97CCFB7399A0B05A CRC64;
 Query Match 99.9%; Score 3717; DB 2; Length 702;
 Best Local Similarity 99.9%; Pred. No. 1e-203;
 Matches 701; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY
 1 MESPSAPPHRWCIPMQRLILITASLITFWNPPTAKTIESTPFNVAGKEVLLVNLPLQ 60
 1 MESSAAPPRWCIPQRQLITASLITFWNPPTAKTIESTPFNVAGKEVLLVNLPLQ 60
 61 HLRGYSWYKGGERVQGNRQIIGYVIGVQAMPGPAGYSGRREIYTPNALLIONIQMTGFY 12
 61 HLRGYSWYKGGERVQGNRQIIGYVIGVQAMPGPAGYSGRREIYTPNALLIONIQMTGFY 12
 121 THAVIKSDLVNEATGQFRYPELPKPSISSNNNSPKEDKAVATCEPETQDAYLWWV 18
 121 THAVIKSDLVNEATGQFRYPELPKPSISSNNNSPKEDKAVATCEPETQDAYLWWV 18
 181 NNOSLSPVSPRLQLSNGNRITLFLNVTRNDTASYKCETONPVSAARNSDSVILVLYGPDAP 24
 181 NNOSLSPVSPRLQLSNGNRITLFLNVTRNDTASYKCETONPVSAARNSDSVILVLYGPDAP 24
 241 TISPLNTSFRGENLNLSCHAASNPQTSWFWGTCFOOTQELPQFNPITNNSSYTCO 30
 241 TISPLNTSFRGENLNLSCHAASNPQTSWFWGTCFOOTQELPQFNPITNNSSYTCO 30
 301 AHNSDTGLRRTVTITVVAEPPKRTITSNNSNPVEDDAVALTEPEIQTNTYIWMVN 36
 301 AHNSDTGLRRTVTITVVAEPPKRTITSNNSNPVEDDAVALTEPEIQTNTYIWMVN 36

QY 361 QSLPVSPRLQLSNDNRTLILSVTRDNGPVECGIOLNELSVTHSDRDLVNLTYGPPDPDTI 420
Db 421 SPSYTYYTRPGVNLSSLSCHAASNPQAYSWLIDGNTQHTOFLFISITEKNSGLYCOAN 480
QY 421 SSYTYYTRPGVNLSSLSCHAASNPQAYSWLIDGNTQHTOFLFISITEKNSGLYCOAN 480
Db 481 NSASGHRTTVKTTITSAELPKPSISSNSKPEVDIAVFTCEPAAQNTYLWMMNGQS 540
QY 481 NSASGHRTTVKTTITSAELPKPSISSNSKPEVDIAVFTCEPAAQNTYLWMMNGQS 540
Db 541 LPVSPRIQLSNENRTLTFLNVTNRDARAYVGIIQNSVSANSRSDPVTLDVLGYPDTPITISP 600
QY 541 LPVSPRIQLSNENRTLTFLNVTNRDARAYVGIIQNSVSANSRSDPVTLDVLGYPDTPITISP 600
Db 601 PSSYSGANLMSCHSISASNPQSWRINCIPQDQTQVIFTAKITTPNNNGTYACTVSNL 660
QY 601 PSSYSGANLMSCHSISASNPQSWRINCIPQDQTQVIFTAKITTPNNNGTYACTVSNL 660
Db 661 ATGRNNNSIVKSITVSAAGTSPCLSAAGATVGMIGVIVGVALL 702
QY 661 ATGRNNNSIVKSITVSAAGTSPCLSAAGATVGMIGVIVGVALL 702
Db 661 ATGRNNNSIVKSITVSAAGTSPCLSAAGATVGMIGVIVGVALL 702

RESULT 3

053G3_0 HUMAN
ID 053G3_0; PRT: 702 AA.
AC 053G3_0;
DT 13-SEP-2005 (TREMBLrel. 31, Created)
DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update)
DE 13-SEP-2005 (TREMBLrel. 31, Last annotation update)
DE Carcinoembryonic antigen-related cell adhesion molecule 5 variant
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea;
OC Homo.
RN [1] NCBI_TAXID=9605;
RP Maruyama K., Sugano S.;
RA "Oligo-capping : a simple method to replace the cap structure of
RT eucaryotic mRNAs with oligoribonucleotides.",
RL Gene 138:171-174(1994).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Suzuki Y., Yosimoto K., Maruyama K., Suyama A., Sugano S.;
RT "Construction and characterization of a full length-enriched and a 5'-
RT end-enriched cDNA library.",
RL Gene 200:149-156(1997).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RA Suzuki Y., Sugano S., Tokoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA Suzuki A., Yokoyama S.;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK223101; BAD96821.1; -; mRNA.
FT NON_TER
SQ SEQUENCE 702 AA; 76867 MW; 62992426CDDABBC CRC64;

Query Match 99 %; Score 3713; DB 2; Length 702;
Best Local Similarity 99 %; Pred. No. 1.7e-203; DB 2;
Matches 701; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESPSAPPHICPKQRLLTASLTFWMPPTAKTISTSPENVAEGKEVLVNHLPQ 60
Db 61 HLFGYSWIKGERVGDGRQIGIVIGTQQATPGPAYSGREIYPMASLLIONIQNDTGFY 120
QY 1 MESPSAPPHICPKQRLLTASLTFWMPPTAKTISTSPENVAEGKEVLVNHLPQ 60
Db 61 HLFGYSWIKGERVGDGRQIGIVIGTQQATPGPAYSGREIYPMASLLIONIQNDTGFY 120
QY 121 TLHVTKRSDSLNEEATGQFRVPELPKPSISSNNNSRKPVEDKDAVFTCEPETOQDAYLWWV 180

Best Local Similarity 59.8%; Pred. No. 7.5e-110; Matches 420; Conservative 0; Mismatches 1; Indels 282; Gaps 1;

Db	121 TLAVIDLNEEATQFPRVYPLPKSISNNSKPVEDDKDAVAFTCEPETDATLYWV 180
Oy	181 NNQSLPVSPRQLQSNPQASWFLNPTTUNTRNDTASYKETONPVSARRSVILNLVYGDPA 240
Db	181 NNQSLPVSPRQLQSNPQASWFLNPTTUNTRNDTASYKETONPVSARRSVILNLVYGDPA 240
Oy	241 TISPLNTSYRSGENLNLSCHAASNPQAQYSWFNGTFOQSTOBLFPNTVNNSGTYCQ 300
Db	241 TISPLNTSYRSGENLNLSCHAASNPQAQYSWFNGTFOQSTOBLFPNTVNNSGTYCQ 300
Oy	301 AHNSDTGLNRRTVTTIVYAEPPKPFITSNSNSNPVEDDAVALTCPEBIOINTYLVNN 360
Db	301 AHNSDTGLNRRTVTTIVYAEPPKPFITSNSNSNPVEDDAVALTCPEBIOINTYLVNN 360
Oy	361 QSLPVSPRLQSLNDNRTTLLSUTRNQPGYECGIONELSVDHSDPVLNLUVYGPDTI 420
Db	361 QSLPVSPRLQSLNDNRTTLLSUTRNQPGYECGIONELSVDHSDPVLNLUVYGPDTI 420
Oy	421 SPSYTYYRPGVNLISLSCHAASNPQAQYSWFNGTFOQSTOBLFPNTVNNSGTYCQ 480
Db	421 SPSYTYYRPGVNLISLSCHAASNPQAQYSWFNGTFOQSTOBLFPNTVNNSGTYCQ 480
Oy	481 NSASGHSRRTVKTITVSASGTSPGSAGATVGIMIGVIVGVALL 540
Db	481 NSASGHSRRTVKTITVSASGTSPGSAGATVGIMIGVIVGVALL 540
Oy	541 LPSVPRIQSLNSGRTRTLETFNTRDARYVGQIQSNSKPKISSNSNPVEDDAVALTCPEBIOINTYLVNNQGS 600
Db	541 LPSVPRIQSLNSGRTRTLETFNTRDARYVGQIQSNSKPKISSNSNPVEDDAVALTCPEBIOINTYLVNNQGS 600
Oy	601 PDSSYLGANLNLSCHSASNPQASWFLIDGNTOQHTQBLFISNITEKNSGLYTCAN 660
Db	601 PDSSYLGANLNLSCHSASNPQASWFLIDGNTOQHTQBLFISNITEKNSGLYTCAN 660
Oy	661 ATGRNNNSIVKSITVSASGTSPGSAGATVGIMIGVIVGVALL 702
Db	661 ATGRNNNSIVKSITVSASGTSPGSAGATVGIMIGVIVGVALL 702

RESULT 4

ID 068DM9 HUMAN PRELIMINARY; PRT; 420 AA.

AC 068DM9; 060430; Q13858; Q9UQV9; 01-JAN-1990 (Rel. 13, Created)

DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)

DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)

DE Hypothetical protein DKFZp_81M292.

Name=DKFZp_81M292;

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae; Homo.

OX NCBI_TaxID=9606;

[1] NUCLEOTIDE SEQUENCE.

TISSUE:Colon carcinoma;

The German cDNA Consortium;

RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R., Marmeck S., Mewes H. W., Weil B., Amid C., Oanger A., Fobo G., Han M., Wleemann S.; Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.

DR EMBL; CR749337; CAH18191.1; -; mRNA.

DR InterPro; IPR003599; Ig.

DR InterPro; IPR003598; Ig-like.

DR InterPro; IPR003598; Ig_c2.

DR SMART; SM00049; Ig; 3.

DR PROSITE; PSS0835; Ig_LIKE; 3.

DR HYPOTHETICAL PROTEIN; Immunoglobulin domain.

SEQUENCE 420 AA; 45508 MW; 6E30CB4A0DD0F59 CRC64;

Query Match 55.5%; Score 2066; DB 2; Length 420;

RESULT 5

ID C8A1I1 HUMAN STANDARD; PRT; 526 AA.

AC P13685; 060430; Q13858; Q9UQV9; 01-JUL-1993 (Rel. 13, Created)

DT 01-JUL-1993 (Rel. 26, Last sequence update)

DT 13-SEP-2005 (Rel. 49, Last annotation update)

DE Carcinoembryonic antigen-related cell adhesion molecule 1 precursor (Biliary glycoprotein 1) (BGP-1) (Antigen CD66) (CD66a antigen). Name=C8A1I1; Synonyms=BGP, BGP1; OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae; Homo.

OX NCBI_TaxID=9606;

[1] NUCLEOTIDE SEQUENCE (ISOFORM A), AND PARTIAL PROTEIN SEQUENCE.

RX MEDLINE=8832055; PubMed=245722;

RA Hinoda Y., Neumann M., Hefta S.A., Drzeniek Z., Wagener C., Shively L., Heffa L.J.F., Shively J.E., Paxton R.J.;

RT "Molecular cloning of a cDNA coding biliary glycoprotein I: primary

- RT structure of a glycoprotein immunologically crossreactive with
RT carcinembryonic antigen.";
RT Proc. Natl. Acad. Sci. U.S.A. 85:6559-6563(1988).
RN [2]
- RP ERRATUM, AND SEQUENCE REVISION.
RA Hinoda Y., Neumaier M., Hefta S.A., Drzeniek Z., Wagener C.,
RA Shively L., Hefta L.J.F., Shively J.E., Paxton R.J.;
RL Proc. Natl. Acad. Sci. U.S.A. 86:1668-1668(1989).
RN [3]
- RP NUCLEOTIDE SEQUENCE (ISOFORMS A AND B); Sequence=VSP_002482, VSP_002483;
RX MEDLINE=8913950; PubMed=253711; DOI=10.1083/jcb.108.2.267;
RA Barnett T.R., Kretschmer A., Austin D.A., Gobel S.J., Hart J.T.,
RA Elting J.J., Kamark M.B.;
RT "Carcinoembryonic antigens: alternative splicing accounts for the
RT multiple mRNAs that code for novel members of the carcinoembryonic
J. Cell Biol. 108:267-276(1989).
RN [4]
- RP NUCLEOTIDE SEQUENCE (ISOFORMS A; B; C; G; H AND I).
RN TISSUE=Leukocyte;
RN MEDLINE=9122218; PubMed=205273;
RA Kuroki M., Arakawa F., Matsuo Y., Oikawa S., Nakazato H., Matsuoka Y.;
RT "Three novel molecular forms of biliary glycoprotein deduced from cDNA
RT clones from a human leukocyte library";
RL Biochem. Biophys. Res. Commun. 176:578-585(1991).
RN [5]
- RP NUCLEOTIDE SEQUENCE (ISOFORM D).
RX MEDLINE=9140765; PubMed=8423792;
RA Barnett T.R., Drake L., Pickle W. II,
RT "Human biliary glycoprotein gene: characterization of a family of
RT novel alternatively spliced RNAs and their expressed proteins.";
RL Mol. Cell. Biol. 13:1273-1282(1993).
RN [6]
- RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX Pubmed=11057824; DOI=10.1038/nature02399;
RA Grinwood J., Gordon A.S., Olsen T., Terry A., Schmutz J.,
RA Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
Aerts A., Altherr M., Aspworth L., Bajorek E., Black S., Branscomb E.,
Caenepeel S., Carrasco Y.V., Coyle C., Chan Y.M., Christensen M.,
Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
Escobar J., Flowers D., Fotopoulos D., Garcia C., Georgescu A.M.,
Glavina T., Gomez M., Groza M., Hamm M., Hawkins T.,
Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
Malfatti S., Martinek D., McCreedy P.M., Medina C., Morgan J.,
Nelson K., Nolan M., Ovcharenko I., Pitlick S., Pollard M.,
Popkie A.P., Preddy P., Quan G., Ramirez L., Rash S., Retterer J.,
Rodriguez J., Rogers S., Salamov A., Salazar A., She X., Retterer J.,
Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
Furey T.S., Desont P., Dickson M., Gordon D., Eichler E.E.,
Pernacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA Rubin E.M., Lucas S.M.,
RA "The DNA sequence and biology of human chromosome 19.";
RT Nature 428:529-535(2004).
RN [7]
- RP NUCLEOTIDE SEQUENCE OF 1-21, AND DISEASE.
RX MEDLINE=9433343; PubMed=805923;
RA Hauck W., Nedellec P., Turbide C., Stanners C.P., Barnett T.R.,
RA Beauchemin N.;
RT "Transcriptional control of the human biliary glycoprotein gene, a CEA
RT gene family member down-regulated in colorectal carcinomas.";
RL Bur. J. Biochem. 223:529-541(1994).
RN [8]
- RP NUCLEOTIDE SEQUENCE OF 1-21.
RX MEDLINE=95354678; PubMed=7624640;
RA Nedellec P., Turbide C., Beauchemin N.;
RT "Characterization and transcriptional activity of the mouse biliary
RT glycoprotein 1 gene, a carcinoembryonic antigen-related gene.";
Eur. J. Biochem. 231:104-114(1995).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein (isoform A, isoform
B and isoform C) Secreted (isoform G, isoform H and isoform I).
CC -!- ALTERNATIVE PRODUCTS:
- CC Event=Alternative splicing; Named isoforms=7;
CC Name=A;
CC IsoID=P13688-1; Sequence=Displayed;
CC Name=G;
CC IsoID=P13688-2; Sequence=VSP_002478, VSP_002479;
CC Name=H;
CC IsoID=P13688-3; Sequence=VSP_002478, VSP_002479;
CC Name=I;
CC IsoID=P13688-4; Sequence=VSP_002480, VSP_002481;
CC Name=B;
CC IsoID=P13688-5; Sequence=VSP_009227;
CC Name=C;
CC IsoID=P13688-6; Sequence=VSP_010938;
CC Name=D;
CC IsoID=P13688-7; Sequence=VSP_012222;
CC -!- DISEASE: Loss or reduced expression is a major event in colorectal
CC carcinogenesis.
CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.
CC -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC domains.
CC -!- SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like)
CC domain.
- CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
- DR EMBL; X13958; AAAS1826.1; -; mRNA.
DR EMBL; X16354; CRA34404.1; -; mRNA.
DR EMBL; D90311; BRA14341.1; -; mRNA.
DR EMBL; D90312; BRA14342.1; -; mRNA.
DR EMBL; D90313; BRA14343.1; -; mRNA.
DR EMBL; X14931; CRA32940.1; -; mRNA.
DR EMBL; M69176; AAAS1825.1; -; mRNA.
DR EMBL; M72238; AAAS1829.1; -; mRNA.
DR EMBL; M76742; AAAS17142.1; -; mRNA.
DR EMBL; AC004785; AAC18433.1; -; Genomic DNA.
DR EMBL; AC004785; AAC18434.1; -; Genomic DNA.
DR EMBL; AC004785; AAC18435.1; -; Genomic DNA.
DR EMBL; AC004785; AAC18436.1; -; Genomic DNA.
DR EMBL; AC004785; AAC18438.1; -; Genomic DNA.
DR EMBL; AC004785; AAC18439.1; -; Genomic DNA.
DR EMBL; X67277; CRA16941.1; -; Genomic DNA.
DR PIR; A32164; A32164.
DR PIR; JH0394; JH0394.
DR PIR; JH0395; JH0395.
DR PIR; JH0396; JH0396.
DR HSSP; Q61353; 116Z.
DR Ensembl; ENSG00000079385; Homo sapiens.
DR HGNC; HGNC:184; CEACAM1.
DR MIM; 109770; -.
DR GO; GO:0005887; C:integral to plasma membrane; NAS.
DR GO; GO:0005624; C:membrane fraction; TAS.
DR GO; GO:0001525; P:angiogenesis; NAS.
DR GO; GO:0016477; P:cell migration; NAS.
DR GO; GO:007156; P:homophilic cell adhesion; NAS.
DR GO; GO:007229; P:integrin-mediated signaling pathway; NAS.
DR GO; GO:007565; P:pregnancy; TAS.
DR InterPro; IPR007110; Ig like.
DR InterPro; IPR003598; Ig_c2.
DR Pfam; PF00047; ig_3.
DR SMART; SM00408; IgG2; 2.
DR PROSITE; PS50825; Ig_LIKE; 3.
DR Alternative splicing; Direct protein sequencing; Glycoprotein;
KW Immunoglobulin domain; Pyrrolidone carboxylic acid; Repeat; Signal;
KW Transmembrane.
FT SIGNAL; 1 34 Carcinoembryonic antigen-related cell
FT CHAIN 35 526

FT	TOPO_DOM	35	428	HS-----NDPPNKNEVYSTLNPEAQOPTQSASPS	512
FT	TRANSMEM	429	452	: : : : : : : : :	
FT	TOPO_DOM	453	526	Extracellular (Potential).	
FT	DOMAIN	35	142	Potential.	
FT	DOMAIN	145	232	Cytoplasmic (Potential).	
FT	DOMAIN	237	317	IG-like V-type.	
FT	MOD_RES	323	413	IG-like C2-type 1.	
FT	CARBOHYD	35	104	IG-like C2-type 2.	
FT	CARBOHYD	104	104	Ig-like C2-type 3.	
FT	CARBOHYD	111	111	Pyroglutamate carboxylic acid.	
FT	CARBOHYD	115	115	N-linked (GlcNAc. . .).	
FT	CARBOHYD	152	152	N-linked (GlcNAc. . .).	
FT	CARBOHYD	182	182	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	197	197	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	208	208	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	224	232	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	232	254	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	274	274	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	288	292	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	292	292	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	302	302	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	309	309	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	345	345	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	351	351	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	363	363	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	378	378	N-linked (GlcNAc. . .) (Potential).	
FT	CARBOHYD	405	405	N-linked (GlcNAc. . .) (Potential).	
FT	DISULFID	467	215	Probable.	
FT	DISULFID	259	299	Missing (in isoform D).	
FT	DISULFID	348	396	/FTid=VSP_012222.	
FT	VARSPLIC	143	416	ELSPVVAKPOIASKTTVGDKDVSNLTCSTNDTGISRWF	
FT	VARSPLIC	320	416	RN [2]	
Query	Match		43.2%	RT variant. ;	
Best Local Similarity	62.7%		Score 1609; DB 1; Length 526;	Blood 84:200-210(1994).	
Matches	326; Conservative		Mismatches 47; MisMatches 121; Indels 26; Gaps 6;	RN [2]	
QY	5 SAPPHRWCIPWQWLTLTASLTFLWPNPPATAKLTIESTPFWNPVAGKEVLLVLVNLPPQHFLG	64	RT NUCLEOTIDE SEQUENCE.		
Db	5 SAPPHRWCIPWQWLTLTASLTFLWPNPPATAKLTIESTPFWNPVAGKEVLLVLVNLPPQHFLG	64	RT NUCLEOTIDE SEQUENCE.		
QY	65 YSMYKGERVDGNOIQIGVIGVQATPGPAYSGREIYPNASLLIONIQIQTGFTYLHV	124	RT NUCLEOTIDE SEQUENCE.		
Db	65 YSMYKGERVDGNOIQIGVIGVQATPGPATSFGPANSGRETYENASLLIONIQIQTGFTYLHV	124	RT NUCLEOTIDE SEQUENCE.		
QY	125 IKSDLVNNEBATGQPHVYPLPKPSISSNSNNPVEDKDAVAFTECEPETQDITLYWWINNO	184	RT NUCLEOTIDE SEQUENCE.		
Db	125 IKSDLVNNEBATGQPHVYPLPKPSISSNSNNPVEDKDAVAFTECEPETQDITLYWWINNO	184	RT NUCLEOTIDE SEQUENCE.		
QY	185 LPYSPRLOLGSNGNLTTLTFLWPNTRDNTASYCETONPVARSRSVSVILVNLVGDAPTI	244	RT NUCLEOTIDE SEQUENCE.		
Db	185 LPYSPRLOLGSNGNLTTLTFLWPNTRDNTASYCETONPVARSRSVSVILVNLVGDAPTI	244	RT NUCLEOTIDE SEQUENCE.		
QY	245 LNTSYRSGENLNLSCHAASNPPAQSWSWFGTFOQSTQELFIMINTVNNSGSYTCQAHNS	304	RT NUCLEOTIDE SEQUENCE.		
Db	245 SDTYVRPGANLSSLSCYYAASNPPAQSWSLINGTFOQSTQELFIMINTVNNSGSYTCQAHNS	304	RT NUCLEOTIDE SEQUENCE.		
QY	305 DTGLRTTWTITVYAEPP---KPFITSNNNSNPVEDEADAVALTCEPELONTTLYWWVNNO	361	RT NUCLEOTIDE SEQUENCE.		
Db	305 VTGGNRTTWKTIIVTELSFWVAKQQIKASKTIVGDKDVSNLTCSTNDTGISRWF	364	RT NUCLEOTIDE SEQUENCE.		
QY	362 SLPPSPRLQLSNDNTRTTLTSLVTRNDVGYEGCGIONEESVHDSDPPIVNLVYG--PDPT	419	RT NUCLEOTIDE SEQUENCE.		
Db	362 SLPPSPRLQLSNDNTRTTLTSLVTRNDVGYEGCGIONEESVHDSDPPIVNLVYG--PDPT	419	RT NUCLEOTIDE SEQUENCE.		
QY	365 SLSSSERMLQSGNTLTSNPVKRDAGTYWCEEVFFNPISKQNSDPPIMLVNVNLPQHNG	424	RT NUCLEOTIDE SEQUENCE.		
Db	420 ISPYTYVYRGVNLISLSCHARSNPPAQSWSLIDG-----NIQOHTQELFINITEK	470	RT NUCLEOTIDE SEQUENCE.		
QY	425 LSPGAA---AGIVIGVVAVALAVALAFLHFKTGGRASDQRDLTIEHKPS--VSNHQD	479	RT NUCLEOTIDE SEQUENCE.		
Db	471 NSGYIQCANNASASGHSRITVKTITVSAELPKPSISSNSNN	510	RT NUCLEOTIDE SEQUENCE.		
QY	RESULT 6		ID Q16170_HUMAN PRELIMINARY; PRT; 464 AA.		
Db	Q16170_HUMAN PRELIMINARY; PRT; 464 AA.		AC Q16170; Q16601;		
Db	Q16170; Q16601; DT 01-NOV-1995 (TREMBREL. 01, Created)		DT 01-NOV-1995 (TREMBREL. 01, Last sequence update)		
Db	DT 01-NOV-1995 (TREMBREL. 01, Last sequence update)		DT 01-FEB-2005 (TREMBREL. 29, Last annotation update)		
Db	DE BGPC_HUMAN; Name=BGPC; Synonyms=BGPI;		DE BGPC_HUMAN; Name=BGPC; Synonyms=BGPI;		
Db	OS Homo sapiens (Human); OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Euarchontoglires; Primates; Cattarrini; Homidae; OC Homo.		OS Homo sapiens (Human); OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Euarchontoglires; Primates; Cattarrini; Homidae; OC Homo.		
Db	OX NCBI_TaxId:9606; RN [1]		OX NCBI_TaxId:9606; RN [1]		
Db	RP NUCLEOTIDE SEQUENCE.		RP NUCLEOTIDE SEQUENCE.		
Db	RX MEDLINE=9489702; PubMed=8018919;		RX MEDLINE=9489702; PubMed=8018919;		
Db	RA Watt S.M., Fawcett J.J., Murdoch S.J., Teixeira A.M., Gschmeissner S.E., RA Hajibagheri N.M., Simmons D.L.,		RA Watt S.M., Fawcett J.J., Murdoch S.J., Teixeira A.M., Gschmeissner S.E., RA Hajibagheri N.M., Simmons D.L.,		
Db	RT "CD66 identifies the biliary glycoprotein (BGP) adhesion molecule: cloning, expression, and adhesion functions of the BGP splice		RT "CD66 identifies the biliary glycoprotein (BGP) adhesion molecule: cloning, expression, and adhesion functions of the BGP splice		
Db	RT variant. ;		RT variant. ;		
Db	RA Burkhardt-Schultz K., Gordon L., Kyle A., Ramirez M., Silwagen S., RA Khan H., Velasco N., Do L., Regala W., Terry A., Garne J., Avila J., RA Dangani L., Poundstone P., Christensen M., Georgescu A., Amico-Keller G., RA Liu S., Attix C., Andreise T., Frankheim M., Amico-Keller G., RA Coefield J., Duarte S., Lucas S., Bruce R., Thomas P., Quan G., RA Kronmiller B., Arellano A., Montgomery M., Ow D., Nolan M., Trong S., RA Kobayashi A., Olsen A.S., Carrasco A.V., RA Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.		RA Burkhardt-Schultz K., Gordon L., Kyle A., Ramirez M., Silwagen S., RA Khan H., Velasco N., Do L., Regala W., Terry A., Garne J., Avila J., RA Dangani L., Poundstone P., Christensen M., Georgescu A., Amico-Keller G., RA Liu S., Attix C., Andreise T., Frankheim M., Amico-Keller G., RA Coefield J., Duarte S., Lucas S., Bruce R., Thomas P., Quan G., RA Kronmiller B., Arellano A., Montgomery M., Ow D., Nolan M., Trong S., RA Kobayashi A., Olsen A.S., Carrasco A.V., DR Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.		
Db	CC -1_SUBCELLULAR LOCATION: Type I membrane protein (By similarity).		CC -1_SUBCELLULAR LOCATION: Type I membrane protein (By similarity).		
Db	DR EMBL; S71326; ARB1133.1; -; mRNA.		DR EMBL; S71326; ARB1133.1; -; mRNA.		
Db	DR InterPro; IPR00598; Ig_c2.		DR InterPro; IPR00598; Ig_c2.		
Db	DR Pfam; PF0047; Ig; 3.		DR Pfam; PF0047; Ig; 3.		
Db	DR SMART; C0127; C0127.		DR SMART; C0127; C0127.		
Db	DR PROSITE; PS00237; G PROTEIN RECP_F1_1; UNKNOWN_1.		DR PROSITE; PS00237; G PROTEIN RECP_F1_1; UNKNOWN_1.		
Db	DR PROSITE; PS00835; Ig_LIKE; 3.		DR PROSITE; PS00835; Ig_LIKE; 3.		
Db	KW Immunoglobulin domain.		KW Immunoglobulin domain.		
Db	SEQUENCE 464 AA; 50521 MW; 598E4D71B05EDAA CRC64;		SEQUENCE 464 AA; 50521 MW; 598E4D71B05EDAA CRC64;		
Query	Match		43.0%; Score 1600.5; DB 2; Length 464;		
Best Local Similarity	73.0%		DB 2; Mismatches 309; Conservative 30; MisMatches 79; Indels 5; Gaps 2;		
Matches	309; Conservative		Matches 309; Conservative 30; MisMatches 79; Indels 5; Gaps 2;		
QY	5 SAPPHRWCIPWQWLTLTASLTFLWPNPPATAKLTIESTPFWNPVAGKEVLLVLVNLPPQHFLG	64	RT NUCLEOTIDE SEQUENCE.		
Db	5 SAPPHRWCIPWQWLTLTASLTFLWPNPPATAKLTIESTPFWNPVAGKEVLLVLVNLPPQHFLG	64	RT NUCLEOTIDE SEQUENCE.		
QY	65 YSMYKGERVDGNOIQIGVIGVQATPGPAYSGREIYPNASLLIONIQIQTGFTYLHV	124	RT NUCLEOTIDE SEQUENCE.		
Db	65 YSMYKGERVDGNOIQIGVIGVQATPGPATSFGPANSGRETYENASLLIONIQIQTGFTYLHV	124	RT NUCLEOTIDE SEQUENCE.		
QY	125 IKSDLVNNEBATGQPHVYPLPKPSISSNSNNPVEDKDAVAFTECEPETQDITLYWWINNO	184	RT NUCLEOTIDE SEQUENCE.		
Db	125 IKSDLVNNEBATGQPHVYPLPKPSISSNSNNPVEDKDAVAFTECEPETQDITLYWWINNO	184	RT NUCLEOTIDE SEQUENCE.		
QY	185 LPYSPRLOLGSNGNLTTLTFLWPNTRDNTASYCETONPVARSRSVSVILVNLVGDAPTI	244	RT NUCLEOTIDE SEQUENCE.		
Db	185 LPYSPRLOLGSNGNLTTLTFLWPNTRDNTASYCETONPVARSRSVSVILVNLVGDAPTI	244	RT NUCLEOTIDE SEQUENCE.		

Query	Match	43.0%	Score	1600.5;	DB	2;	Length	468;
QY	Best Local Similarity	73.0%	Pred.	No	3e-83;			
Db	Matches	309;	Conservative	30;	Mismatches	79;	Indels	5;
QY	Gaps	2;						
Db								
QY	5 SAPPHRWCPWQDNLTLTASLTWFNWPPTAKTIESTPNNVASECKEVLLVHNLPOLFG	64						
Db	5 SAPIHLRVVPWQGLLTLTASLTWFNWPPTAKTIESTPNNVASECKEVLLVHNLPOLFG	64						
QY	365 SLPSSERMKLSQGNTTLSINPVKREBAGTYWCEVFNPISKQNSDPIMLNVNALPOENG	424						
Db	365 SLPSSERMKLSQGNTTLSINPVKREBAGTYWCEVFNPISKQNSDPIMLNVNALPOENG	424						
QY	420 ISP 422							
Db	425 LSP 427							
RESULT	7							
Q66CA7_HUMAN								
ID	Q66CA7_HUMAN PRELIMINARY;	PRT;	468 AA.					
AC								
DT	01-DEC-2001 (TREMBrel. 19, Created)							
DT	01-DEC-2001 (TREMBrel. 19, Last sequence update)							
DT	01-MAR-2004 (TREMBrel. 26, Last annotation update)							
DE	CEACAM1 protein.							
OS	Homo sapiens (Human)							
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoi; Homo;							
OC	NBII_TaxID=9606;							
RN	[1]							
RP	NUCLEOTIDE SEQUENCE.							
RC	TISSUE=Skin;							
RX	MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;							
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shemesh C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Scheuer C.P., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J.J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.B., Brownstein M.J., Usdin T.B., Toshiyuki S., Garniuci P., Prange C., Raha S.S., Logueillo N.A., Peters G.J., Abramson R.D., Mullahy S.J., Bosak S.A., McEwan P.J., McFernan K.J., Malek J.A., Gunnarath P.H., Richards S., Worley K., Hale S., Garcia A.M., Gay L.J., Bulyk S.W., Villard D.K., Muniz D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Halton E., Ketteman M., Madan A., Rodrigues S., Sanchez A., Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield S.N., Krzywinski M.I., Skalska U., Smailus D.E., Schnerer A., Schein J.E., Jones S.J.M., Marron M.A.; NCBI_Taxid=9606;							
RT	"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences."							
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).							
RN	[2]							
RP	NUCLEOTIDE SEQUENCE.							
RC	TISSUE=Skin;							
RA	Strausberg R.; Submitted (SRP-2001) to the EMBL/GenBank/DDBJ databases.							
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).							
DR	EMBL; BC014473; AAH14473.1; -; mRNA.							
DR	HSSP; 061352; 1L6Z.							
DR	Ensembl; ENSG00000079385; Homo sapiens.							
DR	InterPro; IPR00276_GPCR_Rhodopsn.							
DR	InterPro; IPR07110; Ig-like.							
DR	InterPro; IPR003398; Ig_C2.							
DR	PFAM; PF00047; Ig; 3.							
DR	SMART; SM0048; Ig_C2; 2.							
DR	PROSITE; PS010835; Ig_LIKE; 3.							
DR	KW Immunglobulin domain.							
SQ	SEQUENCE 468 AA; 5147 MN; 215C1A3EEFFD68 CRC64;							
Query Match	41.0%		Score	1526.5;	DB	2;	Length	525;

Best Local Similarity 58.8%; Pred. No. 5.7e-79; Matches 310; Conservative 51; Mismatches 125; Indels 41; Gaps 6; Qy 5 SAPPHRWCIPWQRLILRASLULTFWNPPPTAKLIESPPNVAEGKEVLLVWNLPLHFG Db 5 SAPPHRWCIPWQRLILRASLULTFWNPPPTAKLIESPPNVAEGKEVLLVWNLPLHFG 64 Qy 65 YSWYKGERVDGQRQIGVIGVIGTQATPQAYSGREIYPNASLILQNIQDGTGYTLHV Db 65 YSWYKGERVDGQRQIGVIGVIGTQATPQAYSGREIYPNASLILQNIQDGTGYTLHV 124 Qy 125 IKSDLVNEBEATGOFRVYELPKRSISNNSKPVEDKDAVFCBEPETODATTIWWINQS Db 125 IKSDLVNEBEATGOFRVYELPKRSISNNSKPVEDKDAVFCBEPETODATTIWWINQS 184 Qy 185 LQVSPIQLSNGARTLTFLNTRNDTASYKETCQNPSARSDSVIUNLVLGDPATISP Db 185 LQVSPIQLSNGARTLTFLNTRNDTASYKETCQNPSARSDSVIUNLVLGDPATISP 244 Qy 305 DINGLNRTTVTTITYAERP--KFITTSNSNPVEDDAVALCEPELONTTLYWWINQS Db 305 VTONRNRTTVTTITYAERP--KFITTSNSNPVEDDAVALCEPELONTTLYWWINQS 362 Qy 363 LPVSPIQLSNDRTTULSUTRNDVPGYEGIQNEUSVHDSPVINVLGDDPTISP Db 363 LPVSPIQLSNDRTTULSUTRNDVPGYEGIQNEUSVHDSPVINVLGDDPTISP 422 Qy 365 LOSSERMKLQSQVNTLSNPVKREDAGKWCYCEFNLSKNDPIMSVKY Db 365 LOSSERMKLQSQVNTLSNPVKREDAGKWCYCEFNLSKNDPIMSVKY 415 Qy 423 STYIYRPOVN-----LSSCHAASNPAAQYSWLDGNIQHOTELF Db 416 NTPSQEGLSLAGIAIGIVIGVIALVALVALACFLAFRKTRASDQRD-- 471 Db 464 ISNTEKNNSGLYTQOANNASSGHISRTTVTKITVSAELPKPSISSNN 510 Db 472 VSNHQTDSH-----NDPPNKONEVYSTLNFQAQOPTQSISASPS 511

RESULT 9
Q13984_HUMAN
ID 013984_HUMAN PRELIMINARY; PRT; 287 AA.
AC 013984;
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE CEA protein (Fragment).
GN Name=CEA;
OC Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo. NCBI_TAXID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=87660984; PubMed=2955415;
RA Kamdarck M.E., Elting J.J., Hart J.T., Goebel S.J., Rae P.M.,
RA Nothdurft M.A., Nedwin J.J., Barnett T.R.;
RT "Carcinoembryonic antigen family: expression in a mouse L-cell
transfectant and characterization of a partial cDNA in bacteriophage
lambda gtl-1";
RT Proc. Natl. Acad. Sci. U.S.A. 84:5350-5354(1987).
RT InterPro: IPR003598; Ig-like.
RT InterPro: IPR00711; Ig-like.
RT InterPro: IPR003598; Ig_c2.
DR Pfam: PF00047; Ig_3.
DR SMART; Sm00408; IgC2_1.
DR PROSITE; PS50835; IG_LIKE_3.
FT NON-TER 1
FT SEQUENCE 287 AA; 31553 MW; 70BD1CP30FBB1166 CRC64;

RESULT 10
CBAM6_HUMAN STANDARD; PRT; 344 AA.
ID CBAM6_HUMAN STANDARD; PRT; 344 AA.
AC P40199; Q11920; 31, Created
DT 01-FEB-1995 (Rel. 31, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Carcinoembryonic antigen-related cell adhesion molecule 6 precursor
(Normal cross-reacting antigen) (Nonspecific crossreacting antigen)
DE (CD66c antigen).
GN Name=CBAM6; Synonyms=NCA;
OS Homo sapiens (Human).
OC Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo. NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89122014; PubMed=3220478;
RA Barnett T., Goebel S.J., Nothdurft M.A., Elting J.J.;
RT "Carcinoembryonic antigen family: characterization of cDNAs coding for
NCA and CEA and suggestion of nonrandom sequence variation in their
conserved loop-domains.;"
RT Genomics 3:59-66(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE-lung carcinoma;
MEDLINE=88106638; PubMed=3337731;
RA Tawaragi Y., Okawa S., Matsuoaka Y., Kozaki G., Nakazato H.;
RT "primary structure of nonspecific crossreacting antigen (NCA), a
member of carcinoembryonic antigen (CEA) gene family, deduced from
cDNA sequence.;"
RT Biochem. Biophys. Res. Commun. 150:89-96(1988).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].
RC TISSUE-Pancreas;
MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Straubberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shemesh C.M., Schuler G.D.,
RA Altshul S.R., Zeeberg B., Buetow K.H., Schaeffer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schatz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loqueland N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

SQ	SEQUENCE	344 AA;	37237 MW;	4322CSD625849FS CRC64;
RA	Villalon D.K., Muzy D.M., Sodergren B.J., Lu X., Gibbs R.A.,			
RA	Fanty J., Helton B., Kettelman M., Madan A., Rodrigues S., Sanchez A.,			
RA	Whitting M., Young A.M.C., Shavchenko Y., Bouffard G.G.,			
RA	Blokley R.W., Touchman J.W., Green B.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smialius D.E.,			
RA	Schneirach A., Schein J.E., Jones S.J.M., Marz M.A.,			
RA	"Generation and initial analysis of more than 15,000 full-length human			
RT	and mouse cDNA sequences";			
RT	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).			
RL	[4]			
RN	PROTEIN SEQUENCE OF 35-49.			
RP	PubMed=15340151; DOI=10.1101/pb.04682504;			
RA	Zhang Z., Henzel W.J.;			
RT	"Signal peptide prediction based on analysis of experimentally			
RT	verified cleavage sites";			
RL	Protein Sci. 13:2812-2824 (2004).			
CC	-!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.			
CC	-!- SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.			
CC	-!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)			
CC	-!- domains			
CC	-!- SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like)			
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use as long as its content is in no way modified and this statement is not			
CC	removed.			
DR	EML1; M29541; AAA59915.1; ; mRNA.			
DR	EMBL; BC050508; AAH05003.1; ; mRNA.			
DR	HSSP; Q01355; 116Z.			
DR	Ensembl; ENSG00000086548; Homo sapiens.			
DR	HGNC; HGNC:1818; CERACAM5.			
DR	H-InvDB; HIK0015160; .			
DR	MIN; 183980; .			
DR	GO; GO:0005837; C:integral to plasma membrane; TAS.			
DR	GO; GO:0007267; P:cell-cell signaling; TAS.			
DR	GO; GO:0007165; P:signal transduction; TAS.			
DR	InterPro; IPR007110; Ig-like.			
DR	InterPro; IPR003598; Ig_C2.			
DR	Pfam; PF00047; Ig_2.			
DR	SMART; SW00408; IgC2_1.			
DR	PROSITE; PS50035; Ig_LIKE; 2.			
KW	Antigen; Direct protein sequencing; Glycoprotein; GPI-anchor;			
KW	Immunoglobulin domain; Lipoprotein; Membrane; Repeat; Signal.			
FT	SIGNAL	1	34	
FT	CHAIN	35	320	Carcinoembryonic antigen-related cell adhesion molecule 6.
FT	PROPEP	321	344	Removed in mature form (By similarity).
FT	DOMAIN	335	142	Ig-like V-type.
FT	DOMAIN	145	232	Ig-like C2-type 1.
FT	DOMAIN	237	314	Ig-like C2-type 2.
FT	LIPID	320	320	GPI-anchor amidated glycine (By similarity).
FT	CARBHYD	104	104	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	111	111	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	115	115	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	152	152	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	173	173	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	197	197	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	224	224	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	256	256	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	274	274	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	288	288	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	292	292	N-linked (GlcNAc. .) (Potential).
FT	CARBHYD	309	309	N-linked (GlcNAc. .) (Potential).
FT	DISULFID	167	215	Probable.
FT	CONFFLICT	259	299	F > L (in Ref. 1).
FT	CONFFLICT	239	239	V > G (in Ref. 1).
RESULT	11			
RN	Q53XP7_HUMAN			
ID	Q53XP7_HUMAN PRELIMINARY;			
AC	Q53XP7;			
DT	13-SEP-2005 (Tremblrel. 31; Created)			
DT	13-SEP-2005 (Tremblrel. 31; Last annotation update)			
DR	Carcinoembryonic antigen-related cell adhesion molecule 6 (Non-specific cross reacting antigen).			
OS	Homo sapiens (Human).			
OC	Bukaryota; Metazoa; Chordata; Craniata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea; Homo.			
OC	OC			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RA	Kaline N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., Phelan M., Farmer A., Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.			
RA	EMBL; BT00974; AAH88776.1; ; mRNA.			
DR	InterPro; IPR003599; Ig_2.			
DR	InterPro; IPR007110; Ig-like.			
DR	InterPro; IPR003598; Ig_C2.			
DR	Pfam; PF00047; Ig_2.			
DR	SMART; SW00409; Ig_2.			
DR	SMART; SW00508; IgC2_1.			
DR	PROSITE; PS50035; Ig_LIKE; 2.			
KW	Immunoglobulin domain.			
SQ	SEQUENCE	344 AA;	37337 MW;	4322CSD625849FS CRC64;
Query Match	38.8%; Score 1443; DB 2; Length 344;			
Best Local Similarity	83.9%; Pred. No. 1.9e-74;			
Matches	271; Conservative 11; Mismatches 41; Indels 0; Gaps 0;			
OY	1 MESSAPPHRCIPMQLLTLASLTFWNPPPTAKLTISTPFWNAGKELVLLVNLHQ			
Db	1 MGPSAPPCLRHFWKEVLITASLTFWNPPPTAKLTISTPFWNAGKELVLLVNLHQ			
OY	61 HLGSWSWYKGKERYDGNGRQIGVYQTPGPGASREIYPAASLQLQNTIONDTCFY			
Db	61 NRIGSWYKGKERYDGNGLISLWVYVIGTQMPGPASREIYPAASLQLQNTIONDTCFY			

QY	121	TIAVVKSDLVNEATGQPRVYBPKSISNSKPVEDKDAVAFCTEPETOQDATLWWV	180	Db	61	NRIGYSWYKGERVGDGSLIVVYVIGQQAATPGPVGSGRETYIPNALLQVNQDITGYF	120
Db	121	TIQVKSVDLVNEATGQPHVPELPKPSISSNSKPVEDKDAVAFCTEPETOQDATLWWV	180	Qy	121	TIAVVKSDLVNEATGQPRVYBPKSISNSKPVEDKDAVAFCTEPETOQDATLWWV	180
QY	181	NNQSLPSPRQLQLSNGNRTLTFLNVTRNDTASYKETONPVARRSIVLNLVYGPDP	240	Db	181	NNQSLPSPRQLQLSNGNRTLTFLNVTRNDTASYKETONPVARRSIVLNLVYGPDP	240
Db	181	NGQSLPSPRQLQLSNGNRTLTFLNVTRNDTASYKETONPVARRSIVLNLVYGPDP	240	Qy	181	NGQSLPSPRQLQLSNGNRTLTFLNVTRNDTASYKETONPVARRSIVLNLVYGPDP	240
Qy	241	TISPLNTSYRSGENLNISCHASNPAAQSYWFGNTFOQSTQBLFINITVNSGSTCQ	300	Db	241	TISPLNTSYRSGENLNISCHASNPAAQSYWFGNTFOQSTQBLFINITVNSGSTCQ	300
Db	241	TISPLNTSYRSGENLNISCHASNPAAQSYWFGNTFOQSTQBLFINITVNSGSTCQ	300	Qy	241	TISPLNTSYRSGENLNISCHASNPAAQSYWFGNTFOQSTQBLFINITVNSGSTCQ	300
QY	301	AHNSDTGLNRTTVTIVYAEPP	323	Db	301	AHNSDTGLNRTTVTIVYAEPP	323
Db	301	AHNSATGQNRTVMTVGSAP	323	Qy	301	AHNSATGQNRTVMTVGSAP	323
RESULT 12							
Q13774	HUMAN	P <small>REL</small> I <small>M</small> INARY; P <small>RE</small> T; 344 AA.		RN	[1]		
AC	Q13774_			RP			
DT	01-NOV-1996	(TREMBLrel. 01, Created)		NUCLEOTIDE SEQUENCE;			
DT	01-NOV-1996	(TREMBLrel. 01, Last sequence update)		MLINK=81139389; PubMed=2930274;			
DE	01-MAR-2004	(TREMBLrel. 26, Last annotation update)		NEumaier M., Zimmermann W., Shively L., Hinoda Y., Riggs A.D.,			
GN	Name=NCA;			OX			
OS	Homo sapiens (Human)			OC			
OC	Mammalia; Eutheria; Buarchoontoglires; Primates; Catarrhini; Hominoidea;			OC			
OC	Homo.			OC			
OX	Bukarrotta; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;			OC			
RN	NCBI_TAXID=9606;			OC			
RP				OC			
RESULT 13							
RA	QSUB49	HUMAN	P <small>REL</small> I <small>M</small> INARY; P <small>RE</small> T; 368 AA.	RN	[1]		
RA	QSUB49_			RP			
RT	QSUB49_	HUMAN	P <small>RE</small> LIMINARY;	NUCLEOTIDE SEQUENCE;			
RT	01-FEB-2005	(TREMBLrel. 29, Created)		MLINK=81139389; PubMed=2930274;			
RT	01-FEB-2005	(TREMBLrel. 29, Last sequence update)		Shively J.E.,			
RL	[2]			"Characterization of a cDNA clone for the non-specific cross-reacting antigen (NCA) and a comparison of NCA and carcinoembryonic antigen.",			
RL	J. Biol. Chem.	263:3202-3207(1988).		Neumaier M., Zimmermann W., Shively L., Hinoda Y., Riggs A.D.,			
RP				OX			
RX				OC			
RA	EDMLIN=81139389;			OC			
RA	Medline=81139389;			OC			
RA	Oikawa S., Kosaki G., Nakazato H.,			OC			
RT	"Molecular cloning of a gene for a member of carcinoembryonic antigen (CEA) gene family; signal peptide and N-terminal domain sequences of (CEA) gene family, signal peptide and N-terminal domain sequences of nonspecific crossreacting antigen (NCA)",			OC			
RT	Biochem. Biophys. Res. Commun. 146:444-463(1987).			OC			
RL				OC			
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein. (By similarity).			OC			
DR	EMBL; M18216; AA051739.1; -, mRNA.			OC			
DR	PIR; A26902; A27681.			OC			
DR	HSSP; Q611353; 1162.			OC			
DR	Ensembl; ENSG00000086548; Homo sapiens.			OC			
DR	InterPro; IPR007110; Ig-like.			OC			
DR	InterPro; IPR003598; Ig_c2.			OC			
DR	SMART; PF00047; 19; 2.			OC			
DR	PFAM; PF00047; 19; 2.			OC			
DR	SMART; SM00408; IgC2; 1.			OC			
DR	PROSITE; PS00835; Ig_LIKE; 2.			OC			
DR	PROSITE; PS00835; Ig_LIKE; 2.			OC			
KW	Immunoglobulin domain; Signal; Transmembrane.			OC			
FT	SIGNAL	1		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 23D7E54B4DC54318 CRC64;		OC			
Query Match	38.3%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 23D7E54B4DC54318 CRC64;		OC			
Query Match	38.3%	Score 14265; DB 2; Length 368;		OC			
Best Local Similarity	76.7%	Pred. No. 1.8e-73; Mismatches 276; Conservative 16; Mismatches 39; Index 29; Gaps 2;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 23D7E54B4DC54318 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 1443; DB 2; Length 344;		OC			
Best Local Similarity	83.9%	Pred. No. 1.9e-74; Mismatches 271; Conservative 11; Indels 0; Gaps 0;		OC			
Matches	276	Conervative 16; Mismatches 39; Index 29; Gaps 2;		OC			
FT	SEQUENCE	368 AA; 39871 MW; 28469487A7C18A4 CRC64;		OC			
FT	CHAIN	35		OC			
SQ	SEQUENCE	344 AA; 37195 MW; 28469487A7C18A4 CRC64;		OC			
Query Match	38.8%	Score 14					

RESULT 14

Q13854 HUMAN PRELIMINARY; PRT; 461 AA.

AC Q13854; ID 013854; DE 01-MAR-1996 (T-EMBLrel. 01, Last sequence update)

DT 01-NOV-1996 (T-EMBLrel. 01, Last sequence update)

GN Name-BGP; OC Eukaryota; OC Mammalia; OC Bacteria; OC Archaea; OC Fungi; OC Plantae; OC Insecta; OC Chordata; OC Craniata; OC Vertebrata; OC Buteleostomi; OC Homo sapiens (Human); OC Elting J.J., Kamarck M.B.; OC Barnett T.R., Kretschmer A.; OC Austen D.A., Goebel S.J., Hart J.T., RT "Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family"; RT Cell Biol. 108:267-276(1989).

[2]

NUCLEOTIDE SEQUENCE.

RA Kuroki M., Matsuo Y., Misumi Y., Oikawa S., Matsuoka Y.; RL Submitted (JUN-1992) to the EMBL/GenBank/DBJ databases. CC -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity). DR EMBL: D15052; BAA2063.1; -; mRNA.

DR HSPB1; 116Z; Ensemble; ENSG0000079385; Homo sapiens.

DR InterPro; IPR00276; GPCR_Rhodopsin.

DR InterPro; IPR007110; Ig-like.

DR Pfam; PF00047; Ig; 2.

DR SMART; SM00408; IgG2; 1.

DR PROSITE; PS00237; G PROTEIN_RRCEP_R1_1; UNKNOWN_1.

DR PROSITE; PS50335; Ig_LIKE; 2.

KW Immunoglobulin domain.

SQ SEQUENCE 461 AA; 50298 MW; 4A6F0P05884C4727 CRC64;

Query Match 38 2%; Score 1423; DB 2; Length 461; Best Local Similarity 63.0%; Pred. No. 3.9e-73; Matches 298; Conservative 27; Mismatches 68; Indels 80; Gaps 10;

Qy 5 SAPPHRCWICQWQLLTASLITPPMPPTKLTIESTPPNVAEGKEVLLVHLNQHLS 64

Db 5 SAPLPRVRVWQGLLTASLITPPMPPTKLTIESTPPNVAEGKEVLLVHLNQHLS 64

Qy 65 YSWYKGGERVGCRQQTIGVYVGTQATPGPAYSGRETIYPNLQIONDGTFTLHT 124

Db 65 YSWYKGGERVGCRQQTIGVYVGTQATPGPANSGRETIYPNLQIONDGTFTLQV 124

Qy 125 IKSDLVNEEATGQFRVYPELPKPSISSNNKRPKVEDKDAVFTCEBERTQDTLYWNNNGS 184

Db 125 IKSDLVNEEATGQFRVYPELPKPSISSNNKRPKVEDKDAVFTCEBERTQDTLYWNNNGS 184

Qy 185 LPSPRIQLQSNGRNTLTFVTRNDTASYCETQNPVSARSDSVLNLYGDPARTSP 244

Db 185 LPSPRIQLQSNGRNTLTFVTRNDTASYCETQNPVSARSDSVLNLYGDPARTSP 244

Qy 305 VTGCNRITVKTIIVTERONLTMPLGIDSNWAQTLPSVSOAETTDNALPOENGSLPGA 364

Db 305 VTGCNRITVKTIIVTERONLTMPLGIDSNWAQTLPSVSOAETTDNALPOENGSLPGA 364

RESULT 15

CEAMB HUMAN STANDARD; PRT; 349 AA.

AC P31937; Q00399; Q16574; DE 01-JUL-1993 (Rel. 26, Created)

DT 15-JUL-1999 (Rel. 38, Last sequence update)

DR 10-MAY-2005 (Rel. 47, Last annotation update)

DR Carcinoembryonic antigen molecule 8 precursor (Carcinoembryonic antigen CGM6) (Nonspecific cross-reacting antigen Name=CEACAM8; Synonyms=CCM6; NCBI_TaxID=9605; [1]

GN Homo sapiens (Human); OC Eukaryota; OC Mammalia; OC Bacteria; OC Archaea; OC Plantae; OC Insecta; OC Chordata; OC Craniata; OC Vertebrata; OC Buteleostomi; OC Homo sapiens (Human); OC Elting J.J., Kuroki M., Misumi Y., Oikawa S., Nakazato H., Matsuoka Y.; RL Cancer Res. 50:6534-6539(1990).

DR Nucleotide sequence; TISSUE=Spleen; MEDLINE=9103998; PubMed=2208113;

DR Berlinig B., Koblinger P., Grunert F., Thompson J.A., Brembacher F., Buchegger F., Kleister R., Zimmermann W.; "Cloning of a carcinoembryonic antigen gene family member expressed in leukocytes of chronic myeloid leukemia patients and bone marrow"; RL Biochem. Biophys. Res. Commun. 166:1063-1071(1990).

DR Non-specific cross-reacting antigen (NCA), a member of the CEA gene family; [3]

DR Pubmed=1227854; RA Khan W.N., Frenzenayr L., Teglund S., Israelsson A., Bremer K., RA Hammarstrom S.; RT "Identification of three new genes and estimation of the size of the carcinembryonic antigen family"; RL Genomics 14:384-390(1992).

DR Nucleotide sequence [large scale genomic DNA]. Published=1505784; DOI=10.1038/nature02399; RA Grifwood J., Gordon L.A., Olsen A.S., Terry J., Schmutz J., Tran-Gymfi M., Lamedin J.E., Heilsten R., Goodstein D., Couronne O., Kimball T., Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenpeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M., Copleand A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., Flowers D., Fotopoulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., Gonzales E., Groza M., Hammom N., Hawkins T., Haydn L., Ho I., Huang W., Israeni S., Jett J., Kadner R., Kimball T., Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S., Mallatti S., Martinez D., McCreedy P.M., Medina C., Morgan J., Nelson K., Nolan M., Orcharoen T., Ptak J., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,

RA	Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D., Slezak T., Solovyev V., Thyagarajan N., Trice H., Tsai M., Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu J., Xie G., Yau J., Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., Rubin E.M., Lucas S.M., "The DNA sequence and biology of human chromosome 19.", Nature 428:529-535 (2004).	DR	SMART; SH00409; IG; 3; PROSITE; PS5035; Ig_LIKE; 2; KW
RP	NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].	DR	Antigen; Glycoprotein; GPI-anchor; Immunoglobulin domain; Lipoprotein; Membrane; Polymorphism; Repeat; Signal.
RC	TISSUE=Lung;	DR	SIGNAL
RX	PubMed=22388257; PubMed=12479792; DOI=10.1073/pnas.242603899;	FT	CHAIN
RA	Klaunser R.D., Collins F.S., Wagner L., Grouse L.H., Derge J.G., Shemesh C.M., Schueler G.D., Altschuler S.F., Zeeberg B., Buetow K.H., Schaeffer C.R., Brat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tohjiyuki S., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mallay S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hall S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A., Fahy J., Helton A., Kettman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan A., Young A.C., Shavchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Koziwinski M.I., Skalska U., Smailus D.E., Schnarch A., Schon J.E., Jones S.J.M., Matra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	FT	PROPEP
RL	[16]	FT	DOMAIN
RN	NUCLEOTIDE SEQUENCE OF 1-21.	FT	DOMAIN
RX	Medline=98102450; PubMed=9427723;	FT	DOMAIN
RA	"Mice transgenic for the human CGM6 gene express its product, the granulocyte marker CD6b, exclusively in granulocytes.",	FT	DOMAIN
RT	Bades-Perner A., Thompson J., van der Putten H., Zimmermann W.; Blood 91:663-672 (1998).	FT	DOMAIN
RL	- - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.	FT	DOMAIN
CC	- - TISSUE SPECIFICITY: Expressed in leukocytes of chronic myeloid leukemia patients and bone marrow.	FT	DOMAIN
CC	- - SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.	FT	DOMAIN
CC	- - SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.	FT	DOMAIN
CC	- - SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like) domain.	FT	DOMAIN
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.	FT	DOMAIN
CC	-----	FT	DOMAIN
DR	EMBL; X52378; CAI36604.1; -; mRNA.	FT	DOMAIN
DR	EMBL; M33326; AA059914.1; -; mRNA.	FT	DOMAIN
DR	EMBL; D90646; BA14108.1; -; mRNA.	FT	DOMAIN
DR	EMBL; AC00558; AAC13659.1; -; Genomic_DNA.	FT	DOMAIN
DR	EMBL; BC026263; AAH2663.1; -; mRNA.	FT	DOMAIN
DR	PIR; S13524; A34815.	FT	DOMAIN
DR	HSSP; Q61333; I162.	FT	DOMAIN
DR	Ensembl; ENSG00000124469; Homo sapiens.	FT	DOMAIN
DR	HGNC; HGNC:1820; CEACAM8.	FT	DOMAIN
DR	InterPro; IPR00599; Ig-like.	FT	DOMAIN
DR	InterPro; IPR007110; Ig-like.	FT	DOMAIN
DR	Pfam; PF00047; Ig_1.	FT	DOMAIN
DR	SMART; SH00409; IG; 3; PROSITE; PS5035; Ig_LIKE; 2; KW	FT	PROPEP
DR	Antigen; Glycoprotein; GPI-anchor; Immunoglobulin domain; Lipoprotein; Membrane; Polymorphism; Repeat; Signal.	FT	DOMAIN
DR	SIGNAL	FT	DOMAIN
RA	"The DNA sequence and biology of human chromosome 19.", Nature 428:529-535 (2004).	FT	DOMAIN
RA	Nature 428:529-535 (2004).	FT	DOMAIN
RA	[15]	FT	DOMAIN
RA	NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].	FT	DOMAIN
RA	TISSUE=Lung;	FT	DOMAIN
RA	PubMed=22388257; PubMed=12479792; DOI=10.1073/pnas.242603899;	FT	DOMAIN
RA	Klaunser R.D., Collins F.S., Wagner L., Grouse L.H., Derge J.G., Shemesh C.M., Schueler G.D., Altschuler S.F., Zeeberg B., Buetow K.H., Schaeffer C.R., Brat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tohjiyuki S., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mallay S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hall S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A., Fahy J., Helton A., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shavchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Koziwinski M.I., Skalska U., Smailus D.E., Schnarch A., Schon J.E., Jones S.J.M., Matra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	FT	DOMAIN
RA	[16]	FT	DOMAIN
RA	NUCLEOTIDE SEQUENCE OF 1-21.	FT	DOMAIN
RA	Medline=98102450; PubMed=9427723;	FT	DOMAIN
RA	"Mice transgenic for the human CGM6 gene express its product, the granulocyte marker CD6b, exclusively in granulocytes.",	FT	DOMAIN
RT	Bades-Perner A., Thompson J., van der Putten H., Zimmermann W.; Blood 91:663-672 (1998).	FT	DOMAIN
RL	- - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.	FT	DOMAIN
CC	- - TISSUE SPECIFICITY: Expressed in leukocytes of chronic myeloid leukemia patients and bone marrow.	FT	DOMAIN
CC	- - SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.	FT	DOMAIN
CC	- - SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.	FT	DOMAIN
CC	- - SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like) domain.	FT	DOMAIN
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.	FT	DOMAIN
CC	-----	FT	DOMAIN
DR	EMBL; X52378; CAI36604.1; -; mRNA.	FT	DOMAIN
DR	EMBL; M33326; AA059914.1; -; mRNA.	FT	DOMAIN
DR	EMBL; D90646; BA14108.1; -; mRNA.	FT	DOMAIN
DR	EMBL; AC00558; AAC13659.1; -; Genomic_DNA.	FT	DOMAIN
DR	EMBL; BC026263; AAH2663.1; -; mRNA.	FT	DOMAIN
DR	PIR; S13524; A34815.	FT	DOMAIN
DR	HSSP; Q61333; I162.	FT	DOMAIN
DR	Ensembl; ENSG00000124469; Homo sapiens.	FT	DOMAIN
DR	HGNC; HGNC:1820; CEACAM8.	FT	DOMAIN
DR	InterPro; IPR00599; Ig-like.	FT	DOMAIN
DR	InterPro; IPR007110; Ig-like.	FT	DOMAIN
DR	Pfam; PF00047; Ig_1.	FT	DOMAIN
DR	SMART; SH00409; IG; 3; PROSITE; PS5035; Ig_LIKE; 2; KW	FT	PROPEP
DR	Antigen; Glycoprotein; GPI-anchor; Immunoglobulin domain; Lipoprotein; Membrane; Polymorphism; Repeat; Signal.	FT	PROPEP
DR	SIGNAL	FT	PROPEP
RA	"The DNA sequence and biology of human chromosome 19.", Nature 428:529-535 (2004).	FT	PROPEP
RA	Nature 428:529-535 (2004).	FT	PROPEP
RA	[15]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].	FT	PROPEP
RA	TISSUE=Lung;	FT	PROPEP
RA	PubMed=22388257; PubMed=12479792; DOI=10.1073/pnas.242603899;	FT	PROPEP
RA	Klaunser R.D., Collins F.S., Wagner L., Grouse L.H., Derge J.G., Shemesh C.M., Schueler G.D., Altschuler S.F., Zeeberg B., Buetow K.H., Schaeffer C.R., Brat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tohjiyuki S., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mallay S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hall S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A., Fahy J., Helton A., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shavchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Koziwinski M.I., Skalska U., Smailus D.E., Schnarch A., Schon J.E., Jones S.J.M., Matra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	FT	PROPEP
RA	[16]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE OF 1-21.	FT	PROPEP
RA	Medline=98102450; PubMed=9427723;	FT	PROPEP
RA	"Mice transgenic for the human CGM6 gene express its product, the granulocyte marker CD6b, exclusively in granulocytes.",	FT	PROPEP
RT	Bades-Perner A., Thompson J., van der Putten H., Zimmermann W.; Blood 91:663-672 (1998).	FT	PROPEP
RL	- - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.	FT	PROPEP
CC	- - TISSUE SPECIFICITY: Expressed in leukocytes of chronic myeloid leukemia patients and bone marrow.	FT	PROPEP
CC	- - SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.	FT	PROPEP
CC	- - SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.	FT	PROPEP
CC	- - SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like) domain.	FT	PROPEP
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.	FT	PROPEP
CC	-----	FT	PROPEP
DR	EMBL; X52378; CAI36604.1; -; mRNA.	FT	PROPEP
DR	EMBL; M33326; AA059914.1; -; mRNA.	FT	PROPEP
DR	EMBL; D90646; BA14108.1; -; mRNA.	FT	PROPEP
DR	EMBL; AC00558; AAC13659.1; -; Genomic_DNA.	FT	PROPEP
DR	EMBL; BC026263; AAH2663.1; -; mRNA.	FT	PROPEP
DR	PIR; S13524; A34815.	FT	PROPEP
DR	HSSP; Q61333; I162.	FT	PROPEP
DR	Ensembl; ENSG00000124469; Homo sapiens.	FT	PROPEP
DR	HGNC; HGNC:1820; CEACAM8.	FT	PROPEP
DR	InterPro; IPR00599; Ig-like.	FT	PROPEP
DR	InterPro; IPR007110; Ig-like.	FT	PROPEP
DR	Pfam; PF00047; Ig_1.	FT	PROPEP
DR	SMART; SH00409; IG; 3; PROSITE; PS5035; Ig_LIKE; 2; KW	FT	PROPEP
DR	Antigen; Glycoprotein; GPI-anchor; Immunoglobulin domain; Lipoprotein; Membrane; Polymorphism; Repeat; Signal.	FT	PROPEP
DR	SIGNAL	FT	PROPEP
RA	"The DNA sequence and biology of human chromosome 19.", Nature 428:529-535 (2004).	FT	PROPEP
RA	Nature 428:529-535 (2004).	FT	PROPEP
RA	[15]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].	FT	PROPEP
RA	TISSUE=Lung;	FT	PROPEP
RA	PubMed=22388257; PubMed=12479792; DOI=10.1073/pnas.242603899;	FT	PROPEP
RA	Klaunser R.D., Collins F.S., Wagner L., Grouse L.H., Derge J.G., Shemesh C.M., Schueler G.D., Altschuler S.F., Zeeberg B., Buetow K.H., Schaeffer C.R., Brat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tohjiyuki S., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mallay S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hall S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A., Fahy J., Helton A., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shavchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Koziwinski M.I., Skalska U., Smailus D.E., Schnarch A., Schon J.E., Jones S.J.M., Matra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	FT	PROPEP
RA	[16]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE OF 1-21.	FT	PROPEP
RA	Medline=98102450; PubMed=9427723;	FT	PROPEP
RA	"Mice transgenic for the human CGM6 gene express its product, the granulocyte marker CD6b, exclusively in granulocytes.",	FT	PROPEP
RT	Bades-Perner A., Thompson J., van der Putten H., Zimmermann W.; Blood 91:663-672 (1998).	FT	PROPEP
RL	- - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.	FT	PROPEP
CC	- - TISSUE SPECIFICITY: Expressed in leukocytes of chronic myeloid leukemia patients and bone marrow.	FT	PROPEP
CC	- - SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.	FT	PROPEP
CC	- - SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.	FT	PROPEP
CC	- - SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like) domain.	FT	PROPEP
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.	FT	PROPEP
CC	-----	FT	PROPEP
DR	EMBL; X52378; CAI36604.1; -; mRNA.	FT	PROPEP
DR	EMBL; M33326; AA059914.1; -; mRNA.	FT	PROPEP
DR	EMBL; D90646; BA14108.1; -; mRNA.	FT	PROPEP
DR	EMBL; AC00558; AAC13659.1; -; Genomic_DNA.	FT	PROPEP
DR	EMBL; BC026263; AAH2663.1; -; mRNA.	FT	PROPEP
DR	PIR; S13524; A34815.	FT	PROPEP
DR	HSSP; Q61333; I162.	FT	PROPEP
DR	Ensembl; ENSG00000124469; Homo sapiens.	FT	PROPEP
DR	HGNC; HGNC:1820; CEACAM8.	FT	PROPEP
DR	InterPro; IPR00599; Ig-like.	FT	PROPEP
DR	InterPro; IPR007110; Ig-like.	FT	PROPEP
DR	Pfam; PF00047; Ig_1.	FT	PROPEP
DR	SMART; SH00409; IG; 3; PROSITE; PS5035; Ig_LIKE; 2; KW	FT	PROPEP
DR	Antigen; Glycoprotein; GPI-anchor; Immunoglobulin domain; Lipoprotein; Membrane; Polymorphism; Repeat; Signal.	FT	PROPEP
DR	SIGNAL	FT	PROPEP
RA	"The DNA sequence and biology of human chromosome 19.", Nature 428:529-535 (2004).	FT	PROPEP
RA	Nature 428:529-535 (2004).	FT	PROPEP
RA	[15]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].	FT	PROPEP
RA	TISSUE=Lung;	FT	PROPEP
RA	PubMed=22388257; PubMed=12479792; DOI=10.1073/pnas.242603899;	FT	PROPEP
RA	Klaunser R.D., Collins F.S., Wagner L., Grouse L.H., Derge J.G., Shemesh C.M., Schueler G.D., Altschuler S.F., Zeeberg B., Buetow K.H., Schaeffer C.R., Brat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tohjiyuki S., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mallay S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hall S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A., Fahy J., Helton A., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shavchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Koziwinski M.I., Skalska U., Smailus D.E., Schnarch A., Schon J.E., Jones S.J.M., Matra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	FT	PROPEP
RA	[16]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE OF 1-21.	FT	PROPEP
RA	Medline=98102450; PubMed=9427723;	FT	PROPEP
RA	"Mice transgenic for the human CGM6 gene express its product, the granulocyte marker CD6b, exclusively in granulocytes.",	FT	PROPEP
RT	Bades-Perner A., Thompson J., van der Putten H., Zimmermann W.; Blood 91:663-672 (1998).	FT	PROPEP
RL	- - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.	FT	PROPEP
CC	- - TISSUE SPECIFICITY: Expressed in leukocytes of chronic myeloid leukemia patients and bone marrow.	FT	PROPEP
CC	- - SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.	FT	PROPEP
CC	- - SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.	FT	PROPEP
CC	- - SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like) domain.	FT	PROPEP
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.	FT	PROPEP
CC	-----	FT	PROPEP
DR	EMBL; X52378; CAI36604.1; -; mRNA.	FT	PROPEP
DR	EMBL; M33326; AA059914.1; -; mRNA.	FT	PROPEP
DR	EMBL; D90646; BA14108.1; -; mRNA.	FT	PROPEP
DR	EMBL; AC00558; AAC13659.1; -; Genomic_DNA.	FT	PROPEP
DR	EMBL; BC026263; AAH2663.1; -; mRNA.	FT	PROPEP
DR	PIR; S13524; A34815.	FT	PROPEP
DR	HSSP; Q61333; I162.	FT	PROPEP
DR	Ensembl; ENSG00000124469; Homo sapiens.	FT	PROPEP
DR	HGNC; HGNC:1820; CEACAM8.	FT	PROPEP
DR	InterPro; IPR00599; Ig-like.	FT	PROPEP
DR	InterPro; IPR007110; Ig-like.	FT	PROPEP
DR	Pfam; PF00047; Ig_1.	FT	PROPEP
DR	SMART; SH00409; IG; 3; PROSITE; PS5035; Ig_LIKE; 2; KW	FT	PROPEP
DR	Antigen; Glycoprotein; GPI-anchor; Immunoglobulin domain; Lipoprotein; Membrane; Polymorphism; Repeat; Signal.	FT	PROPEP
DR	SIGNAL	FT	PROPEP
RA	"The DNA sequence and biology of human chromosome 19.", Nature 428:529-535 (2004).	FT	PROPEP
RA	Nature 428:529-535 (2004).	FT	PROPEP
RA	[15]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].	FT	PROPEP
RA	TISSUE=Lung;	FT	PROPEP
RA	PubMed=22388257; PubMed=12479792; DOI=10.1073/pnas.242603899;	FT	PROPEP
RA	Klaunser R.D., Collins F.S., Wagner L., Grouse L.H., Derge J.G., Shemesh C.M., Schueler G.D., Altschuler S.F., Zeeberg B., Buetow K.H., Schaeffer C.R., Brat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tohjiyuki S., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mallay S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hall S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A., Fahy J., Helton A., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shavchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Koziwinski M.I., Skalska U., Smailus D.E., Schnarch A., Schon J.E., Jones S.J.M., Matra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	FT	PROPEP
RA	[16]	FT	PROPEP
RA	NUCLEOTIDE SEQUENCE OF 1-21.	FT	PROPEP
RA	Medline=98102450; PubMed=9427723;	FT	PROPEP
RA	"Mice transgenic for the human CGM6 gene express its product, the granulocyte marker CD6b, exclusively in granulocytes.",	FT	PROPEP
RT	Bades-Perner A., Thompson J., van der Putten H., Zimmermann W.; Blood 91:663-672 (1998).	FT	PROPEP
RL	- - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.	FT	PROPEP
CC	- - TISSUE SPECIFICITY: Expressed in leukocytes of chronic myeloid leukemia patients and bone marrow.	FT	PROPEP
CC	- - SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.	FT	PROPEP
CC	- - SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.	FT	PROPEP
CC	- - SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like) domain.	FT	PROPEP
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.	FT	PROPEP
CC	-----	FT	PROPEP
DR	EMBL; X52378; CAI36604.1; -; mRNA.	FT	PROPEP
DR	EMBL; M33326; AA059914.1; -; mRNA.	FT	PROPEP
DR	EMBL; D90646; BA14108.1; -; mRNA.	FT	PROPEP
DR	EMBL;		

CC mass fingerprinting, and epitope verification. By applying the methods to
 CC the tumour antigen CEA, CEA-derived peptides (see ABB79317-26) were
 CC identified as epitopes that could be involved in the pathogenesis of
 cancer in human patients expressing the DR4 or DR1 class II major
 CC histocompatibility complex (MHC) allele. The epitopes, and altered
 peptide ligands (APL), are used in claimed methods of activating T cell
 reactivity, altering T cell response, diagnosis, and identifying a
 CC reagent for diagnosing cancer. Also claimed are methods of cancer
 therapy, and of identifying a class II MHC-binding fragment of a tumour
 CC antigen. APLs are also useful as vaccines
 XX SQ Sequence 702 AA:

Query Match 100.0%; Score 3721; DB 5; Length 702;
 Best Local Similarity 100.0%; Pred. No. 1. 4e-199; Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCPWORULLTASLLTWNPPPTAKLTTESTPFPNVARGKEVLLVHLNLPQ 60
 1 MESPSAPPHRWCPWORULLTASLLTWNPPPTAKLTTESTPFPNVARGKEVLLVHLNLPQ 60
 Db 61 HLEGYSWYKGERVDGNRQIGVIGVQATPGPAYSREIYPNASLIQNIQNDGFY 120
 Db 61 HLEGYSWYKGERVDGNRQIGVIGVQATPGPAYSREIYPNASLIQNIQNDGFY 120
 Db 61 HLEGYSWYKGERVDGNRQIGVIGVQATPGPAYSREIYPNASLIQNIQNDGFY 120
 QY 121 TLHVIKSDLVNEBAGTQPRVYPLPKSISNNSKPVEDKDAVAFTCPEPETODATYWWV 180
 121 TLHVIKSDLVNEBAGTQPRVYPLPKSISNNSKPVEDKDAVAFTCPEPETODATYWWV 180
 Db 181 NNQSLPVPSPRLQLSNGNRTLTFNVTNDTASYKCFONPVSARRSDSVILNLVLYGDPAP 240
 QY 241 TISPLNTSYRSGENTLNISCHAAASNPAQYSWFGNTFQOSTQBLFINITVNNSGTQ 300
 181 NNQSLPVPSPRLQLSNGNRTLTFNVTNDTASYKCFONPVSARRSDSVILNLVLYGDPAP 240
 Db 241 TISPLNTSYRSGENLNISCHAAASNPAQYSWFGNTFQOSTQBLFINITVNNSGTQ 300
 Db 301 AHNSTDGLNRTTYTVAEPPKPFITSNNSNPVEDDAVALTCPEBQINTYLWAN 360
 Db 301 AHNSTDGLNRTTYTVAEPPKPFITSNNSNPVEDDAVALTCPEBQINTYLWAN 360
 QY 361 QSPLPVSPRLQLSDNDNRTLTLTSVTRNDVGPYRCGIONBLSDHSDPVTINTVLYGDPDTI 420
 Db 361 QSPLPVSPRLQLSDNDNRTLTLTSVTRNDVGPYEGIONBLSDHSDPVTILVNLYGDPDTI 420
 Qy 421 SPSYTYPRGVNLISCHAAASNPAQYSWFLDGENIOQHTELPISNTEKOSGLYTOCAN 480
 Db 421 SPSYTYPRGVNLISCHAAASNPAQYSWFLDGENIOQHTELPISNTEKOSGLYTOCAN 480
 Qy 481 NSASGHSRRTVKITIVSABLKPSISSNNSKPVEDKDAVAFTCPEAONTLWMMQG 540
 Db 481 NSASGHSRRTVKITIVSABLKPSISSNNSKPVEDKDAVAFTCPEAONTLWMMQG 540
 QY 541 LPVSPRIQLNSGNTLTFNVTNDARAYVCGIQNSISUANRDPTVTDVLGYGDPTIISP 600
 Db 541 LPVSPRIQLNSGNTLTFNVTNDARAYVCGIQNSISUANRDPTVTDVLGYGDPTIISP 600
 QY 601 PDSYVLSGANLNUISCHASNSPQSYWNRGIPQOHTQFLIAKITPENNGTYACFYNL 660
 Db 601 PDSYVLSGANLNUISCHASNSPQSYWNRGIPQOHTQFLIAKITPENNGTYACFYNL 660
 QY 661 ATGRNNNSIVKSTRVSASGSPSLSAGATVGMIGVYVGLI 702
 Db 661 ATGRNNNSIVKSTRVSASGSPSLSAGATVGMIGVYVGLI 702
 RESULT 2 ABUS5667 ID ABUS5667 standard; protein: 702 AA.
 AC ABUS5667; XX
 DT 02-APR-2003 (first entry)

XX DE Lung cancer-associated polypeptide #260.
 XX KW Lung cancer-associated polypeptide; cytostatic; emphysema;
 CC antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
 CC KW small cell lung cancer; benign lesion; precancerous lesion; bronchiectasis;
 CC KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
 CC KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis;
 OS Unidentified.

XX RN W0200386443-A2.
 XX PD 31-OCT-2002.
 XX PP 18-APR-2002; 2002WO-US012476.
 XX PR 18-APR-2001; 2001US-0284770P.
 PR 10-MAY-2001; 2001US-0290492P.
 PR 09-NOV-2001; 2001US-0339245P.
 PR 13-NOV-2001; 2001US-0350666P.
 PR 29-NOV-2001; 2001US-0334370P.
 PR 12-APR-2002; 2002US-0372246P.
 PA (EOSB-) EOS BIOTECHNOLOGY INC.
 XX PI Aziz N, Murray R;
 XX DR WPI; 2003-093161/08.
 DR N-FSDB; ABX76395.
 XX PT Detecting a lung cancer-associated transcript in a cell from a patient
 PT for treating lung cancer, by contacting a biological sample from the
 PT patient with a polynucleotide that exhibits increased or decreased
 PT expression in lung cancer.
 XX PS Claim 27; Page 390; 453pp; English.

The invention relates to a method for detecting a lung cancer-associated
 CC transcript in a cell from a patient, comprising contacting a biological
 sample from the patient with a polynucleotide that selectively hybridises
 to a sequence that is at least 80 % identical to a gene that exhibits
 increased or decreased expression in lung cancer samples. Lung cancer-
 CC associated polynucleotides and polypeptides are used for identifying a
 compound that modulates a lung cancer-associated polypeptide. For
 inhibiting proliferation of a lung cancer-associated cell to treat lung
 cancer in a patient and for treating a mammal having lung cancer by
 administering a modulatory compound identified. The methods are useful
 CC for treating lung cancer, such as small cell lung cancer, non-small cell
 lung cancer or other benign or precancerous lesions, e.g. atelectasis,
 CC emphysema, bronchitis, chronic obstructive pulmonary disease, fibrosis,
 CC hypersensitivity pneumonitis, interstitial pulmonary fibrosis, asthma and
 CC bronchiectasis. The genes, polynucleotides and polypeptide are useful
 CC for diagnostic purposes and as targets for screening for therapeutic
 CC compounds that modulate lung cancer, such as antibodies. Sequences
 CC ABUS56745 represent lung cancer-associated polypeptides of the
 invention

XX SQ Sequence 702 AA;

Query Match 100.0%; Score 3721; DB 6; Length 702;
 Best Local Similarity 100.0%; Pred. No. 1. 4e-199; Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCPWORULLTASLLTWNPPPTAKLTTESTPFPNVARGKEVLLVHLNLPQ 60
 1 MESPSAPPHRWCPWORULLTASLLTWNPPPTAKLTTESTPFPNVARGKEVLLVHLNLPQ 60
 Db 61 HLEGYSWYKGERVDGNRQIGVIGVQATPGPAYSREIYPNASLIQNIQNDGFY 120
 Db 61 HLEGYSWYKGERVDGNRQIGVIGVQATPGPAYSREIYPNASLIQNIQNDGFY 120
 QY 121 TLHVIKSDLVNEBAGTQPRVYPLPKSISNNSKPVEDKDAVAFTCPEPETODATYWWV 180

Db	121	TIHVIKSDLVNEBEATGQFPRVYPLPKPSISSNNSKPVEDKDAVFTCEPEIOTDATIWWV	PI	Aziz N.
Qy	181	NNQSLPVSPRQLQLSNGNRLTIFVNTRNDTASYKETQNPVSARRSDSVILNVLYGDDAP	XX	Murray R.
Db	181	NNQSLPVSPRQLQLSNGNRLTIFVNTRNDTASYKETQNPVSARRSDSVILNVLYGDDAP	DR	WPI; 2003-093161/08.
Qy	241	TISPLNTSYRSGENLNLSCHAASNPPAQYSWVFNGTFOQSTQELFIPNITVNSSYTCQ	XX	N-PSDB; ABX76144.
Db	241	TISPLNTSYRSGENLNLSCHAASNPPAQYSWVFNGTFOQSTQELFIPNITVNSSYTCQ	PT	Detecting a lung cancer-associated transcript in a cell from a patient for treating lung cancer, by contacting a biological sample from the patient with a polynucleotide that exhibits increased or decreased expression in lung cancer.
Qy	301	AHNSDGLNRNTVTITIVYABPKPFPITSNNSNPVEDDAVLTCEPEIOTNTYIWWNN	XX	Claim 27; Page 204; 453pp; English.
Db	301	AHNSDGLNRNTVTITIVYABPKPFPITSNNSNPVEDDAVLTCEPEIOTNTYIWWNN	CC	The invention relates to a method for detecting a lung cancer-associated transcript in a cell from a patient, comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence that is at least 80 % identical to a gene that exhibits increased or decreased expression in lung cancer samples. Lung cancer-associated polynucleotides and polypeptides are used for identifying a compound that modulates a lung cancer-associated polypeptide, for inhibiting proliferation of a lung cancer-associated cell to treat lung cancer in a patient and for treating a mammal having lung cancer by administering a modulatory compound identified. The methods are useful for treating lung cancer, such as small cell lung cancer, non-small cell lung cancer or other benign or precancerous lesions, e.g. atelectasis, emphysema, bronchitis, chronic obstructive pulmonary disease, fibrosis, hyperensitivity pneumonitis, interstitial pulmonary fibrosis, asthma and bronchiectasis. The genes, polynucleotides and polypeptides are useful for diagnostic purposes and as targets for screening for therapeutic compounds that modulate lung cancer, such as antibodies, sequences CC invention
Qy	421	SPSYTYPGVLNLSCHAASNPPAQYSWVFNGTFOQSTQELFIPNITVNSSYTCQ	XX	CC
Db	361	OSLPVSPRQLQSLNDRNTLTLISVTRNDVPGYECGIONELSVHDSDPVLNVLYGDDPTI	CC	CC
Db	361	OSLPVSPRQLQSLNDRNTLTLISVTRNDVPGYECGIONELSVHDSDPVLNVLYGDDPTI	CC	CC
Qy	421	SPSYTYPGVLNLSCHAASNPPAQYSWVFNGTFOQSTQELFIPNITVNSSYTCQ	XX	CC
Qy	421	SPSYTYPGVLNLSCHAASNPPAQYSWVFNGTFOQSTQELFIPNITVNSSYTCQ	CC	CC
Db	421	SPSYTYPGVLNLSCHAASNPPAQYSWVFNGTFOQSTQELFIPNITVNSSYTCQ	CC	CC
Qy	481	NSASGSRTVKTITVSAELPKPSTSNNSKPVEDDAVFTCEPEAONTYIWWNGQS	XX	CC
Db	481	NSASGSRTVKTITVSAELPKPSTSNNSKPVEDDAVFTCEPEAONTYIWWNGQS	CC	CC
(EOSB-) EBS BIOTECHNOLOGY INC.				

XK	SQ	Sequence 702 AA;
QY	541	LPVSPIRQLQNSGNRTLTLFNTNTRDARAYCGTQNSVSAINTSDPVTLVLYGPDTPISP 600
Db	541	LPVSPIRQLQNSGNRTLTLFNTNTRDARAYCGTQNSVSAINTSDPVTLVLYGPDTPISP 600
QY	601	PDSSYLSGANLNLSCHASNSNPQYSRINGSIPOQHQTFLAKITPPNNNGTYACFVNL 660
Db	601	PDSSYLSGANLNLSCHASNSNPQYSRINGSIPOQHQTFLAKITPPNNNGTYACFVNL 660
QY	661	ATGRNNNIVKSITVSAAGTSGTISGLSAGATVGIMGVGVALLI 702
Db	661	ATGRNNNIVKSITVSAAGTSGTISGLSAGATVGIMGVGVALLI 702
RESULT 4		
ADA84059	ID	ADA84059 standard; protein; 702 AA.
XX	AC	ADA84059;
XX	DT	20-NOV-2003 (first entry)
XX	DE	Human CBACMS protein.
XX	KW	human; marker; expressed sequence tag; <i>Eschscholzia</i> ; arabidopsis; tumour; stress-induced phenotype; hyperosmotic stress; colon cancer; immunogen; vaccine.
XX	OS	<i>Homo sapiens</i> .
PN	XX	WO2002103028-A2.
PD	XX	27-DEC-2002.
PF	XX	30-MAY-2002; 2002WO-1B004189.
PR	XX	30-MAY-2001; 2001US-0293999P.
PR	XX	22-OCT-2001; 2001US-0330457P.
PR	XX	19-FEB-2002; 2002US-0357144P.
PA	XX	(BIOM-) BIOMEDICAL CENT.
PT	XX	Baranova AV, Yankovsky NK, Kozlov AP, Lobashev AV, Krukovskaya LL;
DR	XX	WPI; 2003-175241/17.
DR	XX	N-PSDB; ADA84058.
PT	XX	Determining if a nucleic acid is a marker for a phenotype/cell type of interest, by global comparison of expressed sequence tags known to be expressed in the phenotype/cell type with all ESTs expressed in normal tissue.
PS	XX	Claim 29; Page 437-440; 516pp; English.
CC	CC	The invention relates to a novel method for determining if a nucleic acid is a marker for a predetermined phenotype/cell type of interest from a biological species. The method comprises performing a global comparison of a group of expressed sequence tags (ESTs) known to be expressed in the phenotype/cell type of interest with all ESTs expressed in normal tissue in order to identify ESTs that are preferentially expressed in the phenotype/cell of interest. A method of the invention is useful for determining whether a nucleic acid is a marker for a predetermined phenotype or cell type of interest from a biological species, preferably Arabidopsis or human. The cell type of interest is an abnormal cell such as a tumour cell, and the predetermined phenotype is a stress-induced phenotype such as hyperosmotic stress or high salt conditions. A method of the invention is also useful for determining the progression of colon cancer in a human, for detecting a tumour cell, and for regulating or preventing the growth of a tumour cell. An antibody of the invention is useful for detecting the absence or presence of peptides encoded by tumour-associated markers. A polypeptide of the invention is useful as an immunogen for vaccinating an animal. The present sequence represents a tumour-associated antigen of the invention.
RESULT 5		
ABP74707	ID	ABP74707 standard; protein; 702 AA.
XX	AC	ABP74707;
XX	DT	03-FEB-2003 (first entry)
XX	DE	Human CEA protein SEQ ID NO:592.
XX	KW	Human; epitope; vaccine; immunotherapeutic; cytostatic; immunogenicity; T cell.
XX	OS	<i>Homo sapiens</i> .
PN	XX	WO20021646-A2.

			PD	17-OCT-2002.
XX	04-APR-2002;	2002WO-US01101.	QY	481 SPSVTYYRPGVNLISLSCHAASNPQAQSWLIDGNIQQHOBFLRISNTTENRSLGTYCQAN 480
XX	05-APR-2001;	2001US-028211P.	Db	481 NSASGHSRTTVKTTIVSABLPKISSNNKPKEDKDAVFTCEPAONTYLMWNGQS 540
PR	07-NOV-2001;	2001US-0337017P.	QY	541 LPSVPLQLNSGNTLTFNVTNDARAYVGQNSVSAARSDPVTLDVLYGPDPITSP 600
PR	07-MAR-2002;	2002US-0362110P.	Db	541 LPSVPLQLNSGNTLTFNVTNDARAYVGQNSVSAARSDPVTLDVLYGPDPITSP 600
PA	(CTRL-)	CTL IMMUNOTHERAPIES CORP.	QY	541 LPSVPLQLNSGNTLTFNVTNDARAYVGQNSVSAARSDPVTLDVLYGPDPITSP 600
XX	Simard JJL,	Diamond DC,	QY	541 LPSVPLQLNSGNTLTFNVTNDARAYVGQNSVSAARSDPVTLDVLYGPDPITSP 600
XX	Liu L,	Xie Z;	Db	541 LPSVPLQLNSGNTLTFNVTNDARAYVGQNSVSAARSDPVTLDVLYGPDPITSP 600
DR	WPT;	2003-067518/06.	QY	601 PSSYLSGANLNSCHSASNPSQYSWINGFOQHTQFLAKTPNNNGTYCFSN 660
XX	N-PSDB;	ABQ83855.	Db	601 PSSYLSGANLNSCHSASNPSQYSWINGFOQHTQFLAKTPNNNGTYCFSN 660
PT	Novel epitopes useful as vaccines, comprises peptides or nucleic acid	QY	661 ATGRANNSTVKSVTVAASGTSPGI-SAGATVGMIGVLGVALL 702	
PT	encoding the peptides, that are useful epitopes of target-associated	Db	661 ATGRANNSTVKSVTVAASGTSPGI-SAGATVGMIGVLGVALL 702	
XX	antigens.	QY		
PS	Claim 1; Page 171; 352pp; English.	Db		
XX	The present invention describes an isolated epitope (I) and an epitope	RESULT 6		
CC	cluster. Also described is a vaccine or immunotherapeutic composition	ID	ABU04837	
CC	(VC) comprising (I). (I) has cytotoxic activity. VC is useful for	ID	ABU04837 standard; protein; 702 AA.	
CC	treating an animal, by administering to an animal the vaccine or	AC	ABU04837;	
CC	immunotherapeutic composition. VC is also useful for evaluating	DT	29-JAN-2003 (first entry)	
CC	immunogenicity of a vaccine or immunotherapeutic composition, by	DE	Human expressed protein tag (EPT) #1503.	
CC	administering VC to an HLA-transgenic animal and evaluating	XX		
CC	immunogenicity based on a characteristic of the animal, or by in vitro	KW	Translational profiling; expressed protein tag; EPT; kinase; phosphatase;	
CC	primary stimulation of a T cell and evaluating immunogenicity. (I) is	KW	protease; protease inhibitor; transporter; cytoskeletal protein;	
CC	useful for determining specific T cell frequency, by contacting T cells	KW	receptor; transcription factor; cancer; MHC; colon cancer; gastric cancer;	
CC	with a MHC-peptide complex, and further comprises ELISPOT analysis, limiting dilution analysis, flow cytometry, in situ hybridisation and/or	KW	major histocompatibility complex; myeloma; adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.	
CC	polymerase chain reaction (PCR). ABQ83843 to ABQ83858 and ABP74128 to	XX		
CC	ABP7413 represent sequences used in the exemplification of the present	OS		
XX	invention.	OS		
SO	Sequence 702 AA;	XX		
Query Match	100.0%; Score 3721; DB 6; Length 702;	PN	W0200278524-A2.	
Best Local Similarity	100.0%; Pred. No. 1-4e-199;	XX		
Matches	702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	PD	10-OCT-2002.	
QY	1 MESPSPAPHRWCIPWQRLLTASLTIFWMPPTAKLTISTPENFAEGKEVLLVHLNLPQ 60	XX		
Db	1 MESPSPAPHRWCIPWQRLLTASLTIFWMPPTAKLTISTPENFAEGKEVLLVHLNLPQ 60	PR	28-MAR-2002; 2002WO-US009671.	
QY	61 HLFGYSWKGEBRVIDGQRQIGVIGVIGTQATPGPAYSGRETIYPNASHLQNIQDGTGFY 120	PR	28-MAR-2001; 2001US-0279495P.	
Db	61 HLFGYSWKGEBRVIDGQRQIGVIGVIGTQATPGPAYSGRETIYPNASHLQNIQDGTGFY 120	PR	21-MAY-2001; 2001US-029244P.	
QY	121 TLWVTKSDLVNEEATGQFRVYPELKPSSISSNNSPVEDKAVALTCPEPTQDAYLWWV 180	PR	08-AUG-2001; 2001US-0310801P.	
Db	121 TLWVTKSDLVNEEATGQFRVYPELKPSSISSNNSPVEDKAVALTCPEPTQDAYLWWV 180	PR	01-OCT-2001; 2001US-0326370P.	
QY	181 NNGSLPLSPRLQPLNSGNRQITLTFNTRDASYKETQPMVSARSDSVLNVLYGPDP 240	PR	04-DEC-2001; 2001US-0336780P.	
Db	181 NNGSLPLSPRLQPLNSGNRQITLTFNTRDASYKETQPMVSARSDSVLNVLYGPDP 240	PR	20-FEB-2002; 2002US-0358985P.	
QY	241 TSPPLNTSRSGENLNLSCHAASNPQAQSWFVNQTFQOSTQELFLPNITVNNNSYTCQ 300	PR		
Db	241 TSPPLNTSRSGENLNLSCHAASNPQAQSWFVNQTFQOSTQELFLPNITVNNNSYTCQ 300	PR		
QY	301 ARNSDTGALRTVYTIVAEPPKFITSNNSNPDEDAVAVALCPEPONTYLMWNN 360	XX		
Db	301 ARNSDTGALRTVYTIVAEPPKFITSNNSNPDEDAVAVALCPEPONTYLMWNN 360	PT	New polypeptides (e.g. kinases, phosphatases, proteases, transporters, cytoskeletal proteins, receptors or transcription factors), useful for treating cancer, e.g. colon cancer, gastric cancer, barcoma, lymphoma or leukemia.	
QY	361 QSLPVSPRLQSLNDRTTILSTYRNDVPGYECGQNEQUSVDHSDPVLNLYGPDDPTI 420	PT	The invention describes a purified polypeptide, which comprises a fragment of a kinase, phosphatase, protease, protease inhibitor, transporter, cytoskeletal protein, receptor or transcription factor. The polypeptide is useful as an immunogenic composition for eliciting in a mammal an immunogenic response directed against any of the purified polypeptide, the purified polypeptide, or the antibody that binds to this polypeptide, is useful for treating cancer. The polypeptide is also useful for identifying compounds that binds to a naturally processed class I or class II MHC-binding polypeptide. The polypeptides and	
Db	361 QSLPVSPRLQSLNDRTTILSTYRNDVPGYECGQNEQUSVDHSDPVLNLYGPDDPTI 420	CC	cyclic polypeptides are particularly useful for treating or preventing	
QY	361 QSLPVSPRLQSLNDRTTILSTYRNDVPGYECGQNEQUSVDHSDPVLNLYGPDDPTI 420	CC		
Db	361 QSLPVSPRLQSLNDRTTILSTYRNDVPGYECGQNEQUSVDHSDPVLNLYGPDDPTI 420	CC		
QY	421 SPSVTYYRPGVNLISLSCHAASNPQAQSWLIDGNIQQHOBFLRISNTTENRSLGTYCQAN 480	CC		
Db	421 SPSVTYYRPGVNLISLSCHAASNPQAQSWLIDGNIQQHOBFLRISNTTENRSLGTYCQAN 480	CC		
PS	Example 2; SEQ ID NO 1503; 134pp; English.	XX		
XX	The invention describes a purified polypeptide, which comprises a fragment of a kinase, phosphatase, protease, protease inhibitor, transporter, cytoskeletal protein, receptor or transcription factor. The polypeptide is useful as an immunogenic composition for eliciting in a mammal an immunogenic response directed against any of the purified polypeptide, the purified polypeptide, or the antibody that binds to this polypeptide, is useful for treating cancer. The polypeptide is also useful for identifying compounds that binds to a naturally processed	CC		
CC	class I or class II MHC-binding polypeptide. The polypeptides and	CC		
CC	cyclic polypeptides are particularly useful for treating or preventing	CC		

CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
 CC lymphoma or leukaemia. These are also useful for screening agents for
 CC treating the above mentioned diseases. This sequence represents an
 CC expressed protein tag (EPT) isolated from human tissue for translational
 CC profiling. Note: This sequence does not appear in the printed
 CC specification but was obtained in electronic format directly from WIPO at
 CC ftp://wipo.int/pub/published_pct_sequences
 XX SQ Sequence 702 AA;

Query Match 100.0%; Score 3721; DB 6; Length 702;

Best Local Similarity 100.0%; Pred. No. 1. 4e-199; Mismatches 0; Indels 0; Gaps 0;

Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCIPWORULLTASLTLFWNPPTAKLTTESTSPFNVAGKEYVLLVHNLPO 60

Db 1 MESPSAPPHRWCIPWORULLTASLTLFWNPPTAKLTTESTSPFNVAGKEYVLLVHNLPO 60

QY 61 HLFGYSMYKGERVGDNRQIGIVGIVQATCPGAYSREIYPNASSLLQIONIQDTGFY 120

Db 61 HLFGYSMYKGERVGDNRQIGIVGIVQATCPGAYSREIYPNASSLLQIONIQDTGFY 120

QY 121 THVIKSDLVNEBEATGQPRVYBPLPKESISNSKPEVDKDAVAFTCEPETODATILWWV 180

Db 121 THVIKSDLVNEBEATGQPRVYBPLPKESISNSKPEVDKDAVAFTCEPETODATILWWV 180

QY 181 NNQSLPSPRLQLSNDNRTRTLTSLVTRNDVGPYTCGIONBLSDVHDSPVILNLVYGPDDP 240

Db 181 NNQSLPSPRLQLSNDNRTRTLTSLVTRNDVGPYTCGIONBLSDVHDSPVILNLVYGPDDP 240

QY 241 TISPLNTSYRSENLSCHASNSNPQAYSWFNGTFOQSQEELFPNITNNSGSTQ 300

Db 241 TISPLNTSYRSENLSCHASNSNPQAYSWFNGTFOQSQEELFPNITNNSGSTQ 300

QY 301 AHNSTDGLNARTTIVTYAEPKPFITSNSNSNPVEDBDALTCBPIQNTLYWWNN 360

Db 301 AHNSTDGLNARTTIVTYAEPKPFITSNSNSNPVEDBDALTCBPIQNTLYWWNN 360

QY 361 QSLPVSPRLQLSNDNRTRTLTSLVTRNDVGPYTCGIONBLSDVHDSPVILNLVYGPDDP 420

Db 361 QSLPVSPRLQLSNDNRTRTLTSLVTRNDVGPYTCGIONBLSDVHDSPVILNLVYGPDDP 420

QY 421 SPSYYTYPGVLNLSCHAASNPQAYSWLIDGNQHTPELISNTEKGSLYQCAN 480

Db 421 SPSYYTYPGVLNLSCHAASNPQAYSWLIDGNQHTPELISNTEKGSLYQCAN 480

QY 481 NSASGHSHRTTVKTTVSALKPEKISSNSKPEVDKDAVAFTCEPEAQNTTYLWWNGOS 540

Db 481 NSASGHSHRTTVKTTVSALKPEKISSNSKPEVDKDAVAFTCEPEAQNTTYLWWNGOS 540

QY 541 LPSPRIQLSNGRTRTLFVNTRNDARAYVCGITQNSVSANRDPVTDLVKDPTPISP 600

Db 541 LPSPRIQLSNGRTRTLFVNTRNDARAYVCGITQNSVSANRDPVTDLVKDPTPISP 600

QY 601 PDSVYSGANTLNLSCHASNSPQYSWRSINGPQHQVQLFAKTTNNNGYACFVNL 660

Db 601 PDSVYSGANTLNLSCHASNSPQYSWRSINGPQHQVQLFAKTTNNNGYACFVNL 660

QY 661 ATGRNNSNLSKSTTVSASCTSPGLSAGAVGVMIGIVGVGVALI 702

Db 661 ATGRNNSNLSKSTTVSASCTSPGLSAGAVGVMIGIVGVGVALI 702

RESULT 7
 ABU0-800 standard; protein: 702 AA.

ID ABU04800

XX DT 29-JAN-2003 (first entry)

XX DE Human expressed protein tag (EPT) #1466.

KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
 KW protease; protease inhibitor; transporter; cytoskeletal protein;
 KW receptor; transcription factor; cancer; MHC;
 KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
 KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
 XX OS Homo sapiens.
 XX PA (ZYCO-) ZYCOS INC.
 XX PI Chicz RM, Tomlinson AJ, Urban RG;
 XX DR WO200278524-A2.
 XX PD 10-OCT-2002.
 XX PR 28-MAR-2002; 2002WO-US009671.
 XX PR 28-MAR-2001; 2001US-027945P.
 XX PR 21-MAY-2001; 2001US-029254P.
 XX PR 08-AUG-2001; 2001US-0310001P.
 XX PR 01-OCT-2001; 2001US-0326370P.
 XX PR 04-DEC-2001; 2001US-0336780P.
 XX PR 20-FEB-2002; 2002US-0358985P.

KW Example 2; SEQ ID NO 1466; 134pp; English.
 CC The invention describes a purified polypeptide, which comprises a
 CC fragment of a kinase, phosphatase, proteases, transporters,
 CC cytoskeletal proteins, receptors or transcription factors, useful for
 CC treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
 CC leukaemia.
 XX PT
 XX PS
 XX DR
 XX PT
 CC New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
 CC cytoskeletal proteins, receptors or transcription factors), useful for
 CC treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
 CC leukaemia.

The invention describes a purified polypeptide, which comprises a
 CC fragment of a kinase, phosphatase, protease, inhibitor, or transcription factor. The
 CC polypeptide is useful as an immunogenic composition for eliciting in a
 CC mammal an immunogenic response directed against any of the purified
 CC polypeptide. The purified polypeptide, or the antibody that binds to this
 CC polypeptide, is useful for treating cancer. The polypeptide is also
 CC useful for identifying compounds that binds to a naturally processed
 CC class I or class II MHC-binding polypeptide. The polypeptides and
 CC polynucleotides are particularly useful for treating or preventing
 CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
 CC lymphoma or leukaemia. These are also useful for screening agents for
 CC treating the above mentioned diseases. This sequence represents an
 CC expressed protein tag (EPT) isolated from human tissue for translational
 CC profiling. Note: This sequence does not appear in the printed
 CC specification but was obtained in electronic format directly from WIPO at
 CC ftp://wipo.int/pub/published_pct_sequences

SQ Sequence 702 AA;

Query Match 100.0%; Score 3721; DB 6; Length 702;

Best Local Similarity 100.0%; Pred. No. 1. 4e-199; Mismatches 0; Indels 0; Gaps 0;

Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCIPWORULLTASLTLFWNPPTAKLTTESTSPFNVAGKEYVLLVHNLPO 60

Db 1 MESPSAPPHRWCIPWORULLTASLTLFWNPPTAKLTTESTSPFNVAGKEYVLLVHNLPO 60

QY 61 HLFGYSMYKGERVGDNRQIGIVGIVQATCPGAYSREIYPNASSLLQIONIQDTGFY 120

Db 61 HLFGYSMYKGERVGDNRQIGIVGIVQATCPGAYSREIYPNASSLLQIONIQDTGFY 120

QY 121 THVIKSDLVNEBEATGQPRVYBPLPKESISNSKPEVDKDAVAFTCEPETODATILWWV 180

Db 121 THVIKSDLVNEBEATGQPRVYBPLPKESISNSKPEVDKDAVAFTCEPETODATILWWV 180

QY 181 NNQSLPSPRLQLSNGNRTLTFLNVTRNDTASYKCETONPVSSARRSDSVLNLVYGPDDP 240

Db 181 NNQSLPSPRLQLSNGNRTLTFLNVTRNDTASYKCETONPVSSARRSDSVLNLVYGPDDP 240

QY	241 TISPLNTSYRSGENLNLSCHAASNPQAQYSWFGNGTFOOSTQBLFINTNNSGTYCQ	300	PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or leukemia.
Db	241 TISPLNTSYRSGENLNLSCHAASNPQAQYSWFGNGTFOOSTQBLFINTNNSGTYCQ	300	PT XX
QY	301 AHNSDTGLNRTRTTVITYAEPKPFTSNSNPRVEDDAVALTCPEIQTNTYLMWN	360	XX Example 2; SEQ ID NO 150; 134pp; English.
Db	301 AHNSDTGLNRTRTTVITYAEPKPFTSNSNPRVEDDAVALTCPEIQTNTYLMWN	360	PS
QY	361 OSLPVSPRLQLSNDRNLTLISVTRNDVPGECQIONELSVDSHPDVLNTLYGPDDPTI	420	XX
Db	361 OSLPVSPRLQLSNDRNLTLISVTRNDVPGECQIONELSVDSHPDVLNTLYGPDDPTI	420	CC
QY	361 OSLPVSPRLQLSNDRNLTLISVTRNDVPGECQIONELSVDSHPDVLNTLYGPDDPTI	420	CC
Db	361 OSLPVSPRLQLSNDRNLTLISVTRNDVPGECQIONELSVDSHPDVLNTLYGPDDPTI	420	CC
QY	421 SPSYTTRPGVLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	480	CC
Db	421 SPSYTTRPGVLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	480	CC
QY	421 SPSYTTRPGVLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	480	CC
Db	421 SPSYTTRPGVLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	480	CC
QY	481 NSASGSRTTVKTTITSAELPKPSISSNNSKPVEDDAVALTCPEIQTNTYLMWN	540	CC
Db	481 NSASGSRTTVKTTITSAELPKPSISSNNSKPVEDDAVALTCPEIQTNTYLMWN	540	CC
QY	541 LPSPRIQLQSLGNRTTLFNTVRNDARAYVGCGIONVSANSRSDPVTDLVYGPDPTI	600	CC
Db	541 LPSPRIQLQSLGNRTTLFNTVRNDARAYVGCGIONVSANSRSDPVTDLVYGPDPTI	600	CC
QY	601 PDSSYSGANLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	660	CC
Db	601 PDSSYSGANLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	660	CC
QY	661 ATGRNNNIVKSITWSAGTSPCLSAQATGVIGMIGVNGVATI	702	CC
Db	661 ATGRNNNIVKSITWSAGTSPCLSAQATGVIGMIGVNGVATI	702	CC
RESULT 8			CC
ID	ABU04834 standard; protein; 702 AA.		CC
XX			CC
AC	ABU04834;		CC
XX			CC
DT	29-JAN-2003 (first entry)		CC
XX			CC
DR	Human expressed protein tag (EPT) #1500.		CC
XX			CC
KW	Translational profiling; expressed protein tag; EPT; kinase; phosphatase; protease; protease inhibitor; transporter; cytoskeletal protein; receptor; transcription factor; cancer; MHC; major histocompatibility complex; myeloma; colon cancer; adenocarcinoma; sarcoma; melanoma; lymphoma; leukemia; Homo sapiens.		CC
XX			CC
OS			CC
PN	WO200278524-A2.		CC
XX	10-OCT-2002.		CC
XX			CC
PF	28-MAR-2002; 2002WO-US009671.		CC
XX			CC
PR	28-MAR-2001; 2001US-0279495P.		CC
PR	21-MAY-2001; 2001US-0292544P.		CC
PR	08-AUG-2001; 2001US-0310801P.		CC
PR	01-OCT-2001; 2001US-0326370P.		CC
PR	04-DEC-2001; 2001US-0336780P.		CC
PR	20-FEB-2002; 2002US-0350985P.		CC
XX	(ZYCO-) ZYCOS INC.		CC
XX	Chicz RM, Tomlinson AJ, Urban RG;		CC
XX	WPI; 2003-040607/03.		CC
PT	New polypeptides (e.g. kinases, phosphatases, proteases, transporters, cytoskeletal proteins, receptors or transcription factors), useful for		CC
QY	541 LPSPRIQLQSLGNRTTLFNTVRNDARAYVGCGIONVSANSRSDPVTDLVYGPDPTI	600	PT
Db	541 LPSPRIQLQSLGNRTTLFNTVRNDARAYVGCGIONVSANSRSDPVTDLVYGPDPTI	600	PT
QY	601 PDSSYSGANLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	660	PT
Db	601 PDSSYSGANLNLSCHASNPQAQYSWLDGNQHTQBLFISNTERNSGLYTQCAN	660	PT

QY 661 ATGRNNNSIVKSVTIVSASGTPGSLSAGATVGMIGIVGVALLI 702
 ID ABU04796 standard; protein: 702 AA.
 XX
 AC ABU04796;
 XX DT 29-JAN-2003 (first entry)
 XX DE Human expressed protein tag (EPT) #1462.
 XX KW translational profiling; expressed protein tag; EPT; kinase; phosphatase; protease; protease inhibitor; transporter; cytoskeletal protein; receptor; transcription factor; cancer; MHC; major histocompatibility complex; myeloma; colon cancer; gastric cancer; adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
 XX OS Homo sapiens.
 XX PN WO200278524-A2.
 XX PD 10-OCT-2002.
 XX PP 28-MAR-2002; 2002WO-US009671.
 XX PR 28-MAR-2001; 2001US-0279495P.
 PR 21-MAY-2001; 2001US-0292544P.
 PR 08-AUG-2001; 2001US-0310801P.
 PR 01-OCT-2001; 2001US-0326370P.
 PR 04-DEC-2001; 2001US-0336780P.
 PR 20-FEB-2002; 2002US-0358985P.
 XX PA (ZYCO-) ZYCOS INC.
 XX PT Chicz RM, Tomlinson AJ, Urban RG;
 XX DR WPI; 2003-040607/03.
 XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters, cytoskeletal proteins, receptors or transcription factors), useful for treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or leukemia.
 XX PS Example 2; SEQ ID NO 1462; 134pp; English.

CC The invention describes a purified polypeptide, which comprises a fragment of a kinase, phosphatase, protease inhibitor, transporter, cytoskeletal protein, receptor or transcription factor. The polypeptide is useful as an immunogenic composition for eliciting in a mammal an immunogenic response directed against any of the purified polypeptide. The purified polypeptide, or the antibody that binds to this polypeptide, is useful for treating cancer. The polypeptide is also useful for identifying compounds that binds to a naturally processed class I or class II MHC-binding polypeptide. The polypeptides and polynucleotides are particularly useful for treating or preventing myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma, lymphoma or leukaemia. These are also useful for screening agents for treating the above mentioned diseases. This sequence represents an expressed protein tag (EPT) isolated from human tissue for translational profiling. Note: This sequence does not appear in the printed specification but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 702 AA;

RESULT 9
 ABU04796
 ID ABU04796 standard; protein: 702 AA.
 XX
 AC ABU04796;
 XX DT 29-JAN-2003 (first entry)
 XX DE Human expressed protein tag (EPT) #1462.
 XX KW translational profiling; expressed protein tag; EPT; kinase; phosphatase; protease; protease inhibitor; transporter; cytoskeletal protein; receptor; transcription factor; cancer; MHC; major histocompatibility complex; myeloma; colon cancer; gastric cancer; adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
 XX OS Homo sapiens.
 XX PN WO200278524-A2.
 XX PD 10-OCT-2002.
 XX PP 28-MAR-2002; 2002WO-US009671.
 XX PR 28-MAR-2001; 2001US-0279495P.
 PR 21-MAY-2001; 2001US-0292544P.
 PR 08-AUG-2001; 2001US-0310801P.
 PR 01-OCT-2001; 2001US-0326370P.
 PR 04-DEC-2001; 2001US-0336780P.
 PR 20-FEB-2002; 2002US-0358985P.
 XX PA (ZYCO-) ZYCOS INC.
 XX PT Chicz RM, Tomlinson AJ, Urban RG;
 XX DR WPI; 2003-040607/03.
 XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters, cytoskeletal proteins, receptors or transcription factors), useful for treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or leukemia.
 XX PS Example 2; SEQ ID NO 1462; 134pp; English.

CC The invention describes a purified polypeptide, which comprises a fragment of a kinase, phosphatase, protease inhibitor, transporter, cytoskeletal protein, receptor or transcription factor. The polypeptide is useful as an immunogenic composition for eliciting in a mammal an immunogenic response directed against any of the purified polypeptide. The purified polypeptide, or the antibody that binds to this polypeptide, is useful for treating cancer. The polypeptide is also useful for identifying compounds that binds to a naturally processed class I or class II MHC-binding polypeptide. The polypeptides and polynucleotides are particularly useful for treating or preventing myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma, lymphoma or leukaemia. These are also useful for screening agents for treating the above mentioned diseases. This sequence represents an expressed protein tag (EPT) isolated from human tissue for translational profiling. Note: This sequence does not appear in the printed specification but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 702 AA;

QY 1 MESPSAPPHRNCIPMQRLLTASLUFFWNPPTAKLTIESPPNVAEGKEVLLVHNLPO 60
 Db 1 MESPSAPPHRNCIPMQRLLTASLUFFWNPPTAKLTIESPPNVAEGKEVLLVHNLPO 60
 QY 61 HLFGYSPYKGSRVDGNRQQIGVIGVQATPGPAYSGREITYPNASLLIONIQNDTGFY 120
 Db 61 HLFGYSPYKGSRVDGNRQQIGVIGVQATPGPAYSGREITYPNASLLIONIQNDTGFY 120
 QY 121 THLVIKSDLVNEBEATGSPRVPELPKESISSNSKEVEDKDAVAFCEPEPETOQDATLYWW 180
 Db 121 THLVIKSDLVNEBEATGSPRVPELPKESISSNSKEVEDKDAVAFCEPEPETOQDATLYWW 180
 QY 181 NNQSLPVSPRQLSNERTLTFENVTNDTASYKETQNVSARSDSVLNLYGPDAP 240
 Db 181 NNQSLPVSPRQLSNERTLTFENVTNDTASYKETQNVSARSDSVLNLYGPDAP 240
 QY 241 TISPLNTSYRSGENLNLSCHASNPAQYSWVNGFFQQSTQELFIPINITNNNSYTQ 300
 Db 241 TISPLNTSYRSGENLNLSCHASNPAQYSWVNGFFQQSTQELFIPINITNNNSYTQ 300
 QY 301 ARNSDTGILNRTIVITVVAEPPKPFITSNNSNPVPEDBDAVLTCEPEIQTLYWWNN 360
 Db 301 ARNSDTGILNRTIVITVVAEPPKPFITSNNSNPVPEDBDAVLTCEPEIQTLYWWNN 360
 QY 361 QSLPVSPRLQLSNDRNTLTLSVTRNDVGPYEGQNLNSVHDSPVILNLYGPDPTI 420
 Db 361 QSLPVSPRLQLSNDRNTLTLSVTRNDVGPYEGQNLNSVHDSPVILNLYGPDPTI 420
 QY 421 SPSYTYYRPGNULSCHAASNPQAQSWLIDGNQHTQELFISNTERNSGLYTCQAN 480
 Db 421 SPSYTYYRPGNULSCHAASNPQAQSWLIDGNQHTQELFISNTERNSGLYTCQAN 480
 QY 481 NSASGHRTVKTIVTWSAELPKSISSSNSKEVEDKDAVATCCEPEAONTYLWMMNGQS 540
 Db 481 NSASGHRTVKTIVTWSAELPKSISSSNSKEVEDKDAVATCCEPEAONTYLWMMNGQS 540
 QY 541 LPSVSPRLQLSNRNTLTLSVTRNDVGPYEGQNLNSVHDSPVILNLYGPDPTI 600
 Db 541 LPSVSPRLQLSNRNTLTLSVTRNDVGPYEGQNLNSVHDSPVILNLYGPDPTI 600
 QY 601 PSSYLSGANLNSCHASNPQYSWIRNGIPOQHTQFLIAKITPPNNGTYACEVSNL 660
 Db 601 PSSYLSGANLNSCHASNPQYSWIRNGIPOQHTQFLIAKITPPNNGTYACEVSNL 660
 QY 661 ATGRNNNSIVKSVTIVSASGTPGSLSAGATVGMIGIVGVALLI 702
 Db 661 ATGRNNNSIVKSVTIVSASGTPGSLSAGATVGMIGIVGVALLI 702

RESULT 10
 ABR82476
 ID ABR82476 standard; protein: 702 AA.
 XX AC ABR82476;
 XX DT 20-NOV-2003 (first entry)
 XX DB Human carinoembryonic antigen (CEA) polypeptide.
 XX KW CEA; immune response; carinoembryonic antigen; antigen presenting cell; APC; cytostatic; vaccine; human; antigen.
 XX OS Homo sapiens.
 XX PH Key peptide 1..34
 FT Peptide /note= "signal peptide"
 FT Protein 35..702 /note= "nature protein"
 XX PN WO2003059379-A2.
 PD 24-JUL-2003.

Query Match 100.0%; Score 3721; DB 6; Length 702;
 Best Local Similarity 100.0%; Pred. No. 1..4e-199;
 Matches 702; Conservative 0; Mismatches 0; Indels 0; Caps 0;

XX
 XX
 XX
 XX
 PR 17-JAN-2003; 2003WO-DK000031.
 PR 17-JAN-2002; 2002DK-0000082.
 PR 17-JAN-2002; 2002US-0350047P.
 XX PA (PHAR-) PHARMEXA AS.
 XX PI Klyster S, Voldborg B;
 DR WPI; 2003-587260/55.
 DR N-PDB; ACFT3563.

PS Claim 19; Page 100-104; 140pp; English.

XX
 PT Inducing an immune response in humans against autologous carcinomaembryonic antigen (CEA) in an animal, e.g. human. The method involves effecting uptake and processing by antigen presenting cells (APCs) in the animal of at least 1 modified CEA polypeptide or of a nucleic acid encoding the modified CEA polypeptide or of a microorganism or virus expressing the modified CEA polypeptide to induce a CTL response and an antibody response that targets the autologous CEA. The method is useful in immunizing actively against diseases characterized by cells that express CEA. The present sequence represents a human CEA polypeptide

SQ Sequence 702 AA:

```
Query Match 100.0%; Score 3721; DB 7; Length 702;
Best Local Similarity 100.0%; Pred. No. 1.4e-199; Mismatches 0; Indels 0; Gaps 0;
Matches 702; Conservative 0; MisMatches 0; Del 0; Insert 0;
```

CC 1 MESPSAPPHRHCIPMQLLTASLITFPWNPPPTAKLTISTPENVAEGKEVLLVHNLPO 60
 CC 1 MESPSAPPHRHCIPMQLLTASLITFPWNPPPTAKLTISTPENVAEGKEVLLVHNLPO 60

QY 61 HLFQYSWYKSERVDGSNQQTIGVYVIGTQATPGPAYSGRETYPNASLLIONDGTGY 120
 PA 61 HLFQYSWYKSERVDGSNQQTIGVYVIGTQATPGPAYSGRETYPNASLLIONDGTGY 120

Db 61 HLFQYSWYKSERVDGSNQQTIGVYVIGTQATPGPAYSGRETYPNASLLIONDGTGY 120

QY 121 TLHVTKSDLVNEEATGQFRYPELPKPSISNSNSKVEDIDAFAVCEPQTQDLYWVY 180
 Db 121 TLHVTKSDLVNEEATGQFRYPELPKPSISNSNSKVEDIDAFAVCEPQTQDLYWVY 180

QY 181 NNQSPVPSPQLQSNQRTILFNTTRDASYKETONIVSARRSDSVILNLVYGPDP 240
 Db 181 NNQSPVPSPQLQSNQRTILFNTTRDASYKETONIVSARRSDSVILNLVYGPDP 240

QY 241 TISPLNTSYSGENLNLSCHASNPQASWVNGTFOQSTQELPFTPTNTNNSSSYTCO 300
 Db 241 TISPLNTSYSGENLNLSCHASNPQASWVNGTFOQSTQELPFTPTNTNNSSSYTCO 300

QY 301 AHNSDTGLNLRTVTUTVYKEPKPITSNNSNPYEDEDAVALCEPEQONTYLMWVN 360
 Db 301 AHNSDTGLNLRTVTUTVYKEPKPITSNNSNPYEDEDAVALCEPEQONTYLMWVN 360

QY 361 QSLPVSPRQLSNDNRITLTLVSVRNDVGTECGQNLBSVDHSDPVLVNLVYGPDDPT 420
 Db 361 QSLPVSPRQLSNDNRITLTLVSVRNDVGTECGQNLBSVDHSDPVLVNLVYGPDDPT 420

QY 421 SPSYYTYRPGVNLISCHAASNPQAQSMWLDGNTOQHTQELFLTSNITEANGSLYTQAN 480
 Db 421 SPSYYTYRPGVNLISCHAASNPQAQSMWLDGNTOQHTQELFLTSNITEANGSLYTQAN 480

QY 481 NSASCHSRITVKTITVSAELPKPSISSNSNSKVEKDAAVFTCEPEAQONTYLMWNGS 540
 Db 481 NSASCHSRITVKTITVSAELPKPSISSNSNSKVEKDAAVFTCEPEAQONTYLMWNGS 540

QY 541 LPVSPVPLQSLSNRNTLTLENTRNDARAYVGQIANSVSARSNDPVTLDVYGPDTPLIISP 600
 QY 601 PDSSYISGANLNLSCASNSNSPQSKWRSINGIPOQMTQFLIAKTFNNNGTYACTFSNL 660
 Db 661 ATGRNNISIVKSITVSSGTSGLSACATVGMIGVGVJL 702
 QY 661 ATGRNNISIVKSITVSSGTSGLSACATVGMIGVGVJL 702

Db RESULT 11
 ADC0591 ADC0591 standard; protein; 702 AA.
 XX ID ADC0591;
 XX AC ADC0591;
 XX DT 18-DEC-2003 (First entry)
 XX DE CEA protein #SEQ ID 592.
 XX KW Epitope; immunological; vaccine; major histocompatibility complex class I; MHC class I; cancer; major histocompatibility complex class II; MHC class II; immunisation.
 XX KW Unidentified.
 XX OS Unidentified.
 XX PN WO2003008537-A2.
 PD 30-JAN-2003.
 XX PR 29-MAR-2002; 2002WO-US010189.
 XX PR 06-APR-2001; 2001US-0282211P.
 PR 07-NOV-2001; 2001US-0337017P.
 PR 07-MAR-2002; 2002US-0363210P.
 XX PA (CTU1-) CPL IMMUNOTHERAPIES CORP.
 PI Simard JJJ, Diamond DC, Liu L, Xie Z;
 DR WPI; 2003-248010/24.

PS Claim 1; SEQ ID NO 592; 239pp; English.

XX
 PT Epitope having high affinity for major histocompatibility complex class I useful for treating an animal, evaluating immunogenicity of a vaccine or therapeutic composition and for diagnosing a disease.

XX
 PS The invention relates to an isolated epitope polypeptide that has high affinity for major histocompatibility complex (MHC) class I, and an epitope cluster comprising the polypeptide. Also disclosed is a vaccine or immunotherapeutic composition containing an epitope of the invention. Compositions of the invention may be used in the treatment of cancer. The method can be combined with a radiation therapy, chemotherapy, biotherapy or surgery. The composition is also useful for evaluating immunogenicity of a vaccine or immunotherapeutic compound. Multimeric MHC -peptide complexes of the invention are useful for determining specific T cell frequency. This method is useful for evaluating immunological response, by performing the method prior to and subsequent to an immunisation step. Compositions of the invention are useful for diagnosing a disease. The current sequence represents an epitope of the invention with high affinity for MHC class I.

SQ Sequence 702 AA:

```
Query Match 100.0%; Score 3721; DB 7; Length 702;
Best Local Similarity 100.0%; Pred. No. 1.4e-199; Mismatches 0; Indels 0; Gaps 0;
Matches 702; Conservative 0; MisMatches 0; Del 0; Insert 0;
```

QY 1 MESPSAPPHRHCIPMQLLTASLITFPWNPPPTAKLTISTPENVAEGKEVLLVHNLPO 60

Db	1 MESPSPAPHRCIPWQOLLTLASLLTWNPNPPTAKLTIESTPFVNVAEGKEVILLVNLHQ	XX
Qy	61 HLFGYSMYKGERVDGNRQIGIVGIVQATCPAYSGREIYPNASLIIQNDTGFY	120
Db	61 HLFGYSMYKGERVDGNRQIGIVGIVQATCPAYSGREIYPNASLIIQNDTGFY	120
Qy	121 TLHVIKSDLVNEBATGQFVYBPKSISSSNSKPVEDKDAVFTCEPETODATILWW	180
Db	121 TLHVIKSDLVNEBATGQFVYBPKSISSSNSKPVEDKDAVFTCEPETODATILWW	180
Qy	181 NNQSLPVSPRLQLSNDNRTITLTLSTYDNGVPGYEGIONEBSWDHSDPVILNVLXGPDTI	240
Db	181 NNQSLPVSPRLQLSNDNRTITLTLSTYDNGVPGYEGIONEBSWDHSDPVILNVLXGPDTI	240
Qy	241 TISPLNTSYRSGENLNLSCHASNPQAQSFWFNGTFOOSTQELFINITNNSGSYTCQ	300
Db	241 TISPLNTSYRSGENLNLSCHASNPQAQSFWFNGTFOOSTQELFINITNNSGSYTCQ	300
Qy	301 AHNSTDGLARTRTTTYYAEPKPFITSNNSNPVEDDAVALTCERIQTNTLYMWN	360
Db	301 AHNSTDGLARTRTTTYYAEPKPFITSNNSNPVEDDAVALTCERIQTNTLYMWN	360
Qy	361 QSLPVSPRLQLSNDNRTITLTLSTYDNGVPGYEGIONEBSWDHSDPVILNVLXGPDTI	420
Db	361 QSLPVSPRLQLSNDNRTITLTLSTYDNGVPGYEGIONEBSWDHSDPVILNVLXGPDTI	420
Qy	421 SPSYTYYRPGVNLSLSCRAASNPAQISWLIDNIOOTQELFISNITEKONGLYTQAN	480
Db	421 SPSYTYYRPGVNLSLSCRAASNPAQISWLIDNIOOTQELFISNITEKONGLYTQAN	480
Qy	481 NSASGHARTTVKITVSSELPRKISSNSKPEVDKDAVFTCEPEAQNTTYLWWNGQ	540
Db	481 NSASGHARTTVKITVSSELPRKISSNSKPEVDKDAVFTCEPEAQNTTYLWWNGQ	540
Qy	541 LPSPSPQIQLSNGNRTLTFLVTRNDARAYCGIQNSVSANRSDPVTADLVLGDPDTISP	600
Db	541 LPSPSPQIQLSNGNRTLTFLVTRNDARAYCGIQNSVSANRSDPVTADLVLGDPDTISP	600
Qy	601 PDSYSLSGANLNLSCHASNSPQSYWRNGIPQOHTQVLFAKTTPNNTNGTACFVNL	660
Db	601 PDSYSLSGANLNLSCHASNSPQSYWRNGIPQOHTQVLFAKTTPNNTNGTACFVNL	660
Qy	661 ATGRNNSTVKSITVSASSTSPLSAGATVGIMGVLVGVALI	702
Db	661 ATGRNNSTVKSITVSASSTSPLSAGATVGIMGVLVGVALI	702
RBSULT 12		
ADD2526		
ID	ADD2526 standard; protein; 702 AA.	
XX		
AC		
XX		
DT	15-JAN-2004 (first entry)	
XX		
DE	Binding domain-immunoglobulin fusion protein-associated protein #40.	
XX		
KW	Antiarthritic; immunosuppressive; antidiabetic; anithyroid; neuroprotective; hinge region; immunoglobulin heavy chain;	
KW	CH2 constant region; CH3 constant region; IgG1; antigen-binding domain; cell-mediated cytotoxicity; ADCC; complement fixation; malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma; rheumatoid arthritis; myasthenia gravis; Grave's disease; type I diabetes mellitus; multiple sclerosis or autoimmune disease.	
KW	Unidentified.	
OS		
XX		
PN	US2003118592-A1.	
XX		
PD	26-JUN-2003.	
XX		
PP	25-JUL-2002; 2002US-00207655.	
Qy		
Db	1 MESPSPAPHRCIPWQOLLTLASLLTWNPNPPTAKLTIESTPFVNVAEGKEVILLVNLHQ	60
Qy	1 MESPSPAPHRCIPWQOLLTLASLLTWNPNPPTAKLTIESTPFVNVAEGKEVILLVNLHQ	60
Db	1 MESPSPAPHRCIPWQOLLTLASLLTWNPNPPTAKLTIESTPFVNVAEGKEVILLVNLHQ	60
Qy	61 HLFGYSMYKGERVDGNRQIGIVGIVQATCPAYSGREIYPNASLIIQNDTGFY	120
Db	61 HLFGYSMYKGERVDGNRQIGIVGIVQATCPAYSGREIYPNASLIIQNDTGFY	120
Qy	121 TLHVIKSDLVNEBATGQFVYBPKSISSSNSKPVEDKDAVFTCEPETODATILWW	180

Db	121 TLAVIKSDIVNEEATQGRVYELPKPSISSNNNSKPVEDKDAVAFTEPEAQTDYLWW 180	PT	New composition comprising two or more isolated polypeptides, useful for preparing a medicament for treating pain in an animal.
Qy	181 NNQSLSPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 240	XX	
Db	181 NNQSLSPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 240	PS	
Qy	241 TISPLANTSYSRGENLNLSCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 300	XX	
Db	241 TISPLANTSYSRGENLNLSCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 300	CC	The invention discloses a composition comprising two or more isolated rat or human polynucleotides or a polynucleotide which represents a fragment, derivative or allelic variation of the nucleic acid sequence. Also claimed are a vector comprising the novel polynucleotide, a host cell comprising the vector, a method for identifying a nucleotide sequence which is differentially regulated in an animal subjected to pain and a kit to perform the method, an array, a method for identifying an agent that increases or decreases the expression of the polynucleotide sequence that is differentially expressed in neuronal tissue of a first animal subjected to pain, a method for identifying a compound which regulates the expression of a polynucleotide sequence which is differentially expressed in an animal subjected to pain, a method for identifying a compound that regulates the activity of one or more of the polynucleotides, a method for producing a pharmaceutical composition, a method for identifying a compound or small molecule that regulates the activity in an animal of one or more of the polypeptides given in the specification, a method for identifying a compound useful in treating pain and a pharmaceutical composition comprising the one or more polypeptides or their antibodies. The Polynucleotide or the compound that modulates its activity is useful for preparing a medicament for treating pain (e.g., spinal segmental nerve injury (Chung), chronic constriction injury (CCI) and spared nerve injury (SNI) in an animal (e.g. gene therapy). The sequence presented is a human protein (shown in Table 2 of the specification) which is differentially expressed during pain. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic form directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
Qy	301 AHNSDTGILNRTTWTITVYAEPPKFTTSNNNSNPKVEDDAVALTCPEAQTDYLWWNN 360	CC	
Db	301 AHNSDTGILNRTTWTITVYAEPPKFTTSNNNSNPKVEDDAVALTCPEAQTDYLWWNN 360	CC	
Qy	361 QSLPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 420	CC	
Db	361 QSLPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 420	CC	
Qy	421 SPSITYYRPGVNLISLCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 480	CC	
Db	421 SPSITYYRPGVNLISLCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 480	CC	
Qy	481 NSASGHSTTVKITIVSABLKPKSISSNNNSKPVEDKDAVAFTEPEAQTDYLWWNGQS 540	CC	
Db	481 NSASGHSTTVKITIVSABLKPKSISSNNNSKPVEDKDAVAFTEPEAQTDYLWWNGQS 540	CC	
Qy	481 NSASGHSTTVKITIVSABLKPKSISSNNNSKPVEDKDAVAFTEPEAQTDYLWWNGQS 540	CC	
Db	481 NSASGHSTTVKITIVSABLKPKSISSNNNSKPVEDKDAVAFTEPEAQTDYLWWNGQS 540	CC	
Qy	541 LPVSPLRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 600	CC	
Db	541 LPVSPLRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 600	CC	
Qy	601 PDSSVLSGANLNLSCHASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 660	CC	
Db	601 PDSSVLSGANLNLSCHASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 660	CC	
Qy	661 ATGRNNISIVSITVWASGTSPGLSAGATVGIMIGVLGVALLI 702	XX	
Db	661 ATGRNNISIVSITVWASGTSPGLSAGATVGIMIGVLGVALLI 702	XX	
RESULT 13			
ADD46175	ID ADD46175 standard; protein; 702 AA.		
XX	AC ADD46175;		
XX	DT 29-JAN-2004 (first entry)		
XX	DE Human Protein P06731, SEQ ID NO 11850.		
XX	KW Human; pain; neuronal tissue; gene therapy;		
KW	Spinal segmental nerve injury; chronic constriction injury; CCI;		
KW	spared nerve injury; SNI; Chung.		
OS Homo sapiens.			
XX	PN WO2003016475-A2.		
XX	PD 27-FEB-2003.		
XX	14-AUG-2002; 2002WO-US025765.		
XX	14-AUG-2001; 2001US-0312147P.		
PR	01-NOV-2001; 2001US-0346382P.		
PR	26-NOV-2001; 2001US-0333347P.		
PR	(GEHO) GEN HOSPITAL CORP.		
PA	(FARB) BAYER AG.		
PI	Woolf C, D'urso D, Befort K, Costigan M,		
XX	WPI; 2003-268312/26.		
DR	GENBANK; P06731.		
Qy	Query Match Best Local Similarity 100.0%; Score 3721; DB 7; Length 702; Matches 702; Similarity 100.0%; Pred. No. 1.4e-19; Mismatches 0; Indels 0; Gaps 0;		
Qy	1 MESPSAPPHRCPWORLTLTASLTFNPFPTAKLTISTPENAGKEVTLVLYHNLPO 60		
Db	1 MESPSAPPHRCPWORLTLTASLTFNPFPTAKLTISTPENAGKEVTLVLYHNLPO 60		
Qy	61 HLGCSWYKGERDGNRQIGYVIGTQATPGPAYSGRBTIYVNLQIONDTGYF 120		
Db	61 HLGCSWYKGERDGNRQIGYVIGTQATPGPAYSGRBTIYVNLQIONDTGYF 120		
Qy	121 TLAVIKSDIVNEEATQGRVYELPKPSISSNNNSKPVEDKDAVAFTEPEAQTDYLWW 180		
Db	121 TLAVIKSDIVNEEATQGRVYELPKPSISSNNNSKPVEDKDAVAFTEPEAQTDYLWW 180		
Qy	181 NNQSLSPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 240		
Db	181 NNQSLSPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 240		
Qy	241 TISPLANTSYSRGENLNLSCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 300		
Db	241 TISPLANTSYSRGENLNLSCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 300		
Qy	301 AHNSDTGILNRTTWTITVYAEPPKFTTSNNNSNPKVEDDAVALTCPEAQTDYLWWNN 360		
Db	301 AHNSDTGILNRTTWTITVYAEPPKFTTSNNNSNPKVEDDAVALTCPEAQTDYLWWNN 360		
Qy	361 QSLPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 420		
Db	361 QSLPVSPRQLQSNRNLTVLNFVNTRNTASYCETONPVSAARRSVDVLVLYGDPAP 420		
Qy	421 SPSITYYRPGVNLISLCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 480		
Db	421 SPSITYYRPGVNLISLCHAASNPAAQYSWFGNGTFOOSTQELFIPNITVNNGSYTQO 480		
Qy	481 NSASGHSTTVKITIVSABLKPKSISSNNNSKPVEDKDAVAFTEPEAQTDYLWWNGQS 540		

		Best Local Similarity Matches	Pred. No.	1.4e-199;	Indels	0;	Mismatches	0;	Gaps	0;
Db	481 NSASGHRTTVKTTIVSALPKPISNNSKVEDKDAVAFCTCEPEAQNTTYLWNGQS	540								
QY	541 LPSVPRQLSGNRTLTLFVNTRNDARAYVGCGTQNSVANSNSDPVTDVLIGPDTIISP	600								
Db	541 LPSVPRQLSGNRTLTLFVNTRNDARAYVGCGTQNSVANSNSDPVTDVLIGPDTIISP	600								
QY	601 PDSSYLSGANLNLSCHASASNPSQYSRPTGQATPQHQLTAKITENNNGTYACFVNL	660								
Db	601 PDSSYLSGANLNLSCHASASNPSQYSRPTGQATPQHQLTAKITENNNGTYACFVNL	660								
QY	661 ATGRNNNSIVKSITVSASGSTSPGLSAGATVGMIGVLGVVALI	702								
Db	661 ATGRNNNSIVKSITVSASGSTSPGLSAGATVGMIGVLGVVALI	702								
RESULT 14										
ID	ADD84721 standard; protein: 702 AA.									
XX										
AC	ADD84721;									
XX										
DT	29-JAN-2004 (First entry)									
XX	Human carcinoembryonic antigen (CEA) primary amino acid sequence.									
DE										
XX	Identification:									
KW	class I major histocompatibility complex-binding fragment;									
KW	class I MHC molecule; class I MHC-binding fragment; cytostatic; cancer;									
KW	human; carcinoembryonic antigen; CEA; epitope.									
XX										
OS	Synthetic.									
OS	Homo sapiens.									
XX										
PN	WO2003082317-A1.									
XX										
PD	09-OCT-2003.									
XX										
PP	20-MAR-2003; 2003WO-US008427.									
XX										
PR	22-MAR-2002; 2002US-0366822P.									
XX										
PA	(ZYCO-) ZYCOS INC.									
PA	(AVET) AVENTIS PASTEUR INC.									
XX										
PI	Chicz RM, Tomlinson AJ;									
XX										
DR	WPI; 2003-902907/82.									
XX										
PT	Identifying a class I major histocompatibility complex (MHC)-binding fragment of a polypeptide comprises isolating an MHC molecule, eluting the peptide from the molecule, and identifying the peptide as a polypeptide fragment.									
PT	Disclosure; Fig 8; 98pp; English.									
XX										
CC	The present invention describes a method for identifying a class I major histocompatibility complex (MHC)-binding fragment of a polypeptide by isolating from the tissue/cell line a class I MHC molecule bound to a peptide, where the peptide is a class I MHC-binding fragment of the polypeptide, eluting the peptide from the class I MHC molecule, and identifying the peptide as a fragment of the polypeptide. A class I MHC-binding fragment has cytostatic activity. Compositions and methods from the present invention can be used in diagnosing, preventing or treating cancer. The method may also be used in identifying peptides involved in the pathogenesis of or protection from diseases associated with expression of class I MHC molecules. The present sequence represents the human carcinoembryonic antigen (CEA) primary amino acid sequence, which is used in the exemplification of the present invention.									
XX										
PS	Sequence 702 AA;									
XX										
AC	ADN3 9014 standard; protein: 702 AA.									
XX										
AC	ADN3 9014;									
XX										
DT	17-JUN-2004 (First entry)									
XX	Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:332.									
DE										
XX	Human; differential expression; cancer; angiogenic disorder; fibrotic disorder; priapism; ischaemia; heart disease; atherosclerosis; inflammatory disease; autoimmune disease; scarring; uterine fibroid; retinal neovascularization syndrome; drug screening; drug targeting; wound healing; contraception; cytostatic; cardiotonic; immunomodulatory; pulmonary; gene therapy; vaccine.									
OS	Homo sapiens.									
XX										
PN	WO2003042661-A2.									

Query Match.

100.0%; Score 3721; DB 7; Length 702;

"THIS PAGE LEFT BLANK"

Copyright (c) 1993 - 2006 Biocceleration Ltd.

GenCore version 5.1.7

OM protein - protein search, using sw model

Run on: April 10, 2006, 18:07:51 ; Search time 179.941 Seconds
 (without alignments) 1630.072 Million cell updates/sec

Title: US-10-734-564-72

Perfect score: 3721
 Sequence: 1 MESPSAPPHRWCIPWQRLLL.....LSAGATVGIMIGVVLGVALLI 702

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA_Main:
 1: /cgn2_6/prodata/1/puppaa/us07_pubcomb.dep: *
 2: /cgn2_6/prodata/1/puppaa/us08_pubcomb.dep: *
 3: /cgn2_6/prodata/1/puppaa/us09_pubcomb.dep: *
 4: /cgn2_6/prodata/1/puppaa/us10_pubcomb.dep: *
 5: /cgn2_6/prodata/1/puppaa/us11_pubcomb.dep: *
 6: /cgn2_6/prodata/1/puppaa/us11_pubcomb.dep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3721	100.0	702	4	US-10-157-031-341
2	3721	100.0	702	4	US-10-207-55-87
3	3721	100.0	702	4	US-10-117-937-592
4	3721	100.0	702	4	US-10-295-327-332
5	3721	100.0	702	4	US-10-245-371-282
6	3721	100.0	702	4	US-10-253-286-282
7	3721	100.0	702	4	US-10-380-336-16
8	3721	100.0	702	4	US-10-380-337A-458
9	3721	100.0	702	4	US-10-712-124-74
10	3721	100.0	702	4	US-10-734-564-72
11	3721	100.0	702	4	US-10-657-022-88
12	3721	100.0	702	5	US-10-473-127-1462
13	3721	100.0	702	5	US-10-473-127-1466
14	3721	100.0	702	5	US-10-473-127-1500
15	3721	100.0	702	5	US-10-473-127-1503
16	3721	100.0	702	5	US-10-696-639-65
17	3721	100.0	702	5	US-11-067-064-592
18	3721	100.0	702	5	US-10-696-639-65
19	3721	100.0	702	5	US-10-893-018-2
20	3721	100.0	702	5	US-10-893-018-2
21	3721	100.0	702	5	US-10-756-149-4748
22	3721	100.0	702	6	US-11-067-064-592
23	3721	100.0	702	6	US-11-067-064-592
24	3721	100.0	734	3	US-09-756-551A-17
25	3721	100.0	734	5	US-10-473-127-1489
26	3721	99.9	796	5	US-12-127-1496
27	3701.5	99.5	701	4	US-10-168-417A-4

28 3700 99.4 698 5 US-10-473-127-1464 Sequence 1464, Ap
 29 3700 99.4 698 5 US-10-473-127-1472 Sequence 1472, Ap
 30 3700 99.4 698 5 US-10-473-127-1488 Sequence 1488, Ap
 31 3700 99.4 698 5 US-10-473-127-1493 Sequence 1493, Ap
 32 3694 99.3 702 5 US-10-473-127-1483 Sequence 1483, Ap
 33 3687 99.1 702 5 US-10-473-127-1485 Sequence 1485, Ap
 34 3687 99.1 702 5 US-10-473-127-1491 Sequence 1491, Ap
 35 3685.5 99.0 697 5 US-10-473-127-1475 Sequence 1475, Ap
 36 3683 99.0 702 5 US-10-473-127-1465 Sequence 1465, Ap
 37 3668 98.6 702 5 US-10-473-127-1496 Sequence 1496, Ap
 38 3643 97.9 698 5 US-10-473-127-1482 Sequence 1482, Ap
 39 3625 97.4 681 5 US-10-893-018-4 Sequence 4, Appl
 40 3603 96.8 717 5 US-10-893-018-6 Sequence 6, Appl
 41 3565 95.8 713 5 US-10-893-018-10 Sequence 10, Appl
 42 3535.5 95.0 708 5 US-10-893-018-8 Sequence 8, Appl
 43 3453 92.8 737 3 US-09-925-501-133 Sequence 1133, Ap
 44 3453 92.8 737 5 US-10-473-127-1476 Sequence 1476, Ap
 45 3417 91.8 645 5 US-10-510-523-3 Sequence 3, Appl

ALIGNMENTS

RESULT 1

US-10-157-031-341
 Sequence 341, Application US/10157031
 Publication No. US20030108890A1

GENERAL INFORMATION:

APPLICANT: Baranova, A. V.
 APPLICANT: Yankovsky, N. K.
 APPLICANT: Kozlov, A. P.
 APPLICANT: Lobachev, A. V.

TITLE OF INVENTION:

In silico screening for phenotype-associated expressed sequenc

FILE REFERENCE:

2760-103

CURRENT FILING DATE:

2003-05-30

NUMBER OF SEQ ID NOS:

415

SOFTWARE:

Patentin version 3.1

SEQ ID NO:

341

LENGTH:

702

TYPE:

PRT

ORGANISM:

Homo sapiens

US-10-157-031-341

Query Match

100.0%; Score 3721; DB 4; Length 702;

Best Local Similarity

100.0%; Prod. No. 4-Se-207;

Matches

702; Conservative

Sequence

341, App

Sequence

87, Appl

Sequence

592, App

Sequence

332, App

Sequence

282, App

Sequence

1, App

Sequence

16, App

Sequence

458, App

Sequence

74, Appl

Sequence

72, Appl

Sequence

88, Appl

Sequence

1462, App

Sequence

1466, App

Sequence

1503, App

Sequence

1503, App

Sequence

181, NNQLPFPVPLQLNSNGRNLTLFLNTRNDTASYKCTEPONVSARRSDSVLNLYGPDAP

Sequence

181, NNQLPFPVPLQLNSNGRNLTLFLNTRNDTASYKCTEPONVSARRSDSVLNLYGPDAP

Sequence

241, TISPLNTSYRSGENLNSCHASNPQAQSWPFGTFOOSTELFPIPNLVNNSYTCQ

Sequence

301, AHNSDGLRRTVTITVAAPEPKPTTSNNNNVEDDAVALTCPEQNTYLMVN

Sequence

QY 361 QSLPVSPRLQLSDNRITLTLSVTRNDVGPYEGGIONELSVHSDPVILNLYGPPDPTI 420
Db 361 QSLPVSPRLQLSDNRITLTLSVTRNDVGPYEGGIONELSVHSDPVILNLYGPPDPTI 420
Qy 421 SPSYTYPGVLNLSCHAASNPQYSWLDGNIOHTQELFISITEKNSGLYTCQAN 480
Db 421 SPSYTYPGVLNLSCHAASNPQYSWLDGNIOHTQELFISITEKNSGLYTCQAN 480
Db 421 SPSYTYPGVLNLSCHAASNPQYSWLDGNIOHTQELFISITEKNSGLYTCQAN 480
Qy 481 NSASGHSRRTVKITIVSABELPKPSISSNNSKPVEDKDAVFTCEPEAQNTYLWNGQS 540
Db 481 NSASGHSRRTVKITIVSABELPKPSISSNNSKPVEDKDAVFTCEPEAQNTYLWNGQS 540
Db 481 NSASGHSRRTVKITIVSABELPKPSISSNNSKPVEDKDAVFTCEPEAQNTYLWNGQS 540
Qy 541 LPVSPIQLQSNRNLTLFNVTRNDARAYVGCTQNSVSANRSDPVTLDVLYGPDPTIISP 600
Db 541 LPVSPIQLQSNRNLTLFNVTRNDARAYVGCTQNSVSANRSDPVTLDVLYGPDPTIISP 600
Qy 541 LPVSPIQLQSNRNLTLFNVTRNDARAYVGCTQNSVSANRSDPVTLDVLYGPDPTIISP 600
Db 601 POSSYSGANLNLSCHASNSNPQYSQYSRINGPQOHTQVLFAKTTNNNGTYACFVSNL 660
Qy 601 POSSYSGANLNLSCHASNSNPQYSQYSRINGPQOHTQVLFAKTTNNNGTYACFVSNL 660
Db 601 POSSYSGANLNLSCHASNSNPQYSQYSRINGPQOHTQVLFAKTTNNNGTYACFVSNL 660
Qy 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702
Db 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702
Qy 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702
Db 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702

RESULT 2
US-10-207-655-87
; Sequence 87, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden-Ledbetter, Martha S.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 330069 401C1
; CURRENT APPLICATION NUMBER: US/10/207, 655
; CURRENT FILING DATE: 2002-07-25
; NUMBER OF SEQ ID NOS: 426
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 87
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-207-655-87

Query Match 100.0%; Score 3721; DB 4; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESPSAPHRWCIPWQRLLTASLLTFWNRPPTAKLTTESTPPNVAGKEVILLVHLNLPQ 60
Db 1 MESPSAPHRWCIPWQRLLTASLLTFWNRPPTAKLTTESTPPNVAGKEVILLVHLNLPQ 60
Qy 61 HLFGYSMYKGERVDGNGQIGVWIGTOATCPAYSSREIYPPNASSLIQIONDGFY 120
Db 61 HLFGYSMYKGERVDGNGQIGVWIGTOATCPAYSSREIYPPNASSLIQIONDGFY 120
Qy 121 THVIKSDLVNEBATGQPRVYBLPKPSISSNNSKPVEDKDAVFTCEPETODATYMW 180
Db 121 THVIKSDLVNEBATGQPRVYBLPKPSISSNNSKPVEDKDAVFTCEPETODATYMW 180
Qy 181 NNQSLPVSPRLQLQSNRNLTLFNVTRNDTASYKCTONPVASRSVILNLYGDP 240
Db 181 NNQSLPVSPRLQLQSNRNLTLFNVTRNDTASYKCTONPVASRSVILNLYGDP 240
Qy 241 TISPLNTSYRSGENLNLSCHAASNPQAOYSWFGNGTFOOSTBLFIRNITVNNSGTYCQ 300
Db 241 TISPLNTSYRSGENLNLSCHAASNPQAOYSWFGNGTFOOSTBLFIRNITVNNSGTYCQ 300
Qy 301 AFNSDGLNRTWTTITYAEPKPFTSNNSNPVEDDAVFTCEPEAQNTYLWNGN 360
Db 301 AFNSDGLNRTWTTITYAEPKPFTSNNSNPVEDDAVFTCEPEAQNTYLWNGN 360
Qy 361 QSLPVSPRLQLSDNRITLTLSVTRNDVGPYEGGIONELSVHSDPVILNLYGPPDPTI 420
Db 361 QSLPVSPRLQLSDNRITLTLSVTRNDVGPYEGGIONELSVHSDPVILNLYGPPDPTI 420

RESULT 3
US-10-117-937-52
; Sequence 592, Application US/10117937
; Publication No. US20030220239A1
; GENERAL INFORMATION:
; APPLICANT: CIL IMMUNO THERAPIES CORP.
; APPLICANT: SIMARD, John, J. L.
; APPLICANT: DIAMOND, David, C.
; APPLICANT: LIU, Liping
; APPLICANT: XIE, Zhidong
; TITLE OF INVENTION: EPITOPE SEQUENCES
; FILE REFERENCE: CILMM-027A
; CURRENT APPLICATION NUMBER: US/10/117, 937
; CURRENT FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: US 6/0/282, 211
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 6/0/337, 017
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: US 6/0/363, 210
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 602
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 592
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-117-937-52

Query Match 100.0%; Score 3721; DB 4; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESPSAPHRWCIPWQRLLTASLLTFWNRPPTAKLTTESTPPNVAGKEVILLVHLNLPQ 60
Db 1 MESPSAPHRWCIPWQRLLTASLLTFWNRPPTAKLTTESTPPNVAGKEVILLVHLNLPQ 60
Qy 61 HLFGYSMYKGERVDGNGQIGVWIGTOATCPAYSSREIYPPNASSLIQIONDGFY 120
Db 61 HLFGYSMYKGERVDGNGQIGVWIGTOATCPAYSSREIYPPNASSLIQIONDGFY 120
Qy 121 THVIKSDLVNEBATGQPRVYBLPKPSISSNNSKPVEDKDAVFTCEPETODATYMW 180
Db 121 THVIKSDLVNEBATGQPRVYBLPKPSISSNNSKPVEDKDAVFTCEPETODATYMW 180
Qy 181 NNQSLPVSPRLQLQSNRNLTLFNVTRNDTASYKCTONPVASRSVILNLYGDP 240
Db 181 NNQSLPVSPRLQLQSNRNLTLFNVTRNDTASYKCTONPVASRSVILNLYGDP 240
Qy 241 TISPLNTSYRSGENLNLSCHAASNPQAOYSWFGNGTFOOSTBLFIRNITVNNSGTYCQ 300
Db 241 TISPLNTSYRSGENLNLSCHAASNPQAOYSWFGNGTFOOSTBLFIRNITVNNSGTYCQ 300
Qy 301 AFNSDGLNRTWTTITYAEPKPFTSNNSNPVEDDAVFTCEPEAQNTYLWNGN 360
Db 301 AFNSDGLNRTWTTITYAEPKPFTSNNSNPVEDDAVFTCEPEAQNTYLWNGN 360
Qy 361 QSLPVSPRLQLSDNRITLTLSVTRNDVGPYEGGIONELSVHSDPVILNLYGPPDPTI 420
Db 361 QSLPVSPRLQLSDNRITLTLSVTRNDVGPYEGGIONELSVHSDPVILNLYGPPDPTI 420

RESULT 4
QY 421 SPSYTYPGVLNLSCHAASNPQYSWLDGNIOHTQELFISITEKNSGLYTCQAN 480
Db 421 SPSYTYPGVLNLSCHAASNPQYSWLDGNIOHTQELFISITEKNSGLYTCQAN 480
Db 421 SPSYTYPGVLNLSCHAASNPQYSWLDGNIOHTQELFISITEKNSGLYTCQAN 480
Qy 481 NSASGHSRRTVKITIVSABELPKPSISSNNSKPVEDKDAVFTCEPEAQNTYLWNGQS 540
Db 481 NSASGHSRRTVKITIVSABELPKPSISSNNSKPVEDKDAVFTCEPEAQNTYLWNGQS 540
Db 481 NSASGHSRRTVKITIVSABELPKPSISSNNSKPVEDKDAVFTCEPEAQNTYLWNGQS 540
Qy 541 LPVSPIQLQSNRNLTLFNVTRNDARAYVGCTQNSVSANRSDPVTLDVLYGPDPTIISP 600
Db 541 LPVSPIQLQSNRNLTLFNVTRNDARAYVGCTQNSVSANRSDPVTLDVLYGPDPTIISP 600
Qy 541 LPVSPIQLQSNRNLTLFNVTRNDARAYVGCTQNSVSANRSDPVTLDVLYGPDPTIISP 600
Db 601 POSSYSGANLNLSCHASNSNPQYSQYSRINGPQOHTQVLFAKTTNNNGTYACFVSNL 660
Qy 601 POSSYSGANLNLSCHASNSNPQYSQYSRINGPQOHTQVLFAKTTNNNGTYACFVSNL 660
Db 601 POSSYSGANLNLSCHASNSNPQYSQYSRINGPQOHTQVLFAKTTNNNGTYACFVSNL 660
Qy 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702
Db 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702
Qy 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702
Db 661 ATGRNNSTVKSTIVSAGTSPGLSAGATVGIMGVGVALL 702

RESULT 4
US-10-295-027-332

; Sequence 332, Application US/10295027

; Publication No. US2005023230A1

; GENERAL INFORMATION:

; APPLICANT: Arar, Daniel

; APPLICANT: Aziz, Natasha

; APPLICANT: Ginsberg, Wendy M.

; APPLICANT: Gish, Kurt C.

; APPLICANT: Glynn, Richard

; APPLICANT: Heverzi, Peter A.

; APPLICANT: Mack, David H.

; APPLICANT: Murray, Richard

; APPLICANT: Watson, Susan R.

; APPLICANT: Bos Biotechnology, Inc.

TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and FILE REFERENCE: 018501-012300US CURRENT APPLICATION NUMBER: US10/295,027 CURRENT FILING DATE: 2002-11-13 PRIOR APPLICATION NUMBER: US 09/663,733 PRIOR FILING DATE: 2000-09-15 PRIOR APPLICATION NUMBER: US 60/350,666 PRIOR FILING DATE: 2001-11-13 PRIOR APPLICATION NUMBER: US 60/335,394 PRIOR APPLICATION NUMBER: US 60/332,464 PRIOR FILING DATE: 2001-11-21 PRIOR APPLICATION NUMBER: US 60/334,393 PRIOR FILING DATE: 2001-11-29 PRIOR APPLICATION NUMBER: US 60/340,376 PRIOR APPLICATION NUMBER: US 60/347,211 PRIOR FILING DATE: 2002-01-08 PRIOR APPLICATION NUMBER: US 60/347,349 PRIOR FILING DATE: 2002-01-10 PRIOR APPLICATION NUMBER: US 60/355,250 PRIOR APPLICATION NUMBER: US 60/356,714 PRIOR FILING DATE: 2002-02-13 ; Remaining Prior Application data removed - See File Wrapper or PALM.

Db 241 TISPLNTSYRSGENLNLSCHAASNPAQYSWFGNGTFOOSTOELFIPNITVNNSGTYCQ 300 Qy 301 AHNSDGLNRTVTITVYAEPPKFTTSNNSNPVEDDAVALTCERIQTNTLYWNN 360 Db 301 AHNSDGLNRTVTITVYAEPPKFTTSNNSNPVEDDAVALTCERIQTNTLYWNN 360 Qy 361 OSLPVSPRLQLSNDRTLTLSVTRNDVGPECIONELSDVHDSPVILNVLYGPDPTI 420 Db 361 OSLPVSPRLQLSNDRTLTLSVTRNDVGPECIONELSDVHDSPVILNVLYGPDPTI 420 Qy 421 SPSYTYPGPNLSSLCHAASNPAAQYSWLGNDNQHTQELFISNTEKOSGLYTQCAN 480 Db 421 SPSYTYPGPNLSSLCHAASNPAAQYSWLGNDNQHTQELFISNTEKOSGLYTQCAN 480 Qy 480 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Db 480 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Qy 481 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Db 481 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Qy 541 LPVSPRLQLSNGNRTLTFLNVTRNDARAYVGCGIONVSANRSDPVILDVLYGPDPTI 600 Db 541 LPVSPRLQLSNGNRTLTFLNVTRNDARAYVGCGIONVSANRSDPVILDVLYGPDPTI 600 Qy 601 PDSSYLSGANLNLSCSASNSPQYSWRINGPQHOTLFAKTPNNNGTYACFVSNL 660 Db 601 PDSSYLSGANLNLSCSASNSPQYSWRINGPQHOTLFAKTPNNNGTYACFVSNL 660 Qy 661 ATGRNNISIVKSIVSAGSTGPGSLSAGATVGIMIGVGVALLI 702 Db 661 ATGRNNISIVKSIVSAGSTGPGSLSAGATVGIMIGVGVALLI 702

Db 241 TISPLNTSYRSGENLNLSCHAASNPAQYSWFGNGTFOOSTOELFIPNITVNNSGTYCQ 300 Qy 301 AHNSDGLNRTVTITVYAEPPKFTTSNNSNPVEDDAVALTCERIQTNTLYWNN 360 Db 301 AHNSDGLNRTVTITVYAEPPKFTTSNNSNPVEDDAVALTCERIQTNTLYWNN 360 Qy 361 OSLPVSPRLQLSNDRTLTLSVTRNDVGPECIONELSDVHDSPVILNVLYGPDPTI 420 Db 361 OSLPVSPRLQLSNDRTLTLSVTRNDVGPECIONELSDVHDSPVILNVLYGPDPTI 420 Qy 421 SPSYTYPGPNLSSLCHAASNPAAQYSWLGNDNQHTQELFISNTEKOSGLYTQCAN 480 Db 421 SPSYTYPGPNLSSLCHAASNPAAQYSWLGNDNQHTQELFISNTEKOSGLYTQCAN 480 Qy 480 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Db 480 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Qy 481 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Db 481 NSASGHRTTKITTSABLKPSSISSNNSKVEDDAVAFTCEPEAQNTLYLWWNGQS 540 Qy 541 LPVSPRLQLSNGNRTLTFLNVTRNDARAYVGCGIONVSANRSDPVILDVLYGPDPTI 600 Db 541 LPVSPRLQLSNGNRTLTFLNVTRNDARAYVGCGIONVSANRSDPVILDVLYGPDPTI 600 Qy 601 PDSSYLSGANLNLSCSASNSPQYSWRINGPQHOTLFAKTPNNNGTYACFVSNL 660 Db 601 PDSSYLSGANLNLSCSASNSPQYSWRINGPQHOTLFAKTPNNNGTYACFVSNL 660 Qy 661 ATGRNNISIVKSIVSAGSTGPGSLSAGATVGIMIGVGVALLI 702 Db 661 ATGRNNISIVKSIVSAGSTGPGSLSAGATVGIMIGVGVALLI 702

RESULT 5
US-10-245-871-282

; Sequence 282, Application US/10245871

; Publication No. US20050235594A1

; GENERAL INFORMATION:

; APPLICANT: XU, MINZHEN

; TITLE OF INVENTION: TI-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

; FILE REFERENCE: REH-2013

; CURRENT APPLICATION NUMBER: US/10/245,871

; CURRENT FILING DATE: 2003-01-09

; PRIOR APPLICATION NUMBER: 10/197,000

APPLICANT: Tomlinson, Andy
 TITLE OF INVENTION: PEPTIDE EPITOPES RECOGNIZED BY ANTIGEN
 FILE REFERENCE: 08191-019US1.
 CURRENT APPLICATION NUMBER: US/10/380,136
 CURRENT FILING DATE: 2003-03-11
 PRIORITY APPLICATION NUMBER: PCT/US01/28467
 PRIORITY FILING DATE: 2001-09-12
 PRIORITY APPLICATION NUMBER: US 60/232,185
 PRIORITY FILING DATE: 2000-09-12
 NUMBER OF SEQ ID NOS: 16
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 16
 LENGTH: 702
 TYPE: PRT
 ORGANISM: Homo sapiens
 S-10-380-136-16

Query Match 100.0%; Score 3721; DB 4; Length 702;
 Best Local Similarity 100.0%; Pred. No. 4.5e-207;
 Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MESPSAAPHRWCIPWORLLTASLTLFWNPPTAKLTTESTPFPVNAVGKEVLLVHLNLPQ
 1 MESPSAAPHRWCIPWORLLTASLTLFWNPPTAKLTTESTPFPVNAVGKEVLLVHLNLPQ

61 HLFGYSWYKGERVDGQRQIQIGVIGQATPGAVSGREIYPNASLIQNIQNDTGFY 120
 61 HLFGYSWYKGERVDGQRQIQIGVIGQATPGAVSGREIYPNASLIQNIQNDTGFY 120

121 TLHVKSDLVNEBEATCQFRVPELPKPSISNNSKPVEDKDAVAPTCPEPETODATYWWV 180
 121 TLHVKSDLVNEBEATCQFRVPELPKPSISNNSKPVEDKDAVAPTCPEPETODATYWWV 180

241 TISPINTSYRGENLNLSCHAASNPAAQSYFNGTFFQSQSTQELPFPNITNNSGYTQ 300
 241 TISPINTSYRGENLNLSCHAASNPAAQSYFNGTFFQSQSTQELPFPNITNNSGYTQ 300

301 AHNSDTGLNRITVTITVVAEPPKPIITSNNSPVDEDVALTEBPEIQTNTYWWNN 360
 301 AHNSDTGLNRITVTITVVAEPPKPIITSNNSPVDEDVALTEBPEIQTNTYWWNN 360

361 QSLPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 420
 361 QSLPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 420

421 SPSYYTYRPGVNLISLSCHAASNPAAQSYFNGTFOOSTQELPFPNITNNSGYTQ 300
 421 SPSYYTYRPGVNLISLSCHAASNPAAQSYFNGTFOOSTQELPFPNITNNSGYTQ 300

481 NSASCHSRITVKTITVSAELPKPSISSNNSPVDEDKDAVFTCEPAQNTYLWNGQS 540
 481 NSASCHSRITVKTITVSAELPKPSISSNNSPVDEDKDAVFTCEPAQNTYLWNGQS 540

541 LPVSPLQLQSNGNRITLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 600
 541 LPVSPLQLQSNGNRITLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 600

601 PDSSLSGAMLNLSCHASNPSPQSYFNGTFOOSTQELPFPNITNNSGYTQ 660
 601 PDSSLSGAMLNLSCHASNPSPQSYFNGTFOOSTQELPFPNITNNSGYTQ 660

661 ATGRNNTIVSITASGSPGLSAGTGVIGMIGLVGALLI 702
 661 ATGRNNTIVSITASGSPGLSAGTGVIGMIGLVGALLI 702

Sequence 458, Application US/10/149137A
 Publication No. US20040146519A1
 GENERAL INFORMATION:
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chesnut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elisa
 TITLE OF INVENTION: Inducing Cellular Immune Responses to Carcinoembryonic
 TIME OF INVENTION: Antigen Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2006-0080005
 CURRENT APPLICATION NUMBER: US/10/149,137A
 CURRENT FILING DATE: 2002-06-10
 PRIORITY APPLICATION NUMBER: PCT/US00/33574
 PRIORITY FILING DATE: 2000-12-11
 PRIORITY APPLICATION NUMBER: US 09/458,302
 NUMBER OF SEQ ID NOS: 562
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 458
 LENGTH: 702
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-149-137A-458

Query Match 100.0%; Score 3721; DB 4; Length 702;
 Best Local Similarity 100.0%; Pred. No. 4.5e-207;
 Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MESPSAAPHRWCIPWORLLTASLTLFWNPPTAKLTTESTPFPVNAVGKEVLLVHLNLPQ
 1 MESPSAAPHRWCIPWORLLTASLTLFWNPPTAKLTTESTPFPVNAVGKEVLLVHLNLPQ

61 HLFGYSWYKGERVDGQRQIQIGVIGQATPGAVSGREIYPNASLIQNIQNDTGFY 120
 61 HLFGYSWYKGERVDGQRQIQIGVIGQATPGAVSGREIYPNASLIQNIQNDTGFY 120

121 TLHVKSDLVNEBEATCQFRVPELPKPSISNNSKPVEDKDAVAPTCPEPETODATYWWV 180
 121 TLHVKSDLVNEBEATCQFRVPELPKPSISNNSKPVEDKDAVAPTCPEPETODATYWWV 180

241 TISPINTSYRGENLNLSCHAASNPAAQSYFNGTFFQSQSTQELPFPNITNNSGYTQ 300
 241 TISPINTSYRGENLNLSCHAASNPAAQSYFNGTFFQSQSTQELPFPNITNNSGYTQ 300

301 AHNSDTGLNRITVTITVVAEPPKPIITSNNSPVDEDVALTEBPEIQTNTYWWNN 360
 301 AHNSDTGLNRITVTITVVAEPPKPIITSNNSPVDEDVALTEBPEIQTNTYWWNN 360

361 QSLPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 420
 361 QSLPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 420

421 TISPINTSYRGENLNLSCHAASNPAAQSYFNGTFOOSTQELPFPNITNNSGYTQ 300
 421 TISPINTSYRGENLNLSCHAASNPAAQSYFNGTFOOSTQELPFPNITNNSGYTQ 300

481 NSASCHSRITVKTITVSAELPKPSISSNNSPVDEDKDAVFTCEPAQNTYLWNGQS 540
 481 NSASCHSRITVKTITVSAELPKPSISSNNSPVDEDKDAVFTCEPAQNTYLWNGQS 540

541 OSIPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 600
 541 OSIPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 600

601 361 QSLPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 660
 601 361 QSLPVSPRLQLSNDNRTLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 660

661 421 SPSYYTYRPGVNLISLSCHAASNPAAQSYFNGTFOOSTQELPFPNITNNSGYTQ 702
 661 421 SPSYYTYRPGVNLISLSCHAASNPAAQSYFNGTFOOSTQELPFPNITNNSGYTQ 702

702 481 NSASCHSRITVKTITVSAELPKPSISSNNSPVDEDKDAVFTCEPAQNTYLWNGQS 540
 702 481 NSASCHSRITVKTITVSAELPKPSISSNNSPVDEDKDAVFTCEPAQNTYLWNGQS 540

702 541 LPVSPLQLQSNGNRITLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 600
 702 541 LPVSPLQLQSNGNRITLTLSVTRNDVGPECGTONELSVHDSPVILNLYGDDPTI 600

RESULT 8
US-10-149-137A-456

RESULT 9
US-10-712-124-74
; Sequence 74, Application US/10712124
; Publication No. US20041046907A1
; GENERAL INFORMATION:
; APPLICANT: SMITH, VICTORIA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETECTING DYSPLASIA
; FILE REFERENCE: P2000R1
; CURRENT APPLICATION NUMBER: US/10/712,124
; CURRENT FILING DATE: 2003-11-13
; PRIORITY APPLICATION NUMBER: US 60/425,813
; PRIORITY FILING DATE: 2003-11-13
; NUMBER OF SEQ ID NOS: 123
; SEQ ID NO: 74
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapien
; US-10-712-124-74

Query Match 100.0%; Score 3721; DB 4; Length 702;

Best Local Similarity 100.0%; Pred. No. 4_5e-207; Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESPSPAPHRCIPWQRLLTASLLTFNNPPTAKLTIESTPFNVAEGKEVLLVHLNPQ 60
Db 1 MESPSPAPHRCIPWQRLLTASLLTFNNPPTAKLTIESTPFNVAEGKEVLLVHLNPQ 60
Qy 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Db 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Qy 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Db 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Qy 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Db 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Qy 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Db 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Qy 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSVILNLVYGDAP 240
Db 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSDSVILNLVYGDAP 240
Qy 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSVILNLVYGDAP 240
Db 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSDSVILNLVYGDAP 240
Qy 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Db 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Qy 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Db 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Qy 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Db 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Qy 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Db 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Qy 361 QSLPVSPLQLQSNDRNTLTLSTTRNDGPGYECQIQLNSVHDSDPVILNLVLYGPDDPTI 420
Db 361 QSLPVSPLQLQSNDRNTLTLSTTRNDGPGYECQIQLNSVHDSDPVILNLVLYGPDDPTI 420
Qy 361 QSLPVSPLQLQSNDRNTLTLSTTRNDGPGYECQIQLNSVHDSDPVILNLVLYGPDDPTI 420
Db 361 QSLPVSPLQLQSNDRNTLTLSTTRNDGPGYECQIQLNSVHDSDPVILNLVLYGPDDPTI 420
Qy 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Db 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Qy 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Db 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Qy 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Db 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Qy 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Db 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Qy 541 LPSPSPRQLQSNRNTLTLNFNTRDARAVCGIQNSVANRSPVTDVLVYGPDTIISP 600
Db 541 LPSPSPRQLQSNRNTLTLNFNTRDARAVCGIQNSVANRSPVTDVLVYGPDTIISP 600
Qy 601 PDSSYLSGANLNLSCHASNPSPQYSWRINGTPOQHQLFIATKTPNNNGTACFVNL 660
Db 601 PDSSYLSGANLNLSCHASNPSPQYSWRINGTPOQHQLFIATKTPNNNGTACFVNL 660
Qy 661 ATGRNNNSIVKSITVSAASGTSPGLSAGATVGIMIGVVLGVALLI 702

RESULT 10
US-10-734-564-72
; Sequence 72, Application US/10734564
; Publication No. US20040157278A1
; GENERAL INFORMATION:
; APPLICANT: Christopher C Burgess et al.
; TITLE OF INVENTION: Detection Methods Using TIMP1
; FILE REFERENCE: 1657/2012
; CURRENT APPLICATION NUMBER: US/10/734, 564
; NUMBER OF SEQ ID NOS: 138
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 72
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-734-564-72

Query Match 100.0%; Score 3721; DB 4; Length 702;

Best Local Similarity 100.0%; Pred. No. 4_5e-207; Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESPSPAPHRCIPWQRLLTASLLTFNNPPTAKLTIESTPFNVAEGKEVLLVHLNPQ 60
Db 1 MESPSPAPHRCIPWQRLLTASLLTFNNPPTAKLTIESTPFNVAEGKEVLLVHLNPQ 60
Qy 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Db 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Qy 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Db 61 HLFGYSWYKGERVDGNRQIGIVGIGVQATPGAYSGREITPNASLLIONIQNDGFY 120
Qy 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Db 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Qy 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Db 121 TLUVIKSDLVNEEATGQRVYPELPKPSISNNNSKPVEDDKAVAFCTEPETDYLWV 180
Qy 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSVILNLVYGDAP 240
Db 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSDSVILNLVYGDAP 240
Qy 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSDSVILNLVYGDAP 240
Db 181 NNQSLPSPRQLQSNPNTLNFNTRDNTASYKCETONPVARRSDSVILNLVYGDAP 240
Qy 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Db 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Qy 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Db 241 TISPLNTSYRSGENLNISCHAASNPQYSWFGNGTFOQSTQELFINITVNNSGTQ 300
Qy 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Db 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Qy 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Db 301 AHNSDTGJNRTTWTITVYAEPPKFTTSNNSNPVEDDAVALTCPEPRIQNTLYWNN 360
Qy 361 QSLPVSPLQLQSNDRNTLTLSTTRNDGPGYECQIQLNSVHDSDPVILNLVLYGPDDPTI 420
Db 361 QSLPVSPLQLQSNDRNTLTLSTTRNDGPGYECQIQLNSVHDSDPVILNLVLYGPDDPTI 420
Qy 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Db 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Qy 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Db 421 SISYYTYRPGVNLISCHASNPQYSWMLDGNQHTQBLFISITTEKNSGLYTQCAN 480
Qy 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Db 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Qy 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Db 481 NSASGHSRRTVKITVSABELPKISSNNSKPVEDDKAVAFCTEPQNTLYWNGQS 540
Qy 541 LPSPSPRQLQSNRNTLTLNFNTRDARAVCGIQNSVANRSPVTDVLVYGPDTIISP 600
Db 541 LPSPSPRQLQSNRNTLTLNFNTRDARAVCGIQNSVANRSPVTDVLVYGPDTIISP 600
Qy 601 PDSSYLSGANLNLSCHASNPSPQYSWRINGTPOQHQLFIATKTPNNNGTACFVNL 660
Db 601 PDSSYLSGANLNLSCHASNPSPQYSWRINGTPOQHQLFIATKTPNNNGTACFVNL 660
Qy 661 ATGRNNNSIVKSITVSAASGTSPGLSAGATVGIMIGVVLGVALLI 702

```

Db      661 ATGRNNNSIVKSITVSAGSTSPGLSAGATVGIMIGLVGVALI 702
; Sequence 88, Application US/10657022
; Publication No. US20040180354A1
; GENERAL INFORMATION:
; APPLICANT: Simard, John J. L.
; APPLICANT: Diamond, David C.
; APPLICANT: Liu, Liping
; APPLICANT: Liu, Zheng
; TITLE OF INVENTION: REPTOPE SEQUENCES
; FILE REFERENCE: MANNK_032A
; CURRENT APPLICATION NUMBER: US/10/657, 022
; CURRENT FILING DATE: 2003-09-04
; PRIOR APPLICATION NUMBER: 60/409123
; PRIOR FILING DATE: 2002-09-06
; NUMBER OF SEQ ID NOS: 610
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 88
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-657-022-88

Query Match Similarity 100.0%; Score 3721; DB 4; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MESPSAPRHRNCIPWQRLLTASLTFWNPPTTAKLTIESTPNVAEGKEVLLVNLNPQ 60
Db 1 MESPSAPRHRNCIPWQRLLTASLTFWNPPTTAKLTIESTPNVAEGKEVLLVNLNPQ 60
Qy 61 HLFGYSWYKGERVDGMRQIGVIGVIGTQATPGAVSGRELYPNASLLIONIQNTGYF 120
Db 61 HLFGYSWYKGERVDGMRQIGVIGVIGTQATPGAVSGRELYPNASLLIONIQNTGYF 120
Qy 121 TLHVTKSDLVNEBEATQFVYPLPKPSSISSNSKVEKDQAVAFCEPETOQDATLWWV 180
Db 121 TLHVTKSDLVNEBEATQFVYPLPKPSSISSNSKVEKDQAVAFCEPETOQDATLWWV 180
Qy 181 NNQSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 240
Db 181 NNQSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 240
Qy 241 TISPINTSYSENGLNSCHASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 300
Db 241 TISPINTSYSENGLNSCHASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 300
Qy 301 AHNSDTGLENRTVTITVYAEPPKPKITSNSNSNPVEDDAVLTCEPEIQTLYWNN 360
Db 301 AHNSDTGLENRTVTITVYAEPPKPKITSNSNSNPVEDDAVLTCEPEIQTLYWNN 360
Qy 361 OSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 420
Db 361 OSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 420
Qy 421 SPSYYTYRPGSTLSISCHAASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 480
Db 421 SPSYYTYRPGSTLSISCHAASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 480
Qy 481 NSASGRSRTRKTTITVSAELPKPSISNNSKVEKDQAVFTCEPAAQNTYLWNGQS 540
Db 481 NSASGRSRTRKTTITVSAELPKPSISNNSKVEKDQAVFTCEPAAQNTYLWNGQS 540
Qy 541 LPVSPLQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 600
Db 541 LPVSPLQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 600
Qy 601 PDSSYLSGANLNLSCHASNPQSWFNGTFOQSTOELFPNTINNSSYTCQ 660
Db 601 PDSSYLSGANLNLSCHASNPQSWFNGTFOQSTOELFPNTINNSSYTCQ 660

```

```

Db      601 PDSSYLSGANLNLSCHASNPQSWFNGTFOQSTOELFPNTINNSSYTCQ 660
; Sequence 12, Application US/10473127
; Publication No. US20040236031A1
; GENERAL INFORMATION:
; APPLICANT: Zycos Inc.
; TITLE OF INVENTION: TRANSLATIONAL PROFILING
; FILE REFERENCE: 08191-026W01
; CURRENT APPLICATION NUMBER: US/10/473, 127
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 60/279, 495
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 60/292, 544
; PRIOR FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/310, 801
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/325, 370
; PRIOR FILING DATE: 2001-10-01
; PRIOR APPLICATION NUMBER: 60/336, 780
; PRIOR FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 1462
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-473-127-1462

Query Match Similarity 100.0%; Score 3721; DB 5; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESPSAPRHRNCIPWQRLLTASLTFWNPPTTAKLTIESTPNVAEGKEVLLVNLNPQ 60
Db 1 MESPSAPRHRNCIPWQRLLTASLTFWNPPTTAKLTIESTPNVAEGKEVLLVNLNPQ 60
Qy 61 HLFGYSWYKGERVDGMRQIGVIGVIGTQATPGAVSGRELYPNASLLIONIQNTGYF 120
Db 61 HLFGYSWYKGERVDGMRQIGVIGVIGTQATPGAVSGRELYPNASLLIONIQNTGYF 120
Qy 121 TLHVTKSDLVNEBEATQFVYPLPKPSSISSNSKVEKDQAVAFCEPETOQDATLWWV 180
Db 121 TLHVTKSDLVNEBEATQFVYPLPKPSSISSNSKVEKDQAVAFCEPETOQDATLWWV 180
Qy 181 NNQSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 240
Db 181 NNQSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 240
Qy 241 TISPINTSYSENGLNSCHASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 300
Db 241 TISPINTSYSENGLNSCHASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 300
Qy 301 AHNSDTGLENRTVTITVYAEPPKPKITSNSNSNPVEDDAVLTCEPEIQTLYWNN 360
Db 301 AHNSDTGLENRTVTITVYAEPPKPKITSNSNSNPVEDDAVLTCEPEIQTLYWNN 360
Qy 361 NNQSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 420
Db 361 NNQSLPVSPRIQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 420
Qy 421 TISPINTSYSENGLNSCHASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 480
Db 421 TISPINTSYSENGLNSCHASNPQAQSWFNGTFOQSTOELFPNTINNSSYTCQ 480
Qy 481 NSASGRSRTRKTTITVSAELPKPSISNNSKVEKDQAVFTCEPAAQNTYLWNGQS 540
Db 481 NSASGRSRTRKTTITVSAELPKPSISNNSKVEKDQAVFTCEPAAQNTYLWNGQS 540
Qy 541 LPVSPLQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 600
Db 541 LPVSPLQLQSNRNLTRTLFLNVTRNDTASYKCETONPYRSARRSDSVILNLVYGGDAP 600
Qy 601 PDSSYLSGANLNLSCHASNPQSWFNGTFOQSTOELFPNTINNSSYTCQ 660
Db 601 PDSSYLSGANLNLSCHASNPQSWFNGTFOQSTOELFPNTINNSSYTCQ 660

```

RESULT 13
US-10-473-127-1466
; Sequence 1466, Application US/10473127
; Publication No. US20040236091A1
; GENERAL INFORMATION:
; APPLICANT: ZYCOB Inc.
; TITLE OF INVENTION: TRANSLATIONAL PROFILING
FILE REFERENCE: 08191-026W01
; PRIORITY APPLICATION NUMBER: US/10/473, 127
CURRENT FILING DATE: 2003-09-26
; PRIORITY APPLICATION NUMBER: 60/279, 495
PRIORITY FILING DATE: 2001-03-28
; PRIORITY APPLICATION NUMBER: 60/292, 544
PRIORITY FILING DATE: 2001-05-21
; PRIORITY APPLICATION NUMBER: 60/310, 801
PRIORITY FILING DATE: 2001-08-08
; PRIORITY APPLICATION NUMBER: 60/326, 370
PRIORITY FILING DATE: 2001-10-01
; PRIORITY APPLICATION NUMBER: 60/336, 780
PRIORITY FILING DATE: 2001-12-04
; PRIORITY APPLICATION NUMBER: 60/358, 985
PRIORITY FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 2041
; SOFTWARE: FASTSEQ For Windows Version 4.0
; SEQ ID NO 1466
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-473-127-1466

Query Match 100.0%; Score 3721; DB 5; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESPSPAPHRCPWORLTLTASLLTFWNPPPTAKLTTESTPFNVAGKVEVLLVNLPO 60
Db 1 MESPSPAPHRCPWORLTLTASLLTFWNPPPTAKLTTESTPFNVAGKVEVLLVNLPO 60

Qy 61 HLFGYSMWKGERVGDGNGRQIGWVQATPGPAYSGREIYPNASLLIQNIQDGFY 120
Db 61 HLFGYSMWKGERVGDGNGRQIGWVQATPGPAYSGREIYPNASLLIQNIQDGFY 120

Db 121 THFVIKSDLVNEBEATGQPRVYPLPKESISNSNKPVEDKDAVAFCTCEPETQDATLWWV 180

Qy 121 THFVIKSDLVNEBEATGQPRVYPLPKESISNSNKPVEDKDAVAFCTCEPETQDATLWWV 180

Db 181 MESPSPAPHRCPWORLTLTASLLTFWNPPPTAKLTTESTPFNVAGKVEVLLVNLPO 60

Qy 181 MESPSPAPHRCPWORLTLTASLLTFWNPPPTAKLTTESTPFNVAGKVEVLLVNLPO 60

Db 181 MNPSSLPSPRQLQSNQNTLTFVNTRNDTASYKCETONPVAARRSPSVLINVLYGDAP 240

Qy 181 MNPSSLPSPRQLQSNQNTLTFVNTRNDTASYKCETONPVAARRSPSVLINVLYGDAP 240

Db 241 TISPLNTSYRGENLTSCHASNPAAQYSWFGNTFOQSTQBLFVNTRNDTASYKCETONPVAARRSPSVLINVLYGDAP 300

Qy 241 TISPLNTSYRGENLTSCHASNPAAQYSWFGNTFOQSTQBLFVNTRNDTASYKCETONPVAARRSPSVLINVLYGDAP 300

Db 301 AHNSDTGLARTTTTVAPEPKPITSNSNIPVEDDAVALTCERPIQINTYLWNN 360

Qy 481 NSASGHRTTKITIVSALKPSISSNSNKPVEDKDAVAFCTCEPETQDATLWWN 540

Db 481 NSASGHRTTKITIVSALKPSISSNSNKPVEDKDAVAFCTCEPETQDATLWWN 540

Qy 541 LPVSPIQLSNGRNTLTFVNTRNDARAYVGCTQNSVANSRSDPVTDLVLGDPDTI 600

Db 541 LPVSPIQLSNGRNTLTFVNTRNDARAYVGCTQNSVANSRSDPVTDLVLGDPDTI 600

Qy 601 PDSSYLSGANLNLSCHSASNPSOQSWRINGIPOQHTQVLFIAKITNNNGTYACFVNL 660

Db 601 PDSSYLSGANLNLSCHSASNPSOQSWRINGIPOQHTQVLFIAKITNNNGTYACFVNL 660

Qy 661 ATGRNNSIKVSKITVSASGTSPGLSAGATVGIMIGLVGVALL 702

Db 661 ATGRNNSIKVSKITVSASGTSPGLSAGATVGIMIGLVGVALL 702

RESULT 14
US-10-473-127-1500
; Sequence 1500, Application US/10473127
; Publication No. US20040236091A1
; GENERAL INFORMATION:
; APPLICANT: ZYCOB Inc.
; TITLE OF INVENTION: TRANSLATIONAL PROFILING
FILE REFERENCE: 08191-026W01
; CURRENT FILING DATE: 2003-09-26
; PRIORITY APPLICATION NUMBER: 60/279, 495
; PRIORITY FILING DATE: 2001-03-28
; PRIORITY APPLICATION NUMBER: US/10/473, 127
; PRIORITY FILING DATE: 2001-05-21
; PRIORITY APPLICATION NUMBER: 60/310, 801
; PRIORITY FILING DATE: 2001-08-08
; PRIORITY APPLICATION NUMBER: 60/326, 370
; PRIORITY FILING DATE: 2001-10-01
; PRIORITY APPLICATION NUMBER: 60/336, 780
; PRIORITY FILING DATE: 2001-12-04
; PRIORITY APPLICATION NUMBER: 60/358, 985
; PRIORITY FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 2041
; SOFTWARE: FastSEQ For Windows Version 4.0
; SEQ ID NO 1500
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-473-127-1500

Query Match 100.0%; Score 3721; DB 5; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESPSPAPHRCPWORLTLTASLLTFWNPPPTAKLTTESTPFNVAGKVEVLLVNLPO 60
Db 1 MESPSPAPHRCPWORLTLTASLLTFWNPPPTAKLTTESTPFNVAGKVEVLLVNLPO 60

Qy 61 HLFGYSMWKGERVGDGNGRQIGWVQATPGPAYSGREIYPNASLLIQNIQDGFY 120
Db 61 HLFGYSMWKGERVGDGNGRQIGWVQATPGPAYSGREIYPNASLLIQNIQDGFY 120

QY 181 NNQSLPSPRLQLSNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 240
Db 181 NNQSLPSPRLQLSNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 240
Db 241 TISPLNTSYRSGENLNLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 300
QY 241 TISPLNTSYRSGENLNLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 300
Db 301 AHNSTDGLNRTTVTTIYAEPKPFITSNNSNPVEDDAVALTCBEPINTYLYWNN 360
Db 301 AHNSTDGLNRTTVTTIYAEPKPFITSNNSNPVEDDAVALTCBEPINTYLYWNN 360
Qy 361 QSLPVSPRLQLSNDNRTLTLFSYTRNDVGPYCQIENLSVDHSDPVTILWLYGPDPTI 420
Db 361 QSLPVSPRLQLSNDNRTLTLFSYTRNDVGPYCQIENLSVDHSDPVTILWLYGPDPTI 420
Qy 421 SPSYYTRPGVNLSLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 480
Db 421 SPSYYTRPGVNLSLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 480
Qy 481 NSASGHSRRTVKTITVSAELPKFITSNNSNPVEDDAVALTCBEPINTYLYWNN 540
Db 481 NSASGHSRRTVKTITVSAELPKFITSNNSNPVEDDAVALTCBEPINTYLYWNN 540
Db 541 LPSPRQLQSLNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 600
Qy 541 LPSPRQLQSLNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 600
Db 601 PDSSYLSGANLNLSCHIASNPQAOSWYNGTFOOHTQVLFTAKITPNNGTYACFVSNL 660
Qy 601 PDSSYLSGANLNLSCHIASNPQAOSWYNGTFOOHTQVLFTAKITPNNGTYACFVSNL 660
Db 661 ATGRNNIVKSITVSAGTSPGSLASAGATVGIMIGUVGVALI 702
Qy 661 ATGRNNIVKSITVSAGTSPGSLASAGATVGIMIGUVGVALI 702
Db 661 ATGRNNIVKSITVSAGTSPGSLASAGATVGIMIGUVGVALI 702

RESULT 15

US-10-473-127-1503

; Sequence 1503, Application US/10473127
; Publication No. US20040236091A1
; GENERAL INFORMATION:

; APPLICANT: Zycos Inc.
; TITLE OF INVENTION: TRANSLATIONAL PROFILING
; CURRENT APPLICATION NUMBER: US/10/473,127
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 60/279,495
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 60/292,544
; PRIOR FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/310,801
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/326,370
; PRIOR FILING DATE: 2001-10-01
; PRIOR APPLICATION NUMBER: 60/336,780
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: 60/358,985
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 2041
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1503
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens

QY 100.0%; Score 3721; DB 5; Length 702;
Best Local Similarity 100.0%; Pred. No. 4.5e-207; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCIPWQRLULTLTFLWNPPTAKLTTESTPVAEGKEVLLVHNLPQ 60
Db 61 HLFQYSWYKGERDGNRQIOIGAVIGTQATGPAYGRCIEVNAUSLIONTQDGFY 120
Qy 61 HLFQYSWYKGERDGNRQIOIGAVIGTQATGPAYGRCIEVNAUSLIONTQDGFY 120
Db 121 TLAVIKSLVNEERATGQPRVYBLPKFISNNSKPEVDKDAVAFCTCEPETDYLWV 180
Db 121 TLAVIKSLVNEERATGQPRVYBLPKFISNNSKPEVDKDAVAFCTCEPETDYLWV 180
Qy 181 NNQSLPSPRLQLSNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 240
Db 181 NNQSLPSPRLQLSNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 240
Db 241 TISPLNTSYRSGENLNLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 300
Db 301 AHNSTDGLNRTTVTTIYAEPKPFITSNNSNPVEDDAVALTCBEPINTYLYWNN 360
Qy 361 QSLPVSPRLQLSNDNRTLTLFSYTRNDVGPYCQIENLSVDHSDPVTILWLYGPDPTI 420
Db 361 QSLPVSPRLQLSNDNRTLTLFSYTRNDVGPYCQIENLSVDHSDPVTILWLYGPDPTI 420
Qy 421 SPSYYTRPGVNLSLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 480
Db 421 SPSYYTRPGVNLSLSCHAASNPQAOSWYNGTFOOSTBLFIRINTVNSGTCQ 480
Qy 481 NSASGHSRRTVKTITVSAELPKFITSNNSNPVEDDAVALTCBEPINTYLYWNN 540
Db 481 NSASGHSRRTVKTITVSAELPKFITSNNSNPVEDDAVALTCBEPINTYLYWNN 540
Db 541 LPSPRQLQSLNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 600
Qy 541 LPSPRQLQSLNGNRTLTFVNTRNDTASYKETONPVRSRSDSVILNLYGDP 600
Db 601 PDSSYLSGANLNLSCHIASNPQAOSWYNGTFOOHTQVLFTAKITPNNGTYACFVSNL 660
Qy 601 PDSSYLSGANLNLSCHIASNPQAOSWYNGTFOOHTQVLFTAKITPNNGTYACFVSNL 660
Db 661 ATGRNNIVKSITVSAGTSPGSLASAGATVGIMIGUVGVALI 702
Qy 661 ATGRNNIVKSITVSAGTSPGSLASAGATVGIMIGUVGVALI 702
Db 661 ATGRNNIVKSITVSAGTSPGSLASAGATVGIMIGUVGVALI 702

Search completed: April 10, 2006, 18:12:45
Job time : 181.941 Secs

HIS PAGE LEFT BLANK

OM protein - protein search, using SW model
Run on: April 10, 2006, 18:09:01 ; Search time 25.4851 Seconds
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched:	Total number of hits satisfying chosen parameters:	184161
Minimum DB seq length:	0	
Maximum DB seq length:	200000000	
Post-processing:	Minimum Match 0%	
	Maximum Match 100%	
	Listing first 45 summaries	
Database :	Published Applications AA New:*	
	1: /SIBSS/ptodata/2/pupbaa/us08_NEW_PUB.pep:*	
	2: /SIBSS/ptodata/2/pupbaa/us06_NEW_PUB.pep:*	
	3: /SIBSS/ptodata/2/pupbaa/us07_NEW_PUB.pep:*	
	4: /SIBSS/ptodata/2/pupbaa/pcr_NEW_PUB.pep:*	
	5: /SIBSS/ptodata/2/pupbaa/us09_NEW_PUB.pep:*	
	6: /SIBSS/ptodata/2/pupbaa/us10_NEW_PUB.pep:*	
	7: /SIBSS/ptodata/2/pupbaa/us11_NEW_PUB.pep:*	
	8: /SIBSS/ptodata/2/pupbaa/us60_NSW_PUB.pep:*	

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

```

database : Published Applications AA_New.*  

1: /SIDSS_ptodata/2/pupbaa/US08 NEW_PUB.pep:  

2: /SIDSS_ptodata/2/pupbaa/US06 NEW_PUB.pep:  

3: /SIDSS_ptodata/2/pupbaa/US07 NEW_PUB.pep:  

4: /SIDSS_ptodata/2/pupbaa/PCN NEW_PUB.pep:  

5: /SIDSS_ptodata/2/pupbaa/US09 NEW_PUB.pep:  

6: /SIDSS_ptodata/2/pupbaa/US10 NEW_PUB.pep:  

7: /SIDSS_ptodata/2/pupbaa/US11 NEW_PUB.pep:  

8: /SIDSS_ptodata/2/pupbaa/US60_NSW_PUB.pep:  


```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

Minimum DB seq length: 0

Total number of hits satisfying chosen parameters

Title: US-10-734-564-72
Perfect score: 3721
Sequence: 1 MESPSAPPHRWCIPWQRLL.....LSAGATVGVIMIGIVLVGVALL 702
Scoring table: BLOSUM62
Searched: Gapop 10.0 , Gapext 0.5 -
 184161 seqs, 31191982 residues
Total number of hits satisfying chosen parameters: 184161
 859 197 Million cell updates/see

ALIGNMENT

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.
protein - protein search, using sw model
April 10, 2006, 18:09:01 ; Search time 25.4851 Seconds
(without alignments)
859.197 Million cell updates/sec

26	1391.5	37.4	325	6	US-10-311-822-11
27	1245	33.5	315	7	US-11-050-857-550
28	1245	33.5	315	7	US-11-051-720-1380
29	1148.5	30.9	419	6	US-10-821-234-1664
30	1148.5	30.9	419	6	US-10-948-716-7
31	1141.5	30.7	428	6	US-10-949-716-3
32	1130.5	30.4	426	6	US-10-948-716-9
33	1127.5	30.3	426	6	US-10-948-716-1
34	1114.5	30.2	426	6	US-10-821-234-1585
35	1117.5	30.0	419	6	US-10-948-716-4
36	1104	29.7	424	6	US-10-948-716-6
37	1069	28.7	424	6	US-10-948-716-10
38	1037	27.9	256	7	US-11-050-857-58
39	898	24.1	335	6	US-10-948-711-2
40	890	23.9	335	6	US-10-948-716-5
41	638	17.1	183	7	US-11-050-857-60
42	536	14.4	213	6	US-10-948-711-11
43	462.5	12.4	425	6	US-10-311-822-4
44	449	12.1	405	6	US-10-311-822-9
45	413.5	11.1	5636	7	US-11-055-695-20

Sequence 11, Appli
Sequence 550, Appli
Sequence 1880, Appli
Sequence 1664, Appli
Sequence 7, Appli
Sequence 3, Appli
Sequence 9, Appli
Sequence 1, Appli
Sequence 1585, Appli
Sequence 4, Appli
Sequence 6, Appli
Sequence 10, Appli
Sequence 58, Appli
Sequence 2, Appli
Sequence 5, Appli
Sequence 60, Appli
Sequence 11, Appli
Sequence 4, Appli
Sequence 9, Appli
Sequence 20, Appli

QV 301 AARNSDTGLNRTTVTTITYAEPKPFTNSNSNPVEDEDAVALTCPEBIONTYLWANN 360
Db 301 AHNNDTGLENRTTVTTITYAEPKPFTTSNNSNPVEDEDAVALTCPEBIONTYLWANN 360
QV 361 QSLPVSPRLQLSNDNRTTLSTSFRNDGPPYEGIQLELSVPHSDPVTINLVLYGPDPTI 420
Db 361 QSLPVSPRLQLSNDNRTTLSTSFRNDGPPYEGIQLELSVPHSDPVTINLVLYGPDPTI 420
QV 421 SPSYTYPGPVNLSLSCHARSNPAQWSWLIDGNIOQHTQELFISNITEKNSGLTQAN 480
Db 421 SPSYTYPGPVNLSLSCHARSNPAQWSWLIDGNIOQHTQELFISNITEKNSGLTQAN 480
Db 421 SPSYTYPGPVNLSLSCHARSNPAQWSWLIDGNIOQHTQELFISNITEKNSGLTQAN 480
QV 481 NSASGHSRRTTVTTIVSABLPKPSISSNSKPVEDKDAVFTCEPEAQNTYLMWNGQS 540
Db 481 NSASGHSRRTTVTTIVSABLPKPSISSNSKPVEDKDAVFTCEPEAQNTYLMWNGQS 540
QV 541 LPSVSPRLQLSNGNRTLTFLNVTRNDARAVCGIANSVANSRSDPVTDLVLYGPDPTI 600
Db 541 LPSVSPRLQLSNGNRTLTFLNVTRNDARAVCGIANSVANSRSDPVTDLVLYGPDPTI 600
QV 601 PDSYLSGANLNLSCHSASNPSPOYSWRINGIPOQHQLFKITIPNNGTYACVSNL 660
Db 601 PDSYLSGANLNLSCHSASNPSPOYSWRINGIPOQHQLFKITIPNNGTYACVSNL 660
QV 661 ATGRNNNSIVKSITVSAGTSPGLSAGATVGIMIGVLGVALL 702
Db 661 ATGRNNNSIVKSITVSAGTSPGLSAGATVGIMIGVLGVALL 702

RESULT 2
US-11-097-224B-2
; Sequence 2, Application US/11097224B
; Publication No. US20060024314A1
; GENERAL INFORMATION:
; APPLICANT: Stanners, Clifford P.
; APPLICANT: Ilantzis, Christian
; APPLICANT: Ordóñez-García, Cosme
; APPLICANT: Taheri, Maryam
; APPLICANT: Sereaton, Robert A.
; APPLICANT: Fuchs, Abram
; APPLICANT: Saragovi, H. Uri
; TITLE OF INVENTION: Antibodies and Cyclic Peptides Which Bind CEA (carcinoembryonic
; FILE REFERENCE: 15037
; CURRENT APPLICATION NUMBER: US/11/097,224B
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: US 60/415,520
; PRIOR FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: PCT/CN03/01533
; PRIOR FILING DATE: 2003-10-03
; PRIOR APPLICATION NUMBER: CA 2,224,129
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: PCT/CN9/00119
; PRIOR FILING DATE: 1999-02-11
; PRIOR APPLICATION NUMBER: US 09/637,530
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: US 11/041,199
; PRIOR FILING DATE: 2005-01-25
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Notepad
; SEQ ID NO 2
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-097-224B-2

Query Match 100.0%; Score 3721; DB 7; Length 702;
Best Local Similarity 100.0%; Pred. No. 1.6e-226;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QV 1 MEPSAPPHRCIPWQRLILTASLUTFWNPPTAKLTTESTPENVAEGKEVLLVHVNLHQ 60
Db 1 MEPSAPPHRCIPWQRLILTASLUTFWNPPTAKLTTESTPENVAEGKEVLLVHVNLHQ 60

RESULT 3
US-11-050-857-549
; Sequence 549, Application US/11050857
; Publication No. US20060040278A1
; GENERAL INFORMATION:
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAY'S AND METHODS
; TITLE OF INVENTION: THEREOF FOR DIAGNOSIS OF OVARIAN CANCER
; FILE REFERENCE: 1647_1005
; CURRENT APPLICATION NUMBER: US/11/050,857
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 1150
; SEQ ID NO 549
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-050-857-549

Query Match 100.0%; Score 3721; DB 7; Length 702;
Best Local Similarity 100.0%; Pred. No. 1.6e-226;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QV 1 MEPSAPPHRCIPWQRLILTASLUTFWNPPTAKLTTESTPENVAEGKEVLLVHVNLHQ 60
Db 1 MEPSAPPHRCIPWQRLILTASLUTFWNPPTAKLTTESTPENVAEGKEVLLVHVNLHQ 60

QY 61 HLFGSWYKGERVDGMRQIGVIGVQATPGPASGRBIIYPNASHLQNIQONDGFY 120
Db 61 HLFGSWYKGERVDGMRQIGVIGVQATPGPASGRBIIYPNASHLQNIQONDGFY 120
QY 121 TLHVIKSDLNVEATGOFRTPELPKSISNNSKPVEDKDAVAFCTCEPERDATYLWWV 180
Db 121 TLHVIKSDLNVEATGOFRTPELPKSISNNSKPVEDKDAVAFCTCEPERDATYLWWV 180
QY 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
Db 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
QY 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
Db 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
QY 241 TISPLNTSYRSGENLNLSCHASNPQAQSWFVNGTFOQSTOELFIPNITVNNSGYTCQ 300
Db 241 TISPLNTSYRSGENLNLSCHASNPQAQSWFVNGTFOQSTOELFIPNITVNNSGYTCQ 300
QY 241 TISPLNTSYRSGENLNLSCHASNPQAQSWFVNGTFOQSTOELFIPNITVNNSGYTCQ 300
Db 301 AHNSDTGLENRTVTITVVAEPKPKFTTSNNSNPVEDBDAVALTCEPEIQTLYLWWN 360
QY 301 AHNSDTGLENRTVTITVVAEPKPKFTTSNNSNPVEDBDAVALTCEPEIQTLYLWWN 360
Db 301 AHNSDTGLENRTVTITVVAEPKPKFTTSNNSNPVEDBDAVALTCEPEIQTLYLWWN 360
QY 421 SPSYTYYRPGVLNLSCCHAASNPQAQSWLIDGNIOHTQELFISNTENGLYTCQAN 480
Db 421 SPSYTYYRPGVLNLSCCHAASNPQAQSWLIDGNIOHTQELFISNTENGLYTCQAN 480
QY 421 SPSYTYYRPGVLNLSCCHAASNPQAQSWLIDGNIOHTQELFISNTENGLYTCQAN 480
Db 361 OSLPSPRQLQSLNDNRNLTLTISVTRNDVGPYECGIONELSVHDSDPVILNVLYGDPDPTI 420
Qy 361 OSLPSPRQLQSLNDNRNLTLTISVTRNDVGPYECGIONELSVHDSDPVILNVLYGDPDPTI 420
Db 361 OSLPSPRQLQSLNDNRNLTLTISVTRNDVGPYECGIONELSVHDSDPVILNVLYGDPDPTI 420
Qy 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Db 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Qy 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Db 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Qy 541 LPVSPRLQLSNGRNLTFNVRNDARAVYVGIONVSANSRSDPVILDVLYGDPDPTISP 600
Db 541 LPVSPRLQLSNGRNLTFNVRNDARAVYVGIONVSANSRSDPVILDVLYGDPDPTISP 600
Qy 541 LPVSPRLQLSNGRNLTFNVRNDARAVYVGIONVSANSRSDPVILDVLYGDPDPTISP 600
Db 601 PDSSTISGAMLNLSCHASNPSPQSWRINGIPOQHTQVFLIAKITTPNNGTYACFVSNL 660
Qy 601 PDSSTISGAMLNLSCHASNPSPQSWRINGIPOQHTQVFLIAKITTPNNGTYACFVSNL 660
Db 601 PDSSTISGAMLNLSCHASNPSPQSWRINGIPOQHTQVFLIAKITTPNNGTYACFVSNL 660
Qy 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702
Db 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702
Qy 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702
Db 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702

RESULT 4
US-11-051-720-1451
; Sequence 1451, Application US/11051720
; GENERAL INFORMATION:
; Publication No. US2006004625A1
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS
; TITLE OF INVENTION: THEREOF FOR DIAGNOSIS OF LUNG CANCER
; FILE REFERENCE: 1847-1002
; CURRENT APPLICATION NUMBER: US/11/051,720
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 1780
; SEQ ID NO 1451
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-051-720-1451

Query Match 100.0%; Score 3721; DB 7; Length 702;
Best Local Similarity 100.0%; Pred. No. 1.6e-226;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCIPMORLITASLTIFWNPTAKTIESTPENVAEGKEVLLVHNLHQ 60
Db 1 MESPSAPPHRWCIPMORLITASLTIFWNPTAKTIESTPENVAEGKEVLLVHNLHQ 60
QY 61 HLFGSWYKGERVDGMRQIGVIGVQATPGPASGRBIIYPNASHLQNIQONDGFY 120

QY 61 HLFGSWYKGERVDGMRQIGVIGVQATPGPASGRBIIYPNASHLQNIQONDGFY 120
Db 61 HLFGSWYKGERVDGMRQIGVIGVQATPGPASGRBIIYPNASHLQNIQONDGFY 120
Qy 121 TLHVIKSDLNVEATGOFRTPELPKSISNNSKPVEDKDAVAFCTCEPERDATYLWWV 180
Db 121 TLHVIKSDLNVEATGOFRTPELPKSISNNSKPVEDKDAVAFCTCEPERDATYLWWV 180
Qy 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
Db 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
Qy 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
Db 181 NNQSLPVSPRLQLSNGRNLTFNVRNDTASYKCETQNPVSARSDSVILNVLYGDPDAP 240
Qy 241 TISPLNTSYRSGENLNLSCHASNPQAQSWFVNGTFOQSTOELFIPNITVNNSGYTCQ 300
Db 241 TISPLNTSYRSGENLNLSCHASNPQAQSWFVNGTFOQSTOELFIPNITVNNSGYTCQ 300
Qy 241 TISPLNTSYRSGENLNLSCHASNPQAQSWFVNGTFOQSTOELFIPNITVNNSGYTCQ 300
Db 301 AHNSDTGLENRTVTITVVAEPKPKFTTSNNSNPVEDBDAVALTCEPEIQTLYLWWN 360
Qy 301 AHNSDTGLENRTVTITVVAEPKPKFTTSNNSNPVEDBDAVALTCEPEIQTLYLWWN 360
Db 301 AHNSDTGLENRTVTITVVAEPKPKFTTSNNSNPVEDBDAVALTCEPEIQTLYLWWN 360
Qy 421 SPSYTYYRPGVLNLSCCHAASNPQAQSWLIDGNIOHTQELFISNTENGLYTCQAN 480
Db 421 SPSYTYYRPGVLNLSCCHAASNPQAQSWLIDGNIOHTQELFISNTENGLYTCQAN 480
Qy 421 SPSYTYYRPGVLNLSCCHAASNPQAQSWLIDGNIOHTQELFISNTENGLYTCQAN 480
Db 361 OSLPSPRQLQSLNDNRNLTLTISVTRNDVGPYECGIONELSVHDSDPVILNVLYGDPDPTI 420
Qy 361 OSLPSPRQLQSLNDNRNLTLTISVTRNDVGPYECGIONELSVHDSDPVILNVLYGDPDPTI 420
Db 361 OSLPSPRQLQSLNDNRNLTLTISVTRNDVGPYECGIONELSVHDSDPVILNVLYGDPDPTI 420
Qy 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Db 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Qy 481 NSASGHSRRTVKTTIVSABEPLPKPSISSNNSKPVEDKDAVAFCTCEPEIQTLYLWWNGOS 540
Db 541 LPVSPRLQLSNGRNLTFNVRNDARAVYVGIONVSANSRSDPVILDVLYGDPDPTISP 600
Qy 541 LPVSPRLQLSNGRNLTFNVRNDARAVYVGIONVSANSRSDPVILDVLYGDPDPTISP 600
Db 541 LPVSPRLQLSNGRNLTFNVRNDARAVYVGIONVSANSRSDPVILDVLYGDPDPTISP 600
Qy 601 PDSSTISGAMLNLSCHASNPSPQSWRINGIPOQHTQVFLIAKITTPNNGTYACFVSNL 660
Db 601 PDSSTISGAMLNLSCHASNPSPQSWRINGIPOQHTQVFLIAKITTPNNGTYACFVSNL 660
Qy 601 PDSSTISGAMLNLSCHASNPSPQSWRINGIPOQHTQVFLIAKITTPNNGTYACFVSNL 660
Db 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702
Qy 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702
Db 661 ATGRNNISIVSITVSAGSTSPGLSAGATVGMIGVIMGVLVGVALL 702

RESULT 5
US-11-097-252A-2
; Sequence 2, Application US/11097252A
; Publication No. US20060051352A1
; GENERAL INFORMATION:
; APPLICANT: Stanners, Clifford P.
; APPLICANT: Tlantzas, Christian
; APPLICANT: Ordene-Garcia, Cosme
; TITLE OF INVENTION: CBA Binding Agents and Compositions To Reverse CEA-Mediated
; TITLE OF INVENTION: Tumorigenic Effects on Human Cancer Cells, Restore
; TITLE OF INVENTION: Sensitivity to Drug Induced Apoptosis and Uses Thereof
; FILE REFERENCE: 6 9029/17
; CURRENT APPLICATION NUMBER: US/11/097, 252A
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: CA2,461,375
; PRIORITY DATE: 2004-04-02
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Notepad
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; SEQ ID NO 2
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-097-252A-2

Query Match 100.0%; Score 3721; DB 7; Length 702;
Best Local Similarity 100.0%; Pred. No. 1.6e-226;
Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPPHRWCIPMORLITASLTIFWNPTAKTIESTPENVAEGKEVLLVHNLHQ 60
Db 1 MESPSAPPHRWCIPMORLITASLTIFWNPTAKTIESTPENVAEGKEVLLVHNLHQ 60
QY 61 HLFGSWYKGERVDGMRQIGVIGVQATPGPASGRBIIYPNASHLQNIQONDGFY 120

Query Match 99.0%; Score 3683; DB 6; Length 702;
 Best Local Similarity 99.1%; Pred. No. 4e-224; ; Index 0; Gaps 0;
 Matches 696; Conservative 1; Mismatches 5; ;

Db	1	MESPSAPPHRWCIPWQRLILLASLLFWNPPTAKLTIESTPFPNVAGKEVILLVNLPO	60
Qy	61	HLFGYSWKGERVDGNRIGIVGIVQTAATPPAYSEREIVYPPNAILIONIIONTGFY	120
Db	61	HLFGYSWKGERVDGNRIGIVGIVQTAATPPAYSGREIVYPPNAILIONIIONTGFY	120
Qy	121	TLHVIKSDLVNEEATQPRVYPLPKTSISNNSKPVEDKDAVFTCEPETODATLWWV	180
Db	121	TLHVIKSDLVNEEATQPRVYPLPKTSISNNSKPVEDKDAVFTCEPETODATLWWV	180
Qy	181	NNOSLPLSPRQLQISNGRTLTFLNVTRNDTASYKETQNPSARSDSVILANLYGDDAP	240
Db	181	NNOSLPLSPRQLQISNGRTLTFLNVTRNDTASYKETQNPSARSDSVILANLYGDDAP	240
Qy	241	TISPLNTSYRSGENLNLSCHASNPPAQYSWFNGTFOOSTBLFNTIPNITVNSGSYTQ	300
Db	241	TISPLNTSYRSGENLNLSCHASNPPAQYSWFNGTFOOSTBLFNTIPNITVNSGSYTQ	300
Qy	301	AHNSTDGLNRRTVTTITYAEPKPFTNSNSNPVEDBDAVLTCEPEIONTYLWNN	360
Db	301	AHNSTDGLNRRTVTTITYAEPKPFTNSNSNPVEDBDAVLTCEPEIONTYLWNN	360
Qy	361	QSLPVSPRLQLQISNDNRTLTLSSTRNDGVPYEGIQNLBSVHDSPVILANLYGDDPTI	420
Db	361	QSLPVSPRLQLQISNDNRTLTLSSTRNDGVPYEGIQNLBSVHDSPVILANLYGDDPTI	420
Qy	421	SPSYYTRPGVNLNLSCHASNPQAQSWSLIDNQHTOELFISNTEKNGLYTCAN	480
Db	421	SPSYYTRPGVNLNLSCHASNPQAQSWSLIDNQHTOELFISNTEKNGLYTCAN	480
Qy	481	NSASGHSHRTTKVTIVSABLPKPSISSNSKPEVKDAVFTCEPEAONTYLWNGS	540
Db	481	NSASGHSHRTTKVTIVSABLPKPSISSNSKPEVKDAVFTCEPEAONTYLWNGS	540
Qy	541	LPSVPRQLQISNGRTLTFLNVTRNDARAYCGIQNLBSVHDSPVILANLYGDDPTI	600
Db	541	LPSVPRQLQISNGRTLTFLNVTRNDARAYCGIQNLBSVHDSPVILANLYGDDPTI	600
Qy	601	PDSYSLSGANLNLSCHASNPSFQYSWRINGIPQOHTQVLFIAKITPNNGTYACFVNL	660
Db	601	PDSYSLSGANLNLSCHASNPSFQYSWRINGIPQOHTQVLFIAKITPNNGTYACFVNL	660
Qy	661	ATGRNNNSIVKSITVSASGTSPLSAGATVGIMIGLVGVALL	702
Db	661	ATGRNNNSIVKSITVSASGTSPLSAGATVGIMIGLVGVALL	702

RESULT 6
 US-10-510-101-68
 Sequence 68, Application US/10510101
 Publication No. US20060018915A1
 GENERAL INFORMATION:
 APPLICANT: Epiimmune Inc.
 APPLICANT: Ishioka, Gleun
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Heterocyclic Analogs and Related Methods
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIORITY APPLICATION NUMBER: US 60/413,471
 PRIORITY FILING DATE: 2002-09-26
 PRIORITY APPLICATION NUMBER: US 10/116,118
 PRIORITY FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO: 68
 LENGTH: 702
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-510-101-68

RESULT 7
 US-11-050-557-551
 Sequence 551, Application US/11050857
 Publication No. US20060040278A1
 GENERAL INFORMATION:
 APPLICANT: Compugen Ltd
 TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS THEREOF FOR DIAGNOSIS OF OVARIAN CANCER
 FILE REFERENCE: 1847_1005
 CURRENT APPLICATION NUMBER: US/11/050,857
 CURRENT FILING DATE: 2005-01-27
 NUMBER OF SEQ ID NOS: 1150
 SEQ ID NO: 551
 LENGTH: 719
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-050-557-551

Query Match 96.8%; Score 3601.5; DB 7; Length 719;
 Best Local Similarity 99.1%; Pred. No. 5.4e-219;

Matches 679; Conservative 0; Mismatches 5; Indels 1; Gaps 1;

Oy	1 MESPSAPHRWCIPWQRLLTASLTFUNWPPTAKLTIESTPFNVAGKEVILLVNLHQ	60	Oy	1 MESPSAPHRWCIPWQRLLTASLTFUNWPPTAKLTIESTPFNVAGKEVILLVNLHQ	60
Db	1 MESPSAPHRWCIPWQRLLTASLTFUNWPPTAKLTIESTPFNVAGKEVILLVNLHQ	60	Db	1 MESPSAPHRWCIPWQRLLTASLTFUNWPPTAKLTIESTPFNVAGKEVILLVNLHQ	60
Oy	61 HLFGSWYKGERVDGNRQIGVYIGVQATPGPAYSGREIYPNASLIQNIQNDGFY	120	Oy	61 HLFGSWYKGERVDGNRQIGVYIGVQATPGPAYSGREIYPNASLIQNIQNDGFY	120
Db	61 HLFGSWYKGERVDGNRQIGVYIGVQATPGPAYSGREIYPNASLIQNIQNDGFY	120	Db	61 HLFGSWYKGERVDGNRQIGVYIGVQATPGPAYSGREIYPNASLIQNIQNDGFY	120
Oy	121 TLRVIKSDLVNEATGOFPRVYPLPKISSNNSKPYEDKDAVAFCEPETODATLWWV	180	Oy	121 TLRVIKSDLVNEATGOFPRVYPLPKISSNNSKPYEDKDAVAFCEPETODATLWWV	180
Db	121 TLRVIKSDLVNEATGOFPRVYPLPKISSNNSKPYEDKDAVAFCEPETODATLWWV	180	Db	121 TLRVIKSDLVNEATGOFPRVYPLPKISSNNSKPYEDKDAVAFCEPETODATLWWV	180
Oy	181 NNQSLPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRSVILNLXGPDAP	240	Oy	181 NNQSLPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRSVILNLXGPDAP	240
Db	181 NNQSLPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRSVILNLXGPDAP	240	Db	181 NNQSLPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRSVILNLXGPDAP	240
Oy	241 TISPLNTSYRSGENLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	300	Oy	241 TISPLNTSYRSGENLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	300
Db	241 TISPLNTSYRSGENLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	300	Db	241 TISPLNTSYRSGENLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	300
Oy	301 AHNSDGLNRTTIVTYAEPKPKFTTSNNSNPVEDDAVALTCPEIQTLYLWNN	360	Oy	301 AHNSDGLNRTTIVTYAEPKPKFTTSNNSNPVEDDAVALTCPEIQTLYLWNN	360
Db	301 AHNSDGLNRTTIVTYAEPKPKFTTSNNSNPVEDDAVALTCPEIQTLYLWNN	360	Db	301 AHNSDGLNRTTIVTYAEPKPKFTTSNNSNPVEDDAVALTCPEIQTLYLWNN	360
Oy	361 OSLPVSPRQLQSNDRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	420	Oy	361 OSLPVSPRQLQSNDRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	420
Db	361 OSLPVSPRQLQSNDRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	420	Db	361 OSLPVSPRQLQSNDRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	420
Oy	421 SPSYTYYRPGVLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	480	Oy	421 SPSYTYYRPGVLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	480
Db	421 SPSYTYYRPGVLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	480	Db	421 SPSYTYYRPGVLNLSCHAASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	480
Oy	481 NSASGHRTTVKTITVSALPKPSISNNSKVEDDKAVAFCEPEAQNTYLWNNQGS	540	Oy	481 NSASGHRTTVKTITVSALPKPSISNNSKVEDDKAVAFCEPEAQNTYLWNNQGS	540
Db	481 NSASGHRTTVKTITVSALPKPSISNNSKVEDDKAVAFCEPEAQNTYLWNNQGS	540	Db	481 NSASGHRTTVKTITVSALPKPSISNNSKVEDDKAVAFCEPEAQNTYLWNNQGS	540
Oy	541 LPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	600	Oy	541 LPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	600
Db	541 LPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	600	Db	541 LPVSPRQLQSNRNLTLFLNVTENDTASYKCTONPVRSARRDSVILNLXGPDPTI	600
Oy	601 PDSSYLSGANLNLSCHASASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	660	Oy	601 PDSSYLSGANLNLSCHASASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	660
Db	601 PDSSYLSGANLNLSCHASASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	660	Db	601 PDSSYLSGANLNLSCHASASNPQAQSFWNGTFOQSTQELFPNITVNSYTCQ	660
Oy	661 ATGRNNISIVSITVSAASGPGLSA	685	Oy	661 ATGRNNISIVSITVSAASGPGLSA	685
Db	661 ATGRNNISIVSITVSAASGPGLSA	685	Db	661 ATGRNNISIVSITVSAASGPGLSA	685
Oy	661 ATGRNNISIVSITVSAASGPGLSA	684	Oy	661 ATGRNNISIVSITVSAASGPGLSA	684

RESULT 8

US-11-051-720-1381
; Sequence 1381, Application US/11051720; Publication No. US20060046257A1
; GENERAL INFORMATION:

; APPLICANT: Compugen Ltd

; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS

; TITLE OF INVENTION: THEREOF FOR DIAGNOSIS OF LUNG CANCER

; FILE REFERENCE: 1847_1005

; CURRENT APPLICATION NUMBER: US/11/051,720

; CURRENT FILING DATE: 2005-01-27

; NUMBER OF SEQ ID NOS: 1780

; SEQ ID NO: 181

; LENGTH: 719

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-11-051-720-1381

Query Match 96.8%; Score 3601.5; DB 7; Length 719;
Best Local Similarity 99.1%; Pred. No. 5.4e-219;
Matches 679; Conservative 0; Mismatches 5; Indels 1; Gaps 1;

Oy 1 MESPSAPHRWCIPWQRLLTASHLTFUNWPPTAKLTIESTPFNVAGKEVILLVNLHQ 60

RESULT 9

US-11-050-857-552
; Sequence 552, Application US/11050857
; Publication No. US20060040278A1
; GENERAL INFORMATION:
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS
; TITLE OF INVENTION: THEREOF FOR DIAGNOSIS OF OVARIAN CANCER
; FILE REFERENCE: 1847_1005
; CURRENT APPLICATION NUMBER: US/11/050,857
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 1150
; SEQ ID NO: 552
; LENGTH: 569
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-050-857-552

Query Match 79.8%; Score 2968; DB 7; Length 569;
Best Local Similarity 98.1%; Pred. No. 2.7e-179;
Matches 556; Conservative 2; Mismatches 9; Indels 0; Gaps 0;
Oy 1 MESPSAPHRWCIPWQRLLTASHLTFUNWPPTAKLTIESTPFNVAGKEVILLVNLHQ 60

```

Db 1 MESPSAPPHRWCIPWQRLILTASILTFWMNPPTAKLTTESTPFWVAGEVILLVWHNLQ 60
Qy 61 HLFGSWSYKGERVUNGRNQRLIGYVIGTQATPGPAMSREITYPNMSLILTONDTGFI 120
Db 61 HLFGSWSYKGERVUNGRNQRLIGYVIGTQATPGPAMSREITYPNMSLILTONDTGFI 120
Db 121 TLHVTKSDLVNEATGQFRVYPELPKPSISNNNSKPVEDKDAVFTCBETDQTYMW 180
Qy 121 TLHVTKSDLVNEATGQFRVYPELPKPSISNNNSKPVEDKDAVFTCBETDQTYMW 180
Db 181 NNQSPLPVSRLQLSNGNRLTFLFVNTRNTASYKETQMPVSARRSDSITLNVLYGDP 240
Qy 181 NNQSPLPVSRLQLSNGNRLTFLFVNTRNTASYKETQMPVSARRSDSITLNVLYGDP 240
Db 241 TISPLNTSRSGENIULSCHAASNPQAQISWFMGCTFOOSTQELFIPNIVNNSSGYTCQ 300
Qy 241 TISPLNTSRSGENIULSCHAASNPQAQISWFMGCTFOOSTQELFIPNIVNNSSGYTCQ 300
Db 241 TISPLNTSRSGENIULSCHAASNPQAQISWFMGCTFOOSTQELFIPNIVNNSSGYTCQ 300
Qy 301 AHNSDTGLNRTTVTTIVAAEPPKFITSNSNPVEDAVALTEPEIONTTYLWNN 360
Db 301 AHNSDTGLNRTTVTTIVAAEPPKFITSNSNPVEDAVALTEPEIONTTYLWNN 360
Db 361 QSLVSPRQLQSLNDRTTILSVPNDVGPFEGIQNELSVDHSDPVLNLVKGDDPTI 420
Qy 421 SPSVYRYRGVNLNLSCHAASNPQAQISWFMGCTFOOSTQELFIPNIVNNSSGYTCQ 480
Db 421 SPSVYRYRGVNLNLSCHAASNPQAQISWFMGCTFOOSTQELFIPNIVNNSSGYTCQ 480
Qy 481 NSASGHSRRTVKTITVSAELPKPSISSNNSKPVEDKDAFTCEPEAQNNTLYMWNGS 540
Db 481 NSASGHSRRTVKTITVSAELPKPSISSNNSNPVEDKDAVFTCEPEVQNTYLWNGS 540
Qy 541 LPVSRLQLSNGNRLTFLFVNTRNDAR 567
Db 541 LPVSRLQLSNGNMLTLLSCQKERC 567

RESULT 10
US-11-051-720-1382
; Sequence 1382, Application US/11051720
; Publication No. US20060046257A1
; GENERAL INFORMATION:
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND FILE REFERENCE: 1847-1002
; CURRENT APPLICATION NUMBER: US11/051,720
; NUMBER OF SEQ ID NOS: 1780
; SEQ ID NO 1382
; LENGTH: 569
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-051-720-1382

Query Match 79.8%; Score 2968; DB 7; length 569;
Best Local Similarity 98.1%; Pred. No. 2.7e-179; 9; Mismatches 0; Indels 0; Gaps 0;
Matches 556; Conservative 2; Mismatches 9; InDel 0; Gaps 0;

 1 MESPSAPPHRWCIPWQRLILTASILTFWMNPPTAKLTTESTPFWVAGEVILLVWHNLQ 60
 1 MESPSAPPHRWCIPWQRLILTASILTFWMNPPTAKLTTESTPFWVAGEVILLVWHNLQ 60
 61 HLFGSWSYKGERVUNGRNQRLIGYVIGTQATPGPAMSREITYPNMSLILTONDTGFI 120
 61 HLFGSWSYKGERVUNGRNQRLIGYVIGTQATPGPAMSREITYPNMSLILTONDTGFI 120
 121 TLHVTKSDLVNEATGQFRVYPELPKPSISNNNSKPVEDKDAVFTCBETDQTYMW 180
 121 TLHVTKSDLVNEATGQFRVYPELPKPSISNNNSKPVEDKDAVFTCBETDQTYMW 180
 61 HLFGSWSYKGERVUNGRNQRLIGYVIGTQATPGPAMSREITYPNMSLILTONDTGFI 120
 121 TLHVTKSDLVNEATGQFRVYPELPKPSISNNNSKPVEDKDAVFTCBETDQTYMW 180

```

```

US-11-050-857-554
Sequence 554, Application US/11050857
Publication No. US2006004278A1
; GENERAL INFORMATION:
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS
; FILE REFERENCE: 1847_1005
; CURRENT APPLICATION NUMBER: US11/050, 857
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 1150
; SEQ ID NO 554
; LENGTH: 346
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-050-857-554

Query Match          44.0%;  Score 1637;  DB 7;  Length 346;
Best Local Similarity 49.3%;  Pred. No. 6.5e-96;  0;  Mismatches 356;  Gaps 1;
Matches 346;  Conservative 49.3%;  Pred. No. 6.5e-96;  0;  Indels 356;  Gaps 1;

Qy      1 MESPSAPSPHRWCIPWORLDLTASLTLFWNPPTPAKLTISTPENVAEGKEVLLVHNLPQ 60
Db      1 MESPSAPSPHRWCIPWORLDLTASLTLFWNPPTPAKLTISTPENVAEGKEVLLVHNLPQ 60
Qy      61 HLFPGYSWYKGGERVDGNRQIGVIGVQATPGPAYSGREIYPNASLLIONIQNDTGFY 120
Db      61 HLFPGYSWYKGGERVDGNRQIGVIGVQATPGPAYSGREIYPNASLLIONIQNDTGFY 120
Qy      121 THAVIKSDLVNEBAGTQGPRVYPELPKPSISNNNSNPVEDKDAVATCEPQTDAIYLWW 180
Db      121 THAVIKSDLVNEBAGTQGPRVYPELPKPSISNNNSNPVEDKDAVATCEPQTDAIYLWW 180
Qy      181 NNQSLPVSPRLQNSNRTLFLNTVRNDTASYKETONPVUSARRSDSVLNLYGPDP 240
Db      143 ----- 142
Db      241 TISPLNTSYRSGENLNLSCHAASNNPQAQYSWFVNQTFQQSTQELFIPNITVNNSCSYTQ 300
Db      143 ----- 142
Qy      301 AHNSTDIGNRTVTITVYAEPPKPFITSNNSNPVEDEDAVALTCPEIONTTIVAWVN 360

```

RESULT 12
US-11-051-720-1384
; Sequence 1384 Application US/11051720
; Publication No. US20060046257A1
; GENERAL INFORMATION:
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS FOR REFERENCE, THEREOF FOR DIAGNOSIS OF LUNG CANCER
; FILE REFERENCE: 1847..1002
; CURRENT APPLICATION NUMBER: US/11/051,720
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 1780
; SEQ ID NO 1384
; LENGTH: 346
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-051-720-1384

Query Match Similarity 44.0%; Score 1637; DB 7; Length 346;
Best Local Similarity 49.3%; Pred. No. 6.5e-96; Mismatches 0; Indexes 356; Gaps 1;
Matches 346; Conservative 0; Mismatches 0; Indels 356; Gaps 1;

Qy 1 MESPSAPPRHNCIPWORLLTASLTLFWNPPTAKLTIESPPFNVAEGKEVLLVNLPO 60
Db 1 MESPSAPPRHNCIPWORLLTASLTLFWNPPTAKLTIESPPFNVAEGKEVLLVNLPO 60
Qy 61 HLFGWSWYKGRRVGDGRQIGVYIGVQATPGPAYSGREIYPNALLIONIQDTGFY 120
Db 61 HLFGWSWYKGRRVGDGRQIGVYIGVQATPGPAYSGREIYPNALLIONIQDTGFY 120
Qy 121 TLHVIKSDLVNEATGOFRVPPELPKPSISSNNSKPVEDKDAVFTCEPETOQDATYLWWV 180
Db 121 TLHVIKSDLVNEATGOFRVPPELPKPSISSNNSKPVEDKDAVFTCEPETOQDATYLWWV 180
Qy 181 NNQSIPSPRLQLSNGNRTLTFLNVTRNDATASYKCETONPVSAARRSDSVILVLYGPDA 240
Db 143 ----- 142
Qy 241 TISPLNTSYRSGENLNLSCHAASNPQAQYSWFVNGLTFOOSTELFIPNITVNNSGSYTQ 300
Db 143 ----- 142
Qy 301 AHNSDTGLNRITVTITVIAEPPKPKPITSNSNSNPVEDEDAVALTCPEIONTTYLWWVN 360
Db 143 ----- 142

RESULT 13
US-11-050-857-553
; Sequence 553 Application US/11050857
; Publication No. US20060040278A1
; GENERAL INFORMATION:
; APPLICANT: Compugen Ltd
; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS FOR REFERENCE, THEREOF FOR DIAGNOSIS OF OVARIAN CANCER
; CURRENT APPLICATION NUMBER: US/11/050,857
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 1150
; SEQ ID NO 553
; LENGTH: 346
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-050-857-553

Query Match Similarity 44.0%; Score 1636; DB 7; Length 346;
Best Local Similarity 49.3%; Pred. No. 7.5e-96; Mismatches 0; Indexes 356; Gaps 1;
Matches 346; Conservative 0; Mismatches 0; Indels 356; Gaps 1;

Qy 1 MESPSAPPRHNCIPWORLLTASLTLFWNPPTAKLTIESPPFNVAEGKEVLLVNLPO 60
Db 1 MESPSAPPRHNCIPWORLLTASLTLFWNPPTAKLTIESPPFNVAEGKEVLLVNLPO 60
Qy 61 HLFGWSWYKGRRVGDGRQIGVYIGVQATPGPAYSGREIYPNALLIONIQDTGFY 120
Db 61 HLFGWSWYKGRRVGDGRQIGVYIGVQATPGPAYSGREIYPNALLIONIQDTGFY 120
Qy 121 TLHVIKSDLVNEATGOFRVPPELPKPSISSNNSKPVEDKDAVFTCEPETOQDATYLWWV 180
Db 121 TLHVIKSDLVNEATGOFRVPPELPKPSISSNNSKPVEDKDAVFTCEPETOQDATYLWWV 180
Qy 181 NNQSIPSPRLQLSNGNRTLTFLNVTRNDATASYKCETONPVSAARRSDSVILVLYGPDA 240
Db 181 NNQSIPSPRLQLSNGNRTLTFLNVTRNDATASYKCETONPVSAARRSDSVILVLYGPDA 240
Qy 241 TISPLNTSYRSGENLNLSCHAASNPQAQYSWFVNGLTFOOSTELFIPNITVNNSGSYTQ 300
Db 233 ----- 232
Qy 301 AHNSDTGLNRITVTITVIAEPPKPKPITSNSNSNPVEDEDAVALTCPEIONTTYLWWVN 360
Db 233 ----- 232
Qy 361 QSLPVSPRLQLSNDNNTLTLSVTRNDVGPYECGIONELSVDHSDPVILVLYGPDDPTI 420
Db 143 ----- 142
Qy 421 SPSYYRPGVNLSLSCHAASNPQAQYSWLIDGNQOHTQELFISNTERNSGLYTCQAN 480
Db 143 ----- 142
Qy 481 NSASGHSRRTVKITVSAELPKPSISSNNSKPVEDKDAVFTCEPETOQNTTYLWWNGQ 540
Db 143 ----- 142
Qy 481 NSASGHSRRTVKITVSAELPKPSISSNNSKPVEDKDAVFTCEPETOQNTTYLWWNGQ 540
Db 143 ----- 142
Qy 541 LPVSPRLQLSNGNRTLTFLNVTRNDARAYVGQONSANSNSDPVTLVLYGPDTIISP 600
Db 185 LPVSPRLQLSNGNRTLTFLNVTRNDARAYVGQONSANSNSDPVTLVLYGPDTIISP 244
Qy 601 PDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQHQTQFLTIKTPNNNGTYACFVSNL 660
Db 245 PDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQHQTQFLTIKTPNNNGTYACFVSNL 304
Qy 661 ATGRNNIVKSITVSAGSTPGLSAGATGVGMIGVLYGVALI 702
Db 305 ATGRNNIVKSITVSAGSTPGLSAGATGVGMIGVLYGVALI 346

Db 233 ----- 232
 Qy 421 SPSVTYRPGVNLSLSCHAASNPAPAQYSWLTIDGNIQQHOLEFISNITEKNSGLYTQCAN 480
 Db 233 ----- 232
 Qy 481 NSASGHSRRTVKTITVSAELPKPSISSNNSKPVEDKDAVAFTCBEPQAQNTTYLWWNGQS 540
 Db 233 ----- 232
 Qy 541 LPVSPRLQLQNSGNRTLTLFNVTRNDARAYVGQIONSANSRSDPVTLDVLXGPDPTISP 600
 Db 233 ----- 232
 Qy 601 PDSSYLSGANLNLSCHSASNPSPQYSWRINGIPOQHTQVLIAKTPNNNGTYACFVSNL 660
 Db 245 PDSSYLSGANLNLSCHSASNPSPQYSWRINGIPOQHTQVLIAKTPNNNGTYACFVSNL 304
 Qy 661 ATGRNNNSIVKSITVSASSTSPLSAGATVGMIGLVGVALLI 702
 Db 305 ATGRNNNSIVKSITVSASSTSPLSAGATVGMIGLVGVALLI 346
 ;
 RESULT 14
 US-11-051-720-1383
 ; Sequence 1383, Application US/11051720
 ; Publication No. US20060046257A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Compugen Ltd
 ; TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS
 ; TITLE OF INVENTION: THEREOF FOR DIAGNOSIS OF LUNG CANCER
 ; FILE REFERENCE: 1847.1002
 ; CURRENT APPLICATION NUMBER: US/11/051,720
 ; CURRENT FILING DATE: 2005-01-27
 ; NUMBER OF SEQ ID NOS: 1780
 ; SEQ ID NO 1383
 ; LENGTH: 346
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-11-051-720-1383
 Query Match 44.0%; Score 1636; DB 7; Length 346;
 Best Local Similarity 49.3%; Pred. No. 7.5e-96; Mismatches 0; Indels 356; Gaps 1;
 Matches 346;
 保守型 0; 错配 0; 缺失 356; 插入 1;
 Qy 1 MESPSPAPHRWCIPWQRLTATSLTFFWNPPPTAKLTTESTPFPNVAGKEVLLVHLNPQ 60
 Db 1 MESPSPAPHRWCIPWQRLTATSLTFFWNPPPTAKLTTESTPFPNVAGKEVLLVHLNPQ 60
 Qy 61 HURQYSWYKGERIDGNRQIGYVIGTQATPGAVSGREITPNASLLIONIQNDTGFY 120
 Db 61 HURQYSWYKGERIDGNRQIGYVIGTQATPGAVSGREITPNASLLIONIQNDTGFY 120
 Qy 121 TLQVIKSDLVNEATQGPVYPELPKPSISSNNSKPVEDKDAVAFTCPEPOTADYLYWW 180
 Db 121 TLQVIKSDLVNEATQGPVYPELPKPSISSNNSKPVEDKDAVAFTCPEPOTADYLYWW 180
 Qy 181 NNQSLPSPRQLQNSGNRTLTLFNVTRNDTASYKETQNPSVARSADSVINLYGPDAP 240
 Db 181 NNQSLPSPRQLQNSGNRTLTLFNVTRNDTASYKETQNPSVARSADSVINLYGPDAP 240
 Qy 241 TISPLNTSYRSGENLNLSCHAASNPAPAQYSWFNGTFOQSTQELFINITVNSGSYTCQ 300
 Db 233 ----- 232
 Qy 301 AHNSDTGJNRTTVTTWYAEPPKPFITSNSNSPVEDDAVAVTCBEPFQNTTYLWWNN 360
 Db 233 ----- 232
 Qy 361 QSLPVSPRLQLSDNDRNLTLSVTRNDYGPYECGIONELSLVDHSDPVTLDVLXGPDPTISP 420
 Db 233 ----- 232
 ;
 RESULT 15
 US-11-080-991-4
 ; Sequence 4, Application US/11080991
 ; Publication No. US20050266437A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Veiby, petter Ole
 ; TITLE OF INVENTION: COMPOSITIONS, KITS, AND METHODS FOR
 ; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST
 ; TITLE OF INVENTION: AND OVARIAN CANCER
 ; FILE REFERENCE: WO1 - 039
 ; CURRENT APPLICATION NUMBER: US/11/080,991
 ; CURRENT FILING DATE: 2005-03-11
 ; PRIOR APPLICATION NUMBER: US/10/176,847
 ; PRIOR FILING DATE: 2002-06-21
 ; NUMBER OF SEQ ID NOS: 112
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 4
 ; LENGTH: 344
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-11-080-991-4
 Query Match 38.8%; Score 1443; DB 7; Length 344;
 Best Local Similarity 83.9%; Pred. No. 1e-83; Mismatches 41; Indels 0; Gaps 0;
 Matches 271;
 保守型 83.9%; 错配 41; 缺失 0; 插入 0;
 Qy 1 MESPSPAPHRWCIPWQRLTATSLTFFWNPPPTAKLTTESTPFPNVAGKEVLLVHLNPQ 60
 Db 1 MCPPSPAPCRHLVPKEVLLVHLNPQ 60
 Qy 61 HURGYSWYKGERDGNRQIGYVIGTQATPGAVSGREITPNASLLIONIQNDTGFY 120
 Db 61 HURGYSWYKGERDGNRQIGYVIGTQATPGAVSGREITPNASLLIONIQNDTGFY 120
 Qy 61 NEIGYSWYKGERDGNRQIGYVIGTQATPGAVSGREITPNASLLIONIQNDTGFY 120
 Db 121 TLQVIKSDLVNEATQGPVYPELPKPSISSNNSKPVEDKDAVAFTCPEPOTADYLYWW 180
 Db 121 TLQVIKSDLVNEATQGPVYPELPKPSISSNNSKPVEDKDAVAFTCPEPOTADYLYWW 180
 Qy 181 NNQSLPSPRQLQNSGNRTLTLFNVTRNDTASYKETQNPSVARSADSVINLYGPDAP 240
 Db 181 NNQSLPSPRQLQNSGNRTLTLFNVTRNDTASYKETQNPSVARSADSVINLYGPDAP 240
 Qy 241 TISPLNTSYRSGENLNLSCHAASNPAPAQYSWFNGTFOQSTQELFINITVNSGSYTCQ 300
 Db 232 ----- 301
 Qy 301 AHNSDTGJNRTTVTTWYAEPPKPFITSNSNSPVEDDAVAVTCBEPFQNTTYLWWNN 360
 Db 301 QSLPVSPRLQLSDNDRNLTLSVTRNDYGPYECGIONELSLVDHSDPVTLDVLXGPDPTISP 420
 Db 232 ----- 301
 ;
 Search completed: April 10, 2006, 18:13:23

Wed Apr 12 09:54:36 2006

us-10-734-564-72.rapbn

Page 9

Job time : 27.4851 secs

THIS PAGE LEFT BLANK

Copyright (c) 1993 - 2006 Biocceleration Ltd.
OM protein - protein search, using sw model
GenCore version 5.1.7

RESULT 1
US-09-949-016-6484
; Sequence 6484, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIORITY FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 6484
; LENGTH: 702
; TYPE: PRT
; ORGANISM: Human
; US-09-949-016-6484

Query Match 100.0%; Score 3721; DB 2; Length 702;
Best Local Similarity 100.0%; Pred. No. 2, 8e-271; Indels 0; Gaps 0;
Matches 702; Conservative 0; Mismatches 0;

QY 1 MEPSAPHRCPWQRQLLTASLITLWNPPATAKTIESTPFWAVKEVLLVILNLPQ
Db 1 MEPSAPHRCPWQRQLLTASLITLWNPPATAKTIESTPFWAVKEVLLVILNLPQ 60
QY 61 HLGGSWYKGERDGNRQIGVIGVQATCPGPGAYSGREITYPNASLLQNIQNTGFY 120
Db 61 HLGGSWYKGERDGNRQIGVIGVQATCPGPGAYSGREITYPNASLLQNIQNTGFY 120
QY 121 TLWIKSDUNERATGOPRVYPLPKPISISSNNSKPVEDKDAVAFFCEPERODATLWWV 180
Db 121 TLWIKSDUNERATGOPRVYPLPKPISISSNNSKPVEDKDAVAFFCEPERODATLWWV 180
QY 181 NNQSLPVSPLQLQNSGHTLTFVNTRNDTASYKCTQNPYSPARRSDSVTINVLYGDPAP 240
Db 181 NNQSLPVSPLQLQNSGHTLTFVNTRNDTASYKCTQNPYSPARRSDSVTINVLYGDPAP 240
QY 241 TTSPLNTSYRSGENLNLISCHAASNPQAQISFVNGCFOQSTQELFPNTINNSGTYCQ 300
Db 241 TTSPLNTSYRSGENLNLISCHAASNPQAQISFVNGCFOQSTQELFPNTINNSGTYCQ 300
QY 301 ARNSDTGILRTVTITVYABRKPFTTSNNNSNPVDBDAVALTCPEIQTYYWWVNN 360

ALIGNMENTS

issued 11/2/64

Query Match 100.0%; Score 3721; DB 1; Length 734;
 Best Local Similarity 100.0%; Pred. No. 3e-271; Matches 702; Conserv. 0; Mismatches 0; Indels 0; Gaps 0;

Matches 702; Conserv. 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESPSAPHRHICIPMWRLLTASLITFWNPPTAKLTISTPFWAEGKEVLLVHNLPQ 60
 Db 33 MESPSAPHRHICIPMWRLLTASLITFWNPPTAKLTISTPFWAEGKEVLLVHNLPQ 60
 QY 421 SPSYTYYRPGVNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 480
 Db 61 HLFGYWYKGSRVDGNOIGYVIGTQATPGPAYSGREIYPNALITIONDGFY 120
 QY 421 SPSYTYYRPGVNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 480
 Db 93 HLFGYWYKGSRVDGNOIGYVIGTQATPGPAYSGREIYPNALITIONDGFY 152
 QY 481 NSASGRRTVTKITVSAELPKPSISSNNSPVEDKDAVFTCEPEAONTTYLWVNQ 540
 Db 121 TLHVKSDLVNEEATCQFRYPELKPSISSNNSPVEDKDAVFTCEPEAONTTYLWVNQ 180
 QY 541 LPVSPLQLSNGNRTLTFNTRNDARAYCGIONSVSANSDPVTLDVLYGDPPIISP 600
 Db 153 TLHVKSDLVNEEATCQFRYPELKPSISSNNSPVEDKDAVFTCEPEAONTTYLWVN 212
 QY 601 PDSSYLGANLNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 660
 Db 273 TLSPINTSYRSGENLNLSCHASNPQAQSWFVNQTPQSTOELFIPNNTGSYTCQ 332
 QY 661 ATGRNNNIVSKITVSAAGTSPGLSAGATVGIMIGVLVGVALI 702
 Db 301 AHNSDPLVSPLQLSNGNRTLTFNTRNDASYKETQNSARRSDSVILNLVLYGDPAP 240
 QY 661 ATGRNNNIVSKITVSAAGTSPGLSAGATVGIMIGVLVGVALI 702
 Db 333 AHNSDPLGLNRRTVTTVYAEPPKFTSNNSPVEDDAVFTCEPEAONTTYLWVN 392
 QY 361 OSLPVSPRLQLSNDNRTLTLSVTRNDVGPECQNLSEUDHSDPVTLDVLYGDPDTI 420
 Db 393 OSLPVSPRLQLSNDNRTLTLSVTRNDVGPECQNLSEUDHSDPVTLDVLYGDPDTI 452
 QY 421 SPSYTYYRPGVNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 480
 Db 453 SPSYTYYRPGVNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 512
 QY 481 NSASGRRTVTKITVSAELPKPSISSNNSPVEDKDAVFTCEPEAONTTYLWVNQ 540
 Db 513 NSASGRRTVTKITVSAELPKPSISSNNSPVEDKDAVFTCEPEAONTTYLWVNQ 572
 QY 541 LPVSPLQLSNGNRTLTFNTRNDARAYCGIONSVSANSDPVTLDVLYGDPPIISP 600
 Db 573 LPVSPLQLSNGNRTLTFNTRNDARAYCGIONSVSANSDPVTLDVLYGDPPIISP 632
 QY 601 PDSSYLGANLNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 660
 Db 633 PDSSYLGANLNLSCHASNPQAQSWLIDGNIOQHTQBLFISNTEKNSGLYTCAN 692
 QY 661 ATGRNNNIVSKITVSAAGTSPGLSAGATVGIMIGVLVGVALI 702
 Db 693 ATGRNNNIVSKITVSAAGTSPGLSAGATVGIMIGVLVGVALI 734

RESULT 2
 US-01-389-459A-17
 ; Sequence 17, Application US/08389459A
 ; Patent No. 5817512
 ; GENERAL INFORMATION:
 ; APPLICANT: Morrow, Casey D. and Porter, Donna C.
 ; TITLE OF INVENTION: ENCARSIDATED RECOMBINANT POLIOVIRUS
 ; TITLE OF INVENTION: USING SAME
 ; NUMBER OF SEQUENCES: 23
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: LAHIVE & COCKFIELD
 ; STREET: 60 STATE STREET, SUITE 510
 ; CITY: BOSTON
 ; STATE: MASSACHUSETTS
 ; COUNTRY: USA
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: ASCII
 ; APPLICATION NUMBER: US/08/389,459A
 ; FILING DATE: 15-FEB-1995
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/087,009
 ; FILING DATE: 01-JUL-1993
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Silveri, Jean M.
 ; REGISTRATION NUMBER: 3,9,030
 ; REFERENCE/DOCKET NUMBER: UAG-004CP
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (617) 227-7400
 ; TELEFAX: (617) 227-5941
 ; INFORMATION FOR SEQ ID NO: 17:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 734 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; US-08-389-459A-17

RESULT 3
 US-08-987-867A-17
 ; Sequence 17, Application US/08987867A
 ; Patent No. 603384
 ; GENERAL INFORMATION:
 ; APPLICANT: C. Morrow et al.
 ; TITLE OF INVENTION: ENCARSIDATED RECOMBINANT VIRAL
 ; TITLE OF INVENTION: NUCLEAR ACID AND METHODS OF MAKING AND
 ; TITLE OF INVENTION: USING SAME
 ; NUMBER OF SEQUENCES: 23
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: LAHIVE & COCKFIELD
 ; STREET: 28 STATE STREET,
 ; CITY: BOSTON
 ; STATE: MASSACHUSETTS
 ; COUNTRY: USA
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; COMPUTER: IBM PC compatible
 ; MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/987,867A
 FILING DATE: 09-DEC-1997
 CLASSIFICATION: 424
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US 08/087,009
 FILING DATE: 01-JUL-1993
 ATTORNEY/AGENT INFORMATION:
 NAME: Myers, Louis
 REFERENCE/DOCKET NUMBER: 35,965
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617) 227-7400
 TELEX: (617) 742-4214
 INFORMATION FOR SEQ ID NO: 17:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 734 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-987-867A-17

Query Match 100.0%; Score 3721; DB 2; Length 734;
 Best Local Similarity 100.0%; Pred. No. 3.e-271; Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESPSAPHRNCIPWORLILTASLLTPWNPPRTAKUTIESTPFPNVAGKEVILLYVNLPQ 60
 Db 33 MESPSAPHRNCIPWORLILTASLLTPWNPPRTAKUTIESTPFPNVAGKEVILLYVNLPQ 92
 Qy 61 HLFGYSWYKGERVDGNGRQIGYVIGVQATGPAYSGRELYTPNASSLIONIONDGFY 120
 Db 93 HLFGYSWYKGERVDGNGRQIGYVIGVQATGPAYSGRELYTPNASSLIONIONDGFY 152
 Qy 121 TLHVTKSDLVNEATCQFRYVPELPKPSISSNNSKVEDKDAVAFCEPEPTQDATLYWWV 180
 Db 153 TLHVTKSDLVNEATCQFRYVPELPKPSISSNNSKVEDKDAVAFCEPEPTQDATLYWWV 212
 Qy 181 NNQSLEPVSPRIQLSNGNRTLTFLNVTRNDTASYKCTQNPSVARSDSVILVNLGYDAP 240
 Db 213 NNQSLEPVSPRIQLSNGNRTLTFLNVTRNDTASYKCTQNPSVARSDSVILVNLGYDAP 272
 Qy 241 TISPLNTSYSGENLNLSCHASNPQAQYFWFNGFQFOQSQELFLPNTVNNSYTCQ 300
 Db 273 TISPLNTSYSGENLNLSCHASNPQAQYFWFNGFQFOQSQELFLPNTVNNSYTCQ 332
 Qy 301 AHNSTGGLNRTVTITVVAEPPKPKITSNSNNSPVDEDAAVLTCEPEIONTLYWWNN 360
 Db 333 AHNSTGGLNRTVTITVVAEPPKPKITSNSNNSPVDEDAAVLTCEPEIONTLYWWNN 392
 Qy 361 QSLPVSPRIQLSNDNRTLTFLSVTRNDVPGVECGTONEELSVDHSDPVLNVLYGDDPTI 420
 Db 393 QSLPVSPRIQLSNDNRTLTFLSVTRNDVPGVECGTONEELSVDHSDPVLNVLYGDDPTI 452
 Qy 421 SPSYYTYRGYNLSLSCHAASNPQAQYFWFNGFQFOQSQELFLPNTVNNSYTCQAN 480
 Db 453 SPSYYTYRGYNLSLSCHAASNPQAQYFWFNGFQFOQSQELFLPNTVNNSYTCQAN 512
 Qy 481 NSASGHSRRTVKTITIVSAEPKPSISSNNSKPVEDKDAVFTCERAAQNTYLWNGOS 540
 Db 513 NSASGHSRRTVKTITIVSAEPKPSISSNNSKPVEDKDAVFTCERAAQNTYLWNGOS 572
 Qy 541 LPVSRLIQLQNSGNRRTLTFLNVTRNDARAYTGCIONVSANSRSDPVTDLYGPDPTI 600
 Db 573 LPVSRLIQLQNSGNRRTLTFLNVTRNDARAYTGCIONVSANSRSDPVTDLYGPDPTI 632
 Qy 601 PDSSYLSGANLNLSCSASHSPQSWRNGIPOOHTQVIAKTPNNNGTYACFVSNL 660
 Db 633 PDSSYLSGANLNLSCSASHSPQSWRNGIPOOHTQVIAKTPNNNGTYACFVSNL 692
 Qy 661 ATGRNNSIVVISITVSASGTSPLGLSAGATVGIMIGLVGVALL 702

RESULT 4
 US-09-949-016-8168
 Sequence 8168, Application US/09949016
 ; GENERAL INFORMATION:
 ; Sequence No. 6812339
 ; APPLICANT: VENTER, J. Craig et al.
 ; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
 ; FILE REFERENCE: CI001307
 ; CURRENT APPLICATION NUMBER: US/09/949,016
 ; CURRENT FILING DATE: 2000-04-14
 ; PRIOR APPLICATION NUMBER: 60/241,755
 ; PRIOR FILING DATE: 2000-10-20
 ; PRIOR APPLICATION NUMBER: 60/237,768
 ; PRIOR FILING DATE: 2000-10-03
 ; PRIOR FILING DATE: 60/231,498
 ; PRIOR FILING DATE: 2000-09-08
 ; NUMBER OF SEQ ID NO: 207012
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 8168
 ; LENGTH: 740
 ; TYPE: PRT
 ; ORGANISM: Human
 US-09-949-016-8168

Query Match 100.0%; Score 3721; DB 2; Length 740;
 Best Local Similarity 100.0%; Pred. No. 3.e-271; Matches 702; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESPSAPHRNCIPWORLILTASLLTPWNPPRTAKUTIESTPFPNVAGKEVILLYVNLPQ 60
 Db 39 MESPSAPHRNCIPWORLILTASLLTPWNPPRTAKUTIESTPFPNVAGKEVILLYVNLPQ 98
 Qy 61 HLFGYSWYKGERVDGNGRQIGYVIGVQATGPAYSGRELYTPNASSLIONIONDGFY 120
 Db 99 HLFGYSWYKGERVDGNGRQIGYVIGVQATGPAYSGRELYTPNASSLIONIONDGFY 158
 Qy 121 TLHVTKSDLVNEATCQFRYVPELPKPSISSNNSKVEDKDAVAFCEPEPTQDATLYWWV 180
 Db 159 TLHVTKSDLVNEATCQFRYVPELPKPSISSNNSKVEDKDAVAFCEPEPTQDATLYWWV 218
 Qy 181 NNQSLEPVSPRIQLSNGNRTLTFLNVTRNDTASYKCTQNPSVARSDSVILVNLGYDAP 240
 Db 219 NNQSLEPVSPRIQLSNGNRTLTFLNVTRNDTASYKCTQNPSVARSDSVILVNLGYDAP 278
 Qy 241 TISPLNTSYSGENLNLSCHASNPQAQYFWFNGFQFOQSQELFLPNTVNNSYTCQ 300
 Db 279 TISPLNTSYSGENLNLSCHASNPQAQYFWFNGFQFOQSQELFLPNTVNNSYTCQ 338
 Qy 301 AHNSTGGLNRTVTITVVAEPPKPKITSNSNNSPVDEDAAVLTCEPEIONTLYWWNN 360
 Db 339 AHNSTGGLNRTVTITVVAEPPKPKITSNSNNSPVDEDAAVLTCEPEIONTLYWWNN 398
 Qy 361 QSLPVSPRIQLSNDNRTLTFLSVTRNDVPGVECGTONEELSVDHSDPVLNVLYGDDPTI 420
 Db 399 QSLPVSPRIQLSNDNRTLTFLSVTRNDVPGVECGTONEELSVDHSDPVLNVLYGDDPTI 458
 Qy 481 NSASGHSRRTVKTITIVSAEPKPSISSNNSKPVEDKDAVFTCERAAQNTYLWNGOS 540
 Db 519 NSASGHSRRTVKTITIVSAEPKPSISSNNSKPVEDKDAVFTCERAAQNTYLWNGOS 578
 Qy 541 LPVSRLIQLQNSGNRRTLTFLNVTRNDARAYTGCIONVSANSRSDPVTDLYGPDPTI 600
 Db 579 LPVSRLIQLQNSGNRRTLTFLNVTRNDARAYTGCIONVSANSRSDPVTDLYGPDPTI 638

Qy 601 PDSYSLSGANLNLSCHASNSPQYSWRINGIPQQTQULIPIAKITTPNNNGTYACFVNL 660
Db 639 PDSYSLSGANLNLSCHASNSPQYSWRINGIPQQTQULIPIAKITTPNNNGTYACFVNL 698
Qy 661 ATGRNNISIVKSVITVSAGTSPEGLSAGATVGIMIGVLVGVALI 702
Db 699 ATGRNNISIVKSVITVSAGTSPEGLSAGATVGIMIGVLVGVALI 740

RESULT 5
US-08-602-725-36
; Sequence 36, Application US/08602725
; Patent No. 5165710
GENERAL INFORMATION:
APPLICANT: BODNER, WALTER F
APPLICANT: DURBIN, HELGA
APPLICANT: SNARY, DAVID
APPLICANT: STEWART, LORNA MD
APPLICANT: YOUNG, SUSAN
APPLICANT: BATES, PAUL A
TITLE OF INVENTION: MONOCLONAL ANTIBODIES FOR USE IN
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHVE, P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22201

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/602,725
FILING DATE: 02-FEB-1996
CLASSIFICATION: 530

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB94/01816
FILING DATE: 19-AUG-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 93117423
FILING DATE: 21-AUG-1993

ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36663
REFERENCE DOCKET NUMBER: 1030-8
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4091
TELEFAX: 703-816-4100

INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 698 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-602-725-36

Query Match 99.4%; Score 3700; DB 1; Length 698;
Best Local Similarity 100.0%; Pred. No. 1; e-269;
Matches 698; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 SAPPHRCIPWQLLTLTASLTFWNPPITAUTESTPPNVAEGKEVILVNLNPOLFG 64
Db 1 SAPPHRCIPWQLLTLTASLTFWNPPITAUTESTPPNVAEGKEVILVNLNPOLFG 60

Qy 65 YSYKGERVGDGNRQIGVIGTQATPPGASRBYIPNASHLQIIONDTGFYHLV 124
Db 61 YSYKGERVGDGNRQIGVIGTQATPPGASRBYIPNASHLQIIONDTGFYHLV 120

Qy 125 IKSDLVNEBEATGQFRVVPELPKPSISSNNSKPVEDKDAVAFCEPETODATYLWVNQS 184

RESULT 6
US-08-217-299-1
; Sequence 1, Application US/08217299
; Patent No. 5672513
GENERAL INFORMATION:
APPLICANT: Mach, J. P.
APPLICANT: Pelegrin, A.
APPLICANT: Terkikh, A.
TITLE OF INVENTION: Carcinoembryonic Antigen Derivatives
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: NJ
COUNTRY: USA
ZIP: 07110

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,299
FILING DATE: 25-MAR-1993
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93810214.2
FILING DATE: 25-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Pokras, Bruce A.
REGISTRATION NUMBER: 32,748
REFERENCE DOCKET NUMBER: RAN 4093/096

Db 121 IKSDLVNEBEATGQFRVVPELPKPSISSNNSKPVEDKDAVAFCEPETODATYLWVNQS 180
Db 185 LPSPPLQLSNGNRULTFNTRDNTASYCETOPVSRSDSYLNLVLYGDPARTISP 244
Db 181 LPVSPQLQSLNGNRULTFNTRDNTASYCETOPVSRSDSYLNLVLYGDPARTISP 240

Db 245 LNTSRSGENLNLSCHASNSPQYSWNGTFOOSTQELFIPNITVNNSGSYTCQAHNS 304
Db 241 LNTSRSGENLNLSCHASNSPQYSWNGTFOOSTQELFIPNITVNNSGSYTCQAHNS 300

Db 305 DTGLNRTITVTITVAAPEKFITSNSNPVEDEDAVALTCPEPEIQTNTTLYWWVNQSLP 364
Qy 301 DTGLNRTITVTITVAAPEKFITSNSNPVEDEDAVALTCPEPEIQTNTTLYWWVNQSLP 360
Qy 365 VSPLQLSNDRTRTISLTSVTRNDVGYCPEGQNLNSWDSDPVTLVLYGDPDTISPY 424
Db 361 VSPLQLSNDRTRTISLTSVTRNDVGYCPEGQNLNSWDSDPVTLVLYGDPDTISPY 420
Qy 425 TYRPGNLSLSCHAASNPQYSWMLDGNIQOHQELFLISNITEKNSGLYTQANNAS 484
Db 421 TYRPGNLSLSCHAASNPQYSWMLDGNIQOHQELFLISNITEKNSGLYTQANNAS 480
Qy 485 GHSRRTWKTTITVSAELPKPS1SSNNNSKPVEDKDAVAFTCPEAQNTTYLWVNQSLPVS 544
Db 481 GHSRRTWKTTITVSAELPKPS1SSNNNSKPVEDKDAVAFTCPEAQNTTYLWVNQSLPVS 540
Qy 545 PRQLQSNGRNLTFNTRDNTARAYCQGONSVANSRSDPTDLYGDPPTISPDRPDSS 604
Db 541 PRQLQSNGRNLTFNTRDNTARAYCQGONSVANSRSDPTDLYGDPPTISPDRPDSS 600
Qy 605 YLSGANLNLSCHASNSPQYSWRINGIPQQTQULIPIAKITTPNNNGTYACFVNLGR 664
Db 601 YLSGANLNLSCHASNSPQYSWRINGIPQQTQULIPIAKITTPNNNGTYACFVNLGR 660
Qy 665 NNSIVKSVITVSAGTSPEGLSAGATVGIMIGVLVGVALI 698
Db 661 NNSIVKSVITVSAGTSPEGLSAGATVGIMIGVLVGVALI 698

TELECOMMUNICATION INFORMATION:

TELEPHONE: (201) 235-5801

TELEFAX: (201) 235-3500

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 642 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: unknown

MOLECULE TYPE: protein

HYPOTHETICAL: NO

ANTI-SENSE: NO

FRAGMENT TYPE: C-terminal

ORIGINAL SOURCE:

US-08-217-299-1

Query Match

Best Local Similarity 91.4%; Score 3402; DB 1; Length 642; Matches 642; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

35

KLTISTPPNVAEGKEVLLVHNLPQLRGSWYKGERDGNRQIGVYGTQATPGPA

94

Db

1

KLTISTPPNVAEGKEVLLVHNLPQLRGSWYKGERDGNRQIGVYGTQATPGPA

60

Qy

95

YSGRETIYPNSSLIONITQNDGFTYLHVKDSLVDNEATGQFRVPELPKPSISNN

154

Db

61

YSGRETIYPNSSLIONITQNDGFTYLHVKDSLVDNEATGQFRVPELPKPSISNN

120

Qy

155

KPVEDKDAVFTCEBRTQDTAYLWNNQNLQSLPVSPRLQSLNGRNRTILEFTVNTRASYK

214

Db

121

KPVEDKDAVFTCEBRTQDTAYLWNNQNLQSLPVSPRLQSLNGRNRTILEFTVNTRASYK

180

Qy

215

CETQMPVSARSDSVLNLYVQGDAPTTISPLNTSRSGENLNSCHASNPQAQSWFN

274

Db

181

CETQMPVSARSDSVLNLYVQGDAPTTISPLNTSRSGENLNSCHASNPQAQSWFN

240

Qy

275

GTFOQOSTQEIPINITYVNNSGSYTCAHNSDTGLNRTTVTVAEPPPKFTSNNSNP

334

Db

241

GTFOQOSTQEIPINITYVNNSGSYTCAHNSDTGLNRTTVTVAEPPPKFTSNNSNP

300

Qy

335

VEDEAVALTACPRLEQTNTLWMMUNQSLVSPRQLSNRNTLTLISVTRNDVGPYECG

394

Db

301

VEDEAVALTACPRLEQTNTLWMMUNQSLVSPRQLSNRNTLTLISVTRNDVGPYECG

360

Qy

395

IQNEISVHDHPVIAVLVQGPDDPTISPSTIYRPGVNLISCHAAQNPQAQSYLIDGN

454

Db

361

IQNEISVHDHPVIAVLVQGPDDPTISPSTIYRPGVNLISCHAAQNPQAQSYLIDGN

420

Qy

455

IQQHQBELFISNITEKNGSYTCAQNSAAGHSRTRVKTITVSAELPKPSISNNNSKPE

514

Db

421

IQQHQBELFISNITEKNGSYTCAQNSAAGHSRTRVKTITVSAELPKPSISNNNSKPE

480

Qy

515

DKDVAFTCPEAQNNTLYWMMNGSOLPVSPPRLQSNGNRTLTLVNRTRNDARAVCGIQ

574

Db

481

DKDVAFTCPEAQNNTLYWMMNGSOLPVSPPRLQSNGNRTLTLVNRTRNDARAVCGIQ

540

Qy

575

NSVSANRSQDVTLVYLGPTPTISPPDSSYLSGMLNLSCHASNPQSYQWSRINGPQ

634

Db

541

NSVSANRSQDVTLVYLGPTPTISPPDSSYLSGMLNLSCHASNPQSYQWSRINGPQ

600

Qy

635

QHTQVLFLAKITPNNGTACFVSNLATGRENNSIVKSITSA

676

Db

601

QHTQVLFLAKITPNNGTACFVSNLATGRENNSIVKSITSA

642

Qy

RESULT 7

US-08-602-725-32

Sequence 32, Application US/08602725

Patent No. 5965710

GENERAL INFORMATION:

APPLICANT: BODMER, WALTER F

APPLICANT: DURBIN, HELGA

APPLICANT: SNARY, DAVID
 APPLICANT: STEWART, LORNA MD
 APPLICANT: YOUNG, SUSAN
 APPLICANT: BATES, PAUL A
 TITLE OF INVENTION: MONOCLONAL ANTIBODIES FOR USE IN
 NUMBER OF SEQUENCES: 40
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: NIXON & VANDERHYE P.C.
 STREET: 1100 NORTH GLBEE ROAD, 8TH FLOOR
 CITY: ARLINGTON
 STATE: VA
 COUNTY: USA
 ZIP: 22201
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOSS/MS-DOS
 SOFTWARE: Patent Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/602,725
 FILING DATE: 02-FEB-1996
 CLASSIFICATION: 530
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/GB94/01816
 FILING DATE: 19-AUG-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: GB 9317423
 FILING DATE: 21-AUG-1993
 ATTORNEY/AGENT INFORMATION:
 NAME: SADOF, B.J.
 REGISTRATION NUMBER: 36663
 LENGTH: 464 amino acids
 SEQUENCE CHARACTERISTICS:
 REFERENCE/DOCKET NUMBER: 1090-8
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 703-816-4091
 FAX: 703-815-4100
 INFORMATION FOR SEQ ID NO: 32:
 LENGTH: 464 amino acids
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-602-725-32

Query Match

Best Local Similarity 43.0%; Score 1600.5; DB 1; Length 464; Matches 309; Conservative 30; Mismatches 79; Indels 5; Gaps 2;

Qy

5

SAPPHRWCIPWQRQJLTTASLUTFWNPPTAKUTESTPPNVAEGKEVLLVHNLPQLHFG

64

Db

5

SAPPHRWCIPWQRQJLTTASLUTFWNPPTAKUTESTPPNVAEGKEVLLVHNLPQLHFG

64

Qy

65

YSWYKBRVUDGNRQIGVYIGVYGTQATPGPGRASGRBTTYVNLNSLTLQNTDGTPTYLV

124

Db

65

YSWYKBRVUDGNRQIGVYIGVYGTQATPGPGRASGRBTTYVNLNSLTLQNTDGTPTYLV

124

Qy

125

IKSDLWNEATGQFRVPELPKPSISNNNSNPVDEDDAKAFTCPETOQTLTUVNNQ

184

Db

125

IKSDLWNEATGQFRVPELPKPSISNNNSNPVDEDDAKAFTCPETOQTLTUVNNQ

184

Qy

185

LPVSPRQLQSLNGRNTLTLISVTRNDVGPYECGILQNELSVDFHSDPVILNVLYG

244

Db

185

LPVSPRQLQSLNGRNTLTLISVTRNDVGPYECGILQNELSVDFHSDPVILNVLYG

244

Qy

245

SDTYRPGANLISLCYAAQNPQSYWLNGTFOOSTQELFIPNITVNNSGTCIANS

304

Db

305

DTGLNRTTVTITYAEP---KPTTSNSNPVDEDDAKAFTCPETOQTLTUVNNQ

361

Qy

305

VTGCNRTTVTTLTVEPLSPVWAKPQIKASKTPTVGDKUSVNLTCTNDTGISRWFKNQ

364

Db

362

SLPVSPRQLQSLNDRTTLTUVNNQ

364

Qy

RESULT 8
 US-09-949-016-5116
 ; Sequence 6116, Application US/09949016
 ; Patent No. 6812339
 GENERAL INFORMATION:
 APPLICANT: VENTER, J. Craig et al.
 TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
 WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
 FILE REFERENCE: C1001307
 CURRENT APPLICATION NUMBER: US/09/949, 016
 CURRENT FILING DATE: 2000-04-14
 PRIORITY APPLICATION NUMBER: 60/241, 755
 PRIORITY FILING DATE: 2000-10-20
 PRIORITY APPLICATION NUMBER: 60/237, 768
 PRIORITY FILING DATE: 2000-10-03
 PRIORITY APPLICATION NUMBER: 60/231, 498
 PRIORITY FILING DATE: 2000-09-08
 NUMBER OF SEQ ID NOS: 207012
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 6116
 LENGTH: 464
 TYPE: PRT
 ORGANISM: Human
 US-09-949-016-6116

Query Match 43.0%; Score 1600.5; DB 2; Length 464;
 Best Local Similarity 73.0%; Pred. No. 4.3e-112; Mismatches 79; Indels 5; Gaps 2;
 Matches 309; Conservative 30; MisMatches 79; Indels 5; Gaps 2;

QY 5 SAPPHRWCIPWQLLTLTASLLTFWNPPTTAKLTISTSPFNAEGKEVLLVHNLPOHLFG 64
 Db 5 SAPLHRTRVPWQGLLTASLLTFWNPPTTAQLTESMPNVAEGKEVLLVHNLPOQLFG 64
 QY 65 YSWYKGERVDGHRQIGVGTQOATPGPAYSGRETYPPNASHLQIQLDGFYTLLHV 124
 Db 65 YSWYKGERVDGHRQIVGAIGTOQATPGPANSGRETYPPNASHLQIQLDGFYTLLHV 124
 QY 125 IKSDLVNEBEATQFRYPELPKPSISSNNSPVEDKDAVFTCEBETQDATYLMNNQS 184
 Db 125 IKSDLVNEBEATQFRYPELPKPSISSNNSPVEDKDAVFTCEBETQDATYLMNNQS 184
 QY 185 LPVSPRQLQSNGRNTLTLFVNTRNDTASYKCETQNPVSARSDSVLNVLXGDPAPTISP 244
 Db 185 LPVSPRQLQSNGRNTLTLFVNTRNDTGPYCECIONPVSAKRSDPVTLNVTGDPAPTISP 244
 QY 245 LNTSYRSGENTNLSCHAASNPAQYSNFTVNGFPTQOSTOBELFIPNITYNNNSYTCQAHNS 304
 Db 245 SDTYYRBRGANLSCYASNPQAQYTSWLNGTFOQSTQELFIPNITYNNNSYTCQAHNS 304
 QY 305 DTGLKNTTVITVYAPP--KPFITSNNSNPVEDDAVALTCPEIQTLYLMNNQ 361
 Db 305 VTGCNRITVTKLITVTELSPVVKPAKISKATVTDGDKSDVNLTCSTNDTGTSIRWFFKQ 364
 QY 362 SLPVSPRLQLQSNDRNTLTLFVNTRNDVGPYCGIONELSVHDSPVILNLYG--PDDPT 419
 Db 365 SLPSSEMKLUSQGNTTLSINPVKREDAGTWCVEFNPKNSQDPIMLNVNALPOENG 424
 QY 420 ISP 422
 Db 425 LSP 427

RESULT 9
 US-09-949-016-7525
 ; Sequence 7525, Application US/09949016

RESULT 10
 US-09-949-016-7591
 ; Sequence 7591, Application US/09949016
 ; Patent No. 6812339
 GENERAL INFORMATION:
 APPLICANT: VENTER, J. Craig et al.
 TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
 WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
 FILE REFERENCE: C1001307
 CURRENT APPLICATION NUMBER: US/09/949, 016
 CURRENT FILING DATE: 2000-04-14
 PRIORITY APPLICATION NUMBER: 60/241, 755
 PRIORITY FILING DATE: 2000-10-20
 PRIORITY APPLICATION NUMBER: 60/237, 768

PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 7591
; LENGTH: 365
; TYPE: PRT
; ORGANISM: Human
; US-09-949-016-7591

Query Match 38.8%; Score 1443; DB 2; Length 365;
Best Local Similarity 83.9%; Pred. No. 2.1e-100; Mismatches 41; Indels 0; Gaps 0;
Matches 271; Conservative 11; Mismatches 41; Indels 0; Gaps 0;

QY 1 MESPSAPPHCIPWQLLTLTFFNPNPTAKLTISTPENVAEGKEVLLVHNLPQ 60
2 MGPPSAPPCLHPEPKVEVLTASLTFNPNPTAKLTISTPENVAEGKEVLLVHNLPQ 81

QY 61 HLFGYSWYKGERVUDGNRQIGVYVQATPGPAYSGREITYPNALIIONDTGY 120
82 NRIGYSWYKGERVUDGNLSLIVGIVGQATPGPAYSGREITYPNALIIONDTGY 141

QY 121 TLHVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 180
142 TLQVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 201

QY 181 NNQSLPVSPLQLSGNRTRTLFVNTRNTDASVYKETQPVSAARRSDVSLVNLVYGPDP 240

QY 202 NGQSLPVSPLQLSGNRTRTLFVNTRNTDASVYKETQPVSAARRSDVSLVNLVYGPDP 261

QY 241 TISPLNTSYSGENTLNLSCHASNPRAQYSWVFUNGTFQOQSTQELRFPTNTNNNSYTCQ 300
262 TISPSKANRFGENLNLSCHASNPRAQYSWVFINGTFQOQSTQELFIPNITVNNNSYMCQ 321

QY 301 AHNSDGLNRTTUTVYKEPP 323

Db 322 AHNSAATGLNRTTUTVYKEPP 344

RESULT 11
5169835-17

; Patent No. 5169835
; APPLICANT: WAL-YEE, CHAN
; TITLE OF INVENTION: PREGNANCY SPECIFIC PROTEINS APPLICATIONS
; NUMBER OF SEQUENCES: 48
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/390,409
; FILING DATE: 07-AUG-1989
; SEQ ID NO:17;
; LENGTH: 321

Query Match 38.3%; Score 1424; DB 6; Length 321;
Best Local Similarity 84.3%; Pred. No. 4.7e-99; Mismatches 37; Indels 0; Gaps 0;
Matches 268; Conservative 13; Mismatches 37; Indels 0; Gaps 0;

QY 1 MESSPSAPPHCIPWQLLTLTFFNPNPTAKLTISTPENVAEGKEVLLVHNLPQ 60
1 MGPPSAPPCLHPEPKVEVLTASLTFNPNPTAKLTISTPENVAEGKEVLLVHNLPQ 80

QY 61 HLFGYSWYKGERVUDGNRQIGVYVQATPGPAYSGREITYPNALIIONDTGY 120
61 NRIGYSWYKGERVUDGNLSLIVGIVGQATPGPAYSGREITYPNALIIONDTGY 120

QY 121 TLHVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 180
121 TLQVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 180

QY 181 NNQSLPVSPLQLSGNRTRTLFVNTRNTDASVYKETQPVSAARRSDVSLVNLVYGPDP 240

QY 181 NNQSLPVSPLQLSGNRTRTLFVNTRNTDASVYKETQPVSAARRSDVSLVNLVYGPDP 240

Db 301 AHNSDGLNRTTUTVYKEPP 318

RESULT 12
US-08-602-725-34

; Sequence 34, Application US/08602725
; Patent No. 5965710

GENERAL INFORMATION:

APPLICANT: BOMBER, WALTER F
APPLICANT: DURBIN, HELGA
APPLICANT: SHAW, DAVID
APPLICANT: STEWART, LORNA MD
APPLICANT: YOUNG, SUSAN

APPLICANT: BATES, PAUL A
APPLICANT: MONOCLONAL ANTIBODIES FOR USE IN
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF COLORRECTAL CANCER

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESS:

ADDRESS: NIXON & VANDERKIE P C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22201

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/602,725
FILING DATE: 02-FEB-1996
CLASSIFICATION: 533

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/GB94/01816
FILING DATE: 19-AUG-1994

PRIOR APPLICATION NUMBER: GB 9317423
FILING DATE: 21-AUG-1993

ATTORNEY/AGENT INFORMATION:

NAME: SADOF, B.J.
REGISTRATION NUMBER: 36663
REFERENCE/DOCKET NUMBER: 1090-8
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4091
TELEFAX: 703-816-4100

INFORMATION FOR SEQ ID NO: 34:

SEQUENCE CHARACTERISTICS:
LENGTH: 344 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein

Query Match 38.0%; Score 1415; DB 1; Length 344;
Best Local Similarity 82.7%; Pred. No. 2.5e-98; Mismatches 44; Indels 0; Gaps 0;
Matches 267; Conservative 12; Mismatches 44; Indels 0; Gaps 0;

QY 1 MESPSAPPHCIPWQLLTLTFFNPNPTAKLTISTPENVAEGKEVLLVHNLPQ 60
1 MGPPSAPPCLHPEPKVEVLTASLTFNPNPTAKLTISTPENVAEGKEVLLVHNLPQ 60

QY 61 HLFGYSWYKGERVUDGNRQIGVYVQATPGPAYSGREITYPNALIIONDTGY 120
61 NRIGYSWYKGERVUDGNLSLIVGIVGQATPGPAYSGREITYPNALIIONDTGY 120

QY 121 TLHVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 180
121 TLQVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 180

QY 181 NNQSLPVSPLQLSGNRTRTLFVNTRNTDASVYKETQPVSAARRSDVSLVNLVYGPDP 240

QY 181 NNQSLPVSPLQLSGNRTRTLFVNTRNTDASVYKETQPVSAARRSDVSLVNLVYGPDP 240

Db 301 AHNSDGLNRTTUTVYKEPP 318

QY 241 TISPLNTSYSGENTLNLSCHASNPRAQYSWVFUNGTFQOQSTQELRFPTNTNNNSYTCQ 300
241 TISPSKANRFGENLNLSCHASNPRAQYSWVFINGTFQOQSTQELFIPNITVNNNSYTCQ 300

QY 61 HLFGYSWYKGERVUDGNRQIGVYVQATPGPAYSGREITYPNALIIONDTGY 120
61 NRIGYSWYKGERVUDGNLSLIVGIVGQATPGPAYSGREITYPNALIIONDTGY 120

QY 121 TLHVIKSDLVNEEATGQFRVPELPKPSISSNNNSKPVEDKDAVFTCPETODATLYWWV 180

RESULT 13
; SEQ ID NO:2:
; LENGTH: 419
; 5169835-2
; Query Match 30.3%; Score 1126.5; DB 6; Length 419;
; Best Local Similarity 46.9%; Pred. No. 1.6e-76;
; Matches 234; Conservative 54; M1 matches 124; Indels 87; Gaps 3;
; APPLICANT: GOLDENBERG, DAVID M.
; APPLICANT: HANSEN, HANS J.
; TITLE OF INVENTION: IMMUNOTHERAPY FOR CHRONIC MYELOCYTIC LEUKEMIA
; FILE REFERENCE: 018733-1055
; CURRENT APPLICATION NUMBER: US/09/924,103
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO: 4
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-924-103-4

Query Match 34.2%; Score 1272; DB 2; Length 349;
Best Local Similarity 76.8%; Pred. No. 1.4e-87;
Matches 241; Conservative 19; Mismatches 54; Indels 0; Gaps 0;

Qy 5 SAPPHRICIPMORLLITASLLTFWNRPITAKLIESTPFVNVAEGKEVLLVHNLPOHLFG 64
Db 5 SAPCRSPRIPMORLLITASLLTFWNRPITAKLIESTPFVNVAEGKEVLLVHNLPOHLFG 64

Qy 65 YSWYKGERVDGQRQIGIVGIGTQATGPAGSGREITYPNASLLIONIQNDTGFTLVH 124
Db 65 YWYKGETFVDAARRIGIVVSNQQTGPAVSNSRETYPNASLLMRVTKDGTSYLQV 124

Qy 125 IKSDLVNBEATQFRVPELKPESISSNSNPKVEDKDAVAFCEPEPETOQDATYLVWNNQS 184
Db 125 IKLNLMSEBVTFQPSVHPETPKESISSNSNPKVEDKDAVAFCEPEPETOQDATYLVWNGQS 184

Qy 185 LPSPRIQLSNGRTLTFNVRNTDASYKCTONPVSPARSDSVTFLVNGDAPTSPI 244
Db 185 LPSPRIQLSNGRTLTFNVRNTDASYKCTONPVSPARSDSVTFLVNGDAPTSPI 244

Qy 245 LMTSYRGENNLUSCHAASNPQAQISWVNGTQFQOSTQBLIPNITNNSSYTCAHNS 304
Db 245 SDIYHAGVNLUSCHAASNPQSQYSWVNGTQFQYTKLIFPINITTNSYACHTNS 304

RESULT 14
; SEQ ID NO:2:
; LENGTH: 424
; 5169835-2
; APPLICANT: WAI-YEE, CHAN
; APPLICANT: PATENT NUMBER: 5169835-2
; NUMBER OF INVENTION: PREGNANCY SPECIFIC PROTEINS APPLICATIONS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/390,409
; FILING DATE: 07-AUG-1989

Query Match 29.5%; Score 1099; DB 6; Length 424;
Best Local Similarity 46.9%; Pred. No. 1.9e-74;
Matches 232; Conservative 48; Mismatches 127; Indels 88; Gaps 4;

Qy 5 SAPPHRICIPMORLLITASLLTFWNRPITAKLIESTPFVNVAEGKEVLLVHNLPOHLFG 64
Db 5 SAPCRSPRIPMORLLITASLLTFWNRPITAKLIESTPFVNVAEGKEVLLVHNLPOHLFG 64

Qy 65 YSWYKGERVDGQRQIGIVGIGTQATGPAGSGREITYPNASLLIONIQNDTGFTLVH 124
Db 65 YWYKGETFVDAARRIGIVVSNQQTGPAVSNSRETYPNASLLMRVTKDGTSYLQV 124

Qy 125 IKSDLVNBEATQFRVPELKPESISSNSNPKVEDKDAVAFCEPEPETOQDATYLVWNNQS 182
Db 125 IKRDGTTGGVIGYFTVLYSETPKPSISSNSNPREVMEAVERLICOPPETPDASYLWING 183

Qy 183 QSLPVSPRLQLSNGNRITLFLNFVNTRDTSYKETONPSARRSDSVTLYGPDPTI 242
Db 184 QNLPMTHRLQLSKTRNRTLYLFCVTKYLAGPCEIRNPVASRSDPVTNLI----- 235
Qy 243 SPLNTSPRSGENMLNSCHAASNPAPYSWFGTFOOSTQSLRIPNITVNRNSGYTCQAH 302
Db 236 -----PKL----- 238
Qy 303 NSDTGLNLRTTVTITTYAEPPKPFTTSNNSNPVEDEDAVALTCPEITQNTYLWWNNNQS 362
Db 239 -----EMPYITNNAPREKDVLATCPEISRYTINMINGOS 278
Qy 363 LPVSPLQLQSLNDNRTTTLSSYTRNDYGPYECQIONEILSVDISDPVTLNLYGPDDTISP 422
Db 279 LPVSPRKVKPIENRILILPSYTRNETGCPYCBIRDYGGIRSNPVTLNLYGPDLPRIPE 338
Qy 423 SYTYRPGVNLSCHASINPAQYWLIDENIQHTQELTSNTKEKNSYTQANNS 482
Db 339 SFTYYRSGENLDSLSCFADSNPPEAYFTINGKFOLSGOKLFIPQITTNHSGLYACSVRS 398
Qy 483 ASGHSKITVKITIVS 497
Db 399 ATGKELSKSMITVKVS 413

Search completed: April 10, 2006, 18:08:46
Job time : 53.7426 SECs

15 PAGE LEFT BLANK

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model
Run on: April 10, 2006, 18:07:01 ; Search time 15.2574 Seconds

Title: US-10-734-564-100
Perfect score: 1124
Sequence: 1 MAPFEPPLASGLILLLWLTP.....ACLPREPGCTWOSLRSQIA 207
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 sqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:
1: /cgn2_6/prodata/1/iaa/5_COMB_pep:
2: /cgn2_6/prodata/1/iaa/6_COMB_pep:
3: /cgn2_6/prodata/1/iaa/H_COMB_pep:
4: /cgn2_6/prodata/1/iaa/PCTUS_COMB_pep:
5: /cgn2_6/prodata/1/iaa/RE_COMB_pep:
6: /cgn2_6/prodata/1/iaa/backfilesl.pep:
*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1124	100.0	207	1	US-08-588-163-5
2	1124	100.0	207	1	US-09-111-070-5
3	1124	100.0	207	2	US-08-849-764C-5
4	1124	100.0	207	2	US-09-262-087-5
5	1124	100.0	207	2	US-08-463-61B-11
6	1124	100.0	207	2	US-09-540-530-1
7	1124	100.0	207	2	US-08-134-331C-23
8	1124	100.0	207	2	US-08-728-160-22
9	1124	100.0	207	2	US-10-116-064-5
10	1124	100.0	205	2	US-09-949-016-9699
11	1009	89.8	184	2	US-09-452-317-1
12	995	88.5	207	2	US-08-134-331C-22
13	995	88.5	207	2	US-08-728-160-22
14	902.5	80.3	206	2	US-08-134-331C-24
15	902.5	80.3	206	2	US-08-728-160-24
16	837.5	74.5	205	2	US-08-134-331C-25
17	837.5	74.5	205	2	US-08-728-160-25
18	579	51.5	106	2	US-09-452-17-2
19	415.5	37.0	220	1	US-08-588-163-3
20	415.5	37.0	220	1	US-09-111-070-3
21	415.5	37.0	220	2	US-09-540-530-2
22	415.5	37.0	220	2	US-08-134-231C-27
23	415.5	37.0	220	2	US-09-660-07-11
24	415.5	37.0	220	2	US-08-728-160-27
25	415.5	37.0	220	2	US-08-803-954B-9
26	407.5	36.3	218	2	US-08-849-064C-3
27	407.5	36.3	218	2	US-09-262-087-3

RESULT 1
US-08-588-163-5
; Sequence 5, Application US/08588163
; Patent No. 5643752
GENERAL INFORMATION:
APPLICANT: Hawkins, Phillip R.
TITLE OF INVENTION: A NOVEL TISSUE INHIBITOR OF METALLOPROTEINASES
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADRESSEEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Perrier Drive
CITY: Palo Alto
STATE: CA
COUNTRY: US
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/588,163
FILING DATE: Herewith
CLASSIFICATION: 514
PRIORITY APPLICATION DATA:
APPLICATION NUMBER:
FILED DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Luther, Barbara J.
REGISTRATION NUMBER: 33,954
REFERENCE/DOCKET NUMBER: PP-0053
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
TELEX:
; INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 207 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
SEQUENCE 1, Appli
SEQUENCE 2, Appli
SEQUENCE 3, Appli
SEQUENCE 4, Appli
SEQUENCE 5, Appli
SEQUENCE 6, Appli
SEQUENCE 7, Appli
SEQUENCE 8, Appli
SEQUENCE 9, Appli
SEQUENCE 10, Appli
SEQUENCE 11, Appli
SEQUENCE 12, Appli
SEQUENCE 13, Appli
SEQUENCE 14, Appli
SEQUENCE 15, Appli
SEQUENCE 16, Appli
SEQUENCE 17, Appli
SEQUENCE 18, Appli
SEQUENCE 19, Appli
SEQUENCE 20, Appli
SEQUENCE 21, Appli
SEQUENCE 22, Appli
SEQUENCE 23, Appli
SEQUENCE 24, Appli
SEQUENCE 25, Appli
SEQUENCE 26, Appli
SEQUENCE 27, Appli
SEQUENCE 28, Appli
SEQUENCE 29, Appli
SEQUENCE 30, Appli
SEQUENCE 31, Appli
SEQUENCE 32, Appli
SEQUENCE 33, Appli
SEQUENCE 34, Appli
SEQUENCE 35, Appli
SEQUENCE 36, Appli
SEQUENCE 37, Appli
SEQUENCE 38, Appli
SEQUENCE 39, Appli
SEQUENCE 40, Appli
SEQUENCE 41, Appli
SEQUENCE 42, Appli
SEQUENCE 43, Appli
SEQUENCE 44, Appli
SEQUENCE 45, Appli
SEQUENCE 46, Appli
SEQUENCE 47, Appli
SEQUENCE 48, Appli
SEQUENCE 49, Appli
SEQUENCE 50, Appli
SEQUENCE 51, Appli
SEQUENCE 52, Appli
SEQUENCE 53, Appli
SEQUENCE 54, Appli
SEQUENCE 55, Appli
SEQUENCE 56, Appli
SEQUENCE 57, Appli
SEQUENCE 58, Appli
SEQUENCE 59, Appli
SEQUENCE 60, Appli
SEQUENCE 61, Appli
SEQUENCE 62, Appli
SEQUENCE 63, Appli
SEQUENCE 64, Appli
SEQUENCE 65, Appli
SEQUENCE 66, Appli
SEQUENCE 67, Appli
SEQUENCE 68, Appli
SEQUENCE 69, Appli
SEQUENCE 70, Appli
SEQUENCE 71, Appli
SEQUENCE 72, Appli
SEQUENCE 73, Appli
SEQUENCE 74, Appli
SEQUENCE 75, Appli
SEQUENCE 76, Appli
SEQUENCE 77, Appli
SEQUENCE 78, Appli
SEQUENCE 79, Appli
SEQUENCE 80, Appli
SEQUENCE 81, Appli
SEQUENCE 82, Appli
SEQUENCE 83, Appli
SEQUENCE 84, Appli
SEQUENCE 85, Appli
SEQUENCE 86, Appli
SEQUENCE 87, Appli
SEQUENCE 88, Appli
SEQUENCE 89, Appli
SEQUENCE 90, Appli
SEQUENCE 91, Appli
SEQUENCE 92, Appli
SEQUENCE 93, Appli
SEQUENCE 94, Appli
SEQUENCE 95, Appli
SEQUENCE 96, Appli
SEQUENCE 97, Appli
SEQUENCE 98, Appli
SEQUENCE 99, Appli
SEQUENCE 100, Appli
SEQUENCE 101, Appli
SEQUENCE 102, Appli
SEQUENCE 103, Appli
SEQUENCE 104, Appli
SEQUENCE 105, Appli
SEQUENCE 106, Appli
SEQUENCE 107, Appli
SEQUENCE 108, Appli
SEQUENCE 109, Appli
SEQUENCE 110, Appli
SEQUENCE 111, Appli
SEQUENCE 112, Appli
SEQUENCE 113, Appli
SEQUENCE 114, Appli
SEQUENCE 115, Appli
SEQUENCE 116, Appli
SEQUENCE 117, Appli
SEQUENCE 118, Appli
SEQUENCE 119, Appli
SEQUENCE 120, Appli
SEQUENCE 121, Appli
SEQUENCE 122, Appli
SEQUENCE 123, Appli
SEQUENCE 124, Appli
SEQUENCE 125, Appli
SEQUENCE 126, Appli
SEQUENCE 127, Appli
SEQUENCE 128, Appli
SEQUENCE 129, Appli
SEQUENCE 130, Appli
SEQUENCE 131, Appli
SEQUENCE 132, Appli
SEQUENCE 133, Appli
SEQUENCE 134, Appli
SEQUENCE 135, Appli
SEQUENCE 136, Appli
SEQUENCE 137, Appli
SEQUENCE 138, Appli
SEQUENCE 139, Appli
SEQUENCE 140, Appli
SEQUENCE 141, Appli
SEQUENCE 142, Appli
SEQUENCE 143, Appli
SEQUENCE 144, Appli
SEQUENCE 145, Appli
SEQUENCE 146, Appli
SEQUENCE 147, Appli
SEQUENCE 148, Appli
SEQUENCE 149, Appli
SEQUENCE 150, Appli
SEQUENCE 151, Appli
SEQUENCE 152, Appli
SEQUENCE 153, Appli
SEQUENCE 154, Appli
SEQUENCE 155, Appli
SEQUENCE 156, Appli
SEQUENCE 157, Appli
SEQUENCE 158, Appli
SEQUENCE 159, Appli
SEQUENCE 160, Appli
SEQUENCE 161, Appli
SEQUENCE 162, Appli
SEQUENCE 163, Appli
SEQUENCE 164, Appli
SEQUENCE 165, Appli
SEQUENCE 166, Appli
SEQUENCE 167, Appli
SEQUENCE 168, Appli
SEQUENCE 169, Appli
SEQUENCE 170, Appli
SEQUENCE 171, Appli
SEQUENCE 172, Appli
SEQUENCE 173, Appli
SEQUENCE 174, Appli
SEQUENCE 175, Appli
SEQUENCE 176, Appli
SEQUENCE 177, Appli
SEQUENCE 178, Appli
SEQUENCE 179, Appli
SEQUENCE 180, Appli
SEQUENCE 181, Appli
SEQUENCE 182, Appli
SEQUENCE 183, Appli
SEQUENCE 184, Appli
SEQUENCE 185, Appli
SEQUENCE 186, Appli
SEQUENCE 187, Appli
SEQUENCE 188, Appli
SEQUENCE 189, Appli
SEQUENCE 190, Appli
SEQUENCE 191, Appli
SEQUENCE 192, Appli
SEQUENCE 193, Appli
SEQUENCE 194, Appli
SEQUENCE 195, Appli
SEQUENCE 196, Appli
SEQUENCE 197, Appli
SEQUENCE 198, Appli
SEQUENCE 199, Appli
SEQUENCE 200, Appli
SEQUENCE 201, Appli
SEQUENCE 202, Appli
SEQUENCE 203, Appli
SEQUENCE 204, Appli
SEQUENCE 205, Appli
SEQUENCE 206, Appli
SEQUENCE 207, Appli
SEQUENCE 208, Appli
SEQUENCE 209, Appli
SEQUENCE 210, Appli
SEQUENCE 211, Appli
SEQUENCE 212, Appli
SEQUENCE 213, Appli
SEQUENCE 214, Appli
SEQUENCE 215, Appli
SEQUENCE 216, Appli
SEQUENCE 217, Appli
SEQUENCE 218, Appli
SEQUENCE 219, Appli
SEQUENCE 220, Appli
SEQUENCE 221, Appli
SEQUENCE 222, Appli
SEQUENCE 223, Appli
SEQUENCE 224, Appli
SEQUENCE 225, Appli
SEQUENCE 226, Appli
SEQUENCE 227, Appli
SEQUENCE 228, Appli
SEQUENCE 229, Appli
SEQUENCE 230, Appli
SEQUENCE 231, Appli
SEQUENCE 232, Appli
SEQUENCE 233, Appli
SEQUENCE 234, Appli
SEQUENCE 235, Appli
SEQUENCE 236, Appli
SEQUENCE 237, Appli
SEQUENCE 238, Appli
SEQUENCE 239, Appli
SEQUENCE 240, Appli
SEQUENCE 241, Appli
SEQUENCE 242, Appli
SEQUENCE 243, Appli
SEQUENCE 244, Appli
SEQUENCE 245, Appli
SEQUENCE 246, Appli
SEQUENCE 247, Appli
SEQUENCE 248, Appli
SEQUENCE 249, Appli
SEQUENCE 250, Appli
SEQUENCE 251, Appli
SEQUENCE 252, Appli
SEQUENCE 253, Appli
SEQUENCE 254, Appli
SEQUENCE 255, Appli
SEQUENCE 256, Appli
SEQUENCE 257, Appli
SEQUENCE 258, Appli
SEQUENCE 259, Appli
SEQUENCE 260, Appli
SEQUENCE 261, Appli
SEQUENCE 262, Appli
SEQUENCE 263, Appli
SEQUENCE 264, Appli
SEQUENCE 265, Appli
SEQUENCE 266, Appli
SEQUENCE 267, Appli
SEQUENCE 268, Appli
SEQUENCE 269, Appli
SEQUENCE 270, Appli
SEQUENCE 271, Appli
SEQUENCE 272, Appli
SEQUENCE 273, Appli
SEQUENCE 274, Appli
SEQUENCE 275, Appli
SEQUENCE 276, Appli
SEQUENCE 277, Appli
SEQUENCE 278, Appli
SEQUENCE 279, Appli
SEQUENCE 280, Appli
SEQUENCE 281, Appli
SEQUENCE 282, Appli
SEQUENCE 283, Appli
SEQUENCE 284, Appli
SEQUENCE 285, Appli
SEQUENCE 286, Appli
SEQUENCE 287, Appli
SEQUENCE 288, Appli
SEQUENCE 289, Appli
SEQUENCE 290, Appli
SEQUENCE 291, Appli
SEQUENCE 292, Appli
SEQUENCE 293, Appli
SEQUENCE 294, Appli
SEQUENCE 295, Appli
SEQUENCE 296, Appli
SEQUENCE 297, Appli
SEQUENCE 298, Appli
SEQUENCE 299, Appli
SEQUENCE 300, Appli
SEQUENCE 301, Appli
SEQUENCE 302, Appli
SEQUENCE 303, Appli
SEQUENCE 304, Appli
SEQUENCE 305, Appli
SEQUENCE 306, Appli
SEQUENCE 307, Appli
SEQUENCE 308, Appli
SEQUENCE 309, Appli
SEQUENCE 310, Appli
SEQUENCE 311, Appli
SEQUENCE 312, Appli
SEQUENCE 313, Appli
SEQUENCE 314, Appli
SEQUENCE 315, Appli
SEQUENCE 316, Appli
SEQUENCE 317, Appli
SEQUENCE 318, Appli
SEQUENCE 319, Appli
SEQUENCE 320, Appli
SEQUENCE 321, Appli
SEQUENCE 322, Appli
SEQUENCE 323, Appli
SEQUENCE 324, Appli
SEQUENCE 325, Appli
SEQUENCE 326, Appli
SEQUENCE 327, Appli
SEQUENCE 328, Appli
SEQUENCE 329, Appli
SEQUENCE 330, Appli
SEQUENCE 331, Appli
SEQUENCE 332, Appli
SEQUENCE 333, Appli
SEQUENCE 334, Appli
SEQUENCE 335, Appli
SEQUENCE 336, Appli
SEQUENCE 337, Appli
SEQUENCE 338, Appli
SEQUENCE 339, Appli
SEQUENCE 340, Appli
SEQUENCE 341, Appli
SEQUENCE 342, Appli
SEQUENCE 343, Appli
SEQUENCE 344, Appli
SEQUENCE 345, Appli
SEQUENCE 346, Appli
SEQUENCE 347, Appli
SEQUENCE 348, Appli
SEQUENCE 349, Appli
SEQUENCE 350, Appli
SEQUENCE 351, Appli
SEQUENCE 352, Appli
SEQUENCE 353, Appli
SEQUENCE 354, Appli
SEQUENCE 355, Appli
SEQUENCE 356, Appli
SEQUENCE 357, Appli
SEQUENCE 358, Appli
SEQUENCE 359, Appli
SEQUENCE 360, Appli
SEQUENCE 361, Appli
SEQUENCE 362, Appli
SEQUENCE 363, Appli
SEQUENCE 364, Appli
SEQUENCE 365, Appli
SEQUENCE 366, Appli
SEQUENCE 367, Appli
SEQUENCE 368, Appli
SEQUENCE 369, Appli
SEQUENCE 370, Appli
SEQUENCE 371, Appli
SEQUENCE 372, Appli
SEQUENCE 373, Appli
SEQUENCE 374, Appli
SEQUENCE 375, Appli
SEQUENCE 376, Appli
SEQUENCE 377, Appli
SEQUENCE 378, Appli
SEQUENCE 379, Appli
SEQUENCE 380, Appli
SEQUENCE 381, Appli
SEQUENCE 382, Appli
SEQUENCE 383, Appli
SEQUENCE 384, Appli
SEQUENCE 385, Appli
SEQUENCE 386, Appli
SEQUENCE 387, Appli
SEQUENCE 388, Appli
SEQUENCE 389, Appli
SEQUENCE 390, Appli
SEQUENCE 391, Appli
SEQUENCE 392, Appli
SEQUENCE 393, Appli
SEQUENCE 394, Appli
SEQUENCE 395, Appli
SEQUENCE 396, Appli
SEQUENCE 397, Appli
SEQUENCE 398, Appli
SEQUENCE 399, Appli
SEQUENCE 400, Appli
SEQUENCE 401, Appli
SEQUENCE 402, Appli
SEQUENCE 403, Appli
SEQUENCE 404, Appli
SEQUENCE 405, Appli
SEQUENCE 406, Appli
SEQUENCE 407, Appli
SEQUENCE 408, Appli
SEQUENCE 409, Appli
SEQUENCE 410, Appli
SEQUENCE 411, Appli
SEQUENCE 412, Appli
SEQUENCE 413, Appli
SEQUENCE 414, Appli
SEQUENCE 415, Appli
SEQUENCE 416, Appli
SEQUENCE 417, Appli
SEQUENCE 418, Appli
SEQUENCE 419, Appli
SEQUENCE 420, Appli
SEQUENCE 421, Appli
SEQUENCE 422, Appli
SEQUENCE 423, Appli
SEQUENCE 424, Appli
SEQUENCE 425, Appli
SEQUENCE 426, Appli
SEQUENCE 427, Appli
SEQUENCE 428, Appli
SEQUENCE 429, Appli
SEQUENCE 430, Appli
SEQUENCE 431, Appli
SEQUENCE 432, Appli
SEQUENCE 433, Appli
SEQUENCE 434, Appli
SEQUENCE 435, Appli
SEQUENCE 436, Appli
SEQUENCE 437, Appli
SEQUENCE 438, Appli
SEQUENCE 439, Appli
SEQUENCE 440, Appli
SEQUENCE 441, Appli
SEQUENCE 442, Appli
SEQUENCE 443, Appli
SEQUENCE 444, Appli
SEQUENCE 445, Appli
SEQUENCE 446, Appli
SEQUENCE 447, Appli
SEQUENCE 448, Appli
SEQUENCE 449, Appli
SEQUENCE 450, Appli
SEQUENCE 451, Appli
SEQUENCE 452, Appli
SEQUENCE 453, Appli
SEQUENCE 454, Appli
SEQUENCE 455, Appli
SEQUENCE 456, Appli
SEQUENCE 457, Appli
SEQUENCE 458, Appli
SEQUENCE 459, Appli
SEQUENCE 460, Appli
SEQUENCE 461, Appli
SEQUENCE 462, Appli
SEQUENCE 463, Appli
SEQUENCE 464, Appli
SEQUENCE 465, Appli
SEQUENCE 466, Appli
SEQUENCE 467, Appli
SEQUENCE 468, Appli
SEQUENCE 469, Appli
SEQUENCE 470, Appli
SEQUENCE 471, Appli
SEQUENCE 472, Appli
SEQUENCE 473, Appli
SEQUENCE 474, Appli
SEQUENCE 475, Appli
SEQUENCE 476, Appli
SEQUENCE 477, Appli
SEQUENCE 478, Appli
SEQUENCE 479, Appli
SEQUENCE 480, Appli
SEQUENCE 481, Appli
SEQUENCE 482, Appli
SEQUENCE 483, Appli
SEQUENCE 484, Appli
SEQUENCE 485, Appli
SEQUENCE 486, Appli
SEQUENCE 487, Appli
SEQUENCE 488, Appli
SEQUENCE 489, Appli
SEQUENCE 490, Appli
SEQUENCE 491, Appli
SEQUENCE 492, Appli
SEQUENCE 493, Appli
SEQUENCE 494, Appli
SEQUENCE 495, Appli
SEQUENCE 496, Appli
SEQUENCE 497, Appli
SEQUENCE 498, Appli
SEQUENCE 499, Appli
SEQUENCE 500, Appli
SEQUENCE 501, Appli
SEQUENCE 502, Appli
SEQUENCE 503, Appli
SEQUENCE 504, Appli
SEQUENCE 505, Appli
SEQUENCE 506, Appli
SEQUENCE 507, Appli
SEQUENCE 508, Appli
SEQUENCE 509, Appli
SEQUENCE 510, Appli
SEQUENCE 511, Appli
SEQUENCE 512, Appli
SEQUENCE 513, Appli
SEQUENCE 514, Appli
SEQUENCE 515, Appli
SEQUENCE 516, Appli
SEQUENCE 517, Appli
SEQUENCE 518, Appli
SEQUENCE 519, Appli
SEQUENCE 520, Appli
SEQUENCE 521, Appli
SEQUENCE 522, Appli
SEQUENCE 523, Appli
SEQUENCE 524, Appli
SEQUENCE 525, Appli
SEQUENCE 526, Appli
SEQUENCE 527, Appli
SEQUENCE 528, Appli
SEQUENCE 529, Appli
SEQUENCE 530, Appli
SEQUENCE 531, Appli
SEQUENCE 532, Appli
SEQUENCE 533, Appli
SEQUENCE 534, Appli
SEQUENCE 535, Appli
SEQUENCE 536, Appli
SEQUENCE 537, Appli
SEQUENCE 538, Appli
SEQUENCE 539, Appli
SEQUENCE 540, Appli
SEQUENCE 541, Appli
SEQUENCE 542, Appli
SEQUENCE 543, Appli
SEQUENCE 544, Appli
SEQUENCE 545, Appli
SEQUENCE 546, Appli
SEQUENCE 547, Appli
SEQUENCE 548, Appli
SEQUENCE 549, Appli
SEQUENCE 550, Appli
SEQUENCE 551, Appli
SEQUENCE 552, Appli
SEQUENCE 553, Appli
SEQUENCE 554, Appli
SEQUENCE 555, Appli
SEQUENCE 556, Appli
SEQUENCE 557, Appli
SEQUENCE 558, Appli
SEQUENCE 559, Appli
SEQUENCE 560, Appli
SEQUENCE 561, Appli
SEQUENCE 562, Appli
SEQUENCE 563, Appli
SEQUENCE 564, Appli
SEQUENCE 565, Appli
SEQUENCE 566, Appli
SEQUENCE 567, Appli
SEQUENCE 568, Appli
SEQUENCE 569, Appli
SEQUENCE 570, Appli
SEQUENCE 571, Appli
SEQUENCE 572, Appli
SEQUENCE 573, Appli
SEQUENCE 574, Appli
SEQUENCE 575, Appli
SEQUENCE 576, Appli
SEQUENCE 577, Appli
SEQUENCE 578, Appli
SEQUENCE 579, Appli
SEQUENCE 580, Appli
SEQUENCE 581, Appli
SEQUENCE 582, Appli
SEQUENCE 583, Appli
SEQUENCE 584, Appli
SEQUENCE 585, Appli
SEQUENCE 586, Appli
SEQUENCE 587, Appli
SEQUENCE 588, Appli
SEQUENCE 589, Appli
SEQUENCE 590, Appli
SEQUENCE 591, Appli
SEQUENCE 592, Appli
SEQUENCE 593, Appli
SEQUENCE 594, Appli
SEQUENCE 595, Appli
SEQUENCE 596, Appli
SEQUENCE 597, Appli
SEQUENCE 598, Appli
SEQUENCE 599, Appli
SEQUENCE 600, Appli
SEQUENCE 601, Appli
SEQUENCE 602, Appli
SEQUENCE 603, Appli
SEQUENCE 604, Appli
SEQUENCE 605, Appli
SEQUENCE 606, Appli
SEQUENCE 607, Appli
SEQUENCE 608, Appli
SEQUENCE 609, Appli
SEQUENCE 610, Appli
SEQUENCE 611, Appli
SEQUENCE 612, Appli
SEQUENCE 613, Appli
SEQUENCE 614, Appli
SEQUENCE 615, Appli
SEQUENCE 616, Appli
SEQUENCE 617, Appli
SEQUENCE 618, Appli
SEQUENCE 619, Appli
SEQUENCE 620, Appli
SEQUENCE 621, Appli
SEQUENCE 622, Appli
SEQUENCE 623, Appli
SEQUENCE 624, Appli
SEQUENCE 625, Appli
SEQUENCE 626, Appli
SEQUENCE 627, Appli
SEQUENCE 628, Appli
SEQUENCE 629, Appli
SEQUENCE 630, Appli
SEQUENCE 631, Appli
SEQUENCE 632, Appli
SEQUENCE 633, Appli
SEQUENCE 634, Appli
SEQUENCE 635, Appli
SEQUENCE 636, Appli
SEQUENCE 637, Appli
SEQUENCE 638, Appli
SEQUENCE 639, Appli
SEQUENCE 640, Appli
SEQUENCE 641, Appli
SEQUENCE 642, Appli
SEQUENCE 643, Appli
SEQUENCE 644, Appli
SEQUENCE 645, Appli
SEQUENCE 646, Appli
SEQUENCE 647, Appli
SEQUENCE 648, Appli
SEQUENCE 649, Appli
SEQUENCE 650, Appli
SEQUENCE 651, Appli
SEQUENCE 652, Appli
SEQUENCE 653, Appli
SEQUENCE 654, Appli
SEQUENCE 655, Appli
SEQUENCE 656, Appli
SEQUENCE 657, Appli
SEQUENCE 658, Appli
SEQUENCE 659, Appli
SEQUENCE 660, Appli
SEQUENCE 661, Appli
SEQUENCE 662, Appli
SEQUENCE 663, Appli
SEQUENCE 664, Appli
SEQUENCE 665, Appli
SEQUENCE 666, Appli
SEQUENCE 667, Appli
SEQUENCE 668, Appli
SEQUENCE 669, Appli
SEQUENCE 670, Appli
SEQUENCE 671, Appli
SEQUENCE 672, Appli
SEQUENCE 673, Appli
SEQUENCE 674, Appli
SEQUENCE 675, Appli
SEQUENCE 676, Appli
SEQUENCE 677, Appli
SEQUENCE 678, Appli
SEQUENCE 679, Appli
SEQUENCE 680, Appli
SEQUENCE 681, Appli
SEQUENCE 682, Appli
SEQUENCE 683, Appli
SEQUENCE 684, Appli
SEQUENCE 685, Appli
SEQUENCE 686, Appli
SEQUENCE 687, Appli
SEQUENCE 688, Appli
SEQUENCE 689, Appli
SEQUENCE 690, Appli
SEQUENCE 691, Appli
SEQUENCE 692, Appli
SEQUENCE 693, Appli
SEQUENCE 694, Appli
SEQUENCE 695, Appli
SEQUENCE 696, Appli
SEQUENCE 697, Appli
SEQUENCE 698, Appli
SEQUENCE 699, Appli
SEQUENCE 700, Appli
SEQUENCE 701, Appli
SEQUENCE 702, Appli
SEQUENCE 703, Appli
SEQUENCE 704, Appli
SEQUENCE 705, Appli
SEQUENCE 706, Appli
SEQUENCE 707, Appli
SEQUENCE 708, Appli
SEQUENCE 709, Appli
SEQUENCE 710, Appli
SEQUENCE 711, Appli
SEQUENCE 712, Appli
SEQUENCE 713, Appli
SEQUENCE 714, Appli
SEQUENCE 715, Appli
SEQUENCE 716, Appli
SEQUENCE 717, Appli
SEQUENCE 718, Appli
SEQUENCE 719, Appli
SEQUENCE 720, Appli
SEQUENCE 721, Appli
SEQUENCE 722, Appli
SEQUENCE 723, Appli
SEQUENCE 724, Appli
SEQUENCE 725, Appli
SEQUENCE 726, Appli
SEQUENCE 727, Appli
SEQUENCE 728, Appli
SEQUENCE 729, Appli
SEQUENCE 730, Appli
SEQUENCE 731, Appli
SEQUENCE 732, Appli
SEQUENCE 733, Appli
SEQUENCE 734, Appli
SEQUENCE 735, Appli
SEQUENCE 736, Appli
SEQUENCE 737, Appli
SEQUENCE

Best Local Similarity 100.0%; Pred. No. 8.5e-128; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 2
US-08-849-764C-5
; Sequence 5, Application US/08849764C
; Patent No. 6200310
GENERAL INFORMATION:
APPLICANT: Hawkins, Phillip R.
TITLE OF INVENTION: A NOVEL TISSUE INHIBITOR OF METALLOPROTEINASES
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: US
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/111,070
FILING DATE: CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/588,163
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Luther, Barbara J.
REGISTRATION NUMBER: 33,954
REFERENCE/DOCKET NUMBER: PF-0053
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
TELEX:
; INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 207 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: protein
MOLECULE TYPE: peptide
IMMEDIATE SOURCE: LIBRARY: METALLOPROTEINASES
CLONE: TIMP-1
; US-09-111-070-5

Query Match 100.0%; Score 1124; DB 1; Length 207;
Best Local Similarity 100.0%; Pred. No. 8.5e-128;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGILLMLIAPSRACTCVPHPQTAFCSNDLVRAKVGTPEVNQTLYQR 60
Db 1 MAPPEPLASGILLMLIAPSRACTCVPHPQTAFCSNDLVRAKVGTPEVNQTLYQR 60
QY 61 YEKMTKMYKGQALGDAADRFVYTPAMESVCGYFRSHNRSEEFILAGKLQDGHLIT 120
Db 61 YEKMTKMYKGQALGDAADRFVYTPAMESVCGYFRSHNRSEEFILAGKLQDGHLIT 120
QY 121 TCSFVAPWNSLSLAQRGFTKTYTVCBECTVFPCLSIPCKLQSGTHCLWDQLOGSEK 180
Db 121 TCSFVAPWNSLSLAQRGFTKTYTVCBECTVFPCLSIPCKLQSGTHCLWDQLOGSEK 180
QY 181 GFSRHLACLPRPGCTWQSLSQIA 207
Db 181 GFSRHLACLPRPGCTWQSLSQIA 207

QY 1 MAPPEPLASGILLMLIAPSRACTCVPHPQTAFCSNDLVRAKVGTPEVNQTLYQR 60
Db 1 MAPPEPLASGILLMLIAPSRACTCVPHPQTAFCSNDLVRAKVGTPEVNQTLYQR 60
QY 61 YEKMTKMYKGQALGDAADRFVYTPAMESVCGYFRSHNRSEEFILAGKLQDGHLIT 120
Db 61 YEKMTKMYKGQALGDAADRFVYTPAMESVCGYFRSHNRSEEFILAGKLQDGHLIT 120
QY 121 TCSFVAPWNSLSLAQRGFTKTYTVCBECTVFPCLSIPCKLQSGTHCLWDQLOGSEK 180
Db 121 TCSFVAPWNSLSLAQRGFTKTYTVCBECTVFPCLSIPCKLQSGTHCLWDQLOGSEK 180
QY 181 GFSRHLACLPRPGCTWQSLSQIA 207
Db 181 GFSRHLACLPRPGCTWQSLSQIA 207

RESULT 3
US-08-849-764C-5
; Sequence 5, Application US/08849764C
; Patent No. 6200310
GENERAL INFORMATION:
APPLICANT: ROSEN, CRAIG
TITLE OF INVENTION: HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-4
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: HUMAN GENOME SCIENCES, INC.
STREET: 9410 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
COUNTRY: USA
ZIP: 20850
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/849,764C
FILING DATE: 19-Sep-1997
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: MICHELE M. WALES
REGISTRATION NUMBER: 43,975
REFERENCE/DOCKET NUMBER: PFI48US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-309-8304
TELEFAX: 301-309-8439
; INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 207 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: protein
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-08-849-764C-5

Query Match 100.0%; Score 1124; DB 2; Length 207;
Best Local Similarity 100.0%; Pred. No. 8.5e-128;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGILLMLIAPSRACTCVPHPQTAFCSNDLVRAKVGTPEVNQTLYQR 60
Db 1 MAPPEPLASGILLMLIAPSRACTCVPHPQTAFCSNDLVRAKVGTPEVNQTLYQR 60
QY 61 YEKMTKMYKGQALGDAADRFVYTPAMESVCGYFRSHNRSEEFILAGKLQDGHLIT 120
Db 61 YEKMTKMYKGQALGDAADRFVYTPAMESVCGYFRSHNRSEEFILAGKLQDGHLIT 120

RESULT 4
US-09-262-087-5
; Sequence 5, Application US/09262087
; Patent No. 6391853

GENERAL INFORMATION:
 APPLICANT: GREENE, JOHN M
 APPLICANT: ROSEN, CRAIG
 TITLE OF INVENTION: HUMAN TISSUE INHIBITOR OF
 TITLE OF INVENTION: METALLOPROTEINASE-4
 NUMBER OF SEQUENCES: 11

CORRESPONDENCE ADDRESS:
 ADDRESSEE: HUMAN GENOME SCIENCES, INC.
 STREET: 9410 KEY WEST AVE
 CITY: ROCKVILLE
 STATE: MD
 ZIP: 20850

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/262, 087
 FILING DATE: 04 MAR-1999

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/463, 261

FILING DATE: 05-JUN-1995

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/US94/14498
 FILING DATE: 13-FEB-1994

ATTORNEY/AGENT INFORMATION:
 NAME: A. ANDERS BROOKES
 REGISTRATION NUMBER: 36,373
 REFERENCE/DOCKET NUMBER: PPI48P1D1
 TELEPHONE: 301-309-8439
 TELEFAX: 301-309-8404

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:
 LENGTH: 207 amino acids
 TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

US-09-262-087-5

Query Match 100.0%; Score 1124; DB 2; Length 207;
 Best Local Similarity 100.0%; Pred. No. 8.5e-128;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPFERPLASGLLILWLIAPSRACTCVPPIRQTAFCNSDLVIRAKFGTPEVNQTYQR 60
 1 MAPFERPLASGLLILWLIAPSRACTCVPPIRQTAFCNSDLVIRAKFGTPEVNQTYQR 60

Db 61 YEIKMVKMYKFOALGDAADIRFVTPAMMSVCGYFHRSINRSEEFLLAIGKLQDGHLHT 120
 61 YEIKMVKMYKFOALGDAADIRFVTPAMMSVCGYFHRSINRSEEFLLAIGKLQDGHLHT 120

QY 61 YEIKMVKMYKFOALGDAADIRFVTPAMMSVCGYFHRSINRSEEFLLAIGKLQDGHLHT 120
 61 YEIKMVKMYKFOALGDAADIRFVTPAMMSVCGYFHRSINRSEEFLLAIGKLQDGHLHT 120

Db 121 TCSFVAPWNLSLSLAORGFTKTYTGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180
 121 TCSFVAPWNLSLSLAORGFTKTYTGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180

Db 121 TCSFVAPWNLSLSLAORGFTKTYVGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180
 121 TCSFVAPWNLSLSLAORGFTKTYVGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180

QY 181 GFOSRLACIIPREPGCTWOSLRSQIA 207
 181 GFOSRLACIIPREPGCTWOSLRSQIA 207

RESULT 5
US-08-463-261B-11
Sequence 11, Application US/08463261B
Patent No. 648042

GENERAL INFORMATION:
 ADDRESSEE: John M. Greene and Craig A. Rosen
 STREET: 9410 KEY WEST AVENE
 CITY: ROCKVILLE
 STATE: MARYLAND
 COUNTRY: USA
 ZIP: 20850

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 INCH DISKETTE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: WORD PERFECT 5.1

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/463, 261B
 FILING DATE: 05-JUN-1995

PRIOR APPLICATION DATA:
 ATTORNEY/AGENT INFORMATION:
 NAME: KENLEY K. HOOVER
 REGISTRATION NUMBER: 40,302
 REFERENCE/DOCKET NUMBER: PPI48P1

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 301-610-5790
 TELEX/FAX: 301-610-8439

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:
 LENGTH: 207 AMINO ACIDS
 TYPE: AMINO ACID

STRANDEDNESS:
 TOPOLOGY: LINEAR

MOLECULE TYPE: PROTEIN

US-08-463-261B-11

Query Match 100.0%; Score 1124; DB 2; Length 207;
 Best Local Similarity 100.0%; Pred. No. 8.5e-128;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPFERPLASGLLILWLIAPSRACTCVPPIRQTAFCNSDLVIRAKFGTPEVNQTYQR 60
 1 MAPFERPLASGLLILWLIAPSRACTCVPPIRQTAFCNSDLVIRAKFGTPEVNQTYQR 60

Db 121 TCSFVAPWNLSLSLAORGFTKTYTGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180
 121 TCSFVAPWNLSLSLAORGFTKTYTGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180

Db 121 TCSFVAPWNLSLSLAORGFTKTYVGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180
 121 TCSFVAPWNLSLSLAORGFTKTYVGCEECTVFPCLSIPCKLQSGTHCLWTDLQGSEK 180

QY 181 GFOSRLACIIPREPGCTWOSLRSQIA 207
 181 GFOSRLACIIPREPGCTWOSLRSQIA 207

RESULT 6
US-09-540-530-1
; Sequence 1, Application US/09540530
; Patent No. 6534635
; GENERAL INFORMATION:

RESULT 9
US-10-116-064-5
; Sequence 5, Application US/10116064
; GENERAL INFORMATION:
; APPLICANT: GREENE, JOHN M
; ROSEN, CRAIG
; TITLE OF INVENTION: HUMAN TISSUE INHIBITOR OF
; NUMBER OF SEQUENCES: 11 METALLOPROTEINASE-4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HUMAN GENOME SCIENCES, INC.
; STREET: 9410 KEY WEST AVE
; CITY: ROCKVILLE
; STATE: MD
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/116,064
; FILING DATE: 05-APR-2002
; CLASSIFICATION: <Unknown>
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 09/252,087
; FILING DATE: 04-MAR-1999
; FILING DATE: 13-FEB-1994
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 207 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SUBSEQUENCE DESCRIPTION: SEQ ID NO: 5:
; US-10-116-064-5
Query Match 100.0%; Score 1124; DB 2; Length 254;
Best Local Similarity 100.0%; Pred. No. 1.2e-127; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;
; Sequence 9699, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/999,016
; CURRENT FILING DATE: 2000-04-14
; PRIORITY APPLICATION NUMBER: 60/241,755
; PRIORITY FILING DATE: 2000-10-20
; PRIORITY FILING DATE: 2000-10-03
; PRIORITY FILING DATE: 2000-03-08
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 9699
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Human
; US-09-949-016-9699
Query Match 100.0%; Score 1124; DB 2; Length 254;
Best Local Similarity 100.0%; Pred. No. 1.2e-127; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;
; Sequence 1, Application US/09452817
; Patent No. 634274
; GENERAL INFORMATION:
; APPLICANT: Carmichael, David F
; APPLICANT: Anderson, David C
; APPLICANT: Stricklin, George P
; APPLICANT: Weigus, Howard G
; TITLE OF INVENTION: Human Collagenase Inhibitor, Recombinant Vector System
; TITLE OF INVENTION: For Using Same And Recombinant-DNA Method For
; TITLE OF INVENTION: Manufacture Of Same
; FILE REFERENCE: Serial No. 6342374 09/452,817
; CURRENT APPLICATION NUMBER: US/09/452,817
; CURRENT FILING DATE: 2001-06-22
; PRIORITY APPLICATION NUMBER: 08/474,553
; PRIORITY FILING DATE: 1995-06-07
; PRIORITY APPLICATION NUMBER: 08/050,739
; PRIORITY FILING DATE: 1993-04-21
; PRIORITY APPLICATION NUMBER: 07/853,018
; PRIORITY FILING DATE: 1992-03-18
; PRIORITY APPLICATION NUMBER: 07/517,475
; PRIORITY FILING DATE: 1990-05-01
; PRIORITY APPLICATION NUMBER: 07/320,923
; PRIORITY FILING DATE: 1989-03-08
; PRIORITY APPLICATION NUMBER: 67784,319
; PRIORITY FILING DATE: 1985-10-04
; PRIORITY APPLICATION NUMBER: 067699,181
; PRIORITY FILING DATE: 1985-02-05
RESULT 10
US-09-949-016-9699

NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 184
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-452-817-1

Query Match 89.8%; Score 1009; DB 2; Length 184;
Best Local Similarity 100.0%; Pred. No. 6.2e-114; Matches 184; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 24 CTCVPPHQTAFCNSDLVIRAKFVGTPENQTYLQR 83
Db 1 CTCVPPHQTAFCNSDLVIRAKFVGTPENQTYLQR 60

Qy 84 VITPAMSVCGYFRSHRSRSEERLIAKGLQDGHLHTCSFAPWNSLSLAQRGFTKY 143
Db 61 VITPAMSVCGYFRSHRSRSEERLIAKGLQDGHLHTCSFAPWNSLSLAQRGFTKY 120

Qy 144 TVGCBECTVFPCLSPCKLQSGTCHLWTDQLLOGSEKFGSRHLACLPREGLTWSLR 203
Db 121 TVGCBECTVFPCLSPCKLQSGTCHLWTDQLLOGSEKFGSRHLACLPREGLTWSLR 180

Qy 204 SQ1A 207
Db 181 SQ1A 184

RESULT 12
US-08-134-231C-22
; Sequence 22, Application US/08134231C
; Patent No. 6522596
; GENERAL INFORMATION:
; APPLICANT: Silbiger, Scott M.
; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type Three (TIMP-3) Composition and Method
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegans, Henderson, Farabow, Garrett & Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/728,160
; FILING DATE: 06-OCT-1993
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/134,231
; FILING DATE: 06-OCT-1993
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 207 amino acid
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-728-160-22

Query Match 88.5%; Score 995; DB 2; length 207;
Best Local Similarity 87.0%; Pred. No. 3.7e-112; Matches 180; Conservative 11; Mismatches 16; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGLLMLMILAPSRACTCVPHPQTAFCNSDLVIRAKFVGTPENQTYLQR 60
Db 1 MAPFAPMAGSGLLMLWLTAPSRACTCVPHPQTAFCNSDLVIRAKFVGTAEVNETALYQR 60

Qy 61 VEIKMTMKYKGQALGDADIRFVTFAMESVCGYFRSHRSRSEERLIAKGLQDGHLHT 120
Db 61 VEIKMTMKYKGQALGDADIRFVTFAMESVCGYFRSHRSRSEERLIAKGLQDGHLHT 120

Qy 121 TCSFVAWNSSLAQRGFTKYAAGCCTVFPCLSPCKLQSGTCHLWTDQLLOGSEK 180
Db 121 TCSFVAWNSSLAQRGFTKYAAGCCTVFPCLSPCKLQSGTCHLWTDQLLOGSEK 180

Qy 181 GFQSRLHACLPREGLTWSLR 207
Db 181 GFQSRLHACLPREGLTWSLR 207

RESULT 13
US-08-728-160-22
; Sequence 22, Application US/08728160
; Patent No. 6633155
; GENERAL INFORMATION:
; APPLICANT: Silbiger, Scott M.
; APPLICANT: Kosik, Raymond A.
; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type Three (TIMP-3) Composition and Method
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc./Patent Operations/KMP
; STREET: 1840 Dehavenland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/728,160
; FILING DATE: 06-OCT-1993
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/134,231
; FILING DATE: 06-OCT-1993
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 207 amino acid
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-728-160-22

Query Match 88.5%; Score 995; DB 2; length 207;
Best Local Similarity 87.0%; Pred. No. 3.7e-112; Matches 180; Conservative 11; Mismatches 16; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGLLMLMILAPSRACTCVPHPQTAFCNSDLVIRAKFVGTPENQTYLQR 60
Db 1 MAPFAPMAGSGLLMLWLTAPSRACTCVPHPQTAFCNSDLVIRAKFVGTAEVNETALYQR 60

Qy 61 VEIKMTMKYKGQALGDADIRFVTFAMESVCGYFRSHRSRSEERLIAKGLQDGHLHT 120
Db 61 VEIKMTMKYKGQALGDADIRFVTFAMESVCGYFRSHRSRSEERLIAKGLQDGHLHT 120

Qy 121 TCSFVAWNSSLAQRGFTKYAAGCCTVFPCLSPCKLQSGTCHLWTDQLLOGSEK 180
Db 121 TCSFVAWNSSLAQRGFTKYAAGCCTVFPCLSPCKLQSGTCHLWTDQLLOGSEK 180

US-08-134-231C-24
; Sequence 24, Application US/0814231C
; Patent No. 656295
; GENERAL INFORMATION:
; APPLICANT: Silbiger, Scott M.
; Koski, Raymond A.
; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type
; NUMBER OF SEQUENCES: Three (TIMP-3) Composition and Methods
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett & Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/134,231C
; FILING DATE: 06-Oct-1993
; CLASSIFICATION: <Unknown>
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 206 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: Linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:
; US-08-134-231C-24
; Query Match 80.3%; Score 902.5; DB 2; Length 206;
; Best Local Similarity 80.8%; Pred. No. 6e-101;
; Matches 164; Conservative 13; Mismatches 25; Indels 1; Gaps 1;
; Qy 1 MAPREPLASGLLILMLIAPSRACCTCVPPIRQTAFCNSDLYTRAKFVGTPENQNTLYQR 60
; Db 1 MAPLAALASSMLLWLWVAPSRACTCVCPPHPQTAFCCNDLIVRAKEVGAPENHNTLYQR 60
; Qy 61 YEIKTKMVKQFOALGDAIDRFTVTPAMSVCGYSHKSQNRSSEFLAQLKQDSLHIT 120
; Db 61 YEIKTKMFKGFDALGHATDIRFTVTPAMESVCGYSHKSQNRSSEFLAQLKQDSLHIT 120
; Qy 121 TCSFVAPWNLSLQAORGFRTTYTGCEBCTVFCPLSIPKLOSCPHCLWMDQLGSEK 180
; Db 121 TCSFVUPWNLSFSQSGFRTYAGCDMCTVFCASIFCHESDRICLWTDSS-LGSDK 179
; Qy 181 GFOSRHLACIPREPGCTWOSLR 203
; Db 180 GFOSRHLACIPQEGLCAWESLR 202
; Search completed: April 10, 2006, 18:08:44
; Job time : 16.2574 secs

RESULT 15
US 08-728-160-24
; Sequence 24, Application US/08728160
; Patent No. 6683155
; GENERAL INFORMATION:
; APPLICANT: Silbiger, Scott M.
; Koski, Raymond A.
; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type
; TITLE OF INVENTION: Three (TIMP-3) Composition and Methods
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc./Patent Operations/RMP
; STREET: 1840 Delavalland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789

THIS PAGE LEFT BLANK

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

Sequence 3513, Ap
Sequence 3566, Ap
Sequence 24, Appl
Sequence 20, Appl
Sequence 20, Appl
Sequence 22, Appl
Sequence 22, Appl
Sequence 14, Appl
Sequence 2, Appl
Sequence 202109,
Sequence 27, Appl
Sequence 2, Appl
Sequence 7, Appl
Sequence 10, Appl
Sequence 21, Appl
Sequence 9, Appl

OM protein - protein search, using sw model
Run on: April 10, 2006, 18:07:51 ; Search time 53.0594 seconds
(without alignments) 1630.072 Million cell updates/sec

Title: US-10-734-564-100
Perfect score: 1124
Sequence: 1 MAPPERPLASGILLIILWLIAP.....ACLPRPRLCTWQSLSRSQIA 207

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 200000000
Post-processing: Minimum Match 0%
Maximum Match 10%
Listing first 45 summaries

Database : Published Applications AA_Main:
1: /cgns_6/podata/1/pubpa/us07_PUBCOMB.pep: *
2: /cgns_6/podata/1/pubpa/us08_PUBCOMB.pep: *
3: /cgns_6/podata/1/pubpa/us09_PUBCOMB.pep: *
4: /cgns_6/podata/1/pubpa/us10_PUBCOMB.pep: *
5: /cgns_6/podata/1/pubpa/us10B_PUBCOMB.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1124	100.0	207	4 US-10-116-564-5
2	100.0	207	4 US-10-116-567-23	Sequence 5, Appl
3	100.0	207	4 US-10-301-822-205	Sequence 23, Appl
4	100.0	207	4 US-10-087-888-4	Sequence 205, Appl
5	100.0	207	4 US-10-325-461-1	Sequence 4, Appl
6	100.0	207	4 US-10-712-124-70	Sequence 1, Appl
7	100.0	207	4 US-10-734-564-100	Sequence 70, Appl
8	100.0	207	5 US-10-486-90-9	Sequence 100, Appl
9	100.0	207	5 US-10-971-461-20	Sequence 9, Appl
10	100.0	207	5 US-10-852-35A-129	Sequence 20, Appl
11	100.0	207	5 US-10-971-495-4	Sequence 129, Appl
12	100.0	207	6 US-11-037-713-52	Sequence 4, Appl
13	99.6	207	3 US-09-731-872-291	Sequence 52, Appl
14	99.6	207	3 US-09-876-97-291	Sequence 291, Appl
15	99.6	207	5 US-10-643-936-291	Sequence 9, Appl
16	99.0	204	4 US-10-264-949-3338	Sequence 291, Appl
17	89.9	580	4 US-10-025-514-18	Sequence 3338, Ap
18	89.9	580	6 US-11-077-276-18	Sequence 18, Appl
19	89.8	184	4 US-10-025-514-6	Sequence 6, Appl
20	89.8	184	6 US-11-077-276-6	Sequence 6, Appl
21	89.8	580	4 US-10-025-514-10	Sequence 10, Appl
22	89.8	580	6 US-11-077-276-10	Sequence 10, Appl
23	88.5	207	4 US-10-348-167-22	Sequence 22, Appl
24	80.3	205	4 US-10-314-167-24	Sequence 24, Appl
25	79.6	166	4 US-10-372-683-6	Sequence 6, Appl
26	74.5	205	4 US-10-348-167-25	Sequence 25, Appl
27	69.6	183	3 US-09-925-301-1594	Sequence 1594, Ap

RESULT 1
US-10-116-064-5
; Sequence 5, Application US/10116064
; Publication No. US20020115187A1
; GENERAL INFORMATION:
; APPLICANT: GREENE, JOHN M
; ROSEN, CRAIG
TITLE OF INVENTION: HUMAN TISSUE INHIBITOR OF
METALLOPROTEINASE-4
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: HUMAN GENOME SCIENCES, INC.
STREET: 9410 KEY WEST AVE
CITY: ROCKVILLE
STATE: MD
COUNTRY: USA
ZIP: 20850
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/116,064
FILING DATE: 05-APR-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/262,087
FILING DATE: 04-MAR-1999
APPLICATION NUMBER: PCT/US94/14498
FILING DATE: 13-FEB-1994
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 207 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Protein
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-116-064-5

Query Match Similarity 100.0%; Score 1124; DB 4; Length 207;
Best Local Similarity 100.0%; Pred. No. 1.e-111; Mismatches 0; Indels 0; Gaps 0;
Matches 207; Conservative 0; Sequence 1 MAPPERPLASGILLIILWLIAPSRACTCVPHPQTAFCSNPLIVIRAKFVGSPPEVNMTYQR 60
Qy 1 MAPPERPLASGILLIILWLIAPSRACTCVPHPQTAFCSNPLIVIRAKFVGSPPEVNMTYQR 60
Db 1 MAPPERPLASGILLIILWLIAPSRACTCVPHPQTAFCSNPLIVIRAKFVGSPPEVNMTYQR 60
Dq 61 YEIKWTKMYKGFOALGDAADIRFVTPAMESVCYFYFRSHNRSEFFLINGKLDGLHT 120

RESULT 2
 US-10-348-167-23
 ; Sequence 23, Application US/10348167
 ; Publication No. US20030143693A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Millennium Pharmaceuticals, Inc.
 ; APPLICANT: Berger, Allison
 ; APPLICANT: Guillemette, Tracy L.
 ; APPLICANT: Kamakar, Shubhangi
 ; APPLICANT: Schlegel, Robert
 ; APPLICANT: Monahan, John E.
 ; APPLICANT: Thibodeau, Stephen N.
 ; APPLICANT: Burgart, Lawrence J.
 ; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF COLON CANCER
 ; FILE REFERENCE: MEMO1-029P2RNM
 ; CURRENT APPLICATION NUMBER: US/10/301, 822
 ; CURRENT FILING DATE: 2002-11-21
 ; PRIORITY NUMBER: US 60/339, 971
 ; PRIORITY FILING DATE: 2001-12-10
 ; PRIORITY APPLICATION NUMBER: US 60/361, 978
 ; PRIORITY FILING DATE: 2002-01-05
 ; PRIORITY APPLICATION NUMBER: US 60/381, 988
 ; PRIORITY FILING DATE: 2002-05-20
 ; NUMBER OF SEQ ID NOS: 228
 ; SOFTWARE: FASTSEQ for Windows Version 4.0
 ; SEQ ID NO: 205
 ; LENGTH: 207
 ; TYPE: PRT
 ; ORGANISM: Homo Sapiens
 ; US-10-301-822-205
 ; Query Match 100.0%; Score 1124; DB 4; Length 207;
 ; Best Local Similarity 100.0%; Pred. No. 1.1e-111;
 ; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 ;
 ; 1 MAPPEPLASGLLWLLWLIAPSRACTCPHPOTAFCNSDLVIRAKFVTPENQTLYQR 60
 ; 1 MAPPEPLASGLLWLLWLIAPSRACTCPHPOTAFCNSDLVIRAKFVTPENQTLYQR 60
 ; QY 61 YEIKMTKMYKGFOALGDAADIRFVTPAMEMVCGYFRSHNRSEFLIAGKLDGLHIT 120
 ; Db 61 YEIKMTKMYKGFOALGDAADIRFVTPAMEMVCGYFRSHNRSEFLIAGKLDGLHIT 120
 ; QY 121 TCSFVAWNLSLAQRGKFTKTYVGCECTVPCLSIPCKLQSGTHCLWTDQLQLOGSEK 180
 ; Db 121 TCSFVAWNLSLAQRGKFTKTYVGCECTVPCLSIPCKLQSGTHCLWTDQLQLOGSEK 180
 ; QY 181 GFSRHLACLPRPGLCTWOSLSQIA 207
 ; Db 181 GFSRHLACLPRPGLCTWOSLSQIA 207
 ;
 ; RESULT 3
 ; ORGANISM: Homo sapiens

US-10-087-188-4

PRIOR APPLICATION NUMBER: US 60/425, 813
 PRIORITY FILING DATE: 2002-11-13
 NUMBER OF SEQ ID NOS: 123
 SEQ ID NO: 70
 LENGTH: 207
 TYPE: PRT
 ORGANISM: Homo sapien

Query Match 100 %; Score 1124; DB 4; Length 207;
 Best Local Similarity 100 %; Pred. No. 1.e-111; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPFPEPLASGILLLWILIAPIRSRACTCVPHPOTAFCNDSLIVRAKEVGTPEVNQNTLYQR 60
 Db 1 MAPFPEPLASGILLLWILIAPIRSRACTCVPHPOTAFCNDSLIVRAKEVGTPEVNQNTLYQR 60
 Qy 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFFRSINRSEELIAGKLQDGHLIT 120
 Db 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFFRSINRSEELIAGKLQDGHLIT 120
 Qy 121 TCSFVAPWNNSLSLAQRGFTKTYTVGCECTVFCPLSIPCKLQSGTHCLWTDLQLGSEK 180
 Db 121 TCSFVAPWNNSLSLAQRGFTKTYTVGCECTVFCPLSIPCKLQSGTHCLWTDLQLGSEK 180
 Qy 181 GFQSRHLACLPRREGLCTWOSLRSQLA 207
 Db 181 GFQSRHLACLPRREGLCTWOSLRSQLA 207

RESULT 5

US-10-325-446-1

Query Match 100 %; Score 1124; DB 4; Length 207;
 Best Local Similarity 100 %; Pred. No. 1.e-111; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPFPEPLASGILLLWILIAPIRSRACTCVPHPOTAFCNDSLIVRAKEVGTPEVNQNTLYQR 60
 Db 1 MAPFPEPLASGILLLWILIAPIRSRACTCVPHPOTAFCNDSLIVRAKEVGTPEVNQNTLYQR 60

Qy 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFFRSINRSEELIAGKLQDGHLIT 120
 Db 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFFRSINRSEELIAGKLQDGHLIT 120
 Qy 121 TCSFVAPWNNSLSLAQRGFTKTYTVGCECTVFCPLSIPCKLQSGTHCLWTDLQLGSEK 180
 Db 121 TCSFVAPWNNSLSLAQRGFTKTYTVGCECTVFCPLSIPCKLQSGTHCLWTDLQLGSEK 180
 Qy 181 GFQSRHLACLPRREGLCTWOSLRSQLA 207
 Db 181 GFQSRHLACLPRREGLCTWOSLRSQLA 207

RESULT 6

US-10-325-446-1

Publication No. US20040121438A1

GENERAL INFORMATION:

APPLICANT: Stephen Quirk

TITLE OF INVENTION: Wound Care Compositions

FILE REFERENCE: 1443_048US1

CURRENT APPLICATION NUMBER: US10/325,446

CURRENT FILING DATE: 2002-12-19

NUMBER OF SEQ ID NOS: 21

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ ID NO: 1

LENGTH: 207

TYPE: PRT

ORGANISM: Homo sapiens

US-10-325-446-1

Query Match 100.0%; Score 1124; DB 4; Length 207;
 Best Local Similarity 100.0%; Pred. No. 1.e-111; Mismatches 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SEQ_ID NO: 1

TITLE OF INVENTION: FastSEQ for Windows Version 4.0

FILE REFERENCE: 1443_048US1

CURRENT APPLICATION NUMBER: US10/325,446

CURRENT FILING DATE: 2002-12-19

NUMBER OF SEQ ID NOS: 21

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ_ID NO: 1

LENGTH: 207

TYPE: PRT

ORGANISM: Homo sapiens

US-10-325-446-1

Query Match 100.0%; Score 1124; DB 4; Length 207;
 Best Local Similarity 100.0%; Pred. No. 1.e-111; Mismatches 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SEQ_ID NO: 1

TITLE OF INVENTION: FastSEQ for Windows Version 4.0

FILE REFERENCE: 1443_048US1

CURRENT APPLICATION NUMBER: US10/325,446

CURRENT FILING DATE: 2002-12-19

RESULT 7

US-10-734-564-100

Publication No. US2004015728A1

GENERAL INFORMATION:

APPLICANT: Christopher C Burgess et al

TITLE OF INVENTION: Detection Methods Using TIMP1

FILE REFERENCE: 1657/2012

CURRENT APPLICATION NUMBER: US10/734,564

CURRENT FILING DATE: 2003-12-12

NUMBER OF SEQ ID NOS: 138

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ_ID NO: 100

LENGTH: 207

TYPE: PRT

ORGANISM: Homo sapiens

Query Match 100 %; Score 1124; DB 4; Length 207;
 Best Local Similarity 100 %; Pred. No. 1.e-111; Mismatches 0; Indels 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SEQ_ID NO: 1

TITLE OF INVENTION: FastSEQ for Windows Version 4.0

FILE REFERENCE: 1657/2012

CURRENT APPLICATION NUMBER: US10/734,564

CURRENT FILING DATE: 2003-12-12

NUMBER OF SEQ ID NOS: 138

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ_ID NO: 100

LENGTH: 207

TYPE: PRT

ORGANISM: Homo sapiens

US-10-734-564-100

Query Match 100.0%; Score 1124; DB 4; Length 207;
 Best Local Similarity 100.0%; Pred. No. 1.e-111; Mismatches 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SEQ_ID NO: 1

TITLE OF INVENTION: FastSEQ for Windows Version 4.0

FILE REFERENCE: 1657/2012

CURRENT APPLICATION NUMBER: US10/734,564

CURRENT FILING DATE: 2003-12-12

RESULT 8

US-10-486-090-9

Publication No. US20040235724A1

GENERAL INFORMATION:

APPLICANT: SMITH, VICTORIA

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETECTING DYSPLASIA

FILE REFERENCE: F2008R1

CURRENT APPLICATION NUMBER: US/10/712,124

CURRENT FILING DATE: 2003-11-13

GENERAL INFORMATION:
; APPLICANT: Berdel, Wolfgang B.
; TITLE OF INVENTION: Use of TIMP-1 as an Immunosuppressant
; FILE REFERENCE: 19235_002
; CURRENT FILING DATE: 2004-02-05
; PRIORITY APPLICATION NUMBER: US/10/486,090
; PRIORITY FILING DATE: 2001-08-06
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 207
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE: OTHER INFORMATION: Synthetic construct
; US-10-486-090-9

Query Match 100.0%; Score 1124; DB 5; Length 207;
Best Local Similarity 100.0%; Pred. No. 1.e-11; Mismatches 0; Indels 0; Gaps 0;
Matches 207; Conservative 0; ; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGLIILWLIAPSRACTPVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60
Db 1 MAPFEPPLASGLIILWLIAPSRACTPVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60

QY 61 YEIKMTRNKGFOALGDAADIRFVYTPAMEVGYFRSHRNRSBELLIAKLUQDGHLIT 120
Db 61 YEIKMTRNKGFOALGDAADIRFVYTPAMEVGYFRSHRNRSBELLIAKLUQDGHLIT 120

QY 121 TCSFVAPWNSLSLAQRGGFTKTYTGEECTVFPCLSIPLCKLQSGTHCLWTDQLOGSEK 180
Db 121 TCSFVAPWNSLSLAQRGGFTKTYTGEECTVFPCLSIPLCKLQSGTHCLWTDQLOGSEK 180

Qy 181 GFQSRHHLACLPREPGLCIWTQSLSRQIA 207
Db 181 GFQSRHHLACLPREPGLCIWTQSLSRQIA 207

RESULT 9
US-10-971-461-20
; Sequence 20, Application US/10971461
; Publication No. US20050070477A1
; GENERAL INFORMATION:
; APPLICANT: The Scripps Research Institute
; TIME OF INVENTION: Treatment and Prevention of Pulmonary Conditions
; FILE REFERENCE: 1361_037US1
; CURRENT APPLICATION NUMBER: US/10/971,461
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 207
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-971-461-20

Query Match 100.0%; Score 1124; DB 5; Length 207;
Best Local Similarity 100.0%; Pred. No. 1.e-11; Mismatches 0; Indels 0; Gaps 0;
Matches 207; Conservative 0; ; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGLIILWLIAPSRACTPVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60
Db 1 MAPFEPPLASGLIILWLIAPSRACTPVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60

QY 61 YEIKMTRNKGFOALGDAADIRFVYTPAMEVGYFRSHRNRSBELLIAKLUQDGHLIT 120
Db 61 YEIKMTRNKGFOALGDAADIRFVYTPAMEVGYFRSHRNRSBELLIAKLUQDGHLIT 120

QY 121 TCSFVAPWNSLSLAQRGGFTKTYTGEECTVFPCLSIPLCKLQSGTHCLWTDQLOGSEK 180
Db 121 TCSFVAPWNSLSLAQRGGFTKTYTGEECTVFPCLSIPLCKLQSGTHCLWTDQLOGSEK 180

Qy 181 GFQSRHHLACLPREPGLCIWTQSLSRQIA 207
Db 181 GFQSRHHLACLPREPGLCIWTQSLSRQIA 207

RESULT 11
US-10-971-195-4
; Sequence 4, Application US/10971195
; Publication No. US2005018651A1
; GENERAL INFORMATION:
; APPLICANT: Oh, Esther H.
; APPLICANT: Smith, Catherine M.
; APPLICANT: Prometheus Laboratories Inc.
; APPLICANT: Prometheus Laboratories Inc.
; TIME OF INVENTION: Methods of Diagnosing Tissue Fibrosis
; FILE REFERENCE: 021825-001310US
; CURRENT APPLICATION NUMBER: US/10/971,195
; CURRENT FILING DATE: 2004-10-22
; PRIORITY APPLICATION NUMBER: US 60/514,034
; PRIORITY FILING DATE: 2003-10-24
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 207
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:

OTHER INFORMATION: human tissue inhibitor of metalloproteinase-1
 /US-10-971-195-4

Query Match 100.0%; Score 1124; DB 5; Length 207;
 Best Local Similarity 100.0%; Pred. No. 1.e-111; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Match 1 MAPPEPLASGLIILWLLTAPSRACTCVPHPHQTAFCNSDLVIRAKFVGPENQNTLYQR 60
 1 MAPPEPLASGLIILWLLTAPSRACTCVPHPHQTAFCNSDLVIRAKFVGPENQNTLYQR 60

QY 61 YEIKTMKMYKGFOALGDAADIRFVTPAMESVCGYFIRSHNNSSEEFITAGKQDGLHIT 120
 61 YEIKTMKMYKGFOALGDAADIRFVTPAMESVCGYFIRSHNNSSEEFITAGKQDGLHIT 120

QY 121 TCSFVAPNMSLAAQRGFTKTYVGCBCTVPPCLSPCKLQSGTHCLWTDQIQSQEK 180
 121 TCSFVAPNMSLAAQRGFTKTYVGCBCTVPPCLSPCKLQSGTHCLWTDQIQSQEK 180

QY 181 GFOSRHIALCLPREGLCIWTQSRSQIA 207
 181 GFOSRHIALCLPREGLCIWTQSRSQIA 207

Db 181 GFOSRHIALCLPREGLCIWTQSRSQIA 207

RESULT 12
 US-11-037-713-52
 Sequence 52, Application US/11037713
 Publication No. US200502213398A1
 GENERAL INFORMATION:
 APPLICANT: JACQUEMBER, JOCELYNE
 APPLICANT: BERTUCCI, FRANCOIS
 APPLICANT: BIRNBAUM, DANIEL
 APPLICANT: DEBONO, STEPHANE
 APPLICANT: TAGETT, REBECCA
 TITLE OF INVENTION: PROTEIN EXPRESSION PROFILING AND BREAST CANCER
 FILE REFERENCE: 1016-R-04(B)
 CURRENT APPLICATION NUMBER: US/11/037, 713
 CURRENT FILING DATE: 2005-01-18
 PRIOR APPLICATION NUMBER: 60/537, 412
 PRIOR FILING DATE: 2004-01-16
 NUMBER OF SEQ ID NOS: 54
 SOFTWARE: PatentIn Ver. 3.3
 SEQ ID NO 52
 LENGTH: 207
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-037-713-52

Query Match 99.6%; Score 1120; DB 3; Length 207;
 Best Local Similarity 99.5%; Pred. No. 2.e-111; Matches 206; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Match 1 MAPPEPLASGLIILWLLTAPSRACTCVPHPHQTAFCNSDLVIRAKFVGPENQNTLYQR 60
 1 MAPPEPLASGLIILWLLTAPSRACTCVPHPHQTAFCNSDLVIRAKFVGPENQNTLYQR 60

QY 61 YEIKTMKMYKGFOALGDAADIRFVTPAMESVCGYFIRSHNNSSEEFITAGKQDGLHIT 120
 61 YEIKTMKMYKGFOALGDAADIRFVTPAMESVCGYFIRSHNNSSEEFITAGKQDGLHIT 120

QY 121 TCSFVAPNMSLAAQRGFTKTYVGCBCTVPPCLSPCKLQSGTHCLWTDQIQSQEK 180
 121 TCSFVAPNMSLAAQRGFTKTYVGCBCTVPPCLSPCKLQSGTHCLWTDQIQSQEK 180

QY 181 GFOSRHIALCLPREGLCIWTQSRSQIA 207
 181 GFOSRHIALCLPREGLCIWTQSRSQIA 207

Db 181 GFOSRHIALCLPREGLCIWTQSRSQIA 207

RESULT 14
 US-09-876-997-291
 Sequence 291, Application US/09876997
 Publication No. US20030152921A1
 GENERAL INFORMATION:
 APPLICANT: Dumas Mline Edwards, Jean Baptiste
 APPLICANT: Bouqueret, Lydie
 APPLICANT: Jobert, Severin
 TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
 FILE REFERENCE: 78 USA CIP
 CURRENT APPLICATION NUMBER: US/09/876, 997
 CURRENT FILING DATE: 2001-06-08
 PRIOR APPLICATION NUMBER: US 09/731, 872
 PRIOR FILING DATE: 2000-12-07
 PRIOR APPLICATION NUMBER: US 60/187, 470
 PRIOR FILING DATE: 2000-03-06
 PRIOR APPLICATION NUMBER: US 60/169, 629
 PRIOR FILING DATE: 1999-12-08
 NUMBER OF SEQ ID NOS: 482
 SOFTWARE: Patent .pm
 SEQ ID NO 291
 LENGTH: 207
 TYPE: PRT
 ORGANISM: Homo sapiens
 NAME/KEY: SIGNAL
 FEATURE: SIGNAL
 LOCATION: -23..-1

Patent No. US20020102604A1
 GENERAL INFORMATION:
 APPLICANT: Dumas Mline Edwards, Jean Baptiste
 APPLICANT: Bouqueret, Lydie
 APPLICANT: Jobert, Severin
 TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
 FILE REFERENCE: 78 US3 REG
 CURRENT APPLICATION NUMBER: US/09/731, 872
 CURRENT FILING DATE: 2000-12-07
 PRIOR APPLICATION NUMBER: US 60/169, 629
 PRIOR FILING DATE: 1999-12-08
 PRIOR APPLICATION NUMBER: US 60/187, 470
 PRIOR FILING DATE: 2000-03-06
 NUMBER OF SEQ ID NOS: 482
 SEQ ID NO 291
 LENGTH: 207
 SOFTWARE: Patent .pm
 TYPE: PRT
 ORGANISM: Homo sapiens
 NAME/KEY: SIGNAL
 FEATURE: SIGNAL
 LOCATION: -23..-1

US-09-876-997-291

Search completed: April 10, 2006, 18:12:43
Job time : 54.0594 secs

Query Match 99.6%; Score 1120; DB 5; Length 207;
 Best Local Similarity 99.5%; Pred. No. 2.9e-11; Mismatches 0; Indels 0; Gaps 0;
 Matches 206; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MAPFEPPLASGLLMLTAPSRACTCVPPHQTAFCNSDLVIRAKFGTPEVNQTLYQR 60
 Db 1 MAPFEPPLASGLLMLTAPSRACTCVPPHQTAFCNSDLVIRAKFGTPEVNQTLYQR 60

Qy 61 YEIKMTKMYKGQALGAAADIRFYVTAMESYCGYFRSHRSBEEFLAGKLQDGHLIT 120
 Db 61 YEIKMTKMYKGQALGAAADIRFYVTAMESYCGYFRSHRSBEEFLAGKLQDGHLIT 120

Qy 121 TCSFVAQWNSLSLAQRGFTKTYTVGCBECTVPCISIPCKLQSGTHCLWTDOLQSEK 180
 Db 121 TCSFVAQWNSLSLAQRGFTKTYTVGCBECTVPCISIPCKLQSGTHCLWTDOLQSEK 180

Qy 181 GQSRHHLACLRPGLCTWOSLSRQIA 207
 Db 181 GQSRHHLACLRPGLCTWOSLSRQIA 207

RESULT 15

US-10-643-836-291

; Sequence 291, Application US/10643836

; Publication No. US20050096458A1

; GENERAL INFORMATION:

; APPLICANT: Dumas Milne Edwards, Jean Baptiste

; APPLICANT: Bougueret, Lydie

; APPLICANT: Jobert, Severin

; TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS

; FILE REFERENCE: 78 US3 REG

; CURRENT APPLICATION NUMBER: US/10/643, 836

; CURRENT FILING DATE: 2003-08-19

; PRIOR APPLICATION NUMBER: US/09/731, 872

; PRIOR FILING DATE: 2000-12-07

; PRIOR APPLICATION NUMBER: US 60/169, 629

; PRIOR FILING DATE: 1999-12-08

; PRIOR APPLICATION NUMBER: US 60/187, 470

; PRIOR FILING DATE: 2000-03-06

; NUMBER OF SEQ ID NOS: 482

; SOFTWARE: Patent.pm

; SEQ ID NO 291

; LENGTH: 207

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: SIGNAL

; LOCATION: ..-23..-1

; US-10-643-836-291

Query Match 99.6%; Score 1120; DB 5; Length 207;
 Best Local Similarity 99.5%; Pred. No. 2.9e-11; Mismatches 0; Indels 0; Gaps 0;
 Matches 206; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MAPFEPPLASGLLMLTAPSRACTCVPPHQTAFCNSDLVIRAKFGTPEVNQTLYQR 60
 Db 1 MAPFEPPLASGLLMLTAPSRACTCVPPHQTAFCNSDLVIRAKFGTPEVNQTLYQR 60

Qy 61 YEIKMTKMYKGQALGAAADIRFYVTAMESYCGYFRSHRSBEEFLAGKLQDGHLIT 120
 Db 61 YEIKMTKMYKGQALGAAADIRFYVTAMESYCGYFRSHRSBEEFLAGKLQDGHLIT 120

Qy 121 TCSFVAQWNSLSLAQRGFTKTYTVGCBECTVPCISIPCKLQSGTHCLWTDOLQSEK 180
 Db 121 TCSFVAQWNSLSLAQRGFTKTYTVGCBECTVPCISIPCKLQSGTHCLWTDOLQSEK 180

Qy 181 GQSRHHLACLRPGLCTWOSLSRQIA 207
 Db 181 GQSRHHLACLRPGLCTWOSLSRQIA 207

Copyright (c) 1993 - 2006 Biocceleration Ltd.	GenCore version 5.1.7	26	72	6.4	665	7	US-11-051-720-1497	Sequence 1497, Ap
Run on:	April 10, 2006, 18:09:01 ; Search time 7.51485 seconds	27	72	6.4	782	7	US-11-051-720-1496	Sequence 1496, Ap
Scoring table:	BLOSUM62	28	71.5	6.4	326	7	US-11-037-243-105	Sequence 105, Ap
Gapext:	Gapext 0.5	29	71.5	6.4	473	7	US-11-075-185-12	Sequence 12, Ap
Total number of hits satisfying chosen parameters:	184161	30	71.5	6.4	552	6	US-10-131-826A-332	Sequence 332, Ap
Minimum DB seq length:	0	31	71.5	6.4	552	6	US-10-973-115B-332	Sequence 332, Ap
Maximum DB seq length:	200000000	32	70.5	6.3	415	7	US-11-182-946-6	Sequence 6, Ap
Post-processing:	Minimum Match 0%	33	70.5	6.3	933	7	US-11-072-512-2228	Sequence 2928, Ap
Scoring table:	BLOSUM62	34	70.5	6.3	1588	6	US-10-453-195-2	Sequence 2, Ap
Sequence:	1 MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	35	70	6.2	658	6	US-11-198-819-22	Sequence 22, Ap
Title:	US-10-734-564-100	36	69.5	6.2	375	7	US-11-096-568A-22741	Sequence 12741, A
Perfect score:	1124	37	69	6.1	1198	6	US-10-877-346-35	Sequence 35, Ap
Sequence:	1 MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	38	69	6.1	1433	7	US-11-114-982-1	Sequence 1, Ap
Scored:	184161 seqs, 31191982 residues	39	68.5	6.1	424	7	US-11-098-886-10348	Sequence 10348, A
Total number of hits satisfying chosen parameters:	184161	40	68.5	6.1	1419	7	US-11-114-962-3	Sequence 3, Ap
Minimum DB seq length:	0	41	67.5	6.0	229	7	US-11-087-999-2977	Sequence 2977, Ap
Maximum DB seq length:	200000000	42	67	6.0	378	7	US-11-096-568A-9995	Sequence 9995, Ap
Post-processing:	Minimum Match 0%	43	67	6.0	407	7	US-11-096-568A-9994	Sequence 9994, Ap
Scoring table:	BLOSUM62	44	67	6.0	418	7	US-11-109-156-2	Sequence 2, Ap
Sequence:	1 MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	45	67	6.0	449	7	US-11-096-568A-9993	Sequence 9993, Ap
SUMMARIES								
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.								
Result No.	Score	Query Match Length	DB ID	Description				
1	1124	100.0	207	7 US-11-186-284-205	RESULT 1			
2	1124	100.0	254	6 US-10-821-334-861	US-11-186-284-205	; Sequence 205, Application US/11186284		
3	94.1	197	7 US-11-094-519A-34	Sequence 861, App		; Publication No. US20050266493A1		
4	1050	93.4	211	7 US-11-094-519A-32	GENERAL INFORMATION:			
5	8337	74.5	164	7 US-11-094-519A-30	APPLICANT: Millennium Pharmaceuticals, Inc.			
6	830.5	73.9	160	7 US-11-094-519A-33	APPLICANT: Berger, Alison			
7	782	69.6	143	7 US-11-094-519A-52	APPLICANT: Guillemette, Tracy L.			
8	601	53.5	123	7 US-11-094-519A-31	APPLICANT: Kamatkar, Shubhangi			
9	577	51.3	108	7 US-11-044-640-13	APPLICANT: Schliegel, Robert			
10	551	49.0	147	7 US-11-094-519A-49	APPLICANT: Monahan, John E.			
11	526	46.8	115	7 US-11-094-519A-51	APPLICANT: Thibodeau, Stephen N.			
12	389.5	34.7	211	6 US-10-821-334-467	APPLICANT: Burgart, Lawrence J.			
13	232	20.6	82	7 US-11-094-519A-50	TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER			
14	90.5	8.1	1963	6 US-10-877-246-43	TITLE OF INVENTION: METHOD FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER			
15	80.5	7.2	304	7 US-11-098-686-10425	FILE REFERENCE: NPM01-0228RNM			
16	75.5	6.7	283	7 US-11-087-099-12255	CURRENT APPLICATION NUMBER: US/11/86, 284			
17	75	6.7	259	6 US-10-995-561-883	CURRENT FILING DATE: 2005-07-21			
18	75	6.7	259	6 US-10-995-561-883	PRIOR APPLICATION NUMBER: US 60/339, 971			
19	75	6.7	767	7 US-11-043-693-2	PRIOR FILING DATE: 2001-12-10			
20	75	6.7	1306	6 US-10-995-561-905	PRIOR APPLICATION NUMBER: US 60/361, 978			
21	75	6.7	1336	6 US-10-995-561-904	PRIOR FILING DATE: 2002-01-05			
22	75	6.7	1356	6 US-10-995-561-906	PRIOR APPLICATION NUMBER: US 60/381, 988			
23	74	6.6	764	7 US-11-104-110-8	PRIOR FILING DATE: 2002-05-20			
24	74	6.6	7	US-10-104-111-28	NUMBER OF SEQ ID NOS: 228			
25	72	6.4	285	7 US-11-1051-720-1493	NUMBER OF SEQ ID NOS: 228			
ALIGNMENTS								
QY	1 MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	1	MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	1	MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	1	MAPFELASGLILLIWLIAPIA...ACILPREPGCTWQSLRSQIA 207	1
Qy	61 YEIKKTMKMYKGFOALGDAADIRFYTTPAMESVCYFFHRSHNRSERFLAGKLQGLHIT 120	1	YEIKKTMKMYKGFOALGDAADIRFYTTPAMESVCYFFHRSHNRSERFLAGKLQGLHIT 120	1	YEIKKTMKMYKGFOALGDAADIRFYTTPAMESVCYFFHRSHNRSERFLAGKLQGLHIT 120	1	YEIKKTMKMYKGFOALGDAADIRFYTTPAMESVCYFFHRSHNRSERFLAGKLQGLHIT 120	1

Db 121 TCSFVAPWNSLSLAQRGFTKTYTVSCECTVFPCLSPCKLQSGTHCLWTDQQLQSEK 180

Qy 181 GFOSRHLACLPRREPGLCTWOSLRSQIA 207

Db • 181 GFOSRHLACLPRREPGLCTWOSLRSQIA 207

RESULT 2

US-10-821-234-961

; Sequence 861, Application US/10821234

; GENERAL INFORMATION:

; APPLICANT: Habat, Ivan

; APPLICANT: Stache-Crain, Birgit

; APPLICANT: Andarmani, Susan

; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia

; FILE REFERENCE: 821A

; CURRENT APPLICATION NUMBER: US/10/821, 234

; PRIOR APPLICATION NUMBER: US 60/462, 047

; PRIOR FILING DATE: 2005-04-07

; NUMBER OF SEQ ID NOS: 1704

; SOFTWARE: PR_SEQ_genes Version 1.0

; SEQ ID NO 861

; LENGTH: 254

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-821-234-961

Query Match Best Local Similarity 100.0%; Score 1124; Pred. No. 3e-115; Length 254; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Db 48 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Qy 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 120

Db 48 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 107

Qy 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 120

Db 108 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 167

Qy 121 TCSFVAPWNSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQSEK 180

Db 168 TCSFVAPWNSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQSEK 227

Qy 181 GFOSRHLACLPRREPGLCTWOSLRSQIA 207

Db 228 GFOSRHLACLPRREPGLCTWOSLRSQIA 254

RESULT 3
US-11-094-519A-34

; Sequence 34, Application US/11094519A

; Publication No. US20050281810A1

; GENERAL INFORMATION:

; APPLICANT: BERNSTEIN, Jeanne

; APPLICANT: LEVINE, Zorit

; TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING

; FILE REFERENCE: 2786-0140P

; CURRENT APPLICATION NUMBER: US/11/094, 519A

; PRIOR APPLICATION NUMBER: US/09/695, 293

; PRIOR FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 52

; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 32

; LENGTH: 211

; TYPE: PRT

; ORGANISM: Homo sapiens

US-11-094-519A-32

Query Match Best Local Similarity 94.4%; Score 1050; DB 7; Length 211; Matches 200; Conservative 1; Mismatches 6; Indels 4; Gaps 4;

Qy 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Db 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Qy 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 118

Db 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 120

Qy 119 ITCSFV-APW-NSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQ 176

Db 121 SUTCSFVAPWNSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQ 180

Qy 177 GSEKGFOSRHLACLPRREPGLCTWOSLRSQIA 207

Db 181 GSEKGFOSRHLACLPRREPGLCTWOSLRSQIA 211

US-11-094-519A-34

Query Match 94.1%; Score 1058; DB 7; Length 197;

Best Local Similarity 95.2%; Pred. No. 3.6e-108; Matches 197; Conservative 0; Mismatches

Matches 197; Indels 10; Gaps 1;

Qy 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Db 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 110

Db 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Qy 121 TCSFVAPWNSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQ 120

Db 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 170

Db 111 TCSFVAPWNSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQ 170

Qy 181 GFOSRHLACLPRREPGLCTWOSLRSQIA 207

Db 171 GFOSRHLACLPRREPGLCTWOSLRSQIA 197

RESULT 4

US-11-094-519A-32

; Sequence 32, Application US/11094519A

; GENERAL INFORMATION:

; APPLICANT: BERNSTEIN, Jeanne

; TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING

; FILE REFERENCE: 2786-0140P

; CURRENT APPLICATION NUMBER: US/11/094, 519A

; PRIOR APPLICATION NUMBER: US/09/695, 293

; PRIOR FILING DATE: 1999-10-25

; NUMBER OF SEQ ID NOS: 52

; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 32

; LENGTH: 211

; TYPE: PRT

; ORGANISM: Homo sapiens

US-11-094-519A-32

Query Match Best Local Similarity 94.8%; Score 1050; DB 7; Length 211; Matches 200; Conservative 1; Mismatches 6; Indels 4; Gaps 4;

Qy 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Db 1 MAPPEPLASGILLWILMIAPIRSPACTCVPHPROTAFCNSDLVIRAKEVGTPBEVNQNTLYQR 60

Qy 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 118

Db 61 YEIKMTKMYKGFOQALGDAADIRFVYTPAMESVCGYFRSHRNSEEFLLAGKLQDGLHIT 120

Qy 119 ITCSFV-APW-NSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQ 176

Db 121 SUTCSFVAPWNSLSLAQRGFTKTYTVGCBCTVPPCLSPCKLQSGTHCLWTDQQLQ 180

Qy 177 GSEKGFOSRHLACLPRREPGLCTWOSLRSQIA 207

Db 181 GSEKGFOSRHLACLPRREPGLCTWOSLRSQIA 211

RESULT 5

US-11-094-519A-30

; Sequence 30, Application US/11094519A

; GENERAL INFORMATION:

; APPLICANT: BERNSTEIN, Jeanne

APPLICANT: LEVINE, Zuriit
 TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING
 FILE REFERENCE: 2786-0140P
 CURRENT APPLICATION NUMBER: US/11/094,519A
 CURRENT FILING DATE: 2005-03-31
 PRIOR APPLICATION NUMBER: US/09/695,293
 PRIOR FILING DATE: 2000-10-25
 PRIORITY NUMBER: IL 132558
 NUMBER OF SEQ ID NOS: 52
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 30
 LENGTH: 164
 TYPE: PRT
 ORGANISM: Homo sapiens
 ;US-11-094-519A-30

Query Match 74.5%; Score 837; DB 7; Length 164;
 Best Local Similarity 100.0%; Pred. No. 4.2e-84; Mismatches 0; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPFPLASGILLMLIAPSRACTCVPHPQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60
 Db 1 MAPFPLASGILLMLIAPSRACTCVPHPQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60
 QY 61 YEIKMVKMYKGFOALGDAADIRFVYTPTAMMSVCGYFRSHNRSEELIAGKLQDGHLHT 120
 Db 61 YEIKMVKMYKGFOALGDAADIRFVYTPTAMMSVCGYFRSHNRSEELIAGKLQDGHLHT 120
 QY 121 TCSFVAPWNNSLSLAQRGFTKTYTVCECTVFPC 155
 Db 121 TCSFVAPWNNSLSLAQRGFTKTYTVCECTVFPC 155

RESULT 6
 Sequence 33, Application US/11094519A
 Publication No. US20050281810A1
 GENERAL INFORMATION:
 APPLICANT: BERNSTEIN, Jeanne
 APPLICANT: LEVINE, Zuriit
 TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING
 FILE REFERENCE: 2786-0140P
 CURRENT APPLICATION NUMBER: US/11/094,519A
 CURRENT FILING DATE: 2005-03-31
 PRIOR APPLICATION NUMBER: US/09/695,293
 PRIOR FILING DATE: 2000-10-25
 PRIOR APPLICATION NUMBER: IL 132558
 PRIOR FILING DATE: 1999-10-25
 NUMBER OF SEQ ID NOS: 52
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 33
 LENGTH: 160
 TYPE: PRT
 ORGANISM: Homo sapiens
 ;US-11-094-519A-33

Query Match 73.9%; Score 830.5; DB 7; Length 160;
 Best Local Similarity 77.3%; Pred. No. 2.1e-83; Mismatches 0; Indels 0; Gaps 1;
 Matches 160; Conservative 0; Mismatches 0; Indels 47; Gaps 1;

QY 1 MAPFPLASGILLMLIAPSRACTCVPHPQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60
 Db 1 MAPFPLASGILLMLIAPSRACTCVPHPQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60
 QY 61 YEIKMVKMYKGFOALGDAADIRFVYTPTAMMSVCGYFRSHNRSEELIAGKLQDGHLHT 120
 Db 61 YEIKMVKMYKGFOALGDAADIRFVYTPTAMMSVCGYFRSHNRSEELIAGKLQDGHLHT 120
 QY 121 TCSFVAPWNNSLSLAQRGFTKTYTVCECTVFPC 180
 Db 109 LSIPCKLQSGHCLWDLQLOGSEK 133

RESULT 7
 Sequence 52, Application US/11094519A
 Publication No. US20050281810A1
 GENERAL INFORMATION:
 APPLICANT: BERNSTEIN, Jeanne
 APPLICANT: LEVINE, Zuriit
 TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING
 CURRENT APPLICATION NUMBER: US/11/094,519A
 CURRENT FILING DATE: 2005-03-31
 PRIOR APPLICATION NUMBER: US/09/695,293
 PRIOR FILING DATE: 2000-10-25
 PRIORITY NUMBER: IL 132558
 NUMBER OF SEQ ID NOS: 52
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 52
 LENGTH: 143
 TYPE: PRT
 ORGANISM: Homo sapiens
 ;US-11-094-519A-52

Query Match 69.6%; Score 782; DB 7; Length 143;
 Best Local Similarity 100.0%; Pred. No. 3.7e-78; Mismatches 0; Indels 0; Gaps 0;
 Matches 143; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 65 MTKMYKGFOALGDAADIRFVYTPTAMMSVCGYFRSHNRSEELIAGKLQDGHLHTCSP 124
 Db 1 MTKMYKGFOALGDAADIRFVYTPTAMMSVCGYFRSHNRSEELIAGKLQDGHLHTCSP 60
 QY 125 VAPWNNSLSLAQRGFTKTYTVCECTVFPC 184
 Db 61 VAPWNNSLSLAQRGFTKTYTVCECTVFPC 120
 QY 185 RHLACIIPREPGLCTWOSLRSQIA 207
 Db 121 RHLACIIPREPGLCTWOSLRSQIA 143

RESULT 8
 Sequence 31, Application US/11094519A
 Publication No. US20050281810A1
 GENERAL INFORMATION:
 APPLICANT: BERNSTEIN, Jeanne
 APPLICANT: LEVINE, Zuriit
 TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING
 FILE REFERENCE: 2786-0140P
 CURRENT APPLICATION NUMBER: US/11/094,519A
 CURRENT FILING DATE: 2005-03-31
 PRIOR APPLICATION NUMBER: US/09/695,293
 PRIOR FILING DATE: 2000-10-25
 PRIOR FILING DATE: 1999-10-25
 NUMBER OF SEQ ID NOS: 52
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO: 31
 LENGTH: 123
 TYPE: PRT
 ORGANISM: Homo sapiens
 ;US-11-094-519A-31

Query Match 53.5%; Score 601; DB 7; length 123;
 Best Local Similarity 100.0%; Pred. No. 1.9e-58; Mismatches 0; Indels 0; Gaps 0;
 Matches 113; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPFPLASGILLMLIAPSRACTCVPHPQTAFCNSDLVIRAKFGTPEVNQNTLYQR 60

RESULT 9
US-11-044-640-13
; Sequence 13; Application US/11044640
; Publication No. US2006000296911
; GENERAL INFORMATION:
; APPLICANT: Kyriakides, Themis
; TITLE OF INVENTION: METHODS FOR REDUCING THE FOREIGN BODY REACTION
; FILE REFERENCE: UMTL1A4322
; CURRENT APPLICATION NUMBER: US/11/044 640
; CURRENT FILING DATE: 2005-01-26
; PRIOR APPLICATION NUMBER: US 60/539,821
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Homo Sapiens
; US-11-044-640-13

Query Match 51.3%; Score 577; DB 7; Length 108;
Best Local Similarity 100.0%; Pred. No. 6 9e-56;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLMLIAPSRACTCVPHPHQTAFCNSDLVIRAKVGTPENQNTLYQR 60
Db 1 MAPPEPLASGILLMLIAPSRACTCVPHPHQTAFCNSDLVIRAKVGTPENQNTLYQR 60

RESULT 10
US-11-094-519A-49
; Sequence 49; Application US/11094519A
; Publication No. US20050281810A1
; GENERAL INFORMATION:
; APPLICANT: BERNSTEIN, Jeanne
; APPLICANT: LEVINE, Zurit
; TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING
; FILE REFERENCE: 2786-0140P
; CURRENT APPLICATION NUMBER: US/11/094,519A
; CURRENT FILING DATE: 2005-03-31
; PRIOR APPLICATION NUMBER: US/09/695,293
; PRIOR FILING DATE: 1999-10-25
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 51
; LENGTH: 115
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-094-519A-51

Query Match 46.8%; Score 526; DB 7; Length 115;
Best Local Similarity 100.0%; Pred. No. 2.8e-50;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLMLIAPSRACTCVPHPHQTAFCNSDLVIRAKVGTPENQNTLYQR 60
Db 1 MAPPEPLASGILLMLIAPSRACTCVPHPHQTAFCNSDLVIRAKVGTPENQNTLYQR 60

RESULT 11
US-11-094-519A-51
; Sequence 51; Application US/11094519A
; Publication No. US20050281810A1
; GENERAL INFORMATION:
; APPLICANT: BERNSTEIN, Jeanne
; APPLICANT: LEVINE, Zurit
; TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING
; FILE REFERENCE: 2786-0140P
; CURRENT APPLICATION NUMBER: US/11/094,519A
; CURRENT FILING DATE: 2005-03-31
; PRIOR APPLICATION NUMBER: US/09/695,293
; PRIOR FILING DATE: 1999-10-25
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 51
; LENGTH: 115
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-094-519A-51

Query Match 46.8%; Score 526; DB 7; Length 115;
Best Local Similarity 100.0%; Pred. No. 2.8e-50;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLMLIAPSRACTCVPHPHQTAFCNSDLVIRAKVGTPENQNTLYQR 60
Db 1 MAPPEPLASGILLMLIAPSRACTCVPHPHQTAFCNSDLVIRAKVGTPENQNTLYQR 60

RESULT 12
US-10-821-234-1467
; Sequence 1467; Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andarmani, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pt-SEQ_Genes Version 1.0
; SEQ ID NO 1467
; LENGTH: 211
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-821-234-1467

Query Match 34.7%; Score 389.5; DB 6; Length 211;

Best Local Similarity 39.6%; Pred. No. 56-35; Mismatches 66; Indels 15; Gaps 7; Matches 78; Conservative 38; Mismatches 66; Indels 15; Gaps 7;

Qy 10 GILLUL-WLIAPI--SRACTCVPHPOTAPCNDSLIVRAKFVGTPEVNQ---TTLVQRYE 62
Db 6 GLIVLGAGSWLGDWGAETSPSHQDPAFCNSDIVRAKFVKGKJKEGRGTY--YT 63
Qy 63 IKMTRKMYKGFOALGDAADIRFVTPAMESVCYFHRSHNRSEFLIGKLQDGMLHITC 122
Db 64 IKQMTRKMYTRGFTKM--PHVOIHTEASESLCGL--KLEVKVQYLLTGRVIDGKMYTGLC 118
Qy 123 SFVAPWNLSLAQRGGFTKTYVGCBCTVPLCLSPCKLQSGTHCLWTDLQSGEKG 182
Db 119 NFWERMDQTLTSORKGNYRYHLGC-NCKIKSCYYLPCFVTSKNECIWTDLMSNFGYPGY 177
Qy 183 OSRHLACLPRPGLCTW 199
Db 178 OSKHYACIRKQKGYCSW 194

RESULT 13

US-11-094-519A-50

; Sequence 50, Application US/11094519A

; GENERAL INFORMATION:

; APPLICANT: BERNSTEIN, Jeanne

; TITLE OF INVENTION: VARIANTS OF ALTERNATIVE SPLICING

; FILE REFERENCE: 2786-0140P

; CURRENT APPLICATION NUMBER: US/11/094-519A

; CURRENT FILING DATE: 2005-03-31

; PRIOR APPLICATION NUMBER: US/09/695, 293

; PRIOR FILING DATE: 2000-10-25

; NUMBER OF SEQ ID NOS: 52

; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 50

; LENGTH: 82

; TYPE: PRT

; ORGANISM: Homo sapiens

US-11-094-519A-50

Query Match 20.6%; Score 232; DB 7; Length 82;
Best Local Similarity 95.6%; Pred. No. 2.6e-18; Mismatches 43; Indels 0; Gaps 0; Matches 43; Conservative 2; MisMatches 0; Del 0; Insert 0; Length: 82;

Qy 67 KMYKQFOALGDAADIRFVTPAMESVCYFHRSHNRSEFLIAGK 111
Db 13 QMVKGFOALGDAADIRFVTPAMESVCYFHRSHNRSEFLIAGK 111

RESULT 14

US-10-877-346-43

; Sequence 43, Application US/10877346

; Publication No. US20060014153A1

; GENERAL INFORMATION:

; APPLICANT: Gelach, Valerie L

; APPLICANT: Macbougal, John R

; APPLICANT: Smithson, Gleenda

; APPLICANT: Millet, Isabelle

; APPLICANT: Stone, David

; APPLICANT: Gunther, Erik

; APPLICANT: Ellerman, Karen

; APPLICANT: Grobse, William M

; APPLICANT: Alsobrook II, John P

; APPLICANT: Lepley, Denise M

; APPLICANT: Burgess, Catherine E

; APPLICANT: Padigaru, Muralidhara

; APPLICANT: Kekuda, Ramesh

; APPLICANT: Spirek, Kimberly A

; APPLICANT: Leach, Martin D

; APPLICANT: Shinketsu, Richard A

US-10-877-346-43

Query Match 8.1%; Score 90.5; DB 6; Length 1963;
Best Local Similarity 22.4%; Pred. No. 0.39; Mismatches 97; Indels 43; Gaps 7; Matches 46; Conservative 19; Mismatches 97; Indels 43; Gaps 7;

Qy 10 GILLULWLIASRACHTCVPHPOTAPCNDSLIVRAKFVGTPEVNQ---TTLVQRYEIKTK-- 67
Db 448 GNLELNWLGLKDVOQCTKAPVFPIDDNFCGLD--INOPLGSTPVEGLITYTSRDRMTSVA 505
Qy 68 --MYKQFOAL---GDAADIRFVTPAMESVCYFHRSHNRSEFLIGKLQDGMLHITC 119
Db 506 SYVYNGSYSVVFVGTKEGKLLKIRADGPP-----HGSVQYEMVSVLKQSPIL 552
Qy 120 TTCSFVAPWNLSLAQRGGFTKTYVGCBCTVPLCLSPCKLQSGTHCLWTDLQSG 178
Db 553 RDMAKSIDQXLYVMSRQTRVPSCEVYTTGCLS----SGDPKGWC----- 600
Qy 179 EKGFSRHLACLPRPGLCTWOSLR 203
Db 601 -----AUNNCSSRRDKCQQAQWEPRN 620

RESULT 15

US-11-098-686-10425

; Sequence 10425, Application US/11098686

; Publication No. US20060024696A1

; GENERAL INFORMATION:

; APPLICANT: Kapur, Vivek and Gebhart, Connie J

; TITLE OF INVENTION: NUCLEIC ACID AND POLYPEPTIDE SEQUENCES
TITLE OF INVENTION: FROM LAWSONIA INTRACELLULARIS AND METHODS OF USING
FILE REFERENCE: 09531-12801
CURRENT APPLICATION NUMBER: US/11/098, 686
CURRENT FILING DATE: 2005-04-04

; PRIOR APPLICATION NUMBER: PCT/US03/31318

; PRIOR FILING DATE: 2003-10-01

; PRIOR APPLICATION NUMBER: US 60/416, 395

; NUMBER OF SEQ ID NOS: 11433

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 10425

; LENGTH: 304

; TYPE: PRT
; ORGANISM: *Lawsonia intracellularis*
US-11-098-686-10425

Query	Match	7.2%	Score	80.5	i	DB	7;	Length	304;			
Matches	49;	Conservative	24.0%	Pred.	No.	0.49;	Mismatches	67;	Indels	67;	Gaps	11;
Qy	2 APFPEPLASGLILMLWLIAPSRACTCVPHPHOPAFC-	NSDLV	I--RAKFVGTPEVNO	-TT	56							
Db	24 APFRPVPAGKL-----PPVSC--PPVPGLFQCSRNGSAVARRRQHVASSGGKKKGGK											73
Qy	57 LYORVEIKMTRKMYKGFOALGDAADIREVY--TPAMESVCCYFHRSNRBREFLAGKL											112
Db	74 SYER-----DIKVWIPGTCGEPSTRTVGSCERKAEYQSYPLVGRI											114
Qy	113 QDGLLHITTCFSVAPWNLSLAQRRGFTKTYTVGCEECTVFVFCCLSIPCKLQSGTHCLWT											172
Db	115 GQ-LIHAT-----GLAGRHK-----PCROJIRTLFQKGPGSAKLP											147
Qy	173 QLIQGSBKGFGOSRHLACLPRERGQ											196
Db	148 QTULG--RGRKLUHIPCULFRSGL											169

Search completed: April 10, 2006, 18:13:21
Job time : 8.51485 secs

Copyright (c) 1993 - 2006 Biocceleration Ltd.

GenCore version 5.1.7

OM protein - protein search, using sw model
Run on: April 10, 2006, 17:55:34 ; Search time 70.1386 Seconds
(without alignments)
2082.225 Million cell updates/sec

Title: US-10-734-564-100
Perfect score: 1124
Sequence: 1 MAPFEPFLASGLLILMLWLTAP.....ACLPREPGQLCTMOSLRSOIA 207

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched:

2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt 05.80:
1: uniprot_sprot:
2: uniprot_trembl:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1124	100.0	207_1	TIMPL_HUMAN
2	1124	100.0	207_2	Q6FGX5_HUMAN
3	1124	100.0	207_2	Q5RC60_PONPY
4	1117	99.4	207_1	TIMPL_PARPY
5	1104	98.2	207_1	TIMPL_MACMU
6	1000.5	89.0	188_2	Q5P821_HUMAN
7	99.5	88.5	207_1	TIMPL_BOVIN
8	96.7	86.0	207_1	TIMPL_PIG
9	96.1	85.5	207_1	TIMPL_SHEEP
10	92.6	82.4	207_1	TIMPL_HORSE
11	92.5	82.3	207_2	Q5ENG6_RABBIT
12	91.5	81.1	169_2	Q926Q2_HUMAN
13	91.1	81.0	203_2	Q5ENG7_RABBIT
14	90.3	80.3	207_1	TIMPL_CANFA
15	90.2	80.3	206_1	TIMPL_RABIT
16	83.7	74.5	205_1	TIMPL_MOUSE
17	81.9	72.8	217_1	TIMPL_RAT
18	81.8	72.8	217_2	Q53YM7_RAT
19	78.2	69.6	143_2	Q5H9A7_HUMAN
20	63.3	56.3	137_2	Q5M212_SHEEP
21	52.3	52.3	136_2	Q5H9B4_HUMAN
22	54.3	48.3	164_2	Q5H9A8_HUMAN
23	51.5	45.8	145_2	Q51ZP7_RAT
24	44.9	11.4	2	Q6QLW9_CANFA
25	44.6	39.7	108_2	Q6X809_FELCA
26	44.4	30.5	2	Q5H9B4_HUMAN
27	42.0	37.4	220_1	TIMP2_MOUSE
28	42.0	37.4	220_1	TIMP2_RAT
29	42.0	37.4	220_2	Q546JF_RAT
30	42.0	37.4	220_2	Q6PI17 MOUSE
31	41.6	37.1	220_2	Q8BSJ3_MOUSE

Alignments

32	415.5	37.0	220_1	TIMP2_HUMAN	P16035_homo_sapien
33	407.5	36.3	220_1	TIMP2_CANFA	O9tty1_canis_famil
34	406	36.1	222_2	Q5FVZ1_XENTR	O5fvz1_xenopus_tro
35	406	36.1	222_2	Q66IWO_XENLA	O66iw0_xenopus_lae
36	401.5	35.7	220_1	TIMP2_CAVPO	O9WUC6_cavia_porce
37	401	35.7	220_1	TIMP2_CHICK	O9w146_gallus_gall
38	398.5	35.5	214_1	TIMP3_SCYTO	O9w6b4_scyllorhinu
39	398	35.4	220_2	Q54HWB_ONCMY	O64hw8_oncorhynchu
40	397	35.3	220_2	Q4WTG6_ORYLA	O4wtg6_orzias_lat
41	397	35.3	220_2	Q4JF85_FUGRU	O4jf85_fugu_rubrip
42	386.5	35.3	100_2	Q5GXA9_MOUSE	O6gxa9_pagrus_majus
43	395	35.1	220_1	Q5ORR5_PAGMA	P16368_bos_taurus
44	394.5	35.1	220_1	TIMP2_BOVIN	P16368_bos_taurus
45	393	35.0	220_2	Q5GJMI_XENLA	Q6gjmi_xenopus_lae

- RT "Characterization of three abundant mRNAs from human ovarian granulosa
RT cells"; Cell Biol. 9:479-485(1990).
- RN [6]
- RP NUCLEOTIDE SEQUENCE.
- RX MEDLINE=94123576; PubMed=7507419;
- RA Opbroek A., Kenney M.C., Brown D.;
"Characterization of a human corneal metalloproteinase inhibitor
(TIMP-1)."; Curr. Eye Res. 12:877-883(1993).
- RN [7]
- RP NUCLEOTIDE SEQUENCE [LARGE SCALE mRNA].
- AC TISSUE=Cervix;
- RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
- RA Strausberg R.D., Feingold E.A., Grouse L.H., Derge J.G., Shemesh C.M., Schuler G.D.,
Klaunser R.D., Collins F.S., Wagner L., Shemesh C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J.J., Heile F.,
Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schatz T.E.,
Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulahay S.J.,
Bosak S.A., McEwan P.J., McKerman K.J., Malek J.A., Gunnarsson P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Halyk S.W.,
Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalius D.E.,
Schnarch A., Schein J.E., Jones S.J.M., Marra M.A.;
"Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
- RN [8]
- RP NUCLEOTIDE SEQUENCE OF 42-207.
- RN Matsuda T., Kohno K., Kuwano M.;
Submitted (JUL-1992) to the EMBL/GenBank/DBJ databases.
- RN [9]
- RP NUCLEOTIDE SEQUENCE OF 1-40.
- RN Hardcastle A.J.; Submitted (SEP-1995) to the EMBL/GenBank/DBJ databases.
- RN [10]
- RP DISULFIDE BONDS AND PARTIAL PROTEIN SEQUENCE.
- RX MEDLINE=9303199; PubMed=2163605;
- RA Williamson R.A., Marton F.A.O., Angal S., Koklitis P., Panico M.,
Morris H.R., Carne A.F., Smith B.J., Harris T.J.R., Freedman R.B.;
"Disulphide bond assignment in human tissue inhibitor of
metalloproteinases (TIMP)", Biochem. J. 268:267-274(1990).
- RN [11]
- PROTEIN SEQUENCE OF 24-38.
- RN TISSUE=Synovial fluid;
- RX MEDLINE=92111776; PubMed=1730286; DOI=10.1016/0014-5793(92)80393-U;
- RA Osthuizen A., Knauper V., Oberhoff R., Reinke H., Tschesche H.;
"Isolation and characterization of tissue inhibitors of
metalloproteinases (TIMP-1 and TIMP-2) from human rheumatoid synovial
fluid"; FEBS Lett. 296:16-20(1992).
- RN [12]
- PROTEIN SEQUENCE OF 24-52.
- RX MEDLINE=91355647; PubMed=1653055; DOI=10.1016/1043-4666(91)90021-5;
- RA van Ranst M., Norgia K., Masure P., Proost P., Vandekerckhove F.,
Auwerx J., van Damme J., Opdenakker G.;
"The cytokine protease connection: identification of a 96-kD THP-1
gelatinase and regulation by interleukin-1 and cytokine inducers.",
Cytokine 3:231-239(1991).
- RN [13]
- PROTEIN SEQUENCE OF 24-38.
- RX PubMed=15340161; DOI=10.1101/pb.04682504;
- RA Zhang Z., Henzel W.J.;
"Signal peptide prediction based on analysis of experimentally
verified cleavage sites.", Protein Sci. 13:2819-2824(2004).
- RN [14]
- RP MUTAGENESIS.
- RX MEDLINE=93041700; PubMed=1420137;
- RA O'Shea M., Willenbrock F., Williamson R.A., Cockett M.I.,
Freeman R.B., Reynolds J.J.P., Docherty A.J.P., Murphy G.;
"Site-directed mutations that alter the inhibitory activity of the
tissue inhibitor of metalloproteinases-1: importance of the N-terminal
region between cysteine 3 and cysteine 13.," Biochemistry 31:10146-10152(1992).
- RN [15]
- RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEX WITH MMP-3.
- RX MEDLINE=9743330; PubMed=9288970; DOI=10.1038/37995;
- RA Gomis-Ruth F.X., Maskos K., Betz M., Berger A., Huber R.,
Suzuki K., Yoshida N., Nagase H., Brew K., Bourne G.P.,
Bartunki H., Bode W.,
"Mechanism of inhibition of the human matrix metalloproteinase
stromelysin-1 by TIMP-1," Nature 389:77-81(1997).
- RN [16]
- RP STRUCTURE BY NMR OF 24-149.
- RX MEDLINE=20090931; PubMed=10623524; DOI=10.1006/jmbi.1999.3362;
- RA Wu B., Arumugam S., Gao G., Lee G.I., Semenchenko V., Huang W.,
Raue K., Van Doren S.R.;
"NMR structure of tissue inhibitor of metalloproteinases-1 implicates
localized induced fit in recognition of matrix metalloproteinases.,"
J. Mol. Biol. 295:277-287(2000).
- CC -I FUNCTION: Complexes with metalloproteinases (such as collagenases)
and irreversibly inactivates them. Also mediates erythropoiesis in
vitro; but, unlike IL-3, it is species-specific, stimulating the
growth and differentiation of only human and murine erythroid
progenitors. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, MMP-10, MMP-11, MMP-12, MMP-13 and MMP-16. Does not act on
MMP-14.
- CC -I SUBCELLULAR LOCATION: Secreted.
- CC -I PTM: The activity of TIMP1 is dependent on the presence of
disulfide bonds.
- CC -I SIMILARITY: Belongs to the TIMP family.
- CC -I SIMILARITY: Contains 1 NTR domain.
- CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss-Prot Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
- DR EMBL; X03124; CRX26902.1; -; mRNA.
- DR EMBL; M12670; AA52436.1; -; mRNA.
- DR EMBL; X02598; CRX26443.1; -; mRNA.
- DR EMBL; M59906; AA6323.1; -; mRNA.
- DR EMBL; S68282; ADI14099.1; -; mRNA.
- DR EMBL; BC00866; AAH0866.1; -; mRNA.
- DR EMBL; D11139; BAA01913.1; -; Genomic DNA.
- DR EMBL; L47361; AAJ5558.1; -; Genomic DNA.
- DR EMBL; A10416; CAA00598.1; -; Unassigned RNA.
- DR PIR; A93372; ZYNUEP.
- DR PDB; 1LQH; Model: A=1-207.
- DR PDB; 1LQH; Model: B=24-149.
- DR PDB; 1009; NMR; B=24-143.
- DR PDB; 1UEA; X-ray; B=24-207.
- DR GlycosubteB; P01033; -.
- DR Ensembl; ENSG00000102265; Homo sapiens.
- DR HGNC; HGNC:11820; TIMP1.
- DR H-InvrB; HIX0016764; -.
- DR MTM; 305370; -.
- DR GO; GO:0005376; C:extracellular region; NAS.
- DR GO; GO:0005191; F:metalloendopeptidase inhibitor activity; IDA.
- DR GO; GO:0051045; P:negative regulation of membrane protein ect...; IDA.
- DR GO; GO:0008284; P:positive regulation of cell proliferation; TAS.
- DR InterPro; IPR001134; Netrin C.
- DR InterPro; IPR001820; Prot_inh_TMP.
- DR PANTHER; PTHR1044; Prot_Inh_TMP; 1.
- DR Pfam; PF00965; TIMP; 1.

DR PROSITE; PS50189; NTR; 1.
 DR PROSITE; PS00288; TIMP; 1.

Query Match 100.0%; Score 1124; DB 1; Length 207;
 Best Local Similarity 100.0%; Pred. No. 5.5e-104;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPFEPPLASGILLWILIAPIRSRACTCVPHPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60
 Db 1 MAPFEPPLASGILLWILIAPIRSRACTCVPHPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60

QY 61 YEIKMTKMYKGFOALGDAADIRFVYTIPAMESVCGYFRSHRNSEELIAGKLOGLHIT 120
 Db 61 YEIKMTKMYKGFOALGDAADIRFVYTIPAMESVCGYFRSHRNSEELIAGKLOGLHIT 120

QY 121 TCSFVAPWNSTISLAQORGFTKTYTGCBECCVFPCLSIPCKLQSGTHCLWTDLQLOSEK 180
 Db 121 TCSFVAPWNSTISLAQORGFTKTYTGCBECCVFPCLSIPCKLQSGTHCLWTDLQLOSEK 180

QY 181 GFOSRHLACLPREPGLCTWOSLRSQLA 207
 Db 181 GFOSRHLACLPREPGLCTWOSLRSQLA 207

RESULT 2
 QFGX5 HUMAN PRELIMINARY; PRT; 207 AA.
 ID QFGX5_HUMAN PRELIMINARY; PRT; 207 AA.
 AC QFGX5_HUMAN PRELIMINARY; PRT; 207 AA.
 DT 05-JUL-2004 (T+EMBLrel. 27, Created)
 DT 13-SEP-2005 (T+EMBLrel. 31, Last sequence update)
 DE TIMPL protein (Tissue inhibitor of metalloproteinase 1) (Erythroid
 DE Potentiating activity; collagenase inhibitor).
 GN Name=TIMPL; ORFName=RPI-23051.3-001;
 OS Homo sapiens (Human).
 OC Bukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Buteraria; Euarchontoglires; Primates; Catarrhini; Homidae;
 OC Homo.
 OC OX NCBI_TAXID=9606;
 RN [1]

NUCLEOTIDE SEQUENCE.
 RA Neubert P., Kettang K., Schatten R., Shen B., Henze S., Mar W.,
 RA Korn B., Zuo D., Hu Y., LaBaer J.;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 RN [2]

NUCLEOTIDE SEQUENCE.
 RA Ebert L., Schick M., Neubert P., Schatzen R., Henze S., Korn B.;
 RT "Cloning of human full open reading frames in Gateway(TM) System entry
 vector (PDONR201)."
 RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
 RN [3]

NUCLEOTIDE SEQUENCE.
 RA WRAY P.;
 RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; CR41982; CAD36779_1; -; mRNA.
 DR EMBL; CR41765_1; -; mRNA.
 DR EMBL; 284466; CA14465.1; -; Genomic_DNA.
 DR SMR; QFGX5; 24-204.
 GO; GO:005578; C:extracellular matrix (sensu Metazoa); IEA.
 DR SMR; QFGX5; 24-204.
 DR GO; GO:0008191; F:metalloendopeptidase inhibitor activity; IEA.
 DR InterPro; IPR01134; Netrin_C.
 DR InterPro; IPR01820; Prot_inh_TIMP.
 DR PANIER; PTHR11844; Prot_inh_TIMP; 1.
 DR PFam; PR00965; TIMP; 1.
 DR SMART; SM00205; NTR; 1.
 DR PROSITE; PS50189; NTR; 1.
 DR PROSITE; PS00288; TIMP; 1.
 DR PROSITE; PS00288; TIMP; 1.

RESULT 3
 QSRC60 PONY PRELIMINARY; PRT; 207 AA.
 ID QSRC60_PONY PRELIMINARY; PRT; 207 AA.
 AC QSRC60_PONY PRELIMINARY; PRT; 207 AA.
 DT 01-FEB-2005 (T+EMBLrel. 29, Last sequence update)
 DT 01-FEB-2005 (T+EMBLrel. 29, Last annotation update)
 DR Hypothetical protein DK2PZ46B#0912;
 DR Pongo pygmaeus (Orangutan).
 OS Bukaryota; Metazoa; Chordata; Vertebrata; Buteraria; Euarchontoglires; Primates; Catarrhini; Homidae;
 OC Mammalia; Buteraria; Euarchontoglires; Primates; Catarrhini; Homidae;
 OC Pongo.
 RN [1] -
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Heart;
 RG The German CDNA Consortium;
 RA Pouska A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
 RA Mewes H.W., Weil B., Amid C., Osanger A., Bobo G., Han M., Wiemann S.;
 RL Submitted (NOV-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; CR858421; CARH0650_1; -; mRNA.
 DR SMR; QSRC60; 24-204.
 DR GO; GO:0008191; F:metalloendopeptidase inhibitor activity; IEA.
 DR InterPro; IPR001134; Netrin_C.
 DR InterPro; IPR001820; Prot_inh_TIMP.
 DR PANIER; PTHR11844; Prot_inh_TIMP; 1.
 DR PFam; PR00965; TIMP; 1.
 DR SMART; SM00205; NTR; 1.
 DR PROSITE; PS50189; NTR; 1.
 DR PROSITE; PS00288; TIMP; 1.
 DR PROSITE; PS00288; TIMP; 1.

SEQUENCE 207 AA; 23171 MW; 5AB4F90FFAB2CDC CRC64;

Query Match 100.0%; Score 1124; DB 2; Length 207;
 Best Local Similarity 100.0%; Pred. No. 5.5e-104;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPFEPPLASGILLWILIAPIRSRACTCVPHPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60
 Db 1 MAPFEPPLASGILLWILIAPIRSRACTCVPHPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60

QY 61 YEIKMTKMYKGFOALGDAADIRFVYTIPAMESVCGYFRSHRNSEELIAGKLOGLHIT 120
 Db 61 YEIKMTKMYKGFOALGDAADIRFVYTIPAMESVCGYFRSHRNSEELIAGKLOGLHIT 120

QY 121 TCSFVAPWNSTISLAQORGFTKTYTGCBECCVFPCLSIPCKLQSGTHCLWTDLQLOSEK 180
 Db 121 TCSFVAPWNSTISLAQORGFTKTYTGCBECCVFPCLSIPCKLQSGTHCLWTDLQLOSEK 180

QY 181 GFOSRHLACLPREPGLCTWOSLRSQLA 207
 Db 181 GFOSRHLACLPREPGLCTWOSLRSQLA 207

Query Match 100.0%; Score 1124; DB 2; Length 207;
 Best Local Similarity 100.0%; Pred. No. 5.5e-104;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 6 HUMAN
 ID Q58P21_HUMAN PRELIMINARY; PRT; 188 AA.
 AC Q58P21;
 DT 10-MAY-2005 (T-EMBLrel. 30; Last sequence update)
 DT 10-MAY-2005 (T-EMBLrel. 30; Last annotation update)
 DE Tissue inhibitor of metalloproteinase 1 (Fragment).
 Name=TIMPI;
 Homo sapiens (Human).
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
 Mammalia; Butheria; Buarchontoglires; Primates; Catarrini; Homidae;
 Homo.
 NCBI_TaxID=9606;
 RN [1] NUCLEOTIDE SEQUENCE.
 RX MEDLINE=22383613; PubMed=12496489;
 RA Wang M., Hu Y., Shima I., Stearns M.E.;
 RT "IL-10/IL-10 receptor signaling regulates TIMP-1 expression in primary
 human prostate tumor lines";
 RL Cancer Biol. Ther. 1:556-563 (2002).
 RN [2] NUCLEOTIDE SEQUENCE.
 RX MEDLINE=98451715; PubMed=9778693;
 RA Wang M., Hu Y., Shima I., Stearns M.E.;
 RT "Identification of positive and negative regulator elements for the
 tissue inhibitor of metalloproteinase 1 gene.";
 RL Oncol. Res. 10:219-233 (1998).
 RN [3] NUCLEOTIDE SEQUENCE.
 RA Wang M., Hu Y., Stearns M.E.;
 RT Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
 DR EMBI; AY32824; AAX47478; 1; -; Genomic_DNA.
 DR SMR; Q58P21; 24-187.
 DR GO: GO:005578; C: extracellular matrix (sensu Metazoa); IEA.
 DR GO: GO:00819; R: metalloendopeptidase inhibitor activity; IEA.
 DR InterPro; IPR001134; Netrin_C.
 DR InterPro; IPR001820; Prot_inh_TIMP.
 DR Pfam; PF00965; TIMP; 1.
 DR SMART; SM00206; NTR; 1.
 PROSITE; PS50189; NTR; 1.
 DR PROSITE; PS00288; TIMP; 1.
 DR NON_TER; 188.
 SQ SEQUENCE 188 AA; 20197 MW; DCD275A33ADB6AC7 CRC64;
 Query Match 89.0%; Score 1000.5; DB 2; Length 188;
 Best local Similarity 97.9%; Pred. No. 1.1e-91;
 Matches 185; Conservative 1; Mismatches 0; Indels 3; Gaps 1;
 OQ 1 MAPPEPLASGLILLMLIATSRARCTCUPPHROTAFCNSDLMTRAKVGTPEVNOTTYLQR 60
 1 MAPPEPLASGLILLMLIATSRARCTCUPPHROTAFCNSDLMTRAKVGTPEVNOTTYLQR 60
 Db 61 YEIKMVKYKGQALGDAADIRPVTPAMESVGYFRSHRSRSEELIAGKLDGLHIT 120
 QY 121 TCSFVAAPNSLSLAQRGFTKTYTVGCBECTVPPCLISIPCKLQSGTHCLWTDLQSEK 180
 Db 121 TCSFVAAPNSLSLAQRGFTKTYTVGCBECTVPPCLISIPCKLQSGTHCLWTDLQSEK 180
 QY 181 GROSRLAACLPRPEGLCTWQSRLRMA 207
 181 GROSRLAACLPRPEGLCTWQSRLRMA 207

RESULT 7 BOVIN
 ID TIMPL_BOVIN STANDARD; PRT; 207 AA.
 AC P20414; Q58P22; Q9TVB0;
 DT 01-FEB-1991 (Rel. 17; Last sequence update)
 DT 01-FEB-1991 (Rel. 17; Last annotation update)
 DR 13-SEP-2005 (Rel. 48; Last annotation update)
 DE Metalloproteinase inhibitor 1 precursor (TIMP-1) (EG-1)
 DE Name=TIMPL;
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
 Mammalia; Butheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
 Peccora; Bovidae; Bovinae; Bos.
 NCBI_TaxID=9913;
 RN [1] NUCLEOTIDE SEQUENCE [mRNA].
 RP MEDLINE=90365711; PubMed=2393392;
 RA Freudenstein J.J., Wagner S., Luck R.M., Binspanier R., Scheit K.H.;
 RT "mRNA of bovine tissue inhibitor of metalloproteinase: sequence and
 expression in bovine ovarian tissue";
 RL Biochem. Biophys. Res. Commun. 171:250-256 (1990).
 RN [2] NUCLEOTIDE SEQUENCE [mRNA].
 RP MEDLINE=94257757; PubMed=8193264;
 RA Satoh T., Kobayashi K., Yamashita S., Kikuchi M., Sendai Y., Hoshi H.;
 RT "Tissue inhibitor of metalloproteinases (TIMP-1) produced by granulosa
 and oviduct cells enhances in vitro development of bovine embryo.;"
 RL Biol. Reprod. 50:835-844 (1994).
 RN [3] NUCLEOTIDE SEQUENCE [mRNA].
 RP TISSUE=Adrenal cortex;
 RA Reichenstein M., Reich R., Lehoux J.-G., Hanukoglu I.;
 RT "ACTH induces TIMP-1 expression and inhibits collagenase in adrenal
 cortex cells.";
 RL Mol. Cell. Endocrinol. 215:109-114 (2004).
 RN [4] NUCLEOTIDE SEQUENCE [mRNA] OF 25-191.
 RP TISSUE=Skeletal muscle;
 RA Balcerzak D., Querengesser L., Dixon W.T., Baracos V.E.;
 RT "Involvement of fibroblasts and muscle cells in the expression of an
 extracellular proteolytic cascade in bovine skeletal muscle.";
 RL Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
 RN [5] PRELIMINARY PROTEIN SEQUENCE OF 24-69.
 RX MEDLINE=9008934; PubMed=2551903;
 RA de Clerck Y.A., Yeom T.D., Ratznik B.J., Lu H.S., Langley K.B.;
 RT "Purification and characterization of two related but distinct
 metalloproteinase inhibitors secreted by bovine aortic endothelial
 cells";
 RT J. Biol. Chem. 264:17445-17453 (1989).
 CC 1- FUNCTION: Complexes with metalloproteinases (such as collagenases)
 CC and irreversibly inactivates them.
 CC 1- SUBCELLULAR LOCATION: Secreted.
 CC 1- PM: The activity of TIMP is dependent on the presence of
 CC metalloproteinase inhibitors secreted by bovine aortic endothelial
 CC cells.
 CC 1- SIMILARITY: Belongs to the TIMP family.
 CC 1- FUNCTION: Contains 1 NTR domain.
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC at the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 removed.

CC
DR EMBL; M60073; AAA3084.1; -; mRNA.
DR EMBL; S70341; AAB3082.1; -; mRNA.
DR EMBL; AY25346; AAP4413.1; -; mRNA.
DR EMBL; AF144763; AAD30303.1; -; mRNA.
DR PIR; A35685;
DR HSSP; P01033; IUEA.
DR SMR; P20414; 24-204.
DR Interpro; IPR00134; Netrin_C.
DR Interpro; IPR001820; Prot_inh_TMP.
DR PANTHER; PTHR1184; Prot_Inh_TMP; 1.
DR PIR; PFO065; TIMP; 1.
DR PROSITE; PS50189; NTR; 1.
DR PROSITE; PS50288; TMP; 1.
KW Direct protein sequencing; Erythrocyte maturation; Glycoprotein;
Metalloenzyme inhibitor; Metalloprotease inhibitor; Signal.
FT SIGNAL 1 23
FT CHAIN 24 207 Metalloproteinase inhibitor 1.
FT DOMAIN 24 147 NTR.
FT CARBONYD 53 53 N-linked (GlcNAc. . .) (Potential).
FT CARBONYD 101 101 N-linked (GlcNAc. . .) (Potential).
FT DISULFID 24 93 By similarity.
FT DISULFID 26 122 BY similarity.
FT DISULFID 36 147 BY similarity.
FT DISULFID 150 197 BY similarity.
FT DISULFID 155 160 BY similarity.
FT DISULFID 168 189 BY similarity.
SQ SEQUENCE 207 AA; 23032 MW; E672BBE2E65FP3F7 CRC64;

Query Match 88.5%; Score 995; DB 1; Length 207;
Best Local Similarity 87.0%; Pred. No. 4.4e-91;
Matches 180; Conservative 11; Mismatches 16; Indels 0; Gaps 0;
Oy 1 MAPPEPLASGLIILWLIAPSPACTCVPHPQTAFCNSDLVIRAKVGTPEVNQTTIYQR 60
Db 1 MAPFAPMASGLIILWLIAPSPACTCVPHPQTAFCNSDLVIRAKVGTPEVNQTTIYQR 60

Oy 61 YEIKTMKKGFOALGDAADIRVTPAMESVGYFHRSHNNSBEFLIAKLUQDGHLIT 120
Db 61 YEIKTMKKGFOALGDAADIRVTPAMESVGYFHRSHNNSBEFLIAKLUQDGHLIT 120

Oy 121 TESFVAPWNLSLAQRGGFTKTYVGEFFECTVPCCLSPCKLQSGTHCLWLTDOLLSQEK 180
Db 121 TCSFVAPWNMSAQRGGFTKTYAAGEECTVFPCSSIPCKLQSDTHCLWLTDOLLSQDK 180

Oy 181 GFSRHLACIPRERGLCTWOSRSQIA 207
Db 181 GFSRHLACIPRERGLCTWOSRSQIA 207

RESULT 8
TIMPL_PIG
ID TIMPL_PIG STANDARD; PRT; 207 AA.
AC P35624; Q9T83; Q9TB9;
DT 01-JUN-1994 (Rel. 2.9, Created)
DT 16-OCT-2001 (Rel. 4.0, Last sequence update)
DT 10-MAY-2005 (Rel. 4.7, Last annotation update)
DE Metalloproteinase inhibitor 1 precursor (TIMP-1).
Name=TIMPL;
Sub scrofa (Pig).
Sub bukarvata; Metacora; Chordata; Craniata; Vertebrata; Buteleostomi;
Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
Sub NCBI_TAXID=9823;
RN NUCLEOTIDE_SEQUENCE [mRNA].
RC TISSUE=ovary;
RX MEDLINE=20041478; PubMed=1312961; DOI=10.1016/0303-7207(92)90196-D;
RA Tanaka T., Andoh N., Takeya T., Sato E.;
RT "Differential screening of ovarian cDNA libraries detected the
expression of the porcine collagenase inhibitor gene in functional
corpora lutea.;"
RL Mol. Cell. Endocrinol. 83:65-71(1992).

RN [2] NUCLEOTIDE SEQUENCE OF 34-195.
RP Wang J.Y., Baer A.E., Krueg V.B., Setton L.A.;
RA "Gene expression level of mmp3 and Timp1 in intervertebral disc.";
RR Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RL [3]
RN RP NUCLEOTIDE SEQUENCE OF 37-144.
RC TISSUE=Skin;
RA Wang J.F., Boykew R.H., Reno C.R., Hart D.A., Olson M.E.;
RT "Cloning and sequencing of porcine TIMPs";
RL Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
CC -I- FUNCTION: Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them.
CC -I- SUBCELLULAR LOCATION: Secreted.
CC -I- PWL: The activity of TIMP is dependent on the presence of disulfide bonds.
CC -I- SIMILARITY: Belongs to the TIMP family.
CC -I- SIMILARITY: Contains 1 NTR domain.
CC removed.
CC
DR EMBL; S96211; AAB21865.1; -; mRNA.
DR EMBL; AF201726; AAF24348.1; -; mRNA.
DR EMBL; AF156029; AAF17354.1; -; mRNA.
DR PIR; P147061; I47061.
DR HSSP; P01033; IUEA.
DR SMR; P35624; 24-203.
DR Interpro; IPR00134; Netrin_C.
DR Interpro; IPR001820; Prot_inh_TMP.
DR PANTHER; PTHR1184; Prot_Inh_TMP; 1.
DR PIR; PFO065; TIMP; 1.
DR PROSITE; PS50288; TMP; 1.
DR ERYTHROCYTE MATURATION; Glycoprotein; Metalloenzyme inhibitor;
Metalloprotease inhibitor; Signal.
FT SIGNAL 1 23 Metalloproteinase inhibitor 1.
FT CHAIN 24 147 NTR.
FT DOMAIN 24 147 N-linked (GlcNAc. . .) (Potential).
FT CARBONYD 53 53 N-linked (GlcNAc. . .) (Potential).
FT CARBONYD 101 101 N-linked (GlcNAc. . .) (Potential).
FT DISULFID 24 93 By similarity.
FT DISULFID 26 122 By similarity.
FT DISULFID 36 147 By similarity.
FT DISULFID 150 197 By similarity.
FT DISULFID 155 160 By similarity.
FT DISULFID 168 189 By similarity.
FT CONFLICT 34 34 A -> P (in Ref. 2).
FT CONFLICT 37 37 S -> N (in Ref. 3).
FT CONFLICT 41 41 V -> F (in Ref. 2).
FT CONFLICT 59 59 K -> Q (in Ref. 1).
FT CONFLICT 86 86 T -> A (in Ref. 3).
FT CONFLICT 141 142 EI -> KR (in Ref. 3).
SQ SEQUENCE 207 AA; 23099 MW; B0485846BB56BD0 CRC64;

Query Match 86.0%; Score 967; DB 1; Length 207;
Best Local Similarity 83.6%; Pred. No. 2.8e-88; Indels 0; Gaps 0;
Matches 173; Conservative 15; Mismatches 19; Indels 0; Gaps 0;

Oy 1 MAPPEPLASGLIILWLIAPSPACTCVPHPQTAFCNSDLVIRAKVGTPEVNQTTIYQR 60
Db 1 MAPFAPMASGLIILWLIAPSPACTCVPHPQTAFCNSDLVIRAKVGTPEVNQTTIYQR 60

Oy 61 YEIKTMKKGFOALGDAADIRVTPAMESVGYFHRSHNNSBEFLIAKLUQDGHLIT 120
Db 61 YEIKTMKKGFOALGDAADIRVTPAMESVGYFHRSHNNSBEFLIAKLUQDGHLIT 120

Oy 121 TESFVAPWNLSLAQRGGFTKTYVGEFFECTVPCCLSPCKLQSGTHCLWLTDOLLSQEK 180
Db 121 TCSFVAPWNMSAQRGGFTKTYAAGEECTVFPCCSIPCKLQSDTHCLWLTDOLLSQDK 180

QY 181 GFOSRHLACIPREPGICLCTWQSRSQIA 207
 QY 181 GFOSRHLACIPREPGICLCTWQSRSQIA 207
 Db 1 MALFAFTVSGILLILWLTASRACTCVPHPHQTAFCNSEVIRAKENGTAENETFLYQR 60
 RESULT 9
 TIMPL_SHEEP STANDARD; PRT; 207 AA.
 ID TIMPL_SHEEP STANDARD; PRT; 207 AA.
 AC P50122; 1
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Metalloprotease inhibitor 1 precursor (TIMP-1).
 GN Name-TIMPL;
 OS Ovis aries (Sheep).
 OC Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Bovidae; Caprinae; Ovib.
 OC Peccora; Bovidae; Caprinae; Ovib.
 OX NCBI_TaxID=9940;
 RN [1]_
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Corpus luteum;
 MEDLINE=1042210; PubMed=8275949; DOI=10.1210/en.134.1.344;
 RA Smith G.W., Goetz T.L., Anthony R.V., Smith M.F.;
 RT "Molecular cloning of an ovine ovarian tissue inhibitor of
 metalloproteinases: ontogeny of messenger ribonucleic acid expression
 and in situ localization within preovulatory follicles and luteal
 tissue."
 RT Endocrinology 134:44-332(1994).
 CC --!- FUNCTION: Complexes with metalloproteinases (such as collagenases)
 CC and irreversibly inactivates them.
 CC --!- SUBCELLULAR LOCATION: Secreted.
 CC --!- PTM: The activity of TIMPL is dependent on the presence of
 CC disulfide bonds.
 CC --!- SIMILARITY: Belongs to the TIMP family.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 CC EMBL: S67450; AAB24472.1; ; mRNA.
 DR PIR: 146564; 146964.
 DR HSSP: P01033; 1UEA.
 DR SMR: P50122; 24-203.
 DR InterPro: IPR00134; Netrin_C.
 DR InterPro: IPR001820; Prot_inh_TIMP.
 DR PANTHER: PTHR11844; Prot_Inh_TIMP; 1.
 DR Pfam: PF0095; TIMP; 1.
 DR PROSITE: PS50189; NTR; 1.
 DR PS50288; TIMP; 1.
 KW Erythrocyte maturation; Glycoprotein; Metalloenzyme inhibitor;
 KW Metalloprotease inhibitor; Signal.
 FT SIGNAL 1 23 By similarity.
 FT CHAIN 24 207 Metalloprotease inhibitor 1.
 FT DOMAIN 24 147 NTR.
 FT CARBOHYD 53 53 N-linked (GlcNAc. . .) (Potential).
 FT CARBOHYD 101 101 N-linked (GlcNAc. . .) (Potential).
 FT DISULFID 24 93 By similarity.
 FT DISULFID 26 122 By similarity.
 FT DISULFID 36 147 By similarity.
 FT DISULFID 150 197 By similarity.
 FT DISULFID 155 160 By similarity.
 FT DISULFID 168 189 By similarity.
 SEQUENCE 207 AA; 23058 MW; 1D1BCA2012F80E46 CRC64;

Query Match 85 %; Score 961; DB 1; Length 207;
 Best Local Similarity 85.7%; Pred. No. 1.1e-87;
 Matches 174; Conservative 10; Mismatches 19; Indels 0; Gaps 0;
 FT DISULFID 155 197 By similarity.

QY 1 MAPFERDLASGILLLWLTASRACTCVPHPHQTAFCNSDLWIRAKENGTEVNQTYQR 60
 QY 1 MALFAFTVSGILLILWLTASRACTCVPHPHQTAFCNSEVIRAKENGTAENETFLYQR 60
 Db 61 YEIKMTKQYKFOALGDAAMIRFVUTPAMMSVCGYFRSHNRSERFLAGKLDGLHIT 120
 Db 61 YEIKMTKQYKFOALGDAAMIRFVUTPAMMSVCGYFRSHNRSERFLAGKLDGLHIT 120
 QY 121 TCSFPVAPWNNSLQAQRGFIKITVCECTVPCISIPCKLQSGTHCLWDQIQLGSEK 180
 Db 121 TCSFPVAPWNNSLQAQRGFIKITVCECTVPCISIPCKLQSGTHCLWDQIQLGSEK 180
 QY 181 GFOSRHLACIPREPGICLCTWQSRL 203
 Db 181 GFOSRHLACIPREPGICLCTWQSRL 203

RESULT 10
 TIMPL_HORSE STANDARD; PRT; 207 AA.
 ID TIMPL_HORSE STANDARD; PRT; 207 AA.
 AC 002722; 1
 DT 15-DEC-1998 (Rel. 37, Created)
 DT 15-DEC-1998 (Rel. 37, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Metalloprotease inhibitor 1 precursor (TIMP-1).
 GN Name-TIMPL;
 RT Equus caballus (Horse).
 OC Mammalia; Buttheria; Laurasiatheria; Perissodactyla; Equidae; Equus.
 OX NCBI_TaxID=9706;
 RN [1]_
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Cartilage;
 MEDLINE=95074117; PubMed=9859406;
 RA Richardson D.W., Dodge G.R.;
 RT "Molecular characteristics of equine stromelysin and the tissue
 inhibitor of metalloproteinase 1.";
 RL Am. J. Vet. Res. 59:1557-1562(1998).
 CC --!- FUNCTION: Complexes with metalloproteinases (such as collagenases)
 CC and irreversibly inactivates them (By similarity).
 CC --!- SUBCELLULAR LOCATION: Secreted.
 CC --!- PTM: The activity of TIMP is dependent on the presence of
 CC disulfide bonds (By similarity).
 CC --!- SIMILARITY: Belongs to the TIMP family.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 CC EMBL: U95039; AAB53735.1; ; mRNA.
 DR HSSP: P01033; 1UEA.
 DR SMR: 002722; 24-203.
 DR InterPro: IPR00114; Netrin_C.
 DR InterPro: IPR001820; Prot_inh_TIMP.
 DR PANTHER: PTHR11844; Prot_Inh_TIMP; 1.
 DR Pfam: PF00965; TIMP; 1.
 DR PROSITE: PS50189; NTR; 1.
 DR PROSITE: PS00288; TIMP; 1.
 KW Erythrocyte maturation; Glycoprotein; Metalloenzyme inhibitor;
 KW Metalloprotease inhibitor; Signal.
 FT SIGNAL 1 23 By similarity.
 FT CHAIN 24 207 Metalloprotease inhibitor 1.
 FT DOMAIN 24 147 NTR.
 FT CARBOHYD 53 53 N-linked (GlcNAc. . .) (Potential).
 FT CARBOHYD 101 101 N-linked (GlcNAc. . .) (Potential).
 FT DISULFID 24 93 By similarity.
 FT DISULFID 26 122 By similarity.
 FT DISULFID 36 147 By similarity.
 FT DISULFID 150 197 By similarity.

FT DISULFID 168 189 BY similarity.

SQ SEQUENCE 207 AA; 23046 MW; FD710DA9BD168070 CRC64;

Query Match 82.4%; Score 926; DB 1; Length 207;
Best Local Similarity 82.6%; Pred. No. 3.5e-84;
Matches 171; Conservative 12; Mismatches 24; Indels 0; Gaps 0;

QY 1 MAPPEPLASGILLWLIWPLSPRACTCVPHPQTAFCSNDLVRAKFGTPEVNQNTLYQR 60
1 MAPFAPLVSLGILWLIWPLSPRACTCVPHPQTAFCSSEFLIRAKFGTISVNTLQR 60

Db 61 YEIKMTHNYKGQALGDAADIRFVYTAMESVCGYFRSHNRSEELIAGKLGDLHIT 120
1 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169

QY 1 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169
1 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169

Db 61 YEIKMTHNYKGQALGDAADIRFVYTAMESVCGYFRSHNRSEELIAGKLGDLHIT 120
1 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169

RESULT 12

Q96QM2 HUMAN

ID Q96QM2_HUMAN PRELIMINARY; PRT; 169 AA.

AC Q96QM2;

DT 01-DEC-2001 (T-EMBLrel. 19, Created)
01-DEC-2001 (T-EMBLrel. 25, Last annotation update)

DE TIMP1 protein.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Butheria; Euarchontoglires; Primates; Catarrhini; Homidae;

OC Homo;

OC NCBI_TaxID=9606;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Prostate;

RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strauberg R.D., Feingold E.A., Grouse L.H., Derge J.G.,
Klauser R.D., Collins F.S., Wagner L., Shevchenko C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Bluetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.L., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.F., Cabavant T.L., Scheetz T.E.,
Brownstein M.J., Udin T.B., Yoshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahay S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Muniz D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Heiton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J.J., Schmitz J.J., Myers R.M.,
Butterfield Y.S.N., Krzywinski M.I., Stalska U., Smalius D.E.,
RA Schnech A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RL [2]

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Prostate;

RA Strauberg R.;
RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
DR "Characterization and sequencing of the rabbit TIMP-1 gene.";
DR Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AY829731; RAW79054.1; -; Genomic_DNA.
DR InterPro; IPR01134; Netrin_C.
DR InterPro; IPR01820; Prot_inh_TMP.
DR Pfam; PF00365; TIMP; 1.
DR SMART; SM00206; NTR; 1.
DR PROSITE; PS50189; NTR; 1.
DR PROSITE; PS00288; TIMP; 1.
SQ SBQUENCE; 207 AA; 22937 MW; FA39B19352370B5B CRC64;

Query Match 82.3%; Score 925; DB 2; Length 207;
Best Local Similarity 82.3%; Pred. No. 4.4e-84;
Matches 167; Conservative 12; Mismatches 24; Indels 0; Gaps 0;

QY 1 MAPPEPLASGILLWLIWPLSPRACTCVPHPQTAFCSNDLVRAKFGTPEVNQNTLYQR 60
1 MAPFAPLVSLGILWLIWPLSPRACTCVPHPQTAFCSSEFLIRAKFGTISVNTLQR 60

Db 61 YEIKMTHNYKGQALGDAADIRFVYTAMESVCGYFRSHNRSEELIAGKLGDLHIT 120
1 MAPPEPLASGILLWLIWPLSPRACTCVPHPQTAFCSNDLVRAKFGTPEVNQNTLYQR 60

QY 121 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169
1 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169

Db 61 YEIKMTHNYKGQALGDAADIRFVYTAMESVCGYFRSHNRSEELIAGKLGDLHIT 120
1 TCSFVAWNLSLAQRGFTKTYTVCBECFTVFCPLSIPCKLQSGTHCL 169

QY 181 GEOSRHLAQLPREGLCWTWSLR 203
181 GFOSRHLAQLPREGLCWQSRL 203

Db 181 GFOSRHLAQLPREGLCWQSRL 203

RESULT 13		RX MEDLINE=99132652; PubMed=9931441; DOI=10.1016/S0378-1119(98)00521-6;
Q5ENG7_RABBIT PRELIMINARY;	PRT;	RA Zeiss C.J., Acland G.M., Aguirre G.D., Ray K.; progressive retinal
ID Q5ENG7;	RT "TIMP-1 expression is increased in X-linked progressive retinal	
AC Q5ENG7;	RT atrophy despite its exclusion as a candidate gene.";	
DT 10-MAY-2005 (TiEMBrel. 30, Created)	RT Gene 225:67-75(1998).	
DT 10-MAY-2005 (TiEMBrel. 30, Last sequence update)	RL [3]	
DE Tissue inhibitor of metalloproteinase 1 (Fragment).	RP CHARACTERIZATION.	
GN Name=TIMP-1; Oryctolagus cuniculus (Rabbit).	RX MEDLINE=99175541; PubMed=1794505;	
OS Oryctolagus cuniculus (Rabbit).	RA Chopra R., Kokilis P.A., Bergin S., Rowe J., Angal S.;	
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	RT "Purification of recombinant dog tissue inhibitor of	
OC Mammalia; Butheria; Burchontoglires; Gires; Lagomorpha; Leporidae;	RT metalloproteinases";	
OC Oryctolagus.	RL Biochem. Soc. Trans. 19:372S-372S(1991).	
OX NCBI_TaxID=9986;	CC -1- FUNCTION: Complexes with metalloproteinases (such as collagenases)	
RN [1] NUCLEOTIDE SEQUENCE.	CC -1- SUBCELLULAR LOCATION: Secreted.	
RA Estelle J., Saetre Y., Merchant M., Folch J.M.;	CC -1- TISSUE SPECIFICITY: Ubiquitously expressed.	
RT Characterization and sequencing of the rabbit TIMP-1 gene. ";	CC -1- PM: The activity of TIMP1 is dependent on the presence of	
RL Submitted (NOV-2004) to the EMBL/GenBank/DBJ databases.	CC -1- disulfide bonds.	
DR EMBL: AY029730; AAW79053.1; "-" mRNA.	CC and irreversibly inactivates them.	
DR InterPro; IPR001134; Netrin_C.	CC -1- SIMILARITY: Contains 1 NTR domain.	
DR Pfam; PF00965; TIMP_1.	CC	
DR SMART; SM00206; NTR; 1.	CC	
DR PROSITE; PS50189; NTR; 1.	CC	
DR FT NON_TER 1 1	CC	
FT SEQUENCE 203 AA; 2225 MW; EIDICE13047AEEF5 CRC64;	CC	
Query Match Similarity 81.0%; Score 911; DB 2; Length 203;	CC	
Best Local Similarity 83.2%; Pred. No. 1. le-82; Mismatches 21; Indels 0; Gaps 0;	CC	
Matches 164; Conservative 12; MisMatches 21; Del 0; Insert 0;	CC	
Qy 7 LASGILLMLWLIAPSRACTCYPHPQTAFCMNSDLVIRAKFGTPEUNQNTLYQREYIKMT 66	CC	
Db 3 LASSMLLMLWLIAPSRACTCYPHPQTAFCMNSDLVIRAKFGTPEUNQNTLYQREYIKTT 62	CC	
Qy 67 KMYKGFQALGDAADIRFVYTAMESVCYFIRFSRNRSSEFTIAGKLQHITCSFAV 126	CC	
Db 63 KMFKGFDALGHADIRFVYTAMESVCYFIRFSRNRSSEFTIAGKLQHITCSFAV 122	CC	
Qy 127 PWNSLSLAQRGFGFTKYTVGECTVFCPSLIPCKLQSGCTCLWTDLQGSEKFRSRH 186	CC	
Db 123 PWNSLSLAQRGFGFTKYTVGECTVFCASIPCHLESDTCLWTDLQGSDKGPSRH 182	CC	
Qy 187 LACLPPREPGLCTWOSLR 203	CC	
Db 183 LACLPPREPGLCTWOSLR 199	CC	
RESULT 14	CC	
TIMEPI_CANFA STANDARD;	DR EMBL: AB016817; BAM32393.1; "-" mRNA.	
ID TIMEPI_CANFA STANDARD;	DR EMBL: AF077817; AAD10632.1; "-" mRNA.	
AC P81546; Q07QSS5;	DR Ensembl: ENSCARG0000015155; Canis familiaris.	
DT 15-JUL-1999 (Rel. 38, Created)	DR InterPro; IPR001134; Netrin_C.	
DT 16-OCT-2005 (Rel. 40, Last sequence update)	DR IPR001820; Prot_Inh_TIMP_1.	
DT 10-MAY-2005 (Rel. 47, Last annotation update)	DR PANIER; PTHR1844; Prot_Inh_TIMP_1.	
DE Metalloprotease inhibitor 1 precursor (TIMP-1).	DR PROSITE; PS50189; NTR; 1.	
Name-TIMEPI;	DR Pfam; PF00965; TIMP_1.	
GN Canis familiaris (Dog).	DR	
OS Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	FT PROSITE; PS50188; TIMP; FALSE NEG.	
OC Canis.	FT DOMAIN	
NCBI_TaxID=9615;	FT CARBOHYD	
RC STRAIN=Cocker spaniel; TISSUE=Kidney;	FT CARBOHYD	
RA Noritaka H., Miyamoto H., Goto C., Seiki M., Sato H.;	FT DISURPID	
RT "Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.;"	FT DISURPID	
RT Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.	FT DISURPID	
[1] NUCLEOTIDE SEQUENCE.	FT DISURPID	
Qy 1 MAPFEPFLASGILLMLWLIAPSRACTCYPHPQTAFCMNSDLVIRAKFGTPEUNQNTLYQ 60	FT DISURPID	
RN [1] MAPFEPFLASGILLMLWLIAPSRACTCYPHPQTAFCMNSDLVIRAKFGTPEUNQNTLYQ 60	FT DISURPID	
Qy 61 YEIKMKTQKFGQALGDAADIRFVYTAMESVCYFIRFSRNRSSEFTIAGKLQHIT 120	FT DISURPID	
RN 61 YEIKMKTQKFGQALGDAADIRFVYTAMESVCYFIRFSRNRSSEFTIAGKLQHIT 120	FT DISURPID	
Qy 121 TCSFVAFWNSLSLAQRGFGFTKYTVGECTVFCPSLIPCKLQSGCTCLWTDLQGSEK 180	FT DISURPID	
RN	FT DISURPID	

Db 121 TCSFVAPWSSLSAQRGGFTKTYAAGCSEGTVFCSSIPCKLQSDTHCLWTDHFLGSDK 180
 QY 181 GQSRHIACLPREGPLCTWQSIRSQIA 207
 Db 181 GQSRHIACLPREGPLCTWQSIRSQIA 207

RESULT 15

TIMP-RABIT STANDARD PRT; 206 AA.

ID -TIMPL RABIT STANDARD PRT; 206 AA.

AC P20514;
 DT 01-FEB-1991 (Rel. 17, Created)
 DT 01-FEB-1991 (Rel. 17, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)

DB Metalloproteinase inhibitor 1 precursor (TIMP-1).

GN Name-TIMPL;

OS Oryctolagus cuniculus (Rabbit).
 Bukaryota; Metacoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Butheria; Euarchontoglires; Gires; Lagomorpha; Leporidae;
 OC Oryctolagus
 OC
 OC NCBI_TaxID=9986;
 RN [1]

RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=89214135; PubMed=2708356;
 RA Horowitz S., Darni N., Shapiro D.L., Holm B.A., Notter R.H.,
 RA Quible D.J.;
 RT "Hyperoxic exposure alters gene expression in the lung. Induction of the tissue inhibitor of metalloproteinases mRNA and other mRNAs.";
 RL J. Biol. Chem. 264:7092-7095 (1989).
 CC -!- FUNCTION: Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TIM: The activity of TIMP is dependent on the presence of disulfide bonds.
 CC -!- SIMILARITY: Belongs to the TIMP family.
 CC
 CC
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.

CC
 CC
 CC
 DR EMBL; J04712; AAA31478.1; -; mRNA.
 DR PIR; A33350; A33350.
 DR HSSP; P01033; 1009.
 DR SMR; P20614; 24-202.
 DR InterPro; IPR001134; Netrin_C.
 DR InterPro; IPR001820; Prot_Inh_TMP.
 DR Pfam; PF00965; TIMP; 1.
 DR PROSITE; PS50189; NTR; 1.
 DR PROSITE; PS00288; TMP; 1.
 KW Erythrocyte maturation; Glycoprotein; Metalloenzyme inhibitor;
 KW Metalloprotease inhibitor; Signal.

FT SIGNAL 1 23 Metalloproteinase inhibitor 1.

FT CHAIN 24 205 NTR.

FT DOMAIN 24 147 N-linked (GlcNAc. . .) (Potential).

FT CARBONYD 101 101 N-linked (GlcNAc. . .) (Potential).

FT DISULFD 24 93 By similarity.

FT DISULFD 26 122 By similarity.

FT DISULFD 36 147 By similarity.

FT DISULFD 150 196 By similarity.

FT DISULFD 155 160 By similarity.

FT DISULFD 168 188 By similarity.

SQ SEQUENCE 206 AA; 22758 MW; 183948DE7174EE9E CRC64;

QY 1 MAPPEPIPLASGILLWILAPRACTCUPPHPOQAFACNSDLVIRAKVGTPENQNTLYQR 60
 Db 1 MAPLAALASSMILLIINVAAPRACTCUPPHPOQAFACNSDLVIRAKVGAPENQNTLYQR 60
 QY 61 YIKKMTMKYKGFOALGDAADIRFVYPTPAMESEVGYFRSHNRSEETLIAKGQDGHIT 120
 Db 61 YIKKMTMKYKGFOALGDAADIRFVYPTPAMESEVGYFRSHNRSEETLIAKGQDGHIT 120
 QY 121 TCSFVAPWSSLSAQRGGFTKTYAAGCSEGTVFCSSIPCKLQSDTHCLWTDHFLGSDK 180
 Db 121 TCSFVAPWSSLSAQRGGFTKTYAAGCSEGTVFCSSIPCKLQSDTHCLWTDHFLGSDK 179
 QY 181 GQSRHIACLPREGPLCTWQSIR 203
 Db 180 GQSRHIACLPREGPLCTWQSIR 202

Search completed: April 10, 2006, 18:06:14
 Job time : 73.1386 Bees

Copyright (c) 1993 - 2006 Biocceleration Ltd.

GenCore version 5.1.7

OM protein - protein search, using sw model

Run on:

April 10, 2006, 18:01:46 ; Search time 11.8416 Seconds

(without alignments) 1681.943 Million cell updates/sec

Title: US-10-734-564-100
Perfect score: 1124
Sequence: 1 MAPFEPFLASGILLLMLTAP.....ACLPREPGIQLCTWOSLRSQIA 207
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:
1: Pir1:
2: Pir2:
3: Pir3:
4: Pir4:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

RESULT 1
ZYHUEP
metalloproteinase tissue inhibitor 1 precursor [validated] - human
N;Alternate name: erythroid potentiating activity (EPA); fibroblast collagenase inhib.
C;Species: Homo sapiens (man)
C;Date: 20-May-1986 #sequence revision 28-May-1986 #text_change 09-Jul-2004
C;Accession: A93372; A93363; K23534; M20595; A38826; A48417; S20318; S15872; S152912; S21037
R;Docherty, A.J.P.; Lyons, A.; Smith, B.J.; Wright, E.M.; Stephens, P.E.; Harris, T.J.;
Nature 318, 66-69, 1985
A;Title: Sequence of human tissue inhibitor of metalloproteinases and its identity to
A;Reference: A93372; PMID:86040463; PMID:3903517
A;Accession: A93372
A;Molecule type: mRNA
A;Residues: 1-207 <DOC>
A;Cross-references: UNIPROT:PO1033; UNIPARC:UPI0001135B1; GB:X03124; MID:937182; PMID:769-771, 1985
R;Gasson, J.C.; Goldie, D.W.; Kaufman, S.E.; Westbrook, C.A.; Hewick, R.M.; Kaufman, R.J.;
Nature 318, 66-69, 1985
A;Title: Molecular characterization and expression of the gene encoding human erythroi-

A;Reference number: A93363; MID:85240567; PMID:3839290
A;Accession: A93363
A;Molecule type: mRNA
A;Residue: 1-207 <GAS>
A;Cross-references: UNIPARC:UPI0001135B1
R;Carmichael, D.F.; Sommer, A.; Thompson, R.C.; Anderson, D.C.; Smith, C.G.; Welgus, H.
Proc. Natl. Acad. Sci. U.S.A., 83, 2407-2411, 1986
A;Title: Primary structure and cDNA cloning of human fibroblast collagenase inhibitor.
A;Reference number: A23534; MID:86205964; PMID:301039
A;Accession: A23534
A;Molecule type: mRNA
A;Residues: 1-207 <CAR>
A;Cross-references: UNIPARC:UPI0001135B1; GB:M12670; MID:g182482; PMID:AAA52436.1; PIR
R;Stricklin, G.P.; Welgus, H.G.
J. Biol. Chem. 258, 12252-12258, 1983
A;Title: Human skin fibroblast collagenase inhibitor
A;Reference number: A20595; MID:84032401; PMID:6313647
A;Accession: A20595
A;Molecule type: protein
A;Residue: 1-207 <STR>
A;Cross-references: UNIPARC:UPI00002C59D
A;Note: six disulfide bonds are present

R;Kopp, G.; Freudentein, J.; Klaudiny, J.; Mucha, J.; Wempe, F.; Zimmer, M.; Scheit, F.
DNA Cell Biol. 9, 479-485, 1990
A;Title: Characterization of three abundant mRNAs from human ovarian granulosa cells.
A;Reference number: A35826; MID:91025550; PMID:2171551
A;Accession: A35826
A;Molecule type: mRNA
A;Residues: 1-207 <RAP>
A;Cross-references: UNIPARC:UPI0001135B1; GB:M38188
R;Van Ranst, M.; Norga, K.; Masure, S.; Proost, P.; Vandekerckhove, F.; Auwerx, J.; Van
Cytokine 3, 231-239, 1991

30	77.5	6.9	944	2	566870
31	76.5	6.8	183	2	A32851
32	76.5	6.8	709	2	G96610
33	76	6.8	266	2	S02510
34	75.5	6.7	530	2	F8488
35	75.5	6.7	1513	2	A54895
36	75	6.7	1356	2	JC1402
37	74.5	6.6	430	2	S73269
38	74.5	6.6	444	2	S48656
39	73.5	6.5	993	1	PIVXTA
40	73	6.5	259	2	JC7109
41	73	6.5	480	2	F82796
42	73	6.5	537	2	I49135
43	73	6.5	555	2	D71444
44	72.5	6.5	611	2	A83926
45	72	6.4	589	2	G71462

ALIGNMENTS

A;Title: The cytokine-protease connection: identification of a 96-kD THP-1 gelatinase antagonist
A;Reference number: A48417; MUID:91355647; PMID:1653055
A;Molecule type: protein A48417
A;Residues: 'X', 25, 'X', 27-35, 'X', 37-52 <VAN>
A;Cross-references: UNIPARC:UP0000173235
A;Experimental source: monocytic cell line THP-1
A;Note: sequence modified after extraction from NCBI backbone
A;Note: sequence incorrectly identified as 96K gelatinase
R;Osthues, A.; Knaeuper, V.; Oberhoff, R.; Reinke, H.; Tschesche, H.
FBS Lett. 296, 16-20, 1992

A;Title: Isolation and characterization of tissue inhibitors of metalloproteinases (TIMP-1)
A;Reference number: S2031B; MUID:92111776; PMID:1730286
A;Accession: S2031B
A;Molecule type: protein
A;Residues: 'X', 25, 'X', 27-35, 'X', 37-38 <OST>
A;Cross-references: UNIPARC:UP1000173236
A;Experimental source: rheumatoid synovial fluid
R;Oppenakker, G.; Masure, S.; Proost, P.; Billiau, A.; van Damme, J.
FEBS Lett. 284, 73-78, 1991

A;Title: Natural human monocyte gelatinase and its inhibitor.
A;Reference number: S15872; MUID:91285112; PMID:1647974
A;Accession: S15872
A;Molecule type: protein
A;Residues: 'X', 25, 'X', 27-35, 'X', 37-42, 'X', 44, 'X', 46, 'X', 48-51 <FBB>
A;Cross-references: UNIPARC:UP1000173237
A;Experimental source: peripheral blood monocytes
R;Williamson, R.A.; Marston, F.A.O.; Angal, S.; Koklitis, P.; Panico, M.; Morris, H.R.;
Biochem. J. 268, 267-274, 1990

A;Title: Disulfide bond assignment in human tissue inhibitor of metalloproteinases (TIMP-1)
A;Reference number: A38978; MUID:90303199; PMID:2163605
A;Contents: annotation, disulfide bonds
R;Oppenakker, A.; Kenney, M.C.; Brown, D.
Curr. Eye Res. 12, 877-883, 1993

A;Title: Characterization of a human corneal metalloproteinase inhibitor (TIMP-1).
A;Reference number: 152912; MUID:94123576; PMID:7507419
A;Accession: 152912
A;Status: translated from GB/EMBL/DDJB
A;Molecule type: mRNA
A;Residues: 1-207 <REB>
A;Cross-references: UNIPARC:UPI0001135B1; GB:S68252; NID:9545022; PIDN:AA014009.1; PID:R;Trabel, S.; Blaeser, J.; Gote, T.; Peitz, G.; Schueren, E.; Schmitt, M.; Tschesche, H.
Bur. J. Biochem. 231, 714-719, 1995
A;Title: Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human pol
A;Reference number: S66461; MUID:95377303; PMID:7649172
A;Molecule type: protein
A;Residues: 24-38 <TRI>
A;Cross-references: UNIPARC:UP1000173238
A;Experimental source: polymorphonuclear leukocytes
C;Comment: This protein, found in a variety of body fluids, complexes with metalloproteinases-1 (TIMP-1) in a specific, stimulating the growth and differentiation of only human and murine erythroid C;Comment: The remarkable heat stability of this protein may be due to disulfide bond formation C;Genetics:
A;Gene: GDB:TMPL; CIGI; TIMP
A;Cross-references: GDB:119615; OMM:305370
A;Map position: Xp11.3-Xp11.23
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; glycoprotein; metalloproteinase inhibitor; mitogen
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-207/Product: metalloproteinase inhibitor 1 #status experimental <MT>
F;24-93,-26-122,-36-147,-197,-155-160,-168-189Disulfide bonds: #status experimental
F;53,101/Binding site: carbohydrate (Asn) (covalent) #status experimental

Query Match 100.0% Score 1124; DB 1; Length 207;
Best Local Similarity 99.4%; Score 1117; DB 2; Length 207;
Matches 205; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

RESULT 3
A35685
metallopeptidase inhibitor 1 precursor - bovine
N/Alternate names: cartilage-derived neovascularization inhibitor; TIMP-1; tissue inhibitor
C;Species: Bos primigenius taurus (cattle)
C;Date: 21-Sep-1990 #sequence revision 12-Apr-1995 #text_change 09-Jul-2004
C;Accession: A35685; B34668; B29712; A36833; I46979
R;Freudenstein, J.; Wagner, S.; Luck, R.M.; Binspanier, R.; Scheit, K.H.
Biochem. Biophys. Res. Commun. 171, 250-256, 1990
A;Title: mRNA of bovine tissue inhibitor of metalloproteinase: sequence and expression 1
A;Reference number: A35685; MUID:90365711; PMID:2393392
A;Accession: A35685
A;Molecule type: mRNA
A;Residues: 1-207 <FBB>
A;Cross-references: UNIPROT:P20414; UNIPARC:UPI000136F8A; GB:M60073; NID:9163760; PIDN:R;De Clerck, Y.A.; Yean, T.D.; Ratzkin, B.J.; Lu, H.S.; Langley, K.E.

QY 1 MAPPEPLASGLILLWLIAPSRACTCPVPHQPAFCNSDLVRAKFVGTPEENOTILYQR 60
Db 1 MAPPEPLASGLILLWLIAPSRACTCPVPHQPAFCNSDLVRAKFVGTPEENOTILYQR 60
QY 61 YEIKMTKMYKGFOALGDADIRFVYTPAMESVCGYFRSHNRSEEFLLAGKLUQDGHLHIT 120

J. Biol. Chem. 264, 17445-17453, 1989
A;Title: Purification and characterization of two related but distinct metalloproteinase
A;Reference number: A34468; MUID:9008914; PMID:2551903
A;Accession: B34468
A;Molecule type: protein
A;Residues: '24-'52,'X,'54-57,'L','59-61,'L','63-65,'L','67-68,'P' <DPC>
A;Cross-references: UNIPARC:UPI000173239
A;Experimental source: culture medium of aortic endothelial cells
R;Kaczmarek, M.; Honore, N.; Ribes, V.; Dehoux, P.; Cornet, P.; Cartwright, T.; Streck,
BioTechnology 5, 555-558, 1987
A;Title: Molecular cloning and synthesis of biologically active human tissue inhibitor of
A;Reference number: A29712
A;Accession: B39712
A;Molecule type: protein
A;Residues: 24-37 <RAC>
A;Cross-references: UNIPARC:UPI00017323A
A;Experimental source: culture medium of fibroblastic BC 21 cells
A;Note: protein inhibitor angiogenesis
R;Moser, M.A.; Sudhalter, J.; Langer, R.
Science 248, 1408-1410, 1990
A;Title: Identification of an inhibitor of neovascularization from cartilage.
A;Reference number: A34833; MUID:9028843; PMID:1694043
A;Accession: A34833
A;Molecule type: protein
A;Residues: 24-51 <MOS>
A;Cross-references: UNIPARC:UPI00017323B
A;Experimental source: cartilage
R;Satoh, T.; Kobayashi, K.; Yamashita, S.; Kikuchi, M.; Sendai, Y.; Hoshi, H.
Biol. Reprod. 50, 835-844, 1994
A;Title: Tissue inhibitor of metalloproteinases (TIMP-1) produced by granulosa and oviduct
A;Reference number: I46979; MUID:94257737; PMID:8199264
A;Accession: I46979
A;Status: translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-207 <SAT>
A;Cross-references: UNIPARC:UPI000136F8A; GB:S70841; NID:9546973; PID:PLDN:AB30892.1; PID:
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating activity; transcription induced by cytokines, tumor promoters, and anti-inflammatory agents
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
F;1-23/B domain: signal sequence #status predicted <SIG>
F;24-207/Product: metalloproteinase inhibitor 1 #status experimental <MAT>
F;24-93, 26-122, 36-147, 150-197, 155-160, 168-189/Disulfide bonds: #status predicted
F;53, 101/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 88 %; Score 995; DB 1; Length 207;
Best Local Similarity 87.0%; Pred. No. 5e-89; Matches 180; Conservative 11; Mismatches 16; Indels 0; Gaps 0;
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating activity; transcription induced by cytokines, tumor promoters, and anti-inflammatory agents
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
F;1-23/B domain: signal sequence #status predicted <SIG>
F;24-207/Product: metalloproteinase inhibitor 1 #status experimental <MAT>
F;24-93, 26-122, 36-147, 150-197, 155-160, 168-189/Disulfide bonds: #status predicted
F;53, 101/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 88 %; Score 995; DB 1; Length 207;
Best Local Similarity 87.0%; Pred. No. 5e-89; Matches 180; Conservative 11; Mismatches 16; Indels 0; Gaps 0;
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating activity; transcription induced by cytokines, tumor promoters, and anti-inflammatory agents
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
F;1-23/B domain: signal sequence #status predicted <SIG>
F;24-207/Product: metalloproteinase inhibitor 1 #status experimental <MAT>
F;24-93, 26-122, 36-147, 150-197, 155-160, 168-189/Disulfide bonds: #status predicted
F;53, 101/Binding site: carbohydrate (Asn) (covalent) #status predicted

RESULT 5
I46954
A;Cross-references: UNIPROT:P50122; UNIPARC:UPI000136F92; GB:S67450; NID:9456989; PIID:
C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)
C;Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 09-Jul-2004
C;Accession: I46964
R;Smith, G.W.; Goetz, T.L.; Anthony, R.V.; Smith, M.F.
Endocrinology 134, 344-352, 1994
A;Title: Molecular cloning of an ovine ovarian tissue inhibitor of metalloproteinases in sheep testis.
A;Reference number: I46564; MUID:94102210; PMID:8275949
A;Accession: I46964
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-207 <SMI>
A;Cross-references: UNIPROT:P50122; UNIPARC:UPI000136F92; GB:S67450; NID:9456989; PIID:
C;Superfamily: metalloproteinase inhibitor
C;Keywords:
Query Match 85.5%; Score 961; DB 2; Length 207;
Best Local Similarity 85.7%; Pred. No. 9.8e-86; Matches 174; Conservative 10; Mismatches 19; Indels 0; Gaps 0;
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating activity; transcription induced by cytokines, tumor promoters, and anti-inflammatory agents
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
F;1-23/B domain: signal sequence #status predicted <SIG>
F;24-207/Product: metalloproteinase inhibitor 1 #status experimental <MAT>
F;24-93, 26-122, 36-147, 150-197, 155-160, 168-189/Disulfide bonds: #status predicted
F;53, 101/Binding site: carbohydrate (Asn) (covalent) #status predicted

RESULT 6

A33350 metalloproteinase inhibitor 1 precursor - rabbit
N;Alternate names: TIMP-1; tissue inhibitor of metalloproteinases 1
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 30-Jun-1992 #sequence_revision 12-Apr-1996 #text_change 09-Jul-2004
C;Accession: A33350; A30864
R;Horowitz, S.; Dafni, N.; Shapiro, D.L.; Holm, B.A.; Notter, R.H.; Quible, D.J.
J. Biol. Chem. 264, 7092-7095, 1989
A;Title: Hyperoxic exposure alters gene expression in the lung. Induction of the tissue
A;Reference number: A33350; MUID:89214135; PMID:2708356
A;Accession: A33350
A;Molecule type: mRNA
A;Residues: 1-206 <OR>
A;Cross-references: UNIPROT:P20614; UNIPARC:UPI0000136F90; GB:J04712; NID:9165742; PIDN:
A;Experimental source: hyperoxi-exposed lung of New Zealand White rabbits
C;Comment: Expression of this protein in the lung is induced 6-fold by hyperoxia.
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinase controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating
A;Note: transcription induced by cytokines, tumor promoters, and anti-inflammatory agent
A;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
P;1-23/Domain: signal sequence #status predicted <SIG>
P;24-206/Product: metalloproteinase inhibitor 1 #status predicted <MAT>
P;24-93, 206-122, 36-147, 151-160, 165-188/Diulfide bonds: #status predicted
P;53, 101/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 80.3%; Score 902.5; DB 1; Length 205;
Matches 164; Conservative 13; Mismatches 25; Indels 1; Gaps 1;

Qy 1 MAPPEPLASIGLILLMLIAPSRACTCVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQ 60
Db 1 MAPPLAASSMLLWVVAAPSRACTCVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQ 60

Qy 61 YETKMTMKYKGQALGDAADRFVYTFAMESVCGYFRSHNRSEEFLLAGKLQDGLHIT 120
Db 61 YETKMTMKYKGQALGDAADRFVYTFAMESVCGYFRSHNRSEEFLLAGKLQDGLHIT 120

Qy 121 TCSFVAVPNLSLSLAQRGGFTKTYVGCECTVPCUSIPCKLQSGTHCLWTDQLOSEK 180
Db 121 TCSFVAVPNLSFSRSQSGFTKTYAAGCDMCTVFACASIPCHLESDDTHCLWTDSSL-GSDK 179

Qy 181 GQSRHAACTPRPGCTWQSRL 203
Db 180 GQSRHAACTPRPGCLWESLR 202

RESULT 7

A26106 metalloproteinase inhibitor 1 precursor - mouse
N;Alternate names: erythroid potentiating activity (EPA); fibroblast collagenase inhibitor
C;Species: Mus musculus (house mouse)
C;Date: 05-Oct-1988 #sequence_revision 12-Apr-1996 #text_change 09-Jul-2004
C;Accession: A26106; A26633; A05276
R;Johnson, M.D.; Housey, G.M.; Kirschmeier, P.T.; Weinstein, I.B.
Mol. Cell. Biol. 7, 2821-2829, 1987
A;Title: Molecular cloning of gene sequences regulated by tumor promoters and mitogens
A;Reference number: A26917; MUID:88038821; PMID:3670294
A;Accession: A26917
A;Molecule type: mRNA
A;Cross-references: UNIPROT:P12032; UNIPARC:UPI0000018BB; GB:MI7243; NID:9202111; PIDN:
A;Experimental source: embryonic fibroblast cDNA library
A;Experiments: A growth-responsive gene (16C8) in normal mouse fibroblasts homologous to a hum
A;Reference number: A26106; MUID:87066763; PMID:3024122
A;Accession: A26106
A;Molecule type: mRNA

A;Residues: 1-205 <EDW>
A;Cross-references: UNIPARC:UPI0000018BB; GB:X04684; NID:949702; PIDN:CAA28387.1.; PID
A;Experimental source: embryonic fibroblast cDNA library
R;Gewert, D.R.; Coulombe, B.; Castelino, M.; Skup, D.; Williams, B.R.G.
EMBO J. 6, 651-657, 1987
A;Title: Charactirization and expression of a murine gene homologous to human EPA/TIMP
A;Reference number: A26633; MUID:87218524; PMID:3034603
A;Accession: A26633
A;Molecule type: DNA
A;Residues: 1-51, 'R', '53-66, 'M', '67-116, 'KF', '119-120, 'N', '122-138, 'V', '140-142, 'KN', '144-193
A;Cross-references: UNIPARC:UPI00016394C; GB:M28312; NID:193040; PIDN:AB4219.1; PIT
A;Accession: A05276
A;Molecule type: mRNA
A;Residues: 168-193, 'L', 195-205 <SKU>
A;Cross-references: UNIPARC:UPI00008B041; GB:V00755; GB:J00425; NID:951554; PIDN:CAA24
A;Note: authors thought this clone represented a form of interferon beta
C;Genetics:
A;Gene: Timp
A;Map position: X
A;Introns: 41/3; 68/3; 110/3; 152/3
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinase possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiation
A;Note: transcription induced by cytokines, tumor promoters, and anti-inflammatory agent
A;Superfamily: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression pattern
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
P;1-24/Domain: signal sequence #status predicted <SIG>
P;25-94, 27-123, 37-18, 151-197, 156-161, 169-189/Diulfide bonds: #status predicted
P;54, 102/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 74.5%; Score 837.5; DB 1; Length 205;
Best Local Similarity 74.3%; Pred. No. 9.2e-74%;
Matches 150; Conservative 26; Mismatches 25; Indels 1; Gaps 1;

Qy 1 MAPPEPLASIGLILLMLIAPSRACTCVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQ 60
Db 2 MAPPLAASSMLLWVVAAPSRACTCVPHQTAFCNSDLVIRAKFGTPEVNQNTLYQ 61

Qy 61 YETKMTMKYKGQALGDAADRFVYTFAMESVCGYFRSHNRSEEFLLAGKLQDGLHIT 120
Db 62 YETKMTMKYKGQALGDAADRFVYTFAMESVCGYFRSHNRSEEFLLAGKLQDGLHIT 121

Qy 121 TCSFVAVPNLSLSLAQRGGFTKTYVGCECTVPCUSIPCKLQSGTHCLWTDQLOSEK 180
Db 122 ACSFLVWRTLSPAQAFSKTYSAGGGVCTVPCUSIPCKLQSGTHCLWTDQLOSEK 180

Qy 181 GQSRHAACTPRPGCTWQSRL 202
Db 181 GQSRHAACTPRPGCTWQSRL 202

RESULT 8

JC2557 metalloproteinase inhibitor 1 precursor - rat
N;Alternate names: TIMP-1
C;Species: Rattus norvegicus (Norway rat)
C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004
C;Accession: JC2557; B39120; S20326
R;Okada, A.; Garnier, J.M.; Vilaire, S.; Basset, P.
Gene 147, 301-302, 1994
A;Title: Cloning of the cDNA encoding rat tissue inhibitor of metalloproteinase 1 (TIMP-1)
A;Reference number: JC2557; MUID:95011636; PMID:7926820
A;Accession: JC2557
A;Status: Preliminary
A;Molecule type: mRNA
A;Residues: 1-217 <OK>
A;Cross-references: UNIPROT:P30120; UNIPARC:UPI000136F91; EMBL:U06179; NID:9468057; PID

R;Olson Jr., J.A.; Shiverick, K.T.; Ogilvie, S.; Buh, W.C.; Raizada, M.K.
Proc. Natl. Acad. Sci. U.S.A. 88, 1928-1932, 1991
A;Title: Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue inhibitor of metalloproteinase 2
A;Accession: B39120
A;Status: preliminary
A;Molecule type: protein
A;Residues: 24-36, 'B', 38, 'B', 40-42, 'X', 44 <OLS>
A;Cross-references: UNIPARC:UPI000017323C
R;Roswit, W.T.; McCourt, D.W.; Partridge, N.C.; Jeffrey, J.J.
Arch. Biochem. Biophys. 282, 402-410, 1992
A;Title: Purification and sequence analysis of two rat tissue inhibitors of metalloprotease
A;Reference number: S20325; MUID:92117648; PMID:1309971
A;Accession: S20326
A;Molecule type: protein
A;Residues: 24-45 <ROS>
A;Cross-references: UNIPARC:UPI000017323D
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases, possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating activity
A;Note: transcription induced by cytokines, tumor promoters, and anti-inflammatory agent
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; glycoprotein; metalloproteinase inhibitor
P;1-23/Domain: signal sequence #status predicted <SIG>
P;24-217/Product: metalloproteinase inhibitor 1 #status experimental <MAT>
P;101-130/Binding site: carbohydrate (Asn) (covalent) #status predicted
Qy 1 MAPFPLASGILWLMAPRRACTCVPPIPHQTAFCNSDLVIRAKFGTPEVNQ-TLYQ 60
Db 1 MAPFPLASGILWLMAPRRACTCVPPIPHQTAFCNSDLVIRAKFGTPEVNQ-TLYQ 60
Qy 61 YEIKTKMYKGFOALGDAADIRFVTPAMESVCYFHRSNHRSEELIAGSKLQDGHLTR 120
Db 61 YEIKTKMYKGFOALGDAADIRFVTPAMESVCYFHRSNHRSEELIAGSKLQDGHLTR 120
Qy 121 TCSFWAPWNISLADQRGFTKTYTVCECTVFPCLSIPICKLQSGTHCLWDQQLQSER 180
Db 121 ACSFLVWPWNISLADQRGFTKTYTVCECTVFPCLSIPICKLQSGTHCLWDQQLQSER 180
Qy 181 GFQSRHLACLPREPGLCTWL 202
Db 181 GFQSRHLACLPREPGLCTWL 202
Db 181 GYQSDHFACLPRNPDLCTWQYL 202

RESULT 9

JH083
metalloproteinase inhibitor 2 precursor - mouse
N;Alternate names: TIMP-2; tissue inhibitor of metalloproteinases 2
C;Species: Mus musculus (house mouse)
C;Date: 10-Sep-1999 #sequence revision 10-Sep-1999 #text_change 09-Jul-2004
C;Accession: JH083; JC1234; S18428; S15987; S26189
R;Shimizu, S.; Mailik, K.; Sejima, H.; Kishi, J.; Hayakawa, T.; Koawai, O.
Gene 114, 291-292, 1992
A;Title: Cloning and sequencing of the cDNA encoding a mouse tissue inhibitor of metalloproteinase 2
A;Reference number: JH083; MUID:92290292; PMID:1601112
A;Accession: JH083
A;Molecule type: mRNA
A;Residues: 1-220 <SH1>
A;Cross-references: UNIPROT:P25785; UNIPARC:UPI0000278E8; EMBL:X62622; NID:954801; PIDN:954801
A;Experimental source: 3T3 fibroblast, strain Balb/c
R;Leco, K.J.; Hayden, L.J.; Sharma, R.R.; Rochefeuille, H.; Greenberg, A.H.; Edwards, D.R.
Gene 117, 209-217, 1992
A;Title: Differential regulation of TIMP-1 and TIMP-2 mRNA expression in normal and Ha-r
A;Reference number: JC1234; MUID:92347695; PMID:1639268
A;Accession: JC1234
A;Molecule type: mRNA
A;Residues: 1-11, H', 13-20, L', 22-194, E', 196-220 <LEC>
A;Cross-references: UNIPARC:UPI000016D07D; GB:MB93954; NID:9202053; PIDN:AAA4046.1; PID:

R;Kishi, J.
Matrix 11, 373, 1991
A;Title: Correction
A;Reference number: S18428; MUID:92244125; PMID:1667327

A;Accession: S18428
A;Molecule type: protein
A;Residues: 27-46, 'H', 48-50-53, 'VD', 56, 'DY' <KIS>
A;Cross-references: UNIPARC:UPI0000173246
R;Kishi, J.I.; Ogawa, K.; Yamamoto, S.; Hayakawa, T.
Matrix 11, 10-16, 1991

A;Title: Purification and characterization of a new tissue inhibitor of metalloproteinase
A;Reference number: S15987; MUID:91226375; PMID:1851244
A;Accession: S15987
A;Molecule type: protein
A;Residues: 27-46, 'HIX', 50-52, 'LX', 55-56, 'DXX', 60, 'X', 62 <KL2>
A;Cross-references: UNIPARC:UPI0000173247
A;Note: this sequence has been revised in reference S18428
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases, possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating activity
C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; metalloproteinase inhibitor; mitogen
P;1-16/Domain: signal sequence #status predicted <SIG>
P;27-220/Product: metalloproteinase inhibitor 2 #status experimental <MAT>
P;27-98, 29-127, 39-152, 154-201, 159-164, 172-193/Disulfide bonds: #status predicted

Query Match 72.8%; Score 818; DB 1; Length 217;
Best Local Similarity 72.3%; Pred. No. 7.e-72;
Matches 146; Conservative 24; Mismatches 32; Indels 0; Gaps 0;
Qy 1 MAPFPLASGILWLMAPRRACTCVPPIPHQTAFCNSDLVIRAKFGTPEVNQ-TLYQ 60
Db 1 MAPFPLASGILWLMAPRRACTCVPPIPHQTAFCNSDLVIRAKFGTPEVNQ-TLYQ 60
Qy 61 YEIKTKMYKGFOALGDAADIRFVTPAMESVCYFHRSNHRSEELIAGSKLQDGHLTR 120
Db 61 YEIKTKMYKGFOALGDAADIRFVTPAMESVCYFHRSNHRSEELIAGSKLQDGHLTR 120
Qy 121 TCSFWAPWNISLADQRGFTKTYTVCECTVFPCLSIPICKLQSGTHCLWDQQLQSER 180
Db 121 ACSFLVWPWNISLADQRGFTKTYTVCECTVFPCLSIPICKLQSGTHCLWDQQLQSER 180
Qy 181 GFQSRHLACLPREPGLCTWL 202
Db 181 GFQSRHLACLPREPGLCTWL 202
Db 181 GYQSDHFACLPRNPDLCTWQYL 202

Query Match 37.4%; Score 420.5; DB 2; Length 220;
Best Local Similarity 42.8%; Pred. No. 2.8e-33;
Matches 86; Conservative 30; Mismatches 70; Indels 15; Gaps 6;
Qy 7 LASGILLWLMAPRRACTCVPPIPHQTAFCNSDLVIRAKFGTPEVNQ-TLYQ----- 59
Db 10 LAIGLILATLRPADACSCSPVHQQAFCNADVIRAKAVSEKEVDGNDIYGNPKRI 69
Db 70 QYEIKTKMFK----GPDKQIEFYITAPSSAVCG-VSLDVGGKKEYLAGKAEGLGK 123
Db 119 ITTCSPVAPWNISLADQRGFTKTYTVCECTVFPCLSIPICKLQSGTHCLWDQQLQGS 178
Db 124 ITLCDPFRVWDTLSITQKSLINHRYQMG-ECKITRCMPMCYISSPDECLWMDWTEKS 182
Db 179 EKGQSRHLACLPREPGLCTW 199
Db 183 INGHQAKFACIKRSQSGCAW 203

RESULT 10

153415
tissue inhibitor of metalloproteinase type 2 - rat
C;Species: Rattus sp. (rat)
C;Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 16-Jul-1999
C;Accession: 153415
R;Santoro, M.; Battaglia, C.; Zhang, L.; Carluomigno, F.; Martelli, M.L.; Salvatore, D.
Exp. Cell Res. 213, 398-403, 1994
A;Title: Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene
A;Reference number: 153415; MUID:94326839; PMID:8050496
A;Accession: 153415
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residue: 1-220 <RES>
A;Cross-references: UNIPARC:UPI00000102A; GB:S72594; NID:9619232; PIDN:AAC60687.1; P:
C;Genetic map:
C;Superfamily: metalloproteinase inhibitor
Query Match 37.4%; Score 420.5; DB 2; Length 220;
Best Local Similarity 42.8%; Pred. No. 2.8e-33;
Matches 86; Conservative 30; Mismatches 70; Indels 15; Gaps 6;

Qy 7 LASGILLWLMAPRRACTCVPPIPHQTAFCNSDLVIRAKFGTPEVNQ-TLYQ----- 59
Db 10 LAIGLILATLRPADACSCSPVHQQAFCNADVIRAKAVSEKEVDGNDIYGNPKRI 69

QY 60 RYEIKWTKMYKGFOALGDAADTRFVUTPAMESVCVGYPFRSHINRSEELFLAKLQ-DGLIH 118
Db 70 QYEIKQIKMKF---GPKDKEIFIYTPAPSACV-G-VSLDVGGKKEYLIAKGEGDKMH 123

QY 119 ITTCSEFYAPWMISLAAQRGERFTKTYTGCECTVPCUSICKPLQSGCWTQDGQS 178
Db 124 ITLCDFIVPWPDTLSTITOKSLSNRHYQMG-C-ECKITRCPMIPTCYISSPDECLWMDWTEKS 182

QY 179 EKGFPQSRHLACIPREFGCLTW 199
Db 183 INGHQAKPFACIKRSRSDGCAW 203

RESULT 11

S45683 metalloproteinase inhibitor 2 precursor - rat
N;Alternate names: TIMP-2; tissue inhibitor of metalloproteinases 2
C;Species: *Rattus norvegicus* (Norway rat)
C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004
C;Accession: S45683; S20160
R;Cook, T.F.; Burke, J.S.; Bergman, K.D.; Quinn, C.O.; Jeffrey, J.J.; Partridge, N.C.
Arch. Biochem. Biophys. 311, 313-320, 1994
A;Title: Cloning and regulation of rat tissue inhibitor of metalloproteinases-2 in osteoclasts
A;Reference number: S45683; MUID:94263207; PMID:8203893
A;Accession: S45683
A;Molecule type: mRNA

A;Residues: 1-220 <COP>
A;Cross-references: UNIPROT:P30121; UNIPARC:UPI00001707D2; GB:U14526; NID:9540204; PIDN:
R;Rowitz, W.T.; McCourt, D.W.; Partridge, N.C.; Jeffrey, J.J.
Arch. Biochem. Biophys. 292, 402-410, 1992
A;Title: Purification and sequence analysis of two rat tissue inhibitors of metalloproteinases
A;Reference number: S20325; MUID:92117648; PMID:1309971
A;Accession: S20325
A;Molecule type: protein
A;Residues: 27-48 <ROS>
R;Gibbons, K.L.; O Grady, R.L.; Piper, A.A.
submitted to the EMBL Data Library, June 1995
A;Description: Rat tissue inhibitor of metalloproteinases-2: cDNA cloning and sequence
A;Reference number: S60160
A;Accession: S60160
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-6, 'S', 8-20, 'V', 22-152, 'E', 154-220 <GTB>
A;Cross-references: UNIPARC:UPI0000173249; EMBL:L31884
C;Geants: A;Gene: TIMP-2
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating C;Superfamily: metalloproteinase inhibitor
C;Keywords: erythropoiesis; extracellular matrix; metalloproteinase inhibitor; mitogen F1-56/Domain: Signal sequence #status predicted <SIG>
F;27-220/Product: metalloproteinase inhibitor 2 #status predicted <MAT>
F;27-98,29-127,39-152,154-201,159-164,172-173/Disulfide bonds: #status predicted
Query Match 37.1%; Score 417.5; DB 1; Length 220;
Best Local Similarity 42.3%; Pred. No. 5.4e-33; Matches 85; Conservative 31; Mismatches 70; Indels 15; Gaps 6;

QY 7 LASGILILWLIAPSRACTCPVPHPQTAFCNDSLVLRAKFVTPENQ-TIYQ---- 59
Db 10 LALGILLIATLLRPADACSCSPVHPQAFCNADWVIRAKAVSEKEVDSGNIDYGNPIRKI 69

QY 60 RYEIKWTKMYKGFOALGDAADTRFVUTPAMESVCVGYPFRSHINRSEELFLAKLQ-DGLIH 118
Db 70 QYEIKQIKMKF---GPKDKEIFIYTPAPSACV-G-VSLDVGGKKEYLIAKGEGDKMH 123

QY 119 ITTCSEFYAPWMISLAAQRGERFTKTYTGCECTVPCUSICKPLQSGCWTQDGQS 178
Db 124 ITLCDFIVPWPDTLSTITOKSLSNRHYQMG-C-ECKITRCPMIPTCYISSPDECLWMDWTEKS 182

QY 179 EKGFPQSRHLACIPREFGCLTW 199
Db 183 INGHQAKPFACIKRSRSDGCAW 203

RESULT 12

A37128 metalloproteinase inhibitor 2 precursor [validated] - human
N;Alternate names: chondrocyte-derived angiogenesis inhibitor; TIMP-2; tissue inhibitor
C;Species: Homo Sapiens (man)
C;Accession: 08-Mar-1991 #sequence_revision 12-Apr-1996 #text_change 09-Jul-2004
C;Accession: A37128; B3596; A34464; A34115; S2103; S17165; S58794
R;Steiner-Stevenson, W.G.; Brown, P.D.; Onisko, M.; Levy, A.T.; Liotta, L.A.
J. Biol. Chem. 265, 13933-13938, 1990
A;Title: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell
A;Reference number: A37128; MUID:90338014; PMID:3380196
A;Accession: A37128
A;Molecule type: mRNA
A;Residues: 1-220 <SNE>
A;Cross-references: UNIPROT:P16035; UNIPARC:UPI0000136F99; GB:J05593; NID:9339706; PIDN:
A;Experimental source: A2058 melanoma cell cDNA library
R;Boone, T.C.; Johnson, M.J.; De Clerck, Y.A.; Langley, K.E.
Proc. Natl. Acad. Sci. U.S.A. 87, 2800-2804, 1990
A;Title: cDNA cloning and expression of a metalloproteinase inhibitor related to tissue
A;Reference number: A35996; MUID:90207285; PMID:2157214
A;Accession: B35996
A;Molecule type: mRNA
A;Residues: 1-220 <BOO>
A;Cross-references: UNIPARC:UPI0000136F99; GB:M32304; NID:9187522; PIDN:AAA59581.1; PID:
A;Experimental source: fetal aorta cDNA library
R;Stettler-Stevenson, W.G.; Krutzsch, H.C.; Liotta, L.A.
J. Biol. Chem. 264, 17374-17378, 1989
A;Title: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase family
A;Reference number: A34464; MUID:90008902; PMID:2793861
A;Accession: A34464
A;Molecule type: protein
A;Residues: 27-77, 'K', 79-81, 'I', 83-100, 'E', 102-117, 119-121-'R', 123-149, 'Q', 151-174, 'T', 1
A;Cross-references: UNIPARC:UPI000017323B; UNIPARC:UPI000017323F
A;Experimental source: serum-free culture medium of A2058 cells
R;Goldberg, G.I.; Mammer, B.L.; Grant, G.A.; Eisen, A.Z.; Wilhelm, S.; He, C.
Proc. Natl. Acad. Sci. U.S.A. 86, 8207-8211, 1989
A;Title: Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor
A;Reference number: A34415; MUID:90046765; PMID:2554304
A;Accession: A34415
A;Molecule type: protein
A;Residues: 30-51,128-141,159-173 <GOL>
A;Cross-references: UNIPARC:UPI0000173240; UNIPARC:UPI0000173241; UNIPARC:UPI0000173242
A;Residues: R;Malik, K.; Sejima, H.; Aoki, T.; Iwata, K.
A;Description: Submitted to the EMBL Data Library, August 1990
A;Reference number: S21303
A;Accession: S21303
A;Molecule type: protein
A;Residues: 30-95, 'V', 97-214 <MAL>
A;Cross-references: UNIPARC:UPI000016B0E4; EMBL:X54533; NID:937180; PIDN:CAA38400.1; PDB:
R;Osthues, A.; Knaeuer, V.; Oberhoff, R.; Reinke, H.; Tschesche, H.
FEBS Lett. 296, 16-20, 1992
A;Title: Isolation and characterization of tissue inhibitors of metalloproteinases (TIME)
A;Reference number: S20318; MUID:9211776; PMID:1730286
A;Accession: S20318
A;Molecule type: protein
A;Residues: 'X', 28, 'X', 30-38, 'X', 40-41 <OST>
A;Cross-references: UNIPARC:UPI0000173243
A;Experimental source: rheumatoid synovial fluid
R;Ward, R.V.; Hembry, R.M.; Reynolds, J.J.; Murphy, G.
Arch. Biochem. Biophys. 278, 179-187, 1991
A;Title: The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa preprotein
A;Reference number: S17165
A;Accession: S17165
A;Status: preliminary
A;Molecule type: protein
A;Residues: 27, 'X', 29, 'X', 31-38 <WAR>
A;Cross-references: UNIPARC:UPI0000173244

R; Ooba, Y.; Goto, Y.; Kimura, Y.; Suzuki, F.; Hisa, T.; Takahashi, K.; Takigawa, M.
 Biochim. Biophys. Acta 1245, 1-8, 1995
 A; Reference number: S58794; MUID:95383380; PMID:7544625
 A; Accession: S58794
 A; Status: preliminary
 A; Molecule type: protein
 A; Residues: 27-37 <OHB>
 A; Cross-references: UNIPARC:UPI000173245
 C; Genetics:
 A; Gene: GDB:TMMP2
 A; Cross-references: GDB:132612; OMIM:168825
 A; Map position: 17q25-17q25
 C; Function:
 A; Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentially possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentially C; Superfamily: metalloprotease inhibitor; extracellular matrix; metalloprotease inhibitor; mitogen C; Keywords: erythropoiesis; extracellular matrix; metalloprotease inhibitor; mifogen F; 1-26/Domain: signal sequence #status predicted <SIG> experimental <MAT>
 F; 27-220/Product: metalloprotease inhibitor 2 #status bonds: #status predicted
 F; 27-98, 29-127, 39-152, 154-201, 159-164, 172-193/Disulfide bonds: #status predicted
 Best Local Similarity 37.0%; Score 415.5; DB 1; Length 220;
 Matches 85; Conservative 30; Mismatches 71; Indels 15; Gaps 6;
 Qy 7 LASGILTLLWLIAPSRACTVPPHPIQTAFCNSDLVIRAKFVGTPENQ-TTLQO----- 59
 Db 10 LALGILLLATLRLPADAQSCSPVHQQAFCNADVIRAKAVSEKEVDGNDIYGNPIKR 69
 Qy 60 RYEIKTMTKKGFOALGADIRFVTPAMESVCGYFRSHNRSEFLTAGKQ-DGILH 118
 Db 70 QYEIKIQIKMFK---GPEDIEFYIARTSARAVCG-VSLVGGKKEYLIAKGAGDKOMI 123
 Qy 119 ITTSFVAPWNSLSLAQRRGFTKTYVGCBCCTVPCLSICPKLQSGTHCLWTDQLOQS 178
 Db 124 ITLCDFIVPDTLSTQKESLNHRYQMG-C-ECKITRCPMPCVYSSPDECLWMDWTEK 182
 Qy 179 EKGFSRHLCLPREFGLCTW 199
 Db 183 INGHQAKFFACIKRSRGSCAW 203

RESULT 13

A35996 metalloproteinase inhibitor 2 precursor - bovine
 N; Alternate names: collagenase inhibitor; tissue inhibitor of metalloproteinases (TIMP-2)
 C; Species: Bos primigenius taurus (cattle)
 C; Date: 16-Nov-1990 #sequence revision 12-Apr-1996 #text_change 09-Jul-2004
 C; Accession: A35996; A3468; A25327; S28151
 R; Boone, T.C.; Johnson, M.J.; De Clerck, Y.A.; Langley, K.E.
 Proc. Natl. Acad. Sci. U.S.A. 87, 2800-2804, 1990
 A; Title: cDNA cloning and expression of a metalloproteinase inhibitor related to tissue
 A; Reference number: A35996; MUID:90207285; PMID:2157214
 A; Accession: A35996
 A; Molecule type: mRNA
 A; Residues: 1-1220 <BOO>
 A; Cross-references: UNIPROT:P16368; UNIPARC:UPI000136F93; GB:M32303; NID:9163341; PIDN:
 A; Experimental source: aortic endothelial cDNA library
 A; De Clerck, Y.A.; Yeam, T.D.; Ratzkin, B.J.; Lu, H.S.; Langley, K.E.
 J. Biol. Chem. 264, 17445-17453, 1989
 A; Title: Purification and characterization of two related but distinct metalloproteinase
 A; Reference number: A34468; MUID:9008914; PMID:2551903
 A; Molecule type: protein
 A; Residues: 27-71 <DEC>
 A; Cross-references: UNIPARC:UPI00017324A
 A; Experimental source: culture medium of aortic endothelial cells
 R; Murray, J.B.; Allison, K.; Sudhalter, J.; Langer, R.
 J. Biol. Chem. 261, 4154-4159, 1986
 A; Title: Purification and partial amino acid sequence of a bovine cartilage-derived coll
 A; Reference number: A25322; MUID:8614035; PMID:300531
 A; Accession: A25322

A; Molecule type: protein
 A; Residues: 27-41, 'C', 43-55, 'EX', 58-59, 'X', 61-66, 'XS', 69-71 <MUR>
 A; Cross-references: UNIPARC:UPI00017324B
 A; Experimental source: cartilage
 R; De Clerck, Y.A.; Yeam, T.D.; Lee, Y.; Tomich, J.M.; Langley, K.E.
 Biochem. J. 289, 65-69, 1993
 A; Status: preliminary
 A; Molecule type: protein
 A; Residues: 27-37 <OHB>
 A; Cross-references: UNIPARC:UPI00005F30A; EMBL:U02571; NID:9472309; PIDN:AAA17672.1; P
 C; Genetics:
 A; Gene: GDB:TMMP2
 A; Cross-references: UNIPARC:UPI00017324C
 R; Krishnan, N.S.; Staskub, P.W.; Yang, T.T.; Masiarz, F.R.; Hawkes, S.P.
 Matrix Biol. 14, 479-488, 1994
 A; Title: Identification and characterization of human tissue inhibitor of metalloprotein
 A; Reference number: S553870
 A; Molecule type: protein
 A; Residues: 'X', 25, 'XX', 'X', '30-35,'X', '37, 'X', '39-41 <KIS>
 A; Cross-references: UNIPARC:UPI00017324C
 R; Wick, M.; Buerger, C.; Brueselbach, S.; Lucibello, F.C.; Mueller, R.

RESULT 14

S45317 metalloproteinase inhibitor 3 precursor [validated] - human
 N; Alternate names: mig-5 protein; TIMP-3; tissue inhibitor of metalloproteinases 3
 C; Species: Homo sapiens (man)
 C; Date: 06-Jan-1995 #sequence revision 12-Apr-1996 #text_change 09-Jul-2004
 C; Accession: S45317; S59515; S53970; I38023; A9614; C56537; I5305; S47941
 R; Urias, J.A.; Ferrando, A.A.; Velasco, G.; Freije, J.M.P.; Lopez-Otin, C.
 Cancer Res. 54, 2091-2094, 1994
 A; Title: Structure and expression in breast tumors of human TIMP-3, a new member of the
 A; Reference number: S45317; MUID:94228524; PMID:8174111
 A; Accession: S45317
 A; Molecule type: mRNA
 A; Residues: 1-211 <URI>
 A; Cross-references: UNIPROT:P35625; UNIPARC:UPI00005F30A; EMBL:X76227; NID:9495251; PI
 R; Silbiger, S.M.; Jacobsen, V.L.; Cupples, R.L.; Koski, R.A.
 Gene 141, 293-297, 1994
 A; Title: Cloning of cDNAs encoding human TIMP-3, a novel member of the tissue inhibitor
 A; Reference number: S55915; MUID:94215920; PMID:8163205
 A; Accession: S55915
 A; Status: preliminary
 A; Molecule type: mRNA
 A; Residues: 1-211 <SIL>
 A; Cross-references: UNIPARC:UPI00005F30A; EMBL:U02571; NID:9472309; PIDN:AAA17672.1; P
 R; Krishnan, N.S.; Staskub, P.W.; Yang, T.T.; Masiarz, F.R.; Hawkes, S.P.
 Matrix Biol. 14, 479-488, 1994
 A; Title: Identification and characterization of human tissue inhibitor of metalloprotein
 A; Reference number: S553870
 A; Molecule type: protein
 A; Residues: 'X', 25, 'XX', 'X', '30-35,'X', '37, 'X', '39-41 <KIS>

J. Biol. Chem. 269, 18953-18960, 1994
A;Title: A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family
A;Reference number: I38023; MUID:94308155; PMID:8034652
A;Accession: I18023
A;Molecule type: mRNA
A;Residues: 1-15, 'W', 17, 'T', 20-21, 'P', 24-201, 'X', 203-211 <RES>
A;Experimental source: Fibroblast cell line WI-38
R;Apie, S.S.; Mattei, M.G.; Olsen, B.R.
Genomics 19, 86-90, 1994.
A;Title: Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3)
A;Reference number: A49614; MUID:94245184; PMID:8188246
A;Accession: A49614
A;Molecule type: mRNA
A;Residues: 14-20, 'R', 23-211 <AP1>
A;Cross-references: UNIPARC:UPI00016B0E5; GB:L15078; NID:9407034; PIDN:AA21815.1; PID:
A;Experimental source: placenta cDNA library
R;Apie, S.S.; Olsen, B.R.; Murphy, G.
J. Biol. Chem. 270, 14313-14318, 1995
A;Title: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its isoforms
A;Reference number: C66937; MUID:95301511; PMID:7782289
A;Accession: C66937
A;Molecule type: protein
A;Residues: 'X', 25, 'X', 27-35, 'X', 37 <AP2>
A;Cross-references: UNIPARC:UPI00017324D
R;Wide, C.G.; Hawkins, P.R.; Coleman, R.T.; Levine, W.B.; Deleageane, A.M.; Okamoto, P.M.
DNA Cell Biol. 13, 711-718, 1994
A;Title: Cloning and characterization of human tissue inhibitor of metalloproteinases-3.
A;Reference number: I53025; MUID:95290091; PMID:7772252
A;Accession: I53025
A;Status: translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-211 <R2>
A;Cross-references: UNIPARC:UPI00005F30A; GB:S78453; NID:9998825; PIDN:AA83453.1; PID:
C;Genetics: A;Gene: GDB:TMPI3
A;Cross-references: GDB:138175; OMIM:188826
A;Map position: 22q2.1-22q13.2
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases
A;Note: transcription induced by cytokines, tumor promoters, and anti-inflammatory agent
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: extracellular matrix; metalloproteinase inhibitor
F;1-23/Domain: Signal sequence #status predicted <SIG>
F;24-211/Product: metalloproteinase inhibitor 3 #status experimental <MAT>
F;24-91,26-118,36-143,145-192,150-155,163-184/Disulfide bonds: #status predicted
Query Match 34.6%; Score 388.5; DB: 1; Length 196;
C;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases
A;Note: transcription induced by cytokines, tumor promoters, and anti-inflammatory agent
A;Note: TIMP-1 and TIMP-3 have distinct but overlapping tissue-specific expression patterns
C;Superfamily: metalloproteinase inhibitor
C;Keywords: extracellular matrix; metalloproteinase inhibitor
F;1-23/Domain: Signal sequence #status predicted <SIG>
F;24-211/Product: metalloproteinase inhibitor 3 #status experimental <MAT>
F;24-91,26-118,36-143,145-192,150-155,163-184/Disulfide bonds: #status predicted
Query Match 34.7%; Score 389.5; DB: 1; Length 211;
Best Local Similarity 39.6%; Pred. No. 2.7e-30;
Matches 78; Conservative 38; Mismatches 66; Indels 15; Gaps 7;
Oy 10 GILLLU-WLIAP-SRACTCVPPHPQTAFCMSDLVIRAKFGVTPENQ--TTIYORIE 62
Db 6 GLIVLVLGSWSLGDWGAGTCPSHPQDAFCMSDLVIRAKFGVKGKLUVKEGPFGTLV--YT 63
Oy 63 IKTQTKMYRKFGQALGDAADIRFVYTPAMESVCGYFHRSHRSRSEFLAGKLQDGGLHHTTC 122
Db 64 IKQKMKMTRGFTRM--PHVQYIITEASESSLGL--KLEVNKWQYLUTGRVDFKGMVYGLC 118
Oy 123 SVPAPWNLSLQSRRGFTKTYTGCGEBCTVFFCLSLICKLQSGTHCLWTDPDOLQSGEKGF 182
Db 119 NFVVERWDQLTSORKGLNVRYHLGC-NCKIKSCYYLPFCFVTSKNECLWTMLSNFGVPGY 177
Oy 183 QSRHLAQLPREPOLCTW 199
Db 178 QSKHYACIRQKGGYCSW 194

C;Species: Cricetus longicaudatus (long-tailed hamster)
C;CreateDate: 06-Jan-1995 #sequence_revision 12-Apr-1996 #text_change 09-Jul-2004
C;Accession: S38624
A;Accession: S38624
R;Suizu, Y.
A;Submitted to the EMBL Data Library, November 1993
A;Accession: S38624
A;Molecule type: mRNA
A;Residues: 1-196 <SIZ>
A;Cross-references: UNIPROT:Q60453; UNIPARC:UPI000136F97; EMBL:X75924; NID:9414876; PID:
A;Function:
A;Description: regulation of extracellular matrix remodeling by inhibition of matrix metalloproteinases possibly controlling their activation; TIMP-1 and TIMP-2 possess erythroid potentiating C;Superfamily: metalloproteinase inhibitor
A;Keywords: erythropoiesis; extracellular matrix; metalloproteinase inhibitor 2 #status predicted F;3-196/Product: metalloproteinase inhibitor 2 #status predicted <MAT>
F;3-74,5-103,15-128,1130-177,135-140,148-169/disulfide bonds: #status predicted

Query Match 34.6%; Score 388.5; DB: 1; Length 196;
Best Local Similarity 42.5%; Pred. No. 3.1e-30; Matches 79; Conservative 26; Mismatches 66; Indels 15; Gaps 6;
Db 22 RACTCVPPHPQTAFCMSDLVIRAKFGVTPENQ--TTIYQ----RVEIKMTKMYKGFOA 74
Oy 1 RACSCSVHPPQAFCNADVIRAKAVSEKEUDNSGNDIYGNPIKRIOYEIKOKMFR--- 56
Db 75 LGDAADRFPVYTPAMESVCGYFHRSHRSRSEFLAGKLQ-DGLLHTTCFSVAPWNLSL 133
Oy 57 -GPDKDIEFIYVAPSSAVCG-VSLDVQGGKEYLIAQKAEKGDKOMWHITLCDFRWPDLST 114
Db 134 HQRGFRTKTYTGCGCSTVFFCLSLICKLQSGTHCLWTDPDOLQSGEKGF 193
Oy 115 TORKSLMHRYOMGC-ECKITRCPMIPCYISSPDECILMDWTEKSINGHQAKFFACIKS 173
Db 194 PGICLTW 199
Db 174 DGSCAW 179

Search completed: April 10, 2006, 18:07:32
Job time : 13.8416 sec

RESULT 15
S38624 metalloproteinase inhibitor 2 precursor - long-tailed hamster (fragment)
N;Alternate names: TIMP-2; tissue inhibitor of metalloproteinases 2

GenCore version 5.1.7									
copyright (C) 1993 - 2006 Biocceleration Ltd.									
OM protein - protein search, using sw model									
Run on: April 10, 2006, 17:55:05 , Search time 79.703 Seconds									
(without alignment)									
1141.129 Million cell updates/sec									
Title: US-10-734-564-100	Perfect score: 1124	Sequence: 1 MPPFRPLASGIVLILWLIAP. NCLPRLPGLCTWMSLRSQIA 207	Scoring table: BLOSUM62	Gapop 10.0 , Gapext 0.5	Searched: 2443163 seqs, 439378781 residues	Total number of hits satisfying chosen parameters: 2443163	Minimum DB seq length: 0	Maximum DB seq length: 200000000	Post-processing: Minimum Match 0%
Maximum Match 100%									
Listing first 45 summaries									
Database : A_Geneseq_21:*	1: geneseqp1980s:*	2: geneseqp1990s:*	3: geneseqp2000s:*	4: geneseqp2015s:*	5: geneseqp2002s:*	6: geneseqp2003as:*	7: geneseqp2003bs:*	8: geneseqp2004bs:*	9: geneseqp2005s:*
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.									
SUMMARIES									
Result No.	Score	Query Length	DB ID	Description	XX	XX	XX	XX	RESULT 1
1 1124 100.0	207 1	ADP60592	ADP60592	ADP60592 Sequence	ID	ADP60592 Standard; protein; 207 AA.			ADP60592
2 1124 100.0	207 1	ADP60275	ADP60275	ADP60275 Sequence	AC	ADP60592;			ADP60592
3 1124 100.0	207 1	ADP6786	ADP6786	ADP6786 Sequence	DT	13-AUG-1991 (first entry)			ADP6786
4 1124 100.0	207 2	AQW30309	AQW30309	AQW30309 Human TIM	XX	DE Sequence of a human protein having erythroid potentiating activity (EPA).			AQW30309
5 1124 100.0	207 2	AAY08933	AAY08933	AAY08933 Human TIM	KW	Erythroid precursor growth; anaemia therapy.			AAY08933
6 1124 100.0	207 3	ABJ19073	ABJ19073	ABJ19073 Inhibitor	XX	OS Homo sapiens.			ABJ19073
7 1124 100.0	207 7	ADQ37139	ADQ37139	ADQ37139 Human tis	PF	01-OCT-1984; 84US-00656590.			ADQ37139
8 1124 100.0	207 7	ADL78929	ADL78929	ADL78929 Human tis	XX	PR 01-OCT-1984; 84US-00656590.			ADL78929
9 1124 100.0	207 8	ADG25251	ADG25251	ADG25251 Human TIM	PA	(SANDOZ LTD. (RBGC) REGENTS OF UNIV OF CALIF).			ADG25251
10 1124 100.0	207 8	ADQ07367	ADQ07367	ADQ07367 Human TIM	PI	Brown E, Clark S, Golde DW, Casson JC, Hewick R, Westbrook CA;			ADQ07367
11 1124 100.0	207 8	ADP75947	ADP75947	ADP75947 Human TIM	DR	WPI; 1986-106663/16.			ADP75947
12 1124 100.0	207 8	ADQ29674	ADQ29674	ADQ29674 Human col	DR	N PSDB; AAN0494.			ADQ29674
13 1124 100.0	207 8	ADP23249	ADP23249	ADP23249 PRO polyp	XX	PT Vectors contg. gene for protein having erythroid potentiating activity -			ADP23249
14 1124 100.0	207 8	ADU05696	ADU05696	ADU05696 Novel bro	PT	PT used for producing protein to stimulate growth and formation of erythroid			ADU05696
15 1124 100.0	207 9	ADU70205	ADU70205	ADU70205 Tumor-ass	PT	cells.			ADU70205
16 1124 100.0	207 9	ADY14618	ADY14618	ADY14618 PRO polyp	XX	PS Disclosure; Fig 4; 5opp; English.			ADY14618
17 1124 100.0	207 9	ADB8782	ADB8782	ADB8782 Human TIM	XX	The inventors claim human and gibbon EPA proteins (ADP60592, ADP60593) and cDNA that encodes EPA (AAN06494, AAN06495). The EPA protein has a biological activity of at least about 1,000,000 units per mg of protein and has an apparent molecular weight of about 28,000 daltons			ADB8782
18 1121 99.7	207 1	ADP60593	ADP60593	ADP60593 Sequence	XX	Sequence 207 AA;			ADP60593
19 1120 99.6	207 4	ADG89171	ADG89171	ADG89171 Human sec	CC	The inventors claim human and gibbon EPA proteins (ADP60592, ADP60593) and cDNA that encodes EPA (AAN06494, AAN06495). The EPA protein has a biological activity of at least about 1,000,000 units per mg of protein and has an apparent molecular weight of about 28,000 daltons			ADG89171
20 1119 99.6	207 6	ADM3377	ADM3377	ADM3377 Human pol	CC	Sequence 207 AA;			ADM3377
21 1119 99.6	207 8	ADL30920	ADL30920	ADL30920 Human pro	CC	Query Match 100.0%; Score 1124; DB 1; Length 207;			ADL30920
22 1118 99.5	207 9	ADZ70216	ADZ70216	ADZ70216 Human tis	CC	Best Local Similarity 100.0%; Pred. No. 4.1e-109; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			ADZ70216
23 1104 98.2	207 2	ADB5005	ADB5005	ADB5005 Human tis	CC	Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			ADB5005
24 1073.5	95.5	203 8	ADP28641	ADP28641 Human tis	XX	ADP28641 Human col			ADP28641

QY	1 MAPFPLASGLILWLIWLIAPSRACITCVPHPHQTAFCNSDLVIRAKFVGTPENVNOTLYQR	100.0% Score 1124; DB 1; Length 207;
Db	1 MAPFPLASGLILWLIWLIAPSRACITCVPHPHQTAFCNSDLVIRAKFVGTPENVNOTLYQR	Best Local Similarity 100.0%; Pred. No. 4.1e-109; Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	61 YEIKMTKMYKGFOALGDAADIRFVTPAMESVCGYFHRSHNRSEFLAGKLQDGLLHT 120	
Db	61 YEIKMTKMYKGFOALGDAADIRFVTPAMESVCGYFHRSHNRSEFLAGKLQDGLLHT 120	
QY	121 TCSFVAPWNLSLAQRGRGFTKTYVGCBCITVFFCLSIPECKLQSGTHCLWTDLQLGSEK 180	
Db	121 TCSFVAPWNLSLAQRGRGFTKTYVGCBCITVFFCLSIPECKLQSGTHCLWTDLQLGSEK 180	
QY	181 GFOSRHLACIIPREPGCTWOSLRQIA 207	
Db	181 GFOSRHLACIIPREPGCTWOSLRQIA 207	
RESULT 2		
ID	AAP60275 standard; protein; 207 AA.	
XX		
AC	AAP60275;	
XX		
DT	25-MAR-2003 (revised)	
DT	03-OCT-2002 (revised)	
XX	08-AUG-1991 (first entry)	
DE	Sequence of human natural inhibitor of collagenases (NIC).	
XX		
KW	Metallo-proteinase inhibitor; wound healing; emphysema; rheumatoid arthritis therapy; ulceration; tumour metastasis.	
KW		
XX	OS Homo sapiens.	
PH	Key	location/Qualifiers
PT	Peptide	1. .23 /label= signal
FT	Protein	24. .207 /note= "claimed"
FT	Modified-site	53. .55 /note= "potential glycosylation site"
FT	Modified-site	101. .103 /note= "potential glycosylation site"
FT	EP189784-A.	
PD	06-AUG-1986.	
XX	PP 16-JAN-1986; 86BP-00100482.	
PR	18-JAN-1985; 85US-00692808.	
XX	(SEAR) SEARLE & CO G D.	
PA	XX Galloway WA, Clissold PM, McCullagh KG;	
PR	DR WPI; 1986-205910/32.	
XX	N-PSDB; AAN60277.	
PT	New human natural inhibitor of collagenase - for treating e.g. rheumatoid arthritis or ulceration, and new DNA sequences coding for it.	
XX	Disclosure; Fig 2; 51pp; English.	
CC	The patentors claim the AA SO of human NIC. DNA sequences coding for NIC, and its RNA analogues and plasmids config. this DNA. NIC inhibits the activity of metallo-proteinases, esp. of collagenase, proteoglycanase, gelatinase or a leucocyte, macrophage or tumour cell metallo-proteinase. (Updated on 03-OCT-2002 to add missing OS field.) (Updated on 25-MAR-2003 to correct PA field.)	
CC		
SQ	Sequence 207 AA;	
RESULT 3		
ID	AAP60786 standard; protein; 207 AA.	
XX		
AC	AAP60786;	
XX		
DT	25-MAR-2003 (revised)	
DT	08-AUG-1991 (first entry)	
DE	Sequence of tissue inhibitor of metalloproteinase (TIMP).	
XX		
KW	Connective tissue; extracellular matrix.	
XX	OS Homo sapiens.	
PH	Key	location/Qualifiers
FT	Peptide	1. .23 /label= signal
FT	Protein	24. .207
FT	Modified-site	53. .55 /label= potential N-glycosylation site
FT	Modified-site	101. .103 /label= as above
FT	GB2169295-A.	
PN		
XX	PD 09-JUL-1986.	
XX	PP 06-JAN-1986; 86GB-00000199.	
XX	PR 05-OCT-1983; 83BE-00897924.	
PR	07-JAN-1985; 85GB-00000341.	
PR	07-JAN-1985; 85GB-0050341.	
PR	01-NOV-1985; 85GB-00026951.	
XX	PA (CLLT) CELLTech LTD.	
XX	PA Harris TUR, Reynolds JJ, Docherty AJP, Murphy G;	
XX	DR WPI; 1986-177873/28	
XX	N-PSDB; AAN60338.	
PT	Prodn. of metallo-Proteinase inhibitors - by recombinant DNA technique.	
XX	Disclosure; Fig 3; 16pp; English.	
PS	A gene with residues 64-684 of AAN60538 is claimed. AAN60538 was isolated from human a foetal diploid lung cells (ATCC CRL1535) CDNA library using AAN60539. (Updated on 25-MAR-2003 to correct PA field.)	
CC	Sequence 207 AA;	

Query Match 100.0%; Score 1124; DB 1; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLIILIPSRACCTCUPPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60
 Db 1 MAPPEPLASGILLIILIPSRACCTCUPPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60
 Qy 61 YEIKMVKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSEEFLLAGKQDGHLIT 120
 Db 61 YEIKMVKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSEEFLLAGKQDGHLIT 120
 Qy 121 TCSFVPAWNSLSLAORGRFTKTYTGCECTVFCCLSPCKLQSGTHCLWTDOLQGSEK 180
 Db 121 TCSFVPAWNSLSLAORGRFTKTYTGCECTVFCCLSPCKLQSGTHCLWTDOLQGSEK 180
 Qy 181 GFQSRHLACUPREPGCTWSIRSQIA 207
 Db 181 GFQSRHLACUPREPGCTWSIRSQIA 207

RESULT 4
 AAW0309
 ID AAW0309 standard; protein; 207 AA.
 XX
 AC AAW0309;
 XX
 DT 29-JAN-1998 (first entry)
 DE Human TIMP-1.
 XX
 KW TIMP-3; human; antibody; TIMP-3-mediated disease; malignant tumour cell; cancer progression; TIMP-1.
 XX
 OS Homo sapiens.
 XX
 PN JP09235300-A.
 XX
 PD 09-SEP-1997.
 XX
 PR 29-FEB-1996; 96JP-00067484.
 XX
 PA (FUJY) FUJI PHARM IND CO LTD.
 XX
 DR WPI; 1997-498341/46.
 XX
 DR N-PSDB; AT92631.
 XX
 PT Human TIMP-3 and anti-human TIMP-3 monoclonal antibodies - used in diagnosis of TIMP-3 mediated diseases, especially the detection of malignant tumour cells.
 XX
 PS Example 12; Page 33-34; 37pp; Japanese.

XX
 CC This sequence represents the human TIMP-1 protein. This sequence was used to test the specificity of the monoclonal antibody (Mab) of the invention. The Mab of the invention reacts specifically with human TIMP-3 (see AAW0308), by specific recognition of the TIMP-3 fragments represented by AAW0305-W30307. The Mab can be used in the study or diagnosis of TIMP-3-mediated diseases, particularly for the detection of malignant tumour cells, or the diagnosis of progressiveness of cancers. They can also be used in establishing an immunoassay for TIMP-3 or in purification of TIMP-3. The transformed cells can be used for producing TIMP-3 or its equivalent proteins on a large scale. The immunoassay method for TIMP-3 the Mabs is simple, highly reproducible and highly sensitive

XX
 SQ Sequence 207 AA;

Query Match 100.0%; Score 1124; DB 2; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLIILIPSRACCTCUPPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60
 Db 1 MAPPEPLASGILLIILIPSRACCTCUPPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60
 Qy 61 YEIKMVKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSEEFLLAGKQDGHLIT 120
 Db 61 YEIKMVKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSEEFLLAGKQDGHLIT 120
 Qy 121 TCSFVPAWNSLSLAORGRFTKTYTGCECTVFCCLSPCKLQSGTHCLWTDOLQGSEK 180
 Db 121 TCSFVPAWNSLSLAORGRFTKTYTGCECTVFCCLSPCKLQSGTHCLWTDOLQGSEK 180
 Qy 181 GFQSRHLACUPREPGCTWSIRSQIA 207
 Db 181 GFQSRHLACUPREPGCTWSIRSQIA 207

RESULT 5
 AAY08933
 ID AAY08933 standard; protein; 207 AA.
 XX
 AC AAY08933;
 XX
 DT 19-AUG-1999 (first entry)
 DE Human TIMP-1 protein.
 XX
 KW TIMP-4; tissue inhibitor of metalloprotease; human; antibody; diagnosis; treatment; metastasis; neoplastic cell; angiogenesis; tumour; cervical; uterine; pancreatic; colon; intestinal carcinoma; pregnancy; ulcer; osteoarthritis; pulmonary emphysema; Periodontal disease; corneal; rheumatoid arthritis; diabetic ulcer; lesion; TIMP-4.
 XX
 OS Homo sapiens.
 XX
 PN US5914392-A.
 XX
 PD 22-JUN-1999.
 XX
 PR 07-JUL-1998; 98US-00111070.
 XX
 PR 18-JAN-1996; 96US-00388163.
 XX
 PR 27-JUN-1997; 97US-00884073.
 XX
 PA (INCY-) INCYTE PHARM INC.
 XX
 PI Murry LE, Hawkins PR;
 XX
 DR WPI; 1999-384187/32.
 XX
 PT Anti-tissue inhibitor metalloproteinase antibodies useful for treating and diagnosing cancer.
 XX
 PS Disclosure; Fig 4; 26pp; English.

XX
 CC This invention describes a novel method for the production of antibodies specific for the human tissue inhibitors of metalloproteinase 4, TIMP-4. The anti-TIMP-4 antibodies may be used to treat, prevent or diagnose metastasis of neoplastic cells, angiogenesis and growth tumours such as cervical, uterine, pancreatic, colon or intestinal carcinomas, pregnancy, osteoarthritis, pulmonary emphysema, Periodontal disease, rheumatoid arthritis, corneal or diabetic ulcers or ulcers and lesions caused by microorganisms. This sequence represents TIMP-4 which is used to describe the method of the invention

XX
 SQ Sequence 207 AA;

Query Match 100.0%; Score 1124; DB 2; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;

Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLIILIPSRACCTCUPPHQTAFCNSDLVIRAKFVGTPENQNTLYQR 60

XX
PT Composition useful for treating pulmonary inflammation e.g. chronic
PT obstructive pulmonary disease comprises a lung surfactant polypeptide and
PT a protease inhibitor.

XX
PS Claim 6; SEQ ID NO 20; 137pp; English.

CC The invention relates to a liquid aerosolised composition, comprising a lung surfactant polypeptide and a protease inhibitor. The composition is useful for treating pulmonary inflammation (e.g. inflammation associated with pulmonary hypertension, neonatal pulmonary hypertension, acute bronchopulmonary dysplasia, chronic obstructive pulmonary disease, acute or chronic bronchitis, emphysema, bronchiolitis, bronchiectasis, radiation pneumonitis, hypersensitivity, pneumonitis, acute inflammatory asthma, acute smoke inhalation, thermal lung injury, allergic asthma, iatrogenic asthma, cystic fibrosis, alveolar proteinosis, alpha-1-protease deficiency, pulmonary inflammatory disorders, pneumonia, acute respiratory distress syndrome, and idiopathic pulmonary fibrosis). The current sequence represents a protease inhibitor that may be part of a composition of the invention.

XX Sequence 207 AA;

Query Match Score 1124; DB 8; Length 207;
Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGLILLWLIAPSRACCTVPPHQTAFCNSDLVIRAKFVGTPSVNQNTLYQR 60
Db 1 MAPPEPLASGLILLWLIAPSRACCTVPPHQTAFCNSDLVIRAKFVGTPSVNQNTLYQR 60

QY 61 YERKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSRBERLIAKLGQDGLHIT 120
Db 61 YERKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSRBERLIAKLGQDGLHIT 120

QY 121 TCSFVAPWNISLQAQRGGFTKTYTGCEECTVFPCLSIPICKLUQSGTHCLWTDOLLOGSEK 180
Db 121 TCSFVAPWNISLQAQRGGFTKTYTGCEECTVFPCLSIPICKLUQSGTHCLWTDOLLOGSEK 180

QY 181 GQSRRHIALCPLPREPGLCITWOSLRSQIA 207
Db 181 GQSRRHIALCPLPREPGLCITWOSLRSQIA 207

RESULT 10
ADQ07367 ID ADQ07367 standard; protein; 207 AA.

AC ADQ07367;
XX DT 09-SEP-2004 (first entry)

DE Human tissue inhibitor of metalloproteinase 1 (TIMP1).
XX
KW matrix metalloproteinase; MMP; MMP inhibitor; proteinase inhibitor;
KW scar prevention; skin development; human;
KW tissue inhibitor of metalloproteinase 1; TIMP-1; wound healing; skin;
KW enzyme.

XX OS Homo sapiens.
XX PN US2004121438-A1.
XX PD 24-JUN-2004.
XX PR 19-DEC-2002; 2002US-00325446.
XX PR 19-DEC-2002; 2002US-00325446.
XX PA (QUIRK /) QUIRK S.
XX PI Quirk S;

XX DR WPI; 2004-479683/45.

XX PT New wound care compositions, useful in promoting wound healing, preventing scarring, improving skin tone, and in stimulating the development of a smooth, healthy skin.

XX PS Disclosure; SEQ ID NO 1; 43pp; English.

CC The invention describes an isolated nucleic acid (1). (1) comprises a sequence: encoding a polypeptide comprising a sequence of 108 amino acids (SEQ ID NOS: 5 or 20); or which hybridises under stringent hybridisation conditions to a nucleic acid comprising a sequence of 339 bp (SEQ ID NO: 6). Also described are: an isolated polypeptide comprising SEQ ID NOS: 5 or 20 or comprising SEQ ID NOS: 7 or 21 that has a beta barrel conformation and that can bind to a matrix metalloproteinase; a composition comprising a therapeutic amount of polypeptide or polypeptide inhibitor comprising SEQ ID NOS: 5, 7, 20 or 21 and a pharmaceutical carrier, where the polypeptide or polypeptide inhibitor can inhibit protease activity of matrix metalloproteinase-1 to -13; a wound dressing comprising a polypeptide of (1) and a pharmaceutical carrier, and treating wound comprising administering a therapeutic amount of a polypeptide of (1) to the wound. (1) is nucleic acid comprising a sequence of 339 bp (SEQ ID NO: 6) encoding wound care compositions comprising a sequence of 108 amino acids (SEQ ID NOS: 5 or 20). The nucleic acid and the encoded polypeptide, composition, and method are useful in promoting wound healing, preventing scarring, improving skin tone, and in stimulating the development of a smooth, healthy skin. This is the amino acid sequence of human tissue inhibitor of metalloproteinase 1 (TIMP-1), useful in wound healing and promoting development of healthy skin.

XX SQ Sequence 207 AA;

Query Match Score 1124; DB 8; Length 207;
Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGLILLWLIAPSRACCTVPPHQTAFCNSDLVIRAKFVGTPSVNQNTLYQR 60
Db 1 MAPPEPLASGLILLWLIAPSRACCTVPPHQTAFCNSDLVIRAKFVGTPSVNQNTLYQR 60

QY 61 YERKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSRBERLIAKLGQDGLHIT 120
Db 61 YERKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFRSHRSRBERLIAKLGQDGLHIT 120

QY 121 TCSFVAPWNISLQAQRGGFTKTYTGCEECTVFPCLSIPICKLUQSGTHCLWTDOLLOGSEK 180
Db 121 TCSFVAPWNISLQAQRGGFTKTYTGCEECTVFPCLSIPICKLUQSGTHCLWTDOLLOGSEK 180

QY 181 GQSRRHIALCPLPREPGLCITWOSLRSQIA 207
Db 181 GQSRRHIALCPLPREPGLCITWOSLRSQIA 207

RESULT 11
ADP7547 ID ADP7547 standard; protein; 207 AA.

AC ADP7547;
XX DT 09-SEP-2004 (first entry)

DE Human TIMP1 protein differentially expressed in schizophrenics Seq 151.

XX KW tissue inhibitor of metalloproteinase 1; human; schizophrenia; SCYA2; GADD53; S100A8; CDKN1A; TIR1L; TGK2; MAFF; SERPINA3; GRO1; CD14; KIAA075; CHI3L1; SERPINB1; MTIX; KIAA0620; TIMP1; NUMA1; DDT3; TOB2; neuroleptic; gene therapy.

XX OS Homo sapiens.
XX PN WO2004053157-A2.

XX	PD	24-JUN-2004.
XX	PP	11-DEC-2003; 2003WO-EP014089.
XX	PR	12-DEC-2002; 2002US-0432853P.
PA	PA	(NOVARTIS AG.
CC	PA	(NOVARTIS PHARMA GMBH.
CC	PA	(UAMA-) UNIV MARYLAND BALTIMORE.
XX	PI	Buxton FP, Carpenter WT, Roberts RC, Tamminga CA;
XX	DR	WPI; 2004-507015/4B.
XX	PS	N-PSDB; ADP75928.
PT	PT	Screening or diagnosing schizophrenia comprises determining the magnitude of expression of at least one gene upregulated in the anterior cingulate.
XX	Example 2; SEQ ID NO 151; 63pp; English.	
CC	CC	Screening for schizophrenia in a population or diagnosing schizophrenia in a host comprises determining the magnitude of expression, in members of the population, of at least one of the 19 genes (SCNM2, GADP5B, S100A8, CDKN1A, TIRL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CH131L, SERPINH1, MTIX, KIAA0620, TIPML, NUMA1, DDT3, or TOS2) in a sample. Screening for schizophrenia in a population or diagnosing schizophrenia in a host comprises: determining the magnitude of expression, in members of the population, of at least one of the 19 genes in a sample, and comparing the magnitude of expression to a baseline magnitude of expression of the gene, where increased gene expression indicates the presence of schizophrenia. INDEPENDENT CLAIMS are also included for: treating schizophrenia in a host; a transgenic nonhuman animal comprising stably integrated in its genome an increased copy number of any of the 19 genes, where expression of the gene is enhanced by one or more alterations in regulatory sequences of the gene such that the gene is expressed at higher than baseline levels and the animal exhibits schizophrenic behavior or a transgenic nonhuman knockout animal whose genome comprises a homozygous disruption in one or more of the 19 genes, where the homozygous disruption prevents the expression of the gene, and where the homozygous disruption results in the transgenic knockout animal exhibiting decreased expression levels of the one or more genes as compared to a wild-type animal; screening for a therapeutic agent that modulates symptoms of schizophrenia; and screening for a compound useful in treating schizophrenia. Preferred Method: The sample is taken from brain, spinal cord, lymphatic fluid, blood, urine or feces. The sample is taken from the anterior cingulate. The population or host is human. Treating schizophrenia in a host comprises lowering expression of at least one of the 19 genes by administering to the host: an expression lowering amount of antisense oligonucleotide; an expression lowering amount of a ribozyme which cleaves RNA associated with expression of the gene; or one or more RNA molecules designed to promote triple helix formation with the gene; or one or more RNA molecules designed to inhibit the expression of the gene. Alternatively, the method comprises reducing the amount of at least one protein encoded by any of the 19 genes in a patient by administering an amount of antibody or functional antibody fragment to interfere with the normal activity of the protein. The antibody or functional antibody fragment is whole antibody, humanized antibody, chimeric antibody, Fab fragment, Fab fragment, Fab' ₂ fragment, single chain Fv fragment, or diabody. The method comprises reducing the amount of at least one protein encoded by any of the 19 genes in a patient by administering an amount of antibody or functional antibody fragment to interfere with the normal activity of the protein. The antibody or functional antibody fragment is whole antibody, humanized antibody, chimeric antibody, Fab fragment, Fab fragment, Fab' ₂ fragment, single chain Fv fragment, or diabody.
CC	CC	Screening for a therapeutic agent that modulates symptoms of schizophrenia comprises: administering a candidate compound to a transgenic nonhuman animal of (2) or combining a candidate compound with a transgenic nonhuman animal of (2) and determining the effect of the compound on symptoms associated with schizophrenia. Screening for a compound, useful in treating schizophrenia, comprises operatively linking a reporter gene before and after exposure to the test compound, where a lower level of expression after exposure is indicative of a compound useful for the treatment of schizophrenia. Preferred Transgenic Nonhuman

CC Animal: The transgenic nonhuman animal is a mammal. One or more alterations comprise substitution of a promoter having a higher rate of expression than the native promoter of the gene. The promoter is an inducible promoter. Neuroleptic. No biological data given. Gene Therapy. Dosage is 0.1-10000 mg/kg/kg, by topical, pulmonary, intratracheal, intranasal, enteral, epidermal and transdermal, oral, sublingual, buccal or parenteral, including intravenous, intraperitoneal, intramuscular, infusion, intramedullary, intracranial, intrathecal or intraventricular means. The method is useful for screening for schizophrenia in a population or diagnosing schizophrenia in a host. The methods, compounds and compositions are useful in treating schizophrenia.

CC Sequence 207 AA;

SQ

Query	Match	Score	DB	Length	Best Local Similarity	Pred.	No.	Mismatches	Indels	Gaps	Matches	207;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps
QY	1	MAPPEPLASGILLWILWAPSRACTCVPHPHQTCFNSDILVTRAKPFGPEVNQTYLQR	60	61	YERKMTKMYKGQLGDAADIRFYTPAMESVCYFHRSNRSEPLACKLQDGHLHT	120	61	YERKMTKMYKGQLGDAADIRFYTPAMESVCYFHRSNRSEPLACKLQDGHLHT	120	61	MAPPEPLASGILLWILWAPSRACTCVPHPHQTCFNSDILVTRAKPFGPEVNQTYLQR	60							
Db				QY	121	TCSTVAPWNLSLQARRGFTKTYVGCSECTVFCLSLTICKLQSGTHCLWTQDQLGSEK	180	121	TCSTVAPWNLSLQARRGFTKTYVGCSECTVFCLSLTICKLQSGTHCLWTQDQLGSEK	180	Db								
Qy	181	GFRSRHLLACTPREGCLCTWQSLSQIA	207	181	GFRSRHLLACTPREGCLCTWQSLSQIA	207	Db	181	GFRSRHLLACTPREGCLCTWQSLSQIA	207									

RESULT 12

ADQ29674
 ID ADQ29674 standard; protein; 207 AA.
 XX
 AC ADQ29674;
 XX
 DT 07-OCT-2004 (first entry)
 XX Human colorectal cancer-associated protein #29.
 XX human; colon cancer; TIMP1; RegI-alpha;
 KW colorectal cancer-associated marker.
 XX Homo sapiens.
 XX SP1439393-A2.
 XX PN
 XX PD 21-JUL-2004.
 XX PF 15-DEC-2003; 2003EP-00257840.
 XX PR 13-DEC-2002; 2002US-0433554P.
 XX PR 31-JUL-2003; 2003US-0491397P.
 XX PA (FARB) BAYER HEALTHCARE LLC.
 PA (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
 XX DR N-FSDB; ADQ29670.
 XX
 PT Astle JH, Boardman LA, Bugart LJ, Burgess CC, Catino TJ;
 PI Dwivedi P, Huntress M, Johnson KA, Lewis ME, Maimonis PJ, Myerow SH;
 PI Brown-Shimer SLA, Triagalingam A, Thibodeau SN, Molino GA;
 DR WPI; 2004-545561/53.
 DR N-FSDB; ADQ29670.

PT Diagnosing colon cancer in individual, preferably human, by detecting presence of TIMP 1 in sample, where presence of TIMP 1 in sample is indicative of colon cancer in individual.

CC The invention relates to a novel isolated nucleic acid and the PRO
 CC polypeptide encoded by it. A protein of the invention has
 CC antiinflammatory, antiarthritic, antirheumatic, immunosuppressive,
 CC osteopathic, antidiabetic, dermatological, antipsoriatic, antiallergic,
 CC antiasthmatic, hepatotropic, and respiratory activity. A polynucleotide
 CC of the invention may have a use in gene therapy. The PRO polypeptide, its
 CC agonist, antagonist, or antibody that specifically binds to the
 CC polypeptide is useful for treating an immune related disorder such as
 CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, an
 CC juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an
 CC idiopathic inflammatory myopathy, Sjogren's syndrome, systemic
 CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
 CC thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal
 CC disease, a demyelinating disease of the central or peripheral nervous
 CC system, idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome,
 CC a chronic inflammatory demyelinating polyneuropathy, a hepatobiliary
 CC disease, infectious or autoimmune chronic active hepatitis, primary
 CC biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis,
 CC inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's
 CC disease, an autoimmune or immune-mediated skin disease, a bullous skin
 CC disease, asthma, allergic rhinitis, atopic dermatitis, food
 CC hypersensitivity, urticaria, an immunologic disease of the lung, eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypersensitivity
 CC pneumonitis, a transplantation associated disease, graft rejection or
 CC graft-versus-host disease. The present sequence represents a PRO protein
 CC of the invention.

XX Sequence 207 AA:

Query Match 100.0%; Score 1124; DB 8; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGILLNLIAPIASRACTCVPHPQTAFACNSDLVIRAKFVGTVPEVNQTLYQR 60
 1 MAPPEPLASGILLNLIAPIASRACTCVPHPQTAFACNSDLVIRAKFVGTVPEVNQTLYQR 60

Db 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120
 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120

QY 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120
 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120

Db 121 TCSFVAPWNSLISLAQRGFTKTYTGVCECTVFPCLSIPCKLQSGTHCLWDQQLQSEK 180
 121 TCSFVAPWNSLISLAQRGFTKTYTGVCECTVFPCLSIPCKLQSGTHCLWDQQLQSEK 180

QY 181 GQSRHACLPRPGLCTWQSRSQIA 207
 181 GQSRHACLPRPGLCTWQSRSQIA 207

Db 181 GQSRHACLPRPGLCTWQSRSQIA 207

RESULT 13

ADP23249 standard; protein; 207 AA.

ADP23249 standard; protein; 207 AA.

AC ADP23249; 18-NOV-2004 (first entry)

XX PRO polypeptide SEQ ID NO:343.

XX PRO; antiinflammatory; antiarthritic; antirheumatic; immunosuppressive;
 XX osteopathic; antidiabetic; dermatological; antipsoriatic; antiallergic;
 XX antiasthmatic; hepatotropic; respiratory; gene therapy; immune system.
 XX Unidentified.

OS Unidentified.

XX WO2004041170-A2.

XX 21-MAY-2004.

PP 30-OCT-2003; 2003WO-US034312.

PR 01-NOV-2002; 2002US-0423394P.

XX (GETH) GENENTECH INC.

PA Clark H, Schoenfeld J, Van Lookeren M, Williams PM, Wood WI;
 PT Wu TD; WPI; 2004-419628/39.

XX N-PSDB; ADP23248.

XX New PRO polypeptides and polymucleotides, useful for treating e.g.
 PT erythema, rheumatoid arthritis, diabetes mellitus, immune-mediated
 PT renal disease, or demyelinating diseases of the central or peripheral
 PT nervous system.

XX Claim 7; SEQ ID NO 343; 2940pp; English.

XX

Query Match 100.0%; Score 1124; DB 8; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Mismatches 0; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAPPEPLASGILLNLIAPIASRACTCVPHPQTAFACNSDLVIRAKFVGTVPEVNQTLYQR 60
 1 MAPPEPLASGILLNLIAPIASRACTCVPHPQTAFACNSDLVIRAKFVGTVPEVNQTLYQR 60

Db 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120
 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120

QY 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120
 61 YEIKMTMNYKGFOALGDAADTRFVYTFAMESVCGYFIRSHNRSEEFILAGKLDQGLHIT 120

Db 121 TCSFVAPWNSLISLAQRGFTKTYTGVCECTVFPCLSIPCKLQSGTHCLWDQQLQSEK 180
 121 TCSFVAPWNSLISLAQRGFTKTYTGVCECTVFPCLSIPCKLQSGTHCLWDQQLQSEK 180

QY 181 GQSRHACLPRPGLCTWQSRSQIA 207
 181 GQSRHACLPRPGLCTWQSRSQIA 207

RESULT 14

ADU06596 standard; protein; 207 AA.

ADU06596 standard; protein; 207 AA.

AC ADU06596; 27-JAN-2005 (first entry)

DE Novel bronchial cancer-associated human protein SeqID922.

XX bronchial cancer; cytostatic; tumour-associated protein;
 KW cancer detection; metastasis; tumour; human.

OS Homo sapiens.

XX DB10316701-A1.

XX 04-NOV-2004.

XX 09-APR-2003; 2003DE-01016701.

XX 09-APR-2003; 2003DE-01016701.

XX (HINZ) HINZMANN B.
 PA (HERM) HERMANN K.
 PA (CAST) HEIDEN CASTANOS-VELEZ E.
 XX
 PI Mennetrich D., Brummendorf T., Heiden E., Hermann K., Kinnemann H.;
 LI X., Roepcke S., Staub E., Hinzmann B., Rosenthal A., Pilarsky C.;
 XX WPI; 2004-786403/78.
 DR N-PSDB; ADU06209.
 XX
 PT New nucleic acid and derived proteins, useful for diagnosis of bronchial
 cancer and in screening for therapeutic and diagnostic agents.
 XX
 PS Claim 2; SEQ ID NO 922; 1381pp; German.
 XX
 CC This invention relates to a novel isolated nucleic acid associated with
 bronchial cancer comprising 489 defined sequences given in the
 specification. The invention may be useful for the production of expression
 compounds with a cytostatic activity through the inhibition of expression
 or activity of tumour-associated proteins. The novel DNA sequences and
 the proteins/peptides encoded by them are used for detecting bronchial
 cancer or determining the risk of developing it and to screen for
 specific binding partners of the DNA or protein sequences, where the
 CC binding partners are potentially useful as agents for treating or
 diagnosing bronchial cancer. The DNA or protein sequences can also be
 used for prognosis, detection of metastases and for secondary treatment
 (of tumours that have been stabilised or are no longer detectable).
 Detecting abnormal expression of the DNA sequences provides early
 diagnosis of bronchial cancers. The present sequence is that of a protein
 CC encoded by a novel bronchial cancer-associated human gene sequence of the
 CC invention.
 XX
 Sequence 207 AA:
 SQ

Query Match 100.0%; Score 1124; DB 8; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLMLIAPSRRACTCYPHPQTAFNSDLVIRAKFGTPENQNTLYQR 60
 Db 1 MAPPERPLASGILLMLIAPSRRACTCYPHPQTAFNSDLVIRAKFGTPENQNTLYQR 60
 Qy 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFHRSHRSEEFILAGKLQDGHLIT 120
 Db 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFHRSHRSEEFILAGKLQDGHLIT 120
 Qy 121 TCSFVPAWNLSLQAQRGFTKTYTVCBECTVFCPLSIPCKLQSGTHCLWTDQLGSEK 180
 Db 121 TCSFVPAWNLSLQAQRGFTKTYTVCBECTVFCPLSIPCKLQSGTHCLWTDQLGSEK 180
 Qy 181 GFQSRHLACLRPREGCTWQSRSQIA 207
 Db 181 GFQSRHLACLRPREGCTWQSRSQIA 207
 XX

Sequence 207 AA:

Query Match 100.0%; Score 1124; DB 9; Length 207;
 Best Local Similarity 100.0%; Pred. No. 4.1e-109; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAPPEPLASGILLMLIAPSRRACTCYPHPQTAFNSDLVIRAKFGTPENQNTLYQR 60
 Db 1 MAPPERPLASGILLMLIAPSRRACTCYPHPQTAFNSDLVIRAKFGTPENQNTLYQR 60
 Qy 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFHRSHRSEEFILAGKLQDGHLIT 120
 Db 61 YEIKMTKMYKGFOALGDAADIRFVYTPAMESVCGYFHRSHRSEEFILAGKLQDGHLIT 120
 Qy 121 TCSFVPAWNLSLQAQRGFTKTYTVCBECTVFCPLSIPCKLQSGTHCLWTDQLGSEK 180
 Db 121 TCSFVPAWNLSLQAQRGFTKTYTVCBECTVFCPLSIPCKLQSGTHCLWTDQLGSEK 180
 Qy 181 GFQSRHLACLRPREGCTWQSRSQIA 207
 Db 181 GFQSRHLACLRPREGCTWQSRSQIA 207
 XX

RESULT 15
 ADV0205
 ID ADV0205 standard; protein; 207 AA.
 XX
 AC
 XX
 DT 10-MAR-2005 (first entry)

DE Tumor-associated antigenic target polypeptide TAT47.
 XX KW cytostatic; diagnosis; therapy; tumor;
 KW tumor-associated antigenic target polypeptide; TAT.
 OS Homo sapiens.
 XX PN WO2004112829-A2.
 XX

PD 29-DEC-2004.

XX PR 21-MAY-2004; 2004WO-US016121.

XX PR 23-MAY-2003; 2003US-0473238P.

XX PR 27-FEB-2004; 2004US-0548239P.

XX PA (GBTX) GENENTECH INC.

XX PI Phillips H;

XX DR WPI; 2005-048766/05.

XX DR N-PSDB; ADV70110.

XX PT Treating a mammal having a tumor of glial origin comprising cells that
 express a type A or B glial tumor antigen by contacting the cells with a
 PT composition comprising first and second binding agents.

XX PS Disclosure; SEQ ID NO 129; 374pp; English.

CC The invention describes a method of treating a mammal having a tumor of
 glial origin comprising cells that express a type A or B glial tumor
 antigen comprises contacting the cells with a composition of: a first
 CC binding agent comprising a first antibody, oligopeptide or organic
 CC molecule that binds to a type A or B glial tumor antigen; and a second
 CC binding agent comprising a second antibody, oligopeptide or organic
 CC molecule that binds to a type B or A glial tumor antigen. Also described
 CC is a method of determining the presence of a type A or B glial tumor in a
 CC mammal. The method is useful in treating a mammal having a tumor of glial
 CC origin comprising cells that express a type A or B glial tumor antigen.
 CC This sequence represents a human tumor-associated antigenic target
 CC polypeptide.

Search completed: April 10, 2006, 18:01:20
 Job time : 84.203 sec

THIS PAGE LEFT BLANK